<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06471993-20021029-D00000.TIF SYSTEM "US06471993-20021029-D00000.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00001.TIF SYSTEM "US06471993-20021029-D00001.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00002.TIF SYSTEM "US06471993-20021029-D00002.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00003.TIF SYSTEM "US06471993-20021029-D00003.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00004.TIF SYSTEM "US06471993-20021029-D00004.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00005.TIF SYSTEM "US06471993-20021029-D00005.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00006.TIF SYSTEM "US06471993-20021029-D00006.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00007.TIF SYSTEM "US06471993-20021029-D00007.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00008.TIF SYSTEM "US06471993-20021029-D00008.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00009.TIF SYSTEM "US06471993-20021029-D00009.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00010.TIF SYSTEM "US06471993-20021029-D00010.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00011.TIF SYSTEM "US06471993-20021029-D00011.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00012.TIF SYSTEM "US06471993-20021029-D00012.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00013.TIF SYSTEM "US06471993-20021029-D00013.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00014.TIF SYSTEM "US06471993-20021029-D00014.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00015.TIF SYSTEM "US06471993-20021029-D00015.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00016.TIF SYSTEM "US06471993-20021029-D00016.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00017.TIF SYSTEM "US06471993-20021029-D00017.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00018.TIF SYSTEM "US06471993-20021029-D00018.TIF" NDATA TIF>
<!ENTITY US06471993-20021029-D00019.TIF SYSTEM "US06471993-20021029-D00019.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06471993</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021029</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09463709</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000128</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>A61K  914</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>424486</PDAT></B521>
<B522><PDAT>424484</PDAT></B522>
<B522><PDAT>424487</PDAT></B522>
<B522><PDAT>424422</PDAT></B522>
<B522><PDAT>424423</PDAT></B522>
<B522><PDAT>424424</PDAT></B522>
<B522><PDAT>424425</PDAT></B522>
<B522><PDAT>424426</PDAT></B522>
<B522><PDAT>5147723</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Three-dimensional polymer matrices</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4100238</PDAT></DNUM>
<DATE><PDAT>19780700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Shinomura</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>264 49</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4186448</PDAT></DNUM>
<DATE><PDAT>19800200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Brekke</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>  3  19</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4394370</PDAT></DNUM>
<DATE><PDAT>19830700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Jefferies</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424 15</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4458678</PDAT></DNUM>
<DATE><PDAT>19840700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Yannas et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>128155</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4623472</PDAT></DNUM>
<DATE><PDAT>19861100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Jamison et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>252 122</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4828772</PDAT></DNUM>
<DATE><PDAT>19890500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Lopatin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>264 459</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4963489</PDAT></DNUM>
<DATE><PDAT>19901000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Naughton et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4352401</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5041138</PDAT></DNUM>
<DATE><PDAT>19910800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Vacanti et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>623 16</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5108755</PDAT></DNUM>
<DATE><PDAT>19920400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Daniels et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5133755</PDAT></DNUM>
<DATE><PDAT>19920700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Brekke</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>623 16</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5139529</PDAT></DNUM>
<DATE><PDAT>19920800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Seita et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>623 66</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5232984</PDAT></DNUM>
<DATE><PDAT>19930800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>525 541</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5328695</PDAT></DNUM>
<DATE><PDAT>19940700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Lucas et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5352574</PDAT></DNUM>
<DATE><PDAT>19941000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Guiseppi-Elie</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435  4</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5356630</PDAT></DNUM>
<DATE><PDAT>19941000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Laurencin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5366508</PDAT></DNUM>
<DATE><PDAT>19941100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Brekke</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>623 16</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5380536</PDAT></DNUM>
<DATE><PDAT>19950100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424497</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5393848</PDAT></DNUM>
<DATE><PDAT>19950200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Charbonneau et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>525425</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5514378</PDAT></DNUM>
<DATE><PDAT>19960500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Mikos et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424425</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5518680</PDAT></DNUM>
<DATE><PDAT>19960500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Cima et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>264401</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5522895</PDAT></DNUM>
<DATE><PDAT>19960600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Mikos</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>623 16</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5529914</PDAT></DNUM>
<DATE><PDAT>19960600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435182</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5545409</PDAT></DNUM>
<DATE><PDAT>19960800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Laurencin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5567435</PDAT></DNUM>
<DATE><PDAT>19961000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5567440</PDAT></DNUM>
<DATE><PDAT>19961000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424484</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5573934</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435177</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5589176</PDAT></DNUM>
<DATE><PDAT>19961200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Seare, Jr.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424400</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5605693</PDAT></DNUM>
<DATE><PDAT>19970200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Seare, Jr.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424400</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5624674</PDAT></DNUM>
<DATE><PDAT>19970400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Seare, Jr.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424400</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5626861</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Laurencin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5626863</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5627233</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hubbell et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>525 541</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5629009</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Laurencin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5654381</PDAT></DNUM>
<DATE><PDAT>19970800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hrkach et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>525450</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5677355</PDAT></DNUM>
<DATE><PDAT>19971000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Shalaby et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>521 61</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5681572</PDAT></DNUM>
<DATE><PDAT>19971000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Seare, Jr.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424400</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5711960</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Shikinami</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>424426</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0 299 010</PDAT></DNUM>
<DATE><PDAT>19960600</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Lo et al., &ldquo;Fabrication of controlled release biodegradable foams by phase separation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Tissue Engineering </PDAT></ITALIC></HIL><PDAT>1(1):15-28 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mikos et al., &ldquo;Preparation and characterization of poly(L-lactic acid) foams,&rdquo; </PDAT><HIL><ITALIC><PDAT>Polymer </PDAT></ITALIC></HIL><PDAT>35(5):1068-1077 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mooney et al., &ldquo;Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biomaterials </PDAT></ITALIC></HIL><PDAT>17(14):1417-1422 (1996).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>29</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>424484</PDAT></B582>
<B582><PDAT>424486</PDAT></B582>
<B582><PDAT>424487</PDAT></B582>
<B582><PDAT>424422</PDAT></B582>
<B582><PDAT>424423</PDAT></B582>
<B582><PDAT>424424</PDAT></B582>
<B582><PDAT>424425</PDAT></B582>
<B582><PDAT>424426</PDAT></B582>
<B582><PDAT>5147723</PDAT></B582>
</B580>
<B590><B595><PDAT>19</PDAT></B595><B596><PDAT>36</PDAT></B596><B597US/>
</B590>
</B500>
<B600>
<B630><B631><PARENT-US><CDOC><DOC><DNUM><PDAT>09/463709</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/904780</PDAT></DNUM><DATE><PDAT>19970801</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>03</PDAT></PSTA></PARENT-US></B631></B630>
<B680US><DOC><DNUM><PDAT>60/067234</PDAT></DNUM><DATE><PDAT>19971202</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
<B680US><DOC><DNUM><PDAT>60/069547</PDAT></DNUM><DATE><PDAT>19971212</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Venkatram R.</PDAT></FNM><SNM><STEXT><PDAT>Shastri</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Allston</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Ivan</PDAT></FNM><SNM><STEXT><PDAT>Martin</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Somerville</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Robert S.</PDAT></FNM><SNM><STEXT><PDAT>Langer</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Newton</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Joachim</PDAT></FNM><SNM><STEXT><PDAT>Seidel</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Somerville</PDAT></CITY>
<STATE><PDAT>MA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Massachusetts Institute of Technology</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Cambridge</PDAT></CITY><STATE><PDAT>MA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Clark &amp; Elbing LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
<B741>
<PARTY-US>
<NAM><FNM><PDAT>Kristina</PDAT></FNM><SNM><STEXT><PDAT>Bieker-Brady</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Thurman K.</PDAT></FNM><SNM><STEXT><PDAT>Page</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Liliana</PDAT></FNM><SNM><STEXT><PDAT>Di Nola-Baron</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1615</PDAT></B748US>
</B745>
</B700>
<B800>
<B860>
<B861>
<DOC><DNUM><PDAT>PCT/US98/16020</PDAT></DNUM><DATE><PDAT>19980731</PDAT></DATE><CTRY><PDAT>WO</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC>
</B861>
<B864US><DATE><PDAT>20000929</PDAT></DATE></B864US>
</B860>
<B870>
<B871><DOC><DNUM><PDAT>WO99/09149</PDAT></DNUM><DATE><PDAT>19990225</PDAT></DATE><CTRY><PDAT>WO</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></B871>
</B870>
</B800>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Matrices that include a macrostructure having a semi-solid network and voids, and a microstructure having voids, in which the microstructure is located within the semi-solid network are disclosed. Methods for preparing these matrices are also disclosed.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This invention claims the benefits of provisional application No. 60/069,547, filed Dec. 12, 1997, and No. 60/067,234, filed Dec. 2, 1997, and a continuation of Ser. No. 08/904,780, filed on Aug. 1, 1997, now abandoned.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>STATEMENT OF FEDERALLY SPONSORED RESEARCH</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made with government support under Grant Number NIH-5R01-GM26698 awarded by the National Institutes of Health and Grant Number BES-9525913 m awarded by the National Science Foundation. The government has certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The invention relates to porous polymer matrices.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Porous polymer media, such as membranes, macroporous solids, and cellular solids are used in a wide variety of applications. These materials are used as support structures for gas and solution phase catalysis; support structures for solid phase synthesis; immobilized beds in bioreactors; and thermal insulation.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Recent advances in the field of tissue engineering have led to new uses for these porous materials. Tissue engineering techniques provide alternatives to the prosthetic materials currently used in plastic and reconstructive surgery, and in joint repair and replacement; these techniques are also useful in the formation of organ equivalents to replace diseased, defective, or injured organs. Porous materials are used as scaffolds for the in vitro or in vivo growth and development of tissue. Because these materials are placed in the human body, they must often have structural and functional characteristics that differ from the requirements for materials used in non-therapeutic applications.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>The invention features porous matrices that are useful in a variety of applications, including tissue engineering, electromagnetic shielding, and fuel cell applications.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>In a first aspect, the invention features a matrix including a macrostructure having a semi-solid network and voids; the matrix further includes a microstructure, which preferably has voids; the microstructure is located within the semi-solid network. In a preferred matrix, the semi-solid network includes a polymer or a copolymer. The copolymer can have a carboxylic acid group or an amine group. Another preferred matrix includes a conductive polymer selected from the group consisting of polypyrrole, polyaniline, polyacetylene, and polythiophene.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>In a preferred matrix, the semi-solid network consists essentially of a polymer or mixture of polymers. In another preferred matrix, the semi-solid network is substantially continuous.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The voids of the macrostructure can also be substantially continuous. The voids of the macrostructure and the voids of the microstructure can be connected or not connected. The voids of the macrostructure define openings. In a preferred matrix, the average diameter of the openings and the average diameter of the cross-sections of the semi-solid network have a ratio of from 2:1 to 10:1, and more preferably have a ratio of from 2:1 to 5:1.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>In a preferred embodiment, a cubic matrix having dimensions of about 0.5 cm on all sides and having voids defining openings with an average diameter of 50-500 &mgr;m has a connectivity number of at least 10, and more preferably has a connectivity number of at least 20.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>A ratio of the maximum diameter and the minimum diameter of a cross section of the semi-solid network of a preferred matrix is from 1:1 to 10:1, and more preferably is from 1:1 to 4:1, or from 1:1 to 2:1.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>In another preferred matrix, at least 10% of the voids of the microstructure have a fractal dimension of at least 3; preferably, less than 10% of the voids of the macrostructure of this matrix have a fractal dimension higher than 1. A preferred matrix is three dimensional, and the exterior face of the matrix can be porous.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>The matrix can include an additive, at least 5% of which is located within the microstructure; the preferred additive is selected from the group consisting of transition metal oxides, transition metal sulfates, transition metal carbonates, transition metal phosphates, transition metal nitrates, sodium carbonate, sodium phosphate, calcium carbonate, calcium phosphate, &bgr;-glycerophosphate, and hydroxyapatite having particle sizes of greater than 150 &mgr;m. The additive can also be selected from the group consisting of polyethylene fibers, polypropylene fibers, Teflon&reg; (polytetrafluoroethylene) fibers, nylon fibers, and PGA fibers; it can also be selected from the group consisting of titanium fibers, titanium powder, and titanium dioxide; or from the group consisting of inorganic and organic reducing agents.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>A preferred matrix has a porosity of at least about 20%, and more preferably has a porosity of at least about 40%, 70%, 90%, 92%, or 95%. A preferred matrix is biodegradable, bioerodible, or bioresorbable. The matrix can be permeable or impermeable to cells; it is preferably permeable to bodily fluids. A preferred matrix includes a living cell; preferably, the cell is selected from the group consisting of bone marrow cells, periosteal cells, chondrocytes, smooth muscle cells, endothelial cells, fibroblasts, epithelial cells, tenocytes, neuronal cells, Schwann cells, hepatocytes, Kupffer cells, fibroblasts, pancreatic islet cells, and cardiac myocytes. Another preferred matrix includes a bioactive agent, which is preferably contained in microspheres. The bioactive agent is selected from the group consisting of antibiotics, anesthetics, anti-inflammatory agents, contrast agents, and imaging agents.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>A preferred matrix has a coating; less than 5% of the coating is contained in the voids of the microstructure. The coating may be attached to the matrix by electrostatic forces, by covalent bonding, or as a result of the shape of the coating. In this last case, the coating encases at least a portion of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>The matrix may be coated by any coating known to those skilled in the art to be appropriate, however, another preferred matrix is coated with a hydrophilic material selected from the group consisting of collagen, PEG, PEO, PVA, hydrogels, carboxylic acid-containing substances, fibronectin, vitronectin, laminin, and bone morphogenetic protein (BMP).</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>Yet another preferred matrix includes bioerodible fibers; the fibers preferably include PGA or therapeutic agents. Another preferred matrix includes a protein that is protected with a cyclodextrin.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>A preferred matrix changes in size less than 50% when cells are added to the matrix; another preferred matrix has a compressive modulus which is higher than known polymer matrices having the same components in the same ratio. For example, a preferred matrix has a compressive modulus of at least 0.4 MPa at 4% strain. In addition, a preferred matrix is non-friable.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>In a second aspect, the invention features a porous polymer matrix that changes in size less than 50% when cells are added to the matrix. A preferred matrix changes in size less than 25% when cells are added to the matrix, and more preferably changes in size less than 10%. In a preferred embodiment the change in matrix size is defined as that change which occurs over a limited time period, of over a period of less than &frac12; the time it takes for the matrix to degrade, preferably, less than {fraction (1/10)} the time it takes for the matrix to degrade, most preferably, the period of time during which the initial cells are added to the matrix if such time is less than {fraction (1/10)} the time it takes for the matrix to degrade.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>A preferred matrix has a macrostructure having a semi-solid network and voids and a microstructure having voids; the microstructure is located within the semi-solid network. Preferably, the voids of the macrostructure are substantially continuous. A preferred matrix has a porosity of at least 90%, and more preferably has a porosity of at least 92%, or 95%. A preferred matrix is biodegradable, bioerodible or bioresorbable. A preferred matrix is permeable to bodily fluids. Another preferred matrix includes a living cell or a bioactive agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>A preferred matrix has a coating; less than 5% of the coating is contained in the voids of the microstructure. The coating may be attached to the matrix by electrostatic forces, by covalent bonding, or as a result of the shape of the coating. In this last case, the coating encases at least a portion of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>The matrix may be coated with any suitable coating known to those skilled in the art, another preferred matrix is coated with a hydrophilic material selected from the group consisting of collagen, PEG, PEO, PVA, hydrogels, carboxylic acid-containing substances, fibronectin, vitronectin, laminin, and bone morphogenetic protein (BMP).</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>A preferred matrix is three dimensional. The exterior face of a preferred matrix is porous. Another preferred matrix includes an additive; at least 5% of the additive is located within the microstructure. A preferred matrix has a density of less than about 0.150 g/cc, and more preferably has a density of less than about 0.120 g/cc.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>In a third aspect, the invention features a porous polymer matrix including poly(lactic acid) and/or poly(lactic acid-co-glycolic acid), and at least one hydrophilic polymer selected from the group consisting of poly(ethylene glycol), poly(ethylene oxide), polypropylene oxide, polypropylene glycol, poly(vinyl alcohol), a copolymer of polypropylene oxide and polyethylene oxide, collagen, gelatin, fibronectin, glycosaminoglycan, and polylysine. The poly(ethylene glycol) preferably has ester linkages. A preferred matrix includes a blend of poly(lactic acid), preferably poly(L-lactic acid), and poly(lactic acid-co-glycolic acid).</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>A preferred matrix includes at least 0.1% of the hydrophilic polymer, and more preferably includes at least 1% of the hydrophilic polymer, at least 5% of the hydrophilic polymer, at least 10% of the hydrophilic polymer, or at least 20% of the hydrophilic polymer.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>Preferably, the matrix includes at least one additive selected from the group consisting of calcium carbonate, &bgr;-glycerophosphate, calcium phosphate, sodium phosphate, sodium carbonate, sodium bicarbonate, and sodium chloride.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>A preferred matrix includes calcium carbonate having particle sizes ranging from 5 &mgr;m to 500 &mgr;m. Preferably, the matrix includes 50-100% by weight of calcium carbonate, relative to the weight of poly(lactic acid) or poly(lactic acid-co-glycolic acid), or to the combined weight of poly(lactic acid) and poly(lactic acid-co-glycolic acid), if the matrix includes both of these polymers.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>Another preferred matrix includes &bgr;-glycerophosphate having particle sizes ranging from 5 &mgr;m to 500 &mgr;m. Preferably the matrix includes 50-100% by weight of &bgr;-glycerophosphate, relative to the weight of poly(lactic acid) or poly(lactic acid-co-glycolic acid), or to the combined weight of poly(lactic acid) and poly(lactic acid-co-glycolic acid), if the matrix includes both of these polymers.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>Another preferred matrix includes hydroxyapatite having particle sizes of at least 150 &mgr;m. The matrix preferably includes between 5 and 150% by weight of hydroxyapatite, relative to the weight of the polymer.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>A preferred matrix has a macrostructure having a semi-solid network and voids; the matrix further includes a microstructure having voids; the microstructure is located within the semi-solid network. A preferred matrix has a porosity of at least about 90%. Another preferred matrix includes a living cell or a bioactive agent. A preferred matrix is three dimensional. Preferably, the exterior face of the matrix is porous.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>A preferred matrix includes an additive; at least 5% of the additive is located within the microstructure. Preferably, the matrix changes in size less than 50% when cells are added to the matrix. A preferred matrix has a density of less than about 0.150 g/cc, and more preferably has a density of less than about 0.120 g/cc.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>In a fourth aspect, the invention features a porous matrix consisting essentially of a polymer, or a mixture of polymers, where the matrix has a compressive modulus which is higher than known polymer matrices having the same components in the same ratio. For example, a preferred matrix has a compressive modulus of at least 0.4 MPa at 4% strain. Preferably, the matrix has a porosity of at least about 90%. A preferred matrix is biodegradable, bioerodible, or bioresorbable. Preferably, the matrix includes a living cell or a bioactive agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>A preferred matrix has a coating; less than 5% of the coating is contained in the voids of the microstructure. The coating may be attached to the matrix by electrostatic forces, by covalent bonding, or as a result of the shape of the coating. In this last case, the coating encases at least a portion of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>While the matrix may be coated with any suitable coating known to those skilled in the art, another preferred matrix is coated with a hydrophilic material selected from the group consisting of collagen, PEG, PEO, PVA, hydrogels, carboxylic acid-containing substances, fibronectin, vitronectin, laminin, and bone morphogenetic protein (BMP).</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>A preferred matrix is substantially free of hydroxyapatite. A preferred matrix is three dimensional. Preferably, the exterior face of the matrix is porous. A preferred matrix includes an additive; at least 5% of the additive is located within the microstructure. A preferred matrix changes in size less than 50% when cells are added to the matrix. A preferred matrix has a density of less than about 0.150 g/cc, and more preferably has a density of less than about 0.120 g/cc.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In a fifth aspect, the invention features a matrix having a porosity of at least 90%. A preferred matrix is biodegradable, bioerodible, or bioresorbable. Preferably, the matrix includes a living cell or a bioactive agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>A preferred matrix has a coating; less than 5% of the coating is contained in the voids of the microstructure. The coating may be attached to the matrix by electrostatic forces, by covalent bonding, or as a result of the shape of the coating. In this last case, the coating encases at least a portion of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>Another preferred matrix is coated with a hydrophilic material selected from the group consisting of collagen, PEG, PEO, PVA, hydrogels, carboxylic acid-containing substances, fibronectin, vitronectin, laminin, and bone morphogenetic protein (BMP). Preferably, the matrix is substantially free of hydroxyapatite. A preferred matrix is three dimensional. Preferably, the matrix changes in size less than 50% when cells are added to the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In a sixth aspect, the invention features a porous polymer matrix that bioerodes at substantially the same rate that cells populate the matrix. A preferred matrix has a porosity of at least about 90%. Preferably, the matrix includes a bioactive agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>A preferred matrix has a coating; less than 5% of the coating is contained in the voids of the microstructure. The coating may be attached to the matrix by electrostatic forces, by covalent bonding, or as a result of the shape of the coating. In this last case, the coating encases at least a portion of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>Another preferred matrix is coated with a hydrophilic material selected from the group consisting of collagen, PEG, PEO, PVA, hydrogels, carboxylic acid-containing substances, fibronectin, vitronectin, laminin, and bone morphogenetic protein (BMP).</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>A preferred matrix changes in size less than 50% when cells are added to the matrix. Preferably, the matrix has a compressive modulus which is higher than known polymer matrices having the same components in the same ratio. For example, a preferred matrix has a compressive modulus of at least 0.4 MPa at 4% strain.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In a seventh aspect, the invention features a porous polymer matrix that bioerodes at substantially the same rate that tissue ingrows into the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>In an eighth aspect, the invention features a porous polymer matrix that bioerodes at substantially the same rate that tissue remodeling occurs within the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>In a ninth aspect, the invention features a composition including two layers, each layer including a matrix having voids, where the first layer has voids with an average size of less than 50 &mgr;m, and the second layer has voids with an average size of greater than 100 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>In a tenth aspect, the invention features a porous polymeric fiber. Preferably, the fiber includes a macrostructure having a semi-solid network and voids and a microstructure having voids, where the microstructure is located within the semi-solid network. In a preferred fiber, the voids are elongated and oriented in the same direction. Preferably, the fiber includes a bioactive agent.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>In an eleventh aspect, the invention features a polymer matrix including an additive selected from the group consisting of transition metal oxides, transition metal sulfates, transition metal carbonates, transition metal phosphates, transition metal nitrates, sodium carbonate, sodium phosphate, calcium carbonate, calcium phosphate, &bgr;-glycerophosphate, and hydroxyapatite having particle sizes of greater than 150 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>In a twelfth aspect, the invention features a method of making a porous polymer matrix using a composition including a solvent, a porogen, and a polymer, where at least 50%, and more preferably at least 80%, or at least 90% of the solvent and the porogen are recovered. Preferably, the porogen is biodegradable.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>In a thirteenth aspect, the invention features a method of making a porous polymer matrix. The method includes (a) combining a polymer solution and a porogen to form a mixture, and (b) extracting the porogen from the mixture and precipitating the polymer substantially simultaneously. The step of combining the polymer solution and the porogen can include depositing the polymer solution around the porogen using a three-dimensional printing technique. Preferably, the matrix is bounded on all sides during step (b). Preferably, the porogen is cryo-milled prior to step (a). The solvent is preferably removed by lyophilization. In a preferred method, a protein stabilized with a cyclodextrin is combined with the polymer and the porogen in step (a).</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>In a fourteenth aspect, the invention features a method of making a porous polymer matrix. The method includes (a) combining a polymer solution and an irregularly shaped porogen to form a mixture; and (b) extracting the porogen from the mixture.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>In a fifteenth aspect, the invention features a method of making a porous polymer matrix; the method includes (a) combining a polymer solution and a porogen that has been cryo-milled to form a mixture; and (b) extracting the porogen from the mixture.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>In a sixteenth aspect, the invention features a composition consisting essentially of irregularly shaped and sized wax particles. Preferably, at least 90% of the wax particles are smaller than 5000 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>In a seventeenth aspect, the invention features a method of making wax particles that includes cryo-milling wax. The invention further features a composition consisting essentially of a plurality of wax particles that are formed by cryo-milling wax. The invention also features a porous matrix including voids, where at least 10% of the voids in the matrix are made using this composition.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>In an eighteenth aspect, the invention features a method of making wax particles; the method includes spraying the wax in a liquid solution or a liquid form into a coolant. The invention also features a composition consisting essentially of a plurality of wax particles formed by this method. The invention further features a porous matrix including voids, where at least 10% of the voids in the matrix are made using this composition.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>In a nineteenth aspect, the invention features a method for controlling the mechanical strength of a porous polymer matrix that includes a water insoluble polymer and a water soluble polymer; the mechanical strength of the matrix may be optimized by alterations in the ratio of the water insoluble polymer and the water soluble polymer. Preferably, the porosity of the matrix remains substantially unchanged.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>In a twentieth aspect, the invention features a method for controlling the degradation rate of a porous polymer matrix that includes a water insoluble polymer and a water soluble polymer; the method includes altering the ratio of the water insoluble polymer and the water soluble polymer. Preferably, the porosity of the matrix remains substantially unchanged.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>In a twenty-first aspect, the invention features a mold for shaping an object; the mold has a plurality of sides, each of which defines a plurality of openings; at least two of the sides are permanently joined, and at least one side is detachable. Preferably, the mold includes Teflon&reg; (polytetrafluoroethylene).</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>In a twenty-second aspect, the invention features a method for preparing a three dimensional porous polymer matrix including the steps of: (a) preparing a polymer solution; (b) adding particles with a size of less than 5000 &mgr;m to the polymer solution that are insoluble or sparingly soluble in the polymer solvent at the temperature of the polymer solution when the particles are added; (c) mixing the solid particles and the solution to form a polymer/particle mixture; and (d) extracting the particles from the polymer/particle mixture with a solvent that is a solvent for the particles and a non-solvent for the polymer. In preferred embodiments: the polymer/particle mixture has a consistency between that of a viscous liquid and that of a paste; the method further includes molding or extruding the polymer/particle mixture before the particles are extracted; the method further includes removing the remaining solvent by evaporation; or the polymer is a water-soluble polymer, such as collagen, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, polyethylene oxide-polypropylene oxide copolymer, polyvinyl pyrrolidone, protein, peptide, or cellulose.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>In another preferred embodiment, the polymer is a water-insoluble polymer, and can be selected from the group consisting of polyesters, poly(ester amides), polyamides, polyanhydrides, polyorthoesters, polycarbonates, polyurethanes, polyethers and poly(ether esters). In another preferred embodiment, the particles are made from a material selected from the group consisting of natural waxes, synthetic waxes and wax-like polymers; the particles can also be selected from the group consisting of paraffin, beeswax, and low density polyethylene. The size of the particles is preferably between about 50 and 500 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>In preferred embodiments, the polymer/particle mixture includes a component selected from the group consisting of industrial catalysts, diagnostic agents and therapeutic agents. The therapeutic agents can be selected from the group consisting of cells, osteoinductive materials and osteoconductive materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>In a twenty-third aspect, the invention features a porous polymer matrix prepared by: (a) preparing a polymer solution; (b) adding to the solution an effective amount of solid particles with a size of less than 5000 &mgr;m that are insoluble or sparingly soluble in the polymer solvent at the temperature of the polymer solution when the particles are added; (c) mixing the solid particles and the solution to form a polymer/particle mixture; and (d) extracting the particles from the polymer/particle mixture with a solvent that is a solvent for the particles and a non-solvent for the polymer while simultaneously precipitating the polymer. Preferably, the polymer/particle mixture has a consistency between that of a viscous liquid and that of a paste. A preferred matrix is made by molding or extruding the polymer/particle mixture before the particles are extracted.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>The polymer can be a water-soluble polymer, and can be selected from the group consisting of collagens, polyethylene glycols, polyethylene oxides, polyvinyl alcohols, polyethylene oxide-polypropylene oxide copolymers, polyvinyl pyrrolidones, proteins, peptides, and celluloses. In other embodiments, the polymer is a water-insoluble polymer, and can be selected from the group consisting of polyesters, poly(ester amides), polyamides, polyanhydrides, polyorthoesters, polycarbonates, polyurethanes, polyethers and poly(ether esters).</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>The particles can be particles of natural waxes, synthetic waxes and wax-like polymers. The waxes and wax-like polymers can be selected from the group consisting of paraffin, beeswax, and low density polyethylene. In other embodiments, the particles are polymer particles. Preferably the size of the particles is between about 50 and 500 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>In other preferred embodiments, the polymer/particle mixture includes a component selected from the group consisting of industrial catalysts, diagnostic agents, therapeutic agents. The therapeutic agent can be selected from the group consisting of cells, osteoinductive materials, and osteoconductive materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The matrix can be formed into the shape of a hollow tube; formed into a solid object selected from the group consisting of rods, pins, screws, plates and anatomical shapes; formed into a solid object selected from the group consisting of porous electrodes, porous fibers, and porous solid support materials; or formed into particles suitable for pulmonary delivery or injection.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>In a twenty-fourth aspect, the invention features a polymer matrix with a porosity between about 10 and 95% which is substantially uniform throughout the matrix, prepared by (a) dissolving a water-soluble polymer in a solution; (b) adding particles with a size of less than 5000 &mgr;m to the polymer solution that are insoluble or sparingly soluble in the polymer solvent at the temperature of the polymer solution when the particles are added; (c) mixing the solid particles and the solution to form a polymer/particle mixture; and (d) extracting the particles from the polymer/particle mixture with a solvent that is a solvent for the particles and a non-solvent for the polymer.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>&ldquo;Porous polymer matrix&rdquo; means any solid object made of a polymer, which forms a continuous or discontinuous porous network. Porous polymer matrices include porous membranes, porous foams, and porous beads.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>&ldquo;Macrostructure,&rdquo; as used herein when referring to a matrix, means the semi-solid network of the matrix and the continuous voids defined by the network.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>&ldquo;Microstructure,&rdquo; as used herein when referring to a matrix, means the system of voids that are contained within the semi-solid network of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>&ldquo;Semi-solid,&rdquo; as used herein when referring to a structure, means that the structure can have voids.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>&ldquo;Voids&rdquo; mean portions of a matrix that do not contain the material that makes up the semi-solid network of the matrix; the voids are filled with any substance that is different from the substance that makes up the majority of the semi-solid network.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>The &ldquo;diameter of a void&rdquo; means the diameter of the largest sphere that would fit through the opening defined by the void.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>&ldquo;Connectivity number&rdquo; means the number of cuts that must be made in order to ensure that an object is separated into at least two completely separate pieces.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>A &ldquo;cut&rdquo; means a cut that passes through a meridional circle of the semi-solid network and does not pass through a void of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>A &ldquo;cross-section&rdquo; means a section that can be drawn through a portion of the semi-solid network of the matrix by drawing a meridional curve on the exterior surface of the portion.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>A &ldquo;minimum diameter of a cross section&rdquo; means the shortest straight line that can be drawn that joins two edges of the cross-section and passes through the center of the cross-section.</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>A &ldquo;maximum diameter of a cross section&rdquo; means the longest straight line that can be drawn that joins two edges of the cross-section.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>A &ldquo;diameter of a cross-section&rdquo; is the mean of the minimum and maximum diameters.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>&ldquo;Average diameter of the cross sections of the semi-solid network,&rdquo; means the mean of the diameters of the cross sections of the semi-solid network.</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>&ldquo;Continuous,&rdquo; as used herein when referring to the semi-solid network, means that the relevant portions of the semi-solid network are joined as one piece. That is, a line can be drawn from one point on the surface to another point without leaving the surface of the semi-solid network and without crossing a void. Similarly, continuous, as used herein when referring to voids, means that a line can be drawn connecting a point in the void space with another point in the void space, without leaving the void space and without crossing the semi-solid network.</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>&ldquo;Fractal,&rdquo; as used herein, means an irregular curve or shape that repeats itself over a continuous surface at different scales.</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>An &ldquo;exterior face of the matrix&rdquo; means the face that is adjacent to the mold during formation of the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>&ldquo;Porogen,&rdquo; as used herein, means a non-gaseous material that is soluble in at least one solvent and sparingly soluble in at least one solvent, that is combined with a material to form a mixture, then removed from the mixture to leave voids.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>&ldquo;Sparingly soluble&rdquo; describes a material that, under the conditions of processing, has a solubility of less than 30% by weight in the given solvent, and preferably has a solubility of less than 20% by weight, less than 10% by weight, or less than 2% by weight.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>&ldquo;Non-solvent,&rdquo; as used herein, describes a solvent in which a given material is insoluble or sparingly soluble.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>&ldquo;Hydrophilic&rdquo; describes a material that has a solubility of at least 0.5% by weight in water.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>&ldquo;Microspheres&rdquo; describe objects having an average diameter of about 2 &mgr;m to about 100 &mgr;um. They are composed of synthetic polymers, biological polymers, or blends or combinations thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>&ldquo;Bioactive agent&rdquo; describes a substance that has a physiological or biological effect on a cell, tissue, organ, or other living structure.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>&ldquo;Biodegradable&rdquo; means capable of being broken down into innocuous products when placed within a living system, such as a cell culture system, or a living organism, such as a human or animal, or when exposed to bodily fluids.</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>&ldquo;Bioerodible&rdquo; means capable of being dissolved or suspended in biological fluids.</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>&ldquo;Bioresorbable&rdquo; means capable of being absorbed by the cells, tissue, or fluid in a living body.</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>&ldquo;Bioerodes at substantially the same rate that cells populate&rdquo; means that an object, such as a matrix, bioerodes&mdash;that is, is dissolved or suspended in biological fluids&mdash;at the same rate that cells grow and produce extracellular matrix (ECM), so that the total volume of the matrix material, the cells, and the ECM within the matrix remains substantially constant.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>&ldquo;Substantially constant,&rdquo; when referring to the total volume of the matrix material, the cells, and the extracellular matrix within the matrix, means a change in the total volume of less than 25%, and preferably less than 15%, or 5%. &ldquo;Impermeable,&rdquo; as used herein, means that cells can migrate into the material to a depth of less than 200 &mgr;m. &ldquo;Three-dimensional,&rdquo; as used herein, means that the smallest dimension of an object (e.g., length, width, or depth) is at least 100 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>&ldquo;Non-friable&rdquo; means that when cut, the portions separate into masses with a total loss of materials to flaking or powdering being less than 5% of the total mass of the material.</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>The matrices of the invention offer several advantages over existing matrices. The porous nature of the matrices and the high surface areas provide an environment that is permissive to cell ingrowth. In addition, the highly interconnected structure of the matrices provides them with mechanical strength.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>The methods of the invention provide convenient, cost-effective ways to prepare porous polymer matrices. In addition, the methods of the invention provide novel ways to alter physical properties of the matrices.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00098" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT> is a schematic representation of a mold used to make matrices of the invention; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1B</PDAT></FGREF><PDAT> is a schematic representation of the three permanently connected sides of the mold; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1C</PDAT></FGREF><PDAT> is a schematic representation of four sides of the mold, with one side being connected by means of screws; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1D</PDAT></FGREF><PDAT> is a schematic representation of the top of the mold and the sides of the mold; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1E</PDAT></FGREF><PDAT> is a schematic representation of the top of the mold.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a photograph of a matrix of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT> is a schematic representation of a curve; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3B</PDAT></FGREF><PDAT> is a schematic representation of a surface.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4A</PDAT></FGREF><PDAT> is a schematic representation of the matrix of the invention showing a meridional curve; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4B</PDAT></FGREF><PDAT> is a schematic representation of a cross section of the matrix, showing the minimum and maximum diameters.</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5A and 5B</PDAT></FGREF><PDAT> are photographs of the matrix of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6A</PDAT></FGREF><PDAT> is a schematic representation of a curve with a fractal dimension of zero; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6B</PDAT></FGREF><PDAT> is a schematic representation of a curve with a fractal dimension of 1; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6C</PDAT></FGREF><PDAT> is a schematic representation of a curve with a fractal dimension of 2; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6D</PDAT></FGREF><PDAT> is a schematic representation of a curve with a fractal dimension of 3.</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a schematic representation of a partly filled mold.</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is an electron spectroscopy chemical analysis spectrum of the surface of a matrix of the invention showing carbon and oxygen content.</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> is a schematic representation of the process used to grow cell and polymer constructs.</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 10A and 10C</PDAT></FGREF><PDAT> are photographs of cross sections of a conventional bovine bone marrow cell and PGA mesh construct. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 10B and 10D</PDAT></FGREF><PDAT> are photographs of cross sections of a bovine bone marrow cell and PLA/PEG matrix construct made with matrices of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 11A-11C</PDAT></FGREF><PDAT> are photographs of matrices of the invention with cells. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11A</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine bone marrow stromal cell and PLA matrix construct; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11B</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine bone marrow stromal cell and PLA matrix construct grown in the presence of &bgr;-glycerophosphate and dexamethasone; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11C</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine bone marrow stromal cell and PLA/PEG/calcium carbonate matrix construct grown in the presence of &bgr;-glycerophosphate and dexamethasone.</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT> is a photograph of a cross section of a human bone marrow stromal cell and PLA/PEG construct made with a matrix of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13A</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine chondrocyte and PLA/PEG construct made with a matrix of the invention; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 13B</PDAT></FGREF><PDAT> is a photograph of a cross section of a conventional bovine chondrocyte and PGA mesh construct.</PDAT></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 14A-14C</PDAT></FGREF><PDAT> are photographs of matrices of the invention with cells. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14A</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine chondrocyte and PLA matrix construct; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14B</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine chondrocyte and PLA/PEG (80:20) matrix construct; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14C</PDAT></FGREF><PDAT> is a photograph of a cross section of a bovine chondrocyte and PLA/PEG (60:40) matrix construct.</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 15A</PDAT></FGREF><PDAT> is a photograph of a PLA scaffold of the invention in the shape of a human nose; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 15B</PDAT></FGREF><PDAT> is a photograph of the same scaffold two weeks after bovine chondrocytes were added.</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 16</PDAT></FGREF><PDAT> is a graph showing mechanical properties of polymer and polymer blend matrices.</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 17</PDAT></FGREF><PDAT> is a graph showing ALP release from a PLA/PEG matrix.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DESCRIPTION OF THE PREFERRED EMBODIMENTS</PDAT></STEXT></H>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>The matrices of the invention have a porous macrostructure and preferably have a porous microstructure. They are easy to prepare and have a number of unique properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="7"><PTEXT><PDAT>Methods for Preparing Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>The matrices are prepared by dissolving a polymer in a suitable solvent (referred to as a polymer solvent), then adding solid particles of a material that is insoluble or sparingly soluble in the polymer solvent (the solid particles are referred to herein as porogens) at a temperature at which the particles are blended with the polymer solution, and combining to form a slurry having a consistency ranging between that of a viscous liquid and that of a paste. The viscosity of the polymer/particle blend will vary depending on the types of polymer used, the solvent, and the temperature. Preferably, the polymer solution includes between 50 and 250 grams of polymer per liter of solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>The slurry is then shaped by being molded or extruded. The shaped slurry is treated with a solvent in which the porogen is soluble, and in which the polymer is insoluble or sparingly soluble (referred to as the porogen solvent). The polymer precipitates in this solvent; at the same time, the porogen is extracted from the mixture. Preferably, the amount of solvent used to extract the particles is more than the minimal amount of solvent required to dissolve the particles at the temperature at which the particles are extracted.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>The precipitated polymer forms a continuous, preferably interconnected or reticulated, porous network. The simultaneous precipitation/extraction gives the polymer matrix unique properties. After the initial extraction of the solid particles, the matrix can be subjected to additional extractions to remove residual porogen. The extractions can be done, for example, in a beaker, or in a Soxhlet extraction apparatus. The additional extraction steps, and the continuous nature of the voids, help to ensure that essentially all of the porogen is removed from the finished matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>Alternatively, the polymer/polymer solvent/porogen slurry can be formed by dissolving a polymer in a solvent, then depositing this solution around porogen particles using a free form fabrication technique, such as three-dimensional printing. For example, the slurry can be shaped using the three-dimensional printing techniques described in Cima et al., U.S. Pat. No. 5,518,680, entitled &ldquo;Tissue Regeneration Matrices by Solid Free Form Fabrication Techniques.&rdquo;</PDAT></PTEXT></PARA>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>The method is extremely versatile. The precipitation/extraction step can take place at any temperature at which the polymer does not melt, degrade, or, in the case of proteins, denature. Low temperature extractions, for example, using supercritical fluids such as liquid carbon dioxide, may be preferred for certain applications.</PDAT></PTEXT></PARA>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>The method can be used to generate matrices of a wide variety of shapes and sizes, including three-dimensional matrices. In addition, the method can be scaled up simply by increasing the amounts of polymer, polymer solvent, porogen, and porogen solvent used, and by using a larger mold. The method is advantageous because polymer matrices can be prepared in a relatively short period of time.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><PDAT>Any polymer that is soluble in at least one solvent can be used to make the matrices of the invention. The polymers can be water soluble or insoluble; biodegradable or non-biodegradable; natural or synthetic. Biodegradable polymers are preferred for tissue engineering applications. Synthetic polymers are preferred for this application as well, since they degrade in a more reproducible manner than natural polymers.</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>Synthetic polymers which can be used in the present invention include poly(hydroxy acids) such as poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers)polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides such as poly(ethylene oxide) (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) (jointly referred to herein as &ldquo;polyacrylic acids&rdquo;), and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, poly(propylene fumarate), polyoxymethylene, and poloxamers.</PDAT></PTEXT></PARA>
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>The polymers can optionally include one or more photopolymerizable groups. The polymers can also be derivativatized. For example, the polymers can have substitutions such as alkyl groups, alkylene groups, or other chemical groups. The polymers can also be hydroxylated oxidized, or modified in some other way familiar to those skilled in the art. Blends and co-polymers of these polymers can also be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>Preferred non-biodegradable polymers include ethylene vinyl acetate, polyacrylic acids, polyamides, and copolymers and blends thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>Preferred biodegradable polymers include poly(hydroxy acids) such as PLA, PGA, PLGA, and copolymers with PEG; polyanhydrides, poly(ortho)esters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, and the polymers described in Hubbell et al., U.S. Pat. Nos. 5,654,381; 5,627,233; 5,628,863; 5,567,440; and 5,567,435. In general, these materials degrade in vivo by both non-enzymatic and enzymatic hydrolysis, and by surface or bulk erosion.</PDAT></PTEXT></PARA>
<PARA ID="P-00128" LVL="0"><PTEXT><PDAT>Preferred water-soluble polymers include polyethylene oxides, polyethylene glycols, ethylene oxide-propylene oxide copolymers (poloxamers and poloxamines), polyvinyl alcohols, polyvinylpyrrolidones, poly(acrylic acids), and copolymers and blends thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>Natural polymers that can be used in the invention include polysaccharides such as alginate, dextran, and celluloses; collagens, including derivatized collagens (e.g., alkylated, hydroxylated, oxidized, or PEG-lated collagens, as well as collagens modified by other alterations routinely made by those skilled in the art); hydrophilic proteins such as albumin; hydrophobic proteins such as protamines, and copolymers and mixtures thereof. In general, these materials degrade by enzymatic hydrolysis, by exposure to water in vivo, or by surface or bulk erosion.</PDAT></PTEXT></PARA>
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>Preferred bioadhesive polymers include polyanhydrides and polyacrylic acids. In one embodiment, reactive groups on the polymers, for example, hydroxy, amine, carboxylic acid, thiol, anhydride, ester and vinyl groups, are reacted with reactive groups on agents to be incorporated into the polymer matrix. For example, bioactive compounds such as proteins contain reactive amine groups which can be coupled with reactive carboxylic acid, ester, or anhydride groups on the polymer to form polymers that are covalently bonded to the compounds. In another embodiment, ion pairs are formed between acidic or basic groups on a polymer and basic or acidic groups on a bioactive compound to form a polymer that is ionically bonded to the compounds. Those of skill in the art can readily determine an appropriate bioactive compound and polymer to couple by forming ionic or covalent bonds, and can also readily determine appropriate reaction conditions for forming such bonds.</PDAT></PTEXT></PARA>
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>One factor to be considered when selecting an appropriate polymer is the time required for in vivo stability, i.e., the time in which the polymer matrix is required to degrade, in those embodiments in which the matrix is used in vivo. Preferably, the polymer matrix exhibits an in vivo stability between approximately a few minutes and one year. When used for drug delivery, the in vivo stability is preferably between a few hours and two months. When used for tissue engineering, the in vivo stability is preferably between one week and several months.</PDAT></PTEXT></PARA>
<PARA ID="P-00132" LVL="0"><PTEXT><PDAT>Preferred polymers have a molecular weight of at least 40,000 daltons.</PDAT></PTEXT></PARA>
<PARA ID="P-00133" LVL="0"><PTEXT><PDAT>Materials that can be used as porogens include waxes, such as paraffin, bees wax, and carnuba wax, and wax-like substances, such as low melting or high melting low density polyethylene (LDPE), and petroleum jelly. Other materials include hydrogels such as PEG, alginate, bone wax (fatty acid dimers), fatty acid esters such as mono-, di-, and tri-glycerides, cholesterol and cholesterol esters, and naphthalene. In addition, synthetic or biological polymeric materials such as proteins can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00134" LVL="0"><PTEXT><PDAT>The particles are in a solid state, rather than a liquid or fluent state; the particles may be porous solid particles. The particles must be insoluble or sparingly soluble in the polymer solvent at the temperature at which the polymer and the particles are blended. The particles must also be soluble in a solvent in which the polymer is insoluble or sparingly soluble, and in which the polymer precipitates at the temperature at which the particles are extracted.</PDAT></PTEXT></PARA>
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>The size of the porogen particles used in the invention is preferably less than 5000 &mgr;m, and is more preferably between 500 and 5000 &mgr;m, or 25 and 500 &mgr;m. Particles of the desired size can be prepared, for example, by cryo-milling the particles. Cryo-milling involves cooling the solid material to a suitable temperature, i.e., one at which the particles will not melt during the milling process, and milling the particles. The material can be cooled, for example using coolants such as liquid nitrogen, liquid carbon dioxide, and dry ice. For example, wax can be cooled in liquid nitrogen, and then milled to the desired particle size. Alternatively, liquid material (i.e., dissolved or melted) can be sprayed into a non-solvent for the material, and the particle size can be controlled by controlling the size of the droplets. Suitable solvents include acetone, ethyl acetate, dimethylsulfoxide (DMSO), dimethylformamide (DMF), water, ethers, glymes, glycerol, ethylene glycol, xylene, chloroform, methylene chloride, toluene, and alcohols. In one embodiment, liquid material is sprayed into a coolant, such as liquid nitrogen.</PDAT></PTEXT></PARA>
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>The polymer solvents are solvents in which the polymer dissolves, and in which the solid particles are insoluble or sparingly soluble. The solvent used will depend on the type of polymer and the type of solid particles. For example, some polymers are soluble in halogenated solvents, such as methylene chloride, chloroform, carbon tetrachloride, dichloroethane, trichloroethylene, and hexafluoroisopropanol. Water-soluble polymers can be dissolved or dispersed in water or relatively polar organic solvents such as alcohols, ethyl acetate, acetone, dimethylsulfoxide, dimethylformamide, ethers, glymes, phenols, and chloroform. Those of skill in the art can readily determine an appropriate solvent for dissolving a polymer, in which the solid particles are insoluble or sparingly soluble. The solvent is preferably volatile, so that remaining solvent can be removed while the matrix is formed, or after the matrix is formed. Preferred polymer solvents include xylene, acetone, and halogenated solvents such as dichloromethane(methylene chloride), chloroform, carbon tetrachloride, dichloroethane, trichloroethane, and hexafluoroisopropanol.</PDAT></PTEXT></PARA>
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>Examples of suitable porogen solvents include hydrocarbon solvents such as pentanes, hexanes, heptanes, octanes, benzene, toluene, xylenes, cresols, and vegetable oils. Another suitable solvent is petroleum ether. Volatile solvents are preferred in most embodiments, because residual amounts of these solvents can be readily removed from the resulting polymer matrix once the wax has been extracted.</PDAT></PTEXT></PARA>
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>The following table summarizes examples of a number of polymers, polymer solvents, porogens, and porogen solvents that can be used in combination.</PDAT></PTEXT></PARA>
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>This table is meant to illustrate combinations that can be used in the present invention, and is not intended to be limiting.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Combinations of Polymer, Polymer Solvent, Porogen,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>and Porogen Solvent</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="49pt" align="left"/>
<colspec colname="2" colwidth="56pt" align="left"/>
<colspec colname="3" colwidth="56pt" align="left"/>
<colspec colname="4" colwidth="56pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Polymer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Polymer Solvent</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Porogen</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Porogen Solvent</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>polylactide,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone, ethyl</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyglycolide</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetate,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>methylene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>chloride,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>chloroform,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>hexafluoro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>isopropanol,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>chlorinated</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>aromatic</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>hydrocarbons</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyglycolic</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexafluoro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PLA, PGA, PCL,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>acid (PGA)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>isopropanol</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PS, PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(amorphous)</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyglycolic</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexafluoro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>acid (PGA)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>isopropanol</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(amorphous)</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>poly(&egr;-capro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>chlorinated</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>lactone) (PCL)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons or</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>tetrahydrofuran</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>(THF)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>poly(methyl</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>methacrylate)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tetrahydrofuran,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(PMMA),</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>chlorinated and</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polycarbonate,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>fluorinated</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polystyrene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aliphatic</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>hydrocarbons</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglyccrides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>poly(vinyl-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone, ethyl</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>chloride), poly</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>methyl ketone,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(vinylidine-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>diethyl ketone</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>difluoride</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyvinyl</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>water, ethanol</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>alcohol</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aromatic</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone, mixtures</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>thereof,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyethylene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>water, methylene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>glycol,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>chloride,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyethylene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>chloroform,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aromatic</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>oxide</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ethanol, propanol,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>hexafluoroisopro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone, mixtures</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>panol</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>thereof,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>linear</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>tetrahydrofuran,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hexane, pentane,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polyurethane</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>methylene</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>other aliphatic</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>chloride,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>hydrocarbons,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>chloroform,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>hexafluoroisopro-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>panol</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cbolesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>biopolymers</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>water, buffers</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>paraffin, wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>acetone,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(collagen,</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>bees wax,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>petroleum ether</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>polysugars,</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>carnuba wax,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>hyaluronic</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>petroleum jelly,</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>acid)</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>monoglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>diglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>triglycerides,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>cholesterol esters</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the solid particles are wax particles and the polymer is both soluble in a first solvent that does not dissolve the wax particles, and is insoluble or sparingly soluble in, and precipitates from, a second solvent that dissolves the wax particles. In another embodiment, the solid particles are soluble in water-miscible organic solvents but are insoluble or sparingly soluble in water, and the polymer is soluble in water but is insoluble or sparingly soluble in and precipitates from water-miscible organic solvents. Preferred polymers for this embodiment are polyethylene glycol, polyvinyl pyrrolidone, polyvinyl alcohols, water-soluble proteins, and polysaccharides. In still another embodiment, the solid particles are soluble in water or chlorinated organic solvents but are insoluble or sparingly soluble in water-miscible organic solvents, and the polymer is soluble in water-miscible organic solvents but is insoluble in and precipitates from water or chlorinated organic solvents.</PDAT></PTEXT></PARA>
<PARA ID="P-00141" LVL="0"><PTEXT><PDAT>In an alternative embodiment, particles of salt can also be incorporated into the polymer/particle blend, and the salt particles can be leached out in a separate step than the step in which the solid particles are extracted. This embodiment can provide additional control of the pore size and density of the polymer matrices. Preferably, water-soluble polymers are not used in this embodiment.</PDAT></PTEXT></PARA>
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>In some applications, the slurry of polymer/polymer solvent/porogen is compacted into a mold before the extraction/precipitation step. The mold plays a critical role, as it allows the mixture to maintain its shape and size during the extraction/precipitation step. It is important that at least part of the mold have holes so that the porogen solvent can penetrate the mold during the extraction/precipitation step.</PDAT></PTEXT></PARA>
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>The mold may be made of a variety of materials, including Teflon&reg;, high density polyethylene (HDPE), polypropylene, stainless steel (either regular or hardened), or aluminum. If the mold is made of a material other than Teflon&reg;, it is preferable that the mold is coated with silicone, Teflon&reg; or some other non-stick material, to aid in the removal of the polymer matrix after the extraction/precipitation step.</PDAT></PTEXT></PARA>
<PARA ID="P-00144" LVL="0"><PTEXT><PDAT>An example of a mold is shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 1A-1E</PDAT></FGREF><PDAT>. The outer dimensions of the mold are about 1.60&times;1.60&times;1.85 cm. The mold defines an inner opening having dimensions of about 1.0&times;1.0&times;1.0 cm. The mold has six sides, each side having holes with diameters of 0.95 mm, placed 0.10 cm apart. Three sides of the mold are permanently connected, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1B. A</PDAT></FGREF><PDAT> fourth side of the mold can be attached to the three connected sides by means of screws, as shown in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>C. The top of the mold can be held in place by placing the holes in the fifth side over the guide-pins which protrude from the sides of the mold, as shown in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>D. The bottom of the mold can be held in place by placing the holes in the top over the guide-pins in the sides of the mold, as well. The top of the mold is shown in more detail in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>E.</PDAT></PTEXT></PARA>
<PARA ID="P-00145" LVL="0"><PTEXT><PDAT>Other molds can have a wide variety of sizes and shapes. For example, molds as large as 1.0&times;1.0&times;1.0 inch have been used to make the matrices of the invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>Once the porous polymer matrices are formed, they can be shaped by methods known to those of skill in the art for shaping solid objects. For example, the matrices may be shaped by laser ablation, micromachining, use of a hot wire, and by CAD/CAM (computer aided design/computer aided manufacture) processes.</PDAT></PTEXT></PARA>
<PARA ID="P-00147" LVL="0"><PTEXT><PDAT>In one embodiment, a CAT-scan image is taken of a region of tissue and the image is digitized. This digitized image can then be used in combination with one or more techniques such as CAD/CAM or laser ablation to create a scaffold of a desired shape. This scaffold can then be used as a template for the regeneration of the desired tissue.</PDAT></PTEXT></PARA>
<PARA ID="P-00148" LVL="0"><PTEXT><PDAT>Complex patterns can be produced using laser ablation or laser etching to produce desired shapes. The matrix can also be formed into the desired shape by molding or by extruding. Alternatively, the matrix can be shaped by carving a finished matrix with a blade. The matrix material can be carved easily, as it is generally non-friable.</PDAT></PTEXT></PARA>
<PARA ID="P-00149" LVL="0"><PTEXT><PDAT>The desired shape of the matrix will depend on the particular application. For example, the matrix can be shaped into tubular structures by using a tube-shaped mold or by using a cylindrical mold, then carving out the inside of the cylinder. Tubular matrices are useful for vascular grafts and for intestinal and urethral grafts.</PDAT></PTEXT></PARA>
<PARA ID="P-00150" LVL="7"><PTEXT><PDAT>Properties of the Porous Polymer Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00151" LVL="0"><PTEXT><PDAT>The simultaneous precipitation of the polymer and extraction of the porogen, as described above, gives the polymer matrix of the invention unique properties. The matrix has a macrostructure that includes a highly interconnected, irregularly shaped porous network, as shown in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>. The porosity of the matrix allows for tissue ingrowth into the matrix, and for the matrix to dissolve as the tissue heals.</PDAT></PTEXT></PARA>
<PARA ID="P-00152" LVL="0"><PTEXT><PDAT>The pore size and density of the polymer matrix is controlled by adjusting the size of the solid particles, the viscosity of the polymer/particle blend, and the ratio of polymer to solid particles in the blend. The pore size is roughly the same as the size of the solid particles used to prepare the matrices, and is preferably between about 25 and 500 &mgr;m.</PDAT></PTEXT></PARA>
<PARA ID="P-00153" LVL="0"><PTEXT><PDAT>The network is generally smooth, i.e., there are very few sharp edges and few acute angles. In addition, the curvature of the network is low. Curvature is defined as follows, referring to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 3A and 3B</PDAT></FGREF><PDAT>. Curvature of a plane curve at a point C is a smooth curve lying in the (x,y)-plane; P is a point on C. The orientation of C is indicated by the arrow. At any point Q of C one can define the direction of C at Q to be the angle of the curve to the horizontal as it passes through the point Q. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT> the angles for Q, P and R are approximately 45&deg;, 90&deg; and 210&deg;, respectively. The curvature of C at P is the rate of change of this angle with respect to the distance moved along the curve from P.</PDAT></PTEXT></PARA>
<PARA ID="P-00154" LVL="0"><PTEXT><PDAT>In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT>, close to Q, the curve turns a full 90&deg; over the space of about 10 mm (indicated by hatch-marks in the curve). Since the direction decreases as one moves along the curve in the positive direction, the curvature is</PDAT></PTEXT></PARA>
<PARA ID="P-00155" LVL="0"><PTEXT><F><PTEXT><PDAT>&minus;90&deg;/10 mm&equals;&minus;9 degrees per mm;</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00156" LVL="7"><PTEXT><PDAT>At R, the curvature is close to 0 degrees per mm.</PDAT></PTEXT></PARA>
<PARA ID="P-00157" LVL="0"><PTEXT><PDAT>The curvature of a surface at a point is defined as follows. In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3B</PDAT></FGREF><PDAT>, S is a smooth surface, and P is a point on S. L is the straight line which passes through P and is perpendicular to the surface at P. Any flat plane containing L will intersect the surface in a smooth curve C, which passes through P, and this smooth plane curve C will have some curvature value at P, as defined above. The curvature of S is the maximal magnitude of curvature obtained and is expressed in units of degrees per unit length. Curvature is further described in Bronstein and Somendyayev, </PDAT><HIL><ITALIC><PDAT>Handbook of Mathematics </PDAT></ITALIC></HIL><PDAT>553-554, 566-568 (1985).</PDAT></PTEXT></PARA>
<PARA ID="P-00158" LVL="0"><PTEXT><PDAT>A cross-section can be drawn through a portion of the semi-solid network of the matrix by drawing a meridional curve </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> on the exterior surface of that portion, as shown in FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>A. The minimum diameter </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> of a cross section is the shortest straight line that can be drawn that joins two edges of the cross-section and passes through the center of the cross-section, as shown in FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>B. The maximum diameter </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> is the longest straight line that can be drawn that joins two edges of the cross-section. The diameter of a cross-section is the mean of the minimum and maximum diameters. The cross-sections of the network preferably have minimum and maximum diameters that have a ratio of 1:1 to 10:1, and more preferably have a ratio of 1:1 to 4:1, or 1:1 to 2:1; i.e., the cross-sections are roughly circular in shape.</PDAT></PTEXT></PARA>
<PARA ID="P-00159" LVL="0"><PTEXT><PDAT>The network is continuous, rather than being made up of discrete fibers that come into contact with each other, but are not actually connected. A line can be drawn from one point on the surface to another point without leaving the surface of the semi-solid network and without crossing a void.</PDAT></PTEXT></PARA>
<PARA ID="P-00160" LVL="0"><PTEXT><PDAT>The network is highly connected as well. Connectivity is determined as follows. The matrix may be &ldquo;cut&rdquo; in various places. For the purposes of this invention, a &ldquo;cut&rdquo; is defined as any cut that passes through the semi-solid network of the matrix but does not pass through a void of the matrix. The connectivity number is defined to be the number of cuts that must be made in order to guarantee that the matrix is separated into at least two disjoint pieces. A high connectivity number means that the network is connected to itself in a large number of places; this property helps the network to maintain its shape and mechanical properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00161" LVL="0"><PTEXT><PDAT>The connectivity number must be defined in terms of the overall size and the pore size of the matrix. For example, a cubic matrix that has dimensions of about 0.5 cm on all sides and has voids defining openings with an average diameter of 50-500 &mgr;m preferably has a connectivity number of at least 10, and more preferably has a connectivity number of at least 20.</PDAT></PTEXT></PARA>
<PARA ID="P-00162" LVL="0"><PTEXT><PDAT>The matrix also has irregularly shaped open spaces, referred to as pores or voids, that define openings throughout the network. The ratio of the size of the voids (defined as the average of the diameters of the voids) and the size of cross-sections of the semi-solid portions (defined as the average of the diameters of the cross sections) is about 2:1 to 10:1. In general, the voids are connected, so that the matrix actually has one substantially continuous opening, rather than discrete voids. The continuity of the voids allows fluids to move throughout the matrix easily.</PDAT></PTEXT></PARA>
<PARA ID="P-00163" LVL="0"><PTEXT><PDAT>The semi-solid network of the macrostructure itself is preferably porous, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5A and 5B</PDAT></FGREF><PDAT>. The voids contained within the network make up the microstructure of the matrix. The voids of the microstructure are different in character than the voids of the macrostructure. While the voids of the macrostructure are substantially continuous, the voids of the microstructure are not necessarily connected. In addition, the voids of the microstructure have a fractal dimension, i.e., the voids are connected to smaller voids, which are in turn connected to smaller voids.</PDAT></PTEXT></PARA>
<PARA ID="P-00164" LVL="0"><PTEXT><PDAT>A fractal can be constructed by using an iterative process consisting of an initiator (initial state) and a generator (iterative operation). The fractal is constructed as follows. At iteration zero, the curve is a straight line (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>A). At the first iteration, the straight line (initiator) is replaced by the generator, and the curve thus coincides with the generator (FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>B). The curve has a fractal dimension of 1. At the second iteration, shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6C</PDAT></FGREF><PDAT>, each straight line is again replaced by the generator. The curve has a fractal dimension of 2. The third iteration (fractal dimension 3) is shown in FIG. </PDAT><HIL><BOLD><PDAT>6</PDAT></BOLD></HIL><PDAT>D. Fractals are further described in J. Gouyet, </PDAT><HIL><ITALIC><PDAT>Physics and Fractal Structures</PDAT></ITALIC></HIL><PDAT>, ch. 1 (1996).</PDAT></PTEXT></PARA>
<PARA ID="P-00165" LVL="0"><PTEXT><PDAT>Although the example shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 6A-6D</PDAT></FGREF><PDAT> illustrates a curve with segments of equal length, the segments of a fractal do not necessarily have to be the same length for the purposes of the present invention. For bone applications, the initiator of the fractals of the invention have a length of at least 100 nm. In a preferred matrix, at least 10% of the voids of the microstructure will have a fractal dimension of at least 3, while less than 10% of the voids of the macrostructure have a fractal dimension higher than 1.</PDAT></PTEXT></PARA>
<PARA ID="P-00166" LVL="0"><PTEXT><PDAT>In some embodiments, the voids of the macrostructure and the microstructure are connected. These matrices are useful in applications where it is useful for the extracellular matrix to penetrate the microstructure, thus providing additional mechanical strength to the matrix. They are also useful in applications in which nutrient flow and cell migration are important. In other embodiments, the voids of the macrostructure and microstructure are not generally connected to each other; i.e., the microstructure is largely composed of discrete voids. Preferably, at least 90% of the microstructure voids are completely surrounded by macrostructure. These matrices are useful in applications where an additive is contained within the voids of the microstructure, and controlled delivery of the additive is desired.</PDAT></PTEXT></PARA>
<PARA ID="P-00167" LVL="0"><PTEXT><PDAT>The matrices have high degrees of porosity as well. The porosity is calculated by the following equation:</PDAT></PTEXT></PARA>
<PARA ID="P-00168" LVL="0"><PTEXT><F><PTEXT><PDAT>Porosity(</PDAT><HIL><ITALIC><PDAT>P</PDAT></ITALIC></HIL><PDAT>)&equals;(1&minus;&rgr;</PDAT><HIL><SB><PDAT>rel</PDAT></SB></HIL><PDAT>)&times;100</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00169" LVL="7"><PTEXT><PDAT>where &rgr;</PDAT><HIL><SB><PDAT>rel </PDAT></SB></HIL><PDAT>is defined as the ratio of the density of the matrix to the density of the base material (polymer). The density of the matrix is obtained by dividing the mass (grams) of the cellular material by the volume (cc or cm</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>) of the material. (Conversion: 1 kg/m</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>&equals;1 mg/cc). Alternatively, the density can be determined by helium pycnometry. The matrices of the invention have porosities as high as 90%, and preferably have porosities as high as 92%, or 95%.</PDAT></PTEXT></PARA>
<PARA ID="P-00170" LVL="0"><PTEXT><PDAT>When conventional techniques are used to measure porosity, the matrices containing additive will in some cases have a measured porosity that is lower than a corresponding matrix made without the additive. This result is seen because the additive occupies some of the void space.</PDAT></PTEXT></PARA>
<PARA ID="P-00171" LVL="0"><PTEXT><PDAT>The degree to which a matrix containing an additive will have a measured porosity that is lower than the actual porosity (keeping in mind that even when additives occupy void space, the spaces are still calculated as being voids) depends on the additive used. Very dense additives with small particle sizes tend to decrease porosity less, as they do not fill much volume and in many cases are contained within the semi-solid network. Even when these additives are used, the measured porosities can be as high as 90%.</PDAT></PTEXT></PARA>
<PARA ID="P-00172" LVL="0"><PTEXT><PDAT>The exterior face of the matrix, i.e., the face that is adjacent to the mold wall during formation of the matrix, is porous as well; there is no &ldquo;skin&rdquo; covering this face of the matrix. Since the exterior face of the matrix is porous, fluids and some solids can easily penetrate the matrix. The porosity of the macrostructure of the matrix also allows for the diffusional transport of metabolites between the matrix implant and the surrounding tissue, as well as the vascularization and ingrowth of tissue.</PDAT></PTEXT></PARA>
<PARA ID="P-00173" LVL="0"><PTEXT><PDAT>The porous microstructure of the matrix provides an environment that is permissive to cell proliferation, cell differentiation, and deposition of an extracellular matrix. As the semi-solid portion of the matrix degrades, the voids of the porous microstructure become exposed to the mass of dividing and developing cells. The cells can then grow into the void space and produce extracellular matrix; the extra space allows the cells to develop in their natural shapes, rather than constrained shapes.</PDAT></PTEXT></PARA>
<PARA ID="P-00174" LVL="0"><PTEXT><PDAT>The high degree of porosity also means that the matrices have low densities. Matrices composed essentially of polymer (i.e., containing no 20 additives) have densities in the range of 0.100 g/cc to 0.700 g/cc. Preferred matrices have densities of less than 0.150 g/cc, and preferably have densities of less than 0.120 g/cc. Low densities are important for applications in which a light-weight structure is desirable. Examples include construction materials and materials used for tissue engineering.</PDAT></PTEXT></PARA>
<PARA ID="P-00175" LVL="7"><PTEXT><PDAT>Preparation of Porous Fibers</PDAT></PTEXT></PARA>
<PARA ID="P-00176" LVL="0"><PTEXT><PDAT>Porous fibers can be prepared by extruding the polymer/polymer solvent/porogen slurry into hexane. For example, the slurry can be loaded into a syringe and injected into a container of hexane, or some other porogen solvent. As the slurry comes into contact with the hexane, the polymer precipitates and forms a fiber.</PDAT></PTEXT></PARA>
<PARA ID="P-00177" LVL="0"><PTEXT><PDAT>Due to the extrusion process, the pores of the fiber are elongated and oriented in the same direction, i.e., in the longitudinal direction of the fiber. This orientation is useful in applications such as cardiac tissue repair, muscle repair, and tendon repair.</PDAT></PTEXT></PARA>
<PARA ID="P-00178" LVL="0"><PTEXT><PDAT>Preferred polymers for preparing porous fibers, and, particularly, porous sutures, are biodegradable polymers such as polylactide, polyglycolide, polyorthoesters, poly(ester amides), polyanhydrides, polydioxanones, polycarbonates, and copolymers and blends thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00179" LVL="7"><PTEXT><PDAT>Methods for Preparing Blends</PDAT></PTEXT></PARA>
<PARA ID="P-00180" LVL="0"><PTEXT><PDAT>Matrices containing blends of polymers are prepared using a variation of the method described above. The polymers are combined before the polymer solvent is added. A polymer solvent that dissolves both polymers is used. For example, when PLA, PGA, PLGA, PEG, and poloxamers are used to make blends, methylene chloride, chloroform, acetone, dimethylformamide, dimethyl sulfoxide, dioxane, N-methyl pyrrolidine, or hexafluoroisopropanol can be used as the solvent. In addition, solvent mixtures of water/acetone, acetone/dimethyl sulfoxide, acetone/dimethylformamide, and acetone/dioxane can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00181" LVL="7"><PTEXT><PDAT>Properties of Polymer Blend Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00182" LVL="0"><PTEXT><PDAT>One advantage of using polymer blends is that properties, such as mechanical strength and degradation rate, can be controlled by altering the ratio of the polymers in the blend. Particularly useful blends include those of water insoluble polymers and water soluble polymers. The mechanical properties and degradation rates of the matrices can be controlled, independently of porosity, by altering the relative amounts of the two different polymers; matrices that contain higher relative amounts of water soluble polymers will degrade faster than matrices containing lower amounts of water soluble polymers.</PDAT></PTEXT></PARA>
<PARA ID="P-00183" LVL="0"><PTEXT><PDAT>Examples of water soluble polymers that can be used include PEO, PEG, PVA, the polymers described in Hubbell et al., U.S. Pat. Nos. 5,626,863; 5,567,440; and 5,567,435, and di- and triblock copolymers of polypropylene oxide and polyethylene oxide, generically referred to as poloxamers (available from BASF under the trade name Pluronics&reg;). These water soluble polymers can be blended with water insoluble polymers such as PLA, PGA, PLGA, PLLGA, PCL, polycarbonate, polyethers, polyesters, and polyamides.</PDAT></PTEXT></PARA>
<PARA ID="P-00184" LVL="0"><PTEXT><PDAT>Thus, the degradation rate of a matrix can be fine-tuned using the methods of the invention. The degradation rate is important for many applications. For example, if the matrix degrades too quickly, the cells will not have proper support on which to grow. If the matrix degrades too slowly, the cells will not have enough room to grow or to produce extracellular matrix. Thus, the cells will either not multiply, or will develop with strained shapes. Matrices that degrade at the same rate that tissue ingrows into the matrix, or that tissue remodeling occurs within the matrix, can be prepared.</PDAT></PTEXT></PARA>
<PARA ID="P-00185" LVL="0"><PTEXT><PDAT>The degradation rate can also be controlled by altering the porosity of the matrix, since matrices with higher porosities generally have faster degradation rates. In many applications, however, it is advantageous to be able to alter the degradation rate without altering the porosity. Such applications include tissue engineering and scaffold based drug delivery, including applications in which the scaffold contains microspheres. The present invention thus provides a way to alter degradation rates without altering the porosities of the matrices.</PDAT></PTEXT></PARA>
<PARA ID="P-00186" LVL="0"><PTEXT><PDAT>Matrices with different mechanical properties are useful in different applications. Matrices that can withstand stress without compressing are useful in applications such as muscular and skeletal reconstruction, while matrices that compress relatively easily without breaking, and are able to return to their original size and shape, are useful in a wide variety of applications, such as cartilage repair.</PDAT></PTEXT></PARA>
<PARA ID="P-00187" LVL="0"><PTEXT><PDAT>The matrices can also contain blends of conductive polymers such as polypyrrole, polyaniline, polyacetylene, polythiophene. The resulting matrices will be conductive as well, and can be used in applications such as chromatography, EM shielding, electronics packaging, and fuel cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00188" LVL="7"><PTEXT><PDAT>Materials to be Incorporated into the Polymer Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00189" LVL="0"><PTEXT><PDAT>Various materials can be incorporated into the polymer matrices. These materials can be incorporated when the matrices are formed, or after the matrices are formed.</PDAT></PTEXT></PARA>
<PARA ID="P-00190" LVL="0"><PTEXT><PDAT>For example, catalysts can be incorporated into the polymer matrices. These catalysts can be organic catalysts, such as enzymes and porphyrin catalysts, inorganic industrial catalysts, such as zeolites and other Lewis acids, or organometallic catalysts. Exemplary enzymes include glucose oxidase, heparinase, proteases, and horseradish peroxidase. Exemplary inorganic and organometallic catalysts include zeolites, silica, alumina, oxidizing agents, reducing agents, Zeigler Natta catalysts, aluminum catalysts, nickel catalysts, and zinc catalysts.</PDAT></PTEXT></PARA>
<PARA ID="P-00191" LVL="0"><PTEXT><PDAT>Incorporation of the catalysts in polymer matrices allows them to be readily removed and reused in industrial processes, such as cracking, hydrocracking, hydrogenation, and polymerization.</PDAT></PTEXT></PARA>
<PARA ID="P-00192" LVL="0"><PTEXT><PDAT>Various cells can be seeded or adsorbed onto the porous matrices after the matrices are formed to form artificial organs. For example, skin cells, such as keratinocytes, can be seeded into the matrix for use as artificial skin. Cells from various parenchymal tissues or organs can be seeded into the matrix to form tissue equivalents with the metabolic functions(s) of the tissue from which the cells were derived. Chondrocytes can be seeded into the matrix to form ears, noses, and other cartilaginous body parts.</PDAT></PTEXT></PARA>
<PARA ID="P-00193" LVL="0"><PTEXT><PDAT>The list of cells that can be grown on the matrices of the invention also includes bone marrow cells, periosteal cells, smooth muscle cells, endothelial cells, fibroblasts, epithelial cells, tenocytes, neuronal cells, neuronal support cells (e.g., Schwann cells), hepatocytes, liver cells (e.g., Kupffer cells and fibroblasts), pancreatic islet cells, and cardiac myocytes.</PDAT></PTEXT></PARA>
<PARA ID="P-00194" LVL="0"><PTEXT><PDAT>Other therapeutic agents can be incorporated into the matrices as well. The matrices can then be used for local or systemic delivery of the incorporated agents following administration to a patient. Examples of therapeutic agents include synthetic inorganic and organic compounds, proteins (the term protein refers to both.proteins, which have at least 100 amino acid residues, and peptides, which have less than 100 amino acid residues), polysaccharides and other sugars, lipids, genetic materials that induce cell growth, cell migration, cell division, cell differentiation, and tissue growth, ribozymes and ribozyme guide sequences, and nucleic acid molecules having therapeutic, prophylactic or diagnostic activities. Nucleic acid molecules include genes, plasmid DNA, naked DNA, and antisense molecules which bind to complementary DNA to inhibit transcription.</PDAT></PTEXT></PARA>
<PARA ID="P-00195" LVL="0"><PTEXT><PDAT>Other bioactive or therapeutic agents include vasoactive agents, neuroactive agents, hormones, growth factors, cytokines, anaesthetics, steroids, anticoagulants, anti-inflammatories, immunomodulating agents, cytotoxic agents, prophylactic agents, antibiotics, antivirals, antigens, and antibodies. In some instances, antibodies or antigens would otherwise have to be administered by injection to elicit an appropriate response.</PDAT></PTEXT></PARA>
<PARA ID="P-00196" LVL="0"><PTEXT><PDAT>Other pharmaceutical compounds can also be incorporated into the matrix of the invention. The controlled degradation of the matrix allows for controlled release of the pharmaceutical agents, while the incorporation of the agent into the matrix allows for localized delivery. For example, antibiotics such as gentamycin, vancomycin, erythromycin, and safromycin can be used to treat local infections. These agents are particularly useful in treating bone infections (osteomyelitis) and in spinal fusion procedures. The analgesics lidocaine, bupivacaine, prilocaine, and procaine can be incorporated into matrices and used for local pain management. These agents are particularly useful in spinal fusion, and in bone and cartilage repair. Glucocorticoids, hydrocortisone, and other non-steroidal anti-inflammatory drugs can be incorporated into the matrices and placed in the body to treat local inflammation, especially inflammation resulting from bone repair or spinal fusion. Hormones can also be incorporated.</PDAT></PTEXT></PARA>
<PARA ID="P-00197" LVL="0"><PTEXT><PDAT>In some embodiments, the bioactive agents are contained in microspheres composed of, e.g., PGA, PLA, PLGA, PCL, di- and triblock copolymers of polypropylene oxide and polyethylene oxide, collagen, ethyl cellulose, carboxymethyl cellulose, or gelatin. The polymeric gel materials described in Hubbell et al., U.S. Pat. Nos. 5,573,934, 5,529,914, 5,380,536, and 5,232,984 can be used as well. In other embodiments, the bioactive agents are contained in microcapsules made of, e.g., polyamide or polyesters. The microspheres serve the dual purpose of protecting sensitive bioactive agents during the preparation of the polymer matrices and further controlling the release rate of the agents contained within the microspheres or microcapsules. Compounds with a wide range of molecular weight, for example, between 10 and 500,000 grams per mole, can be encapsulated.</PDAT></PTEXT></PARA>
<PARA ID="P-00198" LVL="0"><PTEXT><PDAT>Any biocompatible or pharmacologically acceptable gas can be incorporated into the particles or trapped in the pores of the particles using technology known to those skilled in the art. The term gas refers to any compound which is a gas or capable of forming a gas at the temperature at which the matrix is used. In one embodiment, retention of gas in the porous matrices is improved by forming a gas-impermeable barrier around the porous matrix. Such barriers are well known to those of skill in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00199" LVL="0"><PTEXT><PDAT>The matrices of the invention can also be used to deliver contrast agents to specific sites. For example, oxytetracycline (OTC) can be incorporated into a matrix and placed in the body to aid in bone imaging. Radioactive agents can be incorporated as well. Matrices including these agents are useful for local tissue irradiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00200" LVL="0"><PTEXT><PDAT>Other imaging agents which may be utilized include commercially available agents used in positron emission tomography (PET), computer assisted tomography (CAT), single photon emission computerized tomography, x-ray, fluoroscopy, and magnetic resonance imaging (MRI).</PDAT></PTEXT></PARA>
<PARA ID="P-00201" LVL="0"><PTEXT><PDAT>Examples of suitable materials for use as contrast agents in MRI include the gadolinium chelates diethylene triamine pentacetic acid (DTPA) and gadopentotate, dimeglumine, iron, magnesium, manganese, copper, and chromium.</PDAT></PTEXT></PARA>
<PARA ID="P-00202" LVL="0"><PTEXT><PDAT>Examples of materials useful for CAT and x-rays include iodine based materials for intravenous administration, such as the ionic monomers diatrizoate and iothalamate, the non-ionic monomers iopamidol, isohexol, and ioversol, the non-ionic dimers iotrol and iodixanol, and the ionic dimer ioxagalte. The contrast or diagnostic agents can be detected using standard techniques available in the art and commercially available equipment.</PDAT></PTEXT></PARA>
<PARA ID="P-00203" LVL="0"><PTEXT><PDAT>Additives can be incorporated into the semi-solid network to change the properties of the matrix. For example, the additives can make the matrix stronger, more flexible, or electrically conductive. Matrices including graphite, metal powders, glass fibers, or glass beads are useful as structural composites for the construction of specialty packaging. Matrices including carbon powder, graphite powder, graphite fibers, metal powders, or metal fibers are useful as porous electrodes and/or solid state electrolytes for battery and fuel cell applications, as well as for electromagnetic (EM) shielding.</PDAT></PTEXT></PARA>
<PARA ID="P-00204" LVL="0"><PTEXT><PDAT>When inorganic salts such as transition metal sulfates, carbonates, phosphates, nitrates, and sodium salts, are used as additives, the resulting matrices are useful in the production of porous ceramics. When other inorganic salts, for example, calcium carbonate, &bgr;-glycerophosphate, calcium phosphate, sodium carbonate, sodium phosphate, and large particulate hydroxyapatite, are incorporated, the resulting matrices are useful for the fabrication of osteoconductive, osteoinductive, chondroconductive, and chondroinductive scaffolds for bone and cartilage tissue engineering.</PDAT></PTEXT></PARA>
<PARA ID="P-00205" LVL="0"><PTEXT><PDAT>The additives polyethylene, polypropylene, Teflon&reg;, nylon powder, and nylon particles can be incorporated as well. The resulting matrices are useful as structural composites for the construction of specialty packaging.</PDAT></PTEXT></PARA>
<PARA ID="P-00206" LVL="0"><PTEXT><PDAT>Polymer fibers (e.g., polyethylene, polypropylene, Teflon&reg;, PGA, or nylon fibers) can be added to the matrices to provide mechanical strength and/or to alter the degradation rate of the matrix. The matrices prepared with these additives can be used as structural composites for construction or for tissue engineering.</PDAT></PTEXT></PARA>
<PARA ID="P-00207" LVL="7"><PTEXT><PDAT>Methods for Incorporating Additives</PDAT></PTEXT></PARA>
<PARA ID="P-00208" LVL="0"><PTEXT><PDAT>Matrices in which additives are incorporated into the semi-solid network are prepared using a variation of the general method described above. Preferably, the agent is incorporated into the polymer matrix by mixing particles, solutions, or suspensions of the agent with the polymer/porogen blend. This method of incorporating the agent is suitable for those agents which are not denatured when placed in contact with the polymer solvent or the porogen solvent. The additives can be contained in the semi-solid network, in the pores of the macrostructure, or in the pores of the microstructure.</PDAT></PTEXT></PARA>
<PARA ID="P-00209" LVL="0"><PTEXT><PDAT>Matrices in which the additive is incorporated into the voids of the microstructure are prepared by first incorporating the additive into the porogen material. The porogen is dissolved in a suitable solvent, and the additive is added. The mixture is stirred to distribute the additive evenly; the solvent is then allowed to evaporate. The porogen material is cryo-milled, as described above. The matrix is then prepared using the procedure described above. An excess of additive can be used in cases where some of the additive is washed out of the matrix during the porogen extraction steps.</PDAT></PTEXT></PARA>
<PARA ID="P-00210" LVL="0"><PTEXT><PDAT>The agents can also be incorporated in microparticles, preferably microparticles prepared from water-soluble polymers, which can be incorporated into the polymer matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00211" LVL="0"><PTEXT><PDAT>Materials can also be incorporated into the porous polymer matrices after the matrices have been prepared. In one embodiment, the matrices can be seeded with cells after the matrices are formed. In another embodiment, diagnostic or therapeutic agents can be incorporated into the polymer matrices by adsorption or absorption after the matrices are prepared.</PDAT></PTEXT></PARA>
<PARA ID="P-00212" LVL="0"><PTEXT><PDAT>When agents are incorporated into the polymer matrix by absorption or adsorption after the polymer matrix is prepared, a solution containing an agent to be incorporated should be prepared using a solvent that is a non-solvent for the polymer. The agent can then be adsorbed or absorbed onto the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00213" LVL="0"><PTEXT><PDAT>Methods in which the additive is contained in a microparticle, or is incorporated into the polymer matrix by after the polymer matrix is prepared, are useful in those embodiments in which the agent can be denatured or otherwise suffer a loss of activity during preparation of the polymer matrices.</PDAT></PTEXT></PARA>
<PARA ID="P-00214" LVL="0"><PTEXT><PDAT>Those of skill in the art can readily determine an appropriate amount of incorporated agents. The amount of agents to be incorporated will depend on several factors, including the types of polymers used, the porosity of the matrix, the type of agent to be delivered and the age and body weight of the patient.</PDAT></PTEXT></PARA>
<PARA ID="P-00215" LVL="0"><PTEXT><PDAT>Titanium, which provides mechanical strength, can be combined with the matrices in a number of ways. Titanium fibers, titanium powders, or titanium dioxide can be incorporated into the semi-solid network, and the network can then be cured. For example, a matrix with titanium dioxide incorporated into the semi-solid network can be cured in a reducing environment (e.g., in the presence of H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>). Matrices including these materials are useful in applications such as spinal fusion (spinal cages).</PDAT></PTEXT></PARA>
<PARA ID="P-00216" LVL="0"><PTEXT><PDAT>Alternatively, a slurry of polymer/polymer solvent/porogen can be poured or pressed into a titanium spinal cage or a titanium mesh. The entire assembly can then be subjected to the extraction procedure; the result is a titanium cage containing the matrix within the cage or a titanium mesh filled with the matrix. The titanium provides mechanical strength, while the matrix acts as a drug-delivery device and as a scaffold to support cell growth and differentiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00217" LVL="0"><PTEXT><PDAT>In yet another method, a matrix with a macrostructure having pore sizes of at least 3 mm to 1 cm, and having a reducing agent incorporated, is prepared. This mesh is plated with titanium using, for example, electrode-less plating techniques. The entire assembly is sintered, causing the polymer macrostructure to disintegrate, leaving a porous titanium macrostructure. The porous titanium structure can then be packed again with a porous polymer matrix that provides a suitable environment for cell and tissue growth, as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00218" LVL="0"><PTEXT><PDAT>Inorganic and organic reducing agents can be included in the matrices as well. When these agents are incorporated into the matrices, metals can be plated (through electrode-less plating) or deposited on the matrices by exposing the matrices to solutions of metal salts such as palladium sulfate, copper sulfate, nickel sulfate, or other metal sulfates under conditions where the metal will precipitate onto the matrix. The coated matrices can be used as high surface area solid supports for catalysis, light weight electrodes for batteries, fuel cells, and as other battery and electronic components.</PDAT></PTEXT></PARA>
<PARA ID="P-00219" LVL="7"><PTEXT><PDAT>Methods for Altering Surface Properties</PDAT></PTEXT></PARA>
<PARA ID="P-00220" LVL="0"><PTEXT><PDAT>The surface properties of the matrices can be altered by coating the matrices. For example, the matrices can be soaked in solutions containing hydrophilic natural or synthetic materials. The matrices can be soaked in natural polymers such as collagen, hyaluronic acid, extracellular matrix proteins (e.g., fibronectin, vitronectin, and laminin), bone morphogenetic protein (BMP), and other growth factors, synthetic materials such as PEG, PEO, hydrogels, and carboxylic acid-containing substances. The matrices can also be soaked in acidic or basic solutions. After the matrices are soaked, they can be lyophilized. The coatings can be used to improve the wettability of the matrices and/or modify the surfaces of the matrices to enhance cell attachment, migration, and differentiation. Fatty acid esters can be used to make the surfaces of the matrices more erodible.</PDAT></PTEXT></PARA>
<PARA ID="P-00221" LVL="0"><PTEXT><PDAT>Alternatively, the surfaces of the matrices can be altered by modifications such as the attachment of hydrophilic groups to the surface layers of the polymers. These techniques can make the surfaces of the matrices more wettable; they can also make the matrices better environments for cell growth and development.</PDAT></PTEXT></PARA>
<PARA ID="P-00222" LVL="7"><PTEXT><PDAT>Preparation of Insoluble Polymer Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00223" LVL="0"><PTEXT><PDAT>Polymer matrices composed entirely of polymers such as high density polyethylene (HDPE) or polypropylene, which are soluble only in boiling aromatic hydrocarbons, can be prepared using a variation of the method described above. These polymers are referred to herein as &ldquo;insoluble polymers.&rdquo;</PDAT></PTEXT></PARA>
<PARA ID="P-00224" LVL="0"><PTEXT><PDAT>A polymer (the &ldquo;carrier polymer&rdquo;) (e.g., PMMA or polystyrene) is dissolved in a polymer solvent, as described above. The insoluble polymer is introduced into the carrier polymer phase as a powder or as microparticles. The porogen (e.g., paraffin, wax, or bees wax) is added as well, and the combination is mixed to form a slurry, as described above. The matrix is molded, as described above. The porogen is then extracted with concurrent precipitation of the carrier polymer phase to yield a composite composed essentially of carrier polymer and insoluble polymer. The composite is then annealed at a temperature higher than the glass transition temperature of the insoluble polymer, but below the melting temperature of the carrier polymer. The particulate insoluble polymer fuses to yield a continuous phase of the insoluble polymer. The carrier polymer is then extracted to yield a porous network of the insoluble polymer (as the insoluble polymer is insoluble in most solvents, a wide variety of solvents can be used). The result is a porous polymer matrix composed essentially of the insoluble polymer.</PDAT></PTEXT></PARA>
<PARA ID="P-00225" LVL="0"><PTEXT><PDAT>In a variation of this approach, an inorganic material is used in combination with the carrier polymer phase. When this material is sintered in the final step, a highly porous ceramic network is obtained. This approach is useful in the production of highly porous hydroxyapatite, other ceramics, or semiconductors.</PDAT></PTEXT></PARA>
<PARA ID="P-00226" LVL="7"><PTEXT><PDAT>Preparation of Multi-layer Matrices</PDAT></PTEXT></PARA>
<PARA ID="P-00227" LVL="0"><PTEXT><PDAT>Matrices can be prepared using a polymer such as PLA with a photo-initiator such as methyl methacrylate incorporated into the polymer. The matrices are prepared in layers. A thin layer of polymer/polymer solvent/porogen slurry is placed on a surface. The layer is then exposed to an ultraviolet light source to initiate cross-linking of the polymer. A new layer of the slurry is placed on the first layer; this layer is then exposed to the light source as well. The process is continued until a matrix of the desired thickness is obtained. The porogen is then extracted from the matrix, as described above. This method can be used to prepare both interpenetrating networks and semi-interpenetrating networks.</PDAT></PTEXT></PARA>
<PARA ID="P-00228" LVL="0"><PTEXT><PDAT>Alternatively, stereospecific curing can be used to create different shapes of cross-linked polymer in the matrix. For example, stereospecific curing can be used to create columns of cross-linked polymer within a matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00229" LVL="0"><PTEXT><PDAT>Matrices can be prepared in which layers of cross-linked polymers are sandwiched between layers of non-cross-linked polymers. The cross-linked and non-cross-linked layers are connected with thin layers of a polymer that will cross-link to both layers, thus holding the layers together. The cross-linked layers are relatively stiff, while the non-cross-linked layers are flexible. Thus, these matrices are useful in applications where the matrix is required to be strong, yet be able to provide cushioning. An example is joint repair.</PDAT></PTEXT></PARA>
<PARA ID="P-00230" LVL="0"><PTEXT><PDAT>Additional layered composites can be formed by laminating two matrices having different properties; the matrices can be laminated, for example, by solvent welding. A matrix having an average pore size of less than 50 &mgr;m can be laminated to a matrix having an average pore size of greater than 100 &mgr;m. Alternatively, such a composite could be formed by layering polymer/porogen slurries with different sized porogens before extraction.</PDAT></PTEXT></PARA>
<PARA ID="P-00231" LVL="0"><PTEXT><PDAT>Bi-layered matrices prepared by these methods are useful in applications where it is desirable to prevent tissue ingrowth for some period of time.</PDAT></PTEXT></PARA>
<PARA ID="P-00232" LVL="7"><PTEXT><PDAT>Use</PDAT></PTEXT></PARA>
<PARA ID="P-00233" LVL="0"><PTEXT><PDAT>Various articles of manufacture can be prepared using the methods and compositions of the invention. These articles include matrices to support cells for cell growth and tissue engineering, drug delivery devices, fuel cells, tubular porous structures, porous fibers, and biodegradable and non-biodegradable foams and packaging materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00234" LVL="0"><PTEXT><PDAT>For tissue engineering applications, the preferred pore size is between 1 &mgr;m and 600 &mgr;m, and the preferred density of the polymer matrix is between about 0.100 g/cc and 0.200 g/cc. The pore size ensures that cells or tissue incorporated into the polymer matrix have adequate access to nutrients. Bioactive agents, such as growth factors, nutrients, and genetic material, can be incorporated into the polymer matrix to facilitate growth, differentiation, and/or function of the incorporated cells or tissue. One of skill in the art can readily determine an appropriate type and amount of growth factor, nutrient, or genetic material for a particular cell type.</PDAT></PTEXT></PARA>
<PARA ID="P-00235" LVL="0"><PTEXT><PDAT>The porous macrostructure has a high surface area to weight ratio, thus providing an environment conducive to colonization by cells. As the semi-solid portion of the matrix degrades, the voids of the porous microstructure become available to the mass of dividing and developing cells. In addition, the porous microstructure of the matrices allows for high nutrient exchange.</PDAT></PTEXT></PARA>
<PARA ID="P-00236" LVL="0"><PTEXT><PDAT>The highly interconnected structure of the matrix (i.e., the high connectivity number) provides it with mechanical strength, enabling the network to maintain its original shape and size for an appropriate period, even when cells are added and/or the matrix is present in the body. This is advantageous, as the size of the resulting tissue will be substantially the same size as the polymer matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00237" LVL="0"><PTEXT><PDAT>Cells and/or tissue can be incorporated into the polymer matrices, for example, by seeding the matrices with cells. Such polymer matrices can be used to grow tissue in various shapes. For example, artificial cartilage can be formed into the shape of a nose or ear. Artificial organs can be prepared using cells from the desired organ. Artificial skin can be prepared using cells from the dermis and/or epidermis.</PDAT></PTEXT></PARA>
<PARA ID="P-00238" LVL="0"><PTEXT><PDAT>Porous matrices prepared from biodegradable polymers can be prepared and used as biodegradable foams. Such foams can be used, for example, in tissue engineering and tissue augmentation applications. Polymers useful for these applications include polyhydroxy acids, such as PLA, PGA, PLGA, polyorthoesters, poly(ester amides), polyanhydrides, polydioxanones, polycarbonates, cellulose, modified cellulose (cellulose esters and ethers), and copolymers and blends thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00239" LVL="0"><PTEXT><PDAT>The site, or sites, where the matrix is to be implanted is determined based on individual need, as is the requisite number of molecules or cells. For cells having organ function, for example, hepatocytes or islet cells, the matrix can be implanted into the mesentery, subcutaneous tissue, retroperitoneum, properitoneal space, and intramuscular space. For formation of cartilage, the matrix can be implanted into the site where cartilage formation is desired.</PDAT></PTEXT></PARA>
<PARA ID="P-00240" LVL="0"><PTEXT><PDAT>Biodegradable matrices can be used to treat bone fractures, since the matrices can provide sufficient strength to permit fixation and good tissue/material compatibility. In addition, the matrices can be easily molded, into potentially complex shapes, for easy placement. The controlled degradation of the polymers permits good tissue integration and optimum bone function upon healing. These materials can reestablish the mechanical integrity of the bone, then subsequently degrade to allow new bone formation. Many of the metallic orthopedic devices currently in use shield stress during healing and can lead to bone atrophy.</PDAT></PTEXT></PARA>
<PARA ID="P-00241" LVL="0"><PTEXT><PDAT>Bone grafts can be prepared by preparing tubular polymer matrices. The tubes can be prepared with a suitable shape and thickness to support the bone and allow bone to grow through the matrix. Preferred polymers for this application are biodegradable polymers such as PLA, PGA, polyanhydrides, polyorthoesters, polydioxanones, poly(amide esters), polyiminocarbonates, polycarbonates, poly(meth)acrylates such as PMMA, and copolymers and blends thereof. Preferably, ceramics such as hydroxyapatite or other osteoinductive and osteoconductive insoluble materials are added to the bone grafts. Those of skill in the art can readily determine an appropriate amount of these materials to include in the polymer matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00242" LVL="0"><PTEXT><PDAT>The matrix can also be implanted as a bulking agent for hard tissue defects, such as bone or cartilage defects, congenital or acquired disease states, or defects resulting from secondary trauma or burns. For example, a matrix can be implanted into the area surrounding the skull where a bony deformity exists.</PDAT></PTEXT></PARA>
<PARA ID="P-00243" LVL="0"><PTEXT><PDAT>The polymer matrices can be formed into the shape of an implant that serves a mechanical function. Examples of such implants include rods, pins, screws, plates, and anatomical shapes.</PDAT></PTEXT></PARA>
<PARA ID="P-00244" LVL="0"><PTEXT><PDAT>Cylindrical polymer matrices with holes in the center and/or channels through the matrices can also be used to prepare vascular grafts and other hollow tubes. The tubes can be seeded with cells to form vascular grafts, bone grafts, ureters, and intestine. Preferred polymers for this application include polyhydroxy acids such as polylactic acid, polyglycolic acid, and copolymers thereof, and also include copolymers and blends with water-soluble polymers such as polyethylene glycol, polyethylene oxide and polyvinyl alcohol.</PDAT></PTEXT></PARA>
<PARA ID="P-00245" LVL="0"><PTEXT><PDAT>The matrices of the invention can also be used in controlled-release delivery systems. Matrices made of PLA, PGA, PLGA, PEG, PEO, and blends thereof are preferred for these release systems. The additives to be released are incorporated into the semi-solid network and the voids of the microstructure, preferably during formation of the matrix. Although most of the additive is contained within the microstructure, a portion of some of the particles may protrude into the voids of the macrostructure. In these cases, the entire particle is calculated as being contained within the microstructure. Typically, the polymer matrices will include between about 0.01% (w/w) and 90% (w/w) of additive.</PDAT></PTEXT></PARA>
<PARA ID="P-00246" LVL="0"><PTEXT><PDAT>The additive can be incorporated in either the semi-solid network or the voids of the microstructure for slow, controlled delivery. As the matrix dissolves, the additive trapped in the voids of the microstructure or the semi-solid network is released. The additive can be incorporated into the voids of the macrostructure when it is desirable to release the additive soon after the matrix is placed in growth medium or in the human body.</PDAT></PTEXT></PARA>
<PARA ID="P-00247" LVL="0"><PTEXT><PDAT>In other embodiments, the bioactive agent-containing matrix can be ground or cut into smaller pieces; for example, the matrix can be ground into 1-2 mm particles. Preferably, the matrix is ground in a refrigerated grinder. These particles can be used in the same ways that microspheres are used. The particles can be combined with a suitable solvent or liquid phase to form a slurry or gelable slurry. This slurry can then be injected into a body or applied directly to a site of bone or tissue repair. The advantage of the slurry is that it can be molded into a desired shape and size at the time of application. The slurry can form a coating on the surface of infected bone, and can deliver antibiotics or growth factors to that site.</PDAT></PTEXT></PARA>
<PARA ID="P-00248" LVL="0"><PTEXT><PDAT>The particles can incorporate small and large drugs, and can release the incorporated drugs over time periods ranging from hours to months. Because the particles can be extremely porous, they can deliver incorporated therapeutic agents at relatively fast rates, compared to other delivery devices. Water-soluble polymers are particularly preferred for use in this application, because the porous matrix rapidly dissolves following administration. Polyethylene glycol is the most preferred water-soluble polymer.</PDAT></PTEXT></PARA>
<PARA ID="P-00249" LVL="0"><PTEXT><PDAT>When injected, the porous polymer particles can be administered in a pharmaceutically acceptable carrier. Similarly, when used in inhalation therapy, the particles can be mixed with a suitable carrier for administration via pulmonary delivery. Those of skill in the art can readily determine an appropriate carrier for these modes of administration. When used for injectable or inhalable delivery devices, the matrices can be formed into particles or microparticles, with a size between 1 and 200 &mgr;m, for example, by laser ablation or micromachining.</PDAT></PTEXT></PARA>
<PARA ID="P-00250" LVL="0"><PTEXT><PDAT>A therapeutically or diagnostically effective amount of the agents is incorporated into the polymeric matrix. An effective amount can be readily determined by a person of ordinary skill in the art, taking into consideration factors such as body weight, age, physical condition, the therapeutic or diagnostic goal desired, the type of agent used, the type of polymer used, the initial burst and subsequent release levels desired, and the desired release rate.</PDAT></PTEXT></PARA>
<PARA ID="P-00251" LVL="0"><PTEXT><PDAT>The matrices of the invention can be placed in a number of sites in the human body, or an animal body. Matrices can be placed in an open surgical site, for example, in the case of bone repair or tissue replacement. Alternatively, they can be placed subdermally. Subdermal placement is useful for the controlled delivery of hormones such as estrogen. Thin sheets or liquid slurries of the matrices can be placed in the tooth pocket to deliver periodontal disease-fighting drugs, as well as to control local pain.</PDAT></PTEXT></PARA>
<PARA ID="P-00252" LVL="0"><PTEXT><PDAT>The materials of the invention can be used in many applications requiring load-bearing capacities and controlled degradation. In a preferred embodiment, the compression modulus of the polymer matrices is on the order of about 0.4 MPa at 4% strain.</PDAT></PTEXT></PARA>
<PARA ID="P-00253" LVL="0"><PTEXT><PDAT>The polymer matrices can be combined with fillers, reinforcement materials, excipients, or other materials as needed for a particular application. Examples of fillers include calcium-sodium-metaphosphate, as described in U.S. Pat. No. 5,108,755, which is incorporated herein by reference. Those of skill in the art can readily determine a suitable amount of these materials to include in the matrix.</PDAT></PTEXT></PARA>
<PARA ID="P-00254" LVL="0"><PTEXT><PDAT>The porous polymer matrices can also be used as fuel cells. In one embodiment, the matrices are used to prepare porous electrodes, and to incorporate solid electrolytes. Suitable electrolytes include polypyrrole, polystyrene sulfonate, sulfonated elastomers, poly(meth)acrylic acid, and other conducting polymers known to those of skill in the art. Alternatively, metals can be plated on porous polymer matrices to form porous electrodes using techniques well known to those of skill in the art. For example, the oxidation of Ag(NH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SP><PDAT>2&plus; </PDAT></SP></HIL><PDAT>to metallic silver in the presence of aldehydes (the Tollen&apos;s test) can be used to plate porous electrodes with silver. Electrodes prepared using the disclosed methodology are significantly less dense than conventional electrodes.</PDAT></PTEXT></PARA>
<PARA ID="P-00255" LVL="0"><PTEXT><PDAT>Solid supports prepared using the matrices can be used in solid phase peptide syntheses and oligonucleotide syntheses, and other applications which involve the use of solid phase supports. Preferred polymers for this embodiment are insoluble or sparingly soluble under the proposed conditions of use.</PDAT></PTEXT></PARA>
<PARA ID="P-00256" LVL="0"><PTEXT><PDAT>As described above, porous fibers can be prepared by preparing a blend of a polymer and a solid particle in an appropriate polymer solvent, shaping, extruding or spinning the blend into a fiber, and extracting the particles in an appropriate solvent. The fibers can be used for a variety of purposes, for example, as sutures, fibers, artificial tendons, and porous filaments. Additionally, the fibers can be woven together to form high strength, low weight materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00257" LVL="0"><PTEXT><PDAT>The materials of the invention can also be used to prepare biodegradable packing materials. Cellulose and modified cellulose are preferred polymers for such applications. Similarly, foams of non-biodegradable polymers, for example, polystyrene, polymethacrylate, polyethylene, polypropylene, and other relatively inexpensive polymers, can be prepared. Such foams can be used for packaging and for other shock absorbing applications.</PDAT></PTEXT></PARA>
<PARA ID="P-00258" LVL="0"><PTEXT><PDAT>The porous matrices can be designed to have high structural strength and low density. Such matrices can be used as lightweight structural materials. For example, the matrices can be used to prepare building materials, to prepare structural components for boats, automobiles, bicycles, airplanes, and vehicles designed to go into space, and for other structural uses. Preferred polymers for these uses are non-degradable, and have high strength. For example, a porous tubular structure with an outer non-porous tubular laminate can be used as a lightweight material. Polyvinyl chloride is especially suitable for this application.</PDAT></PTEXT></PARA>
<PARA ID="P-00259" LVL="0"><PTEXT><PDAT>The following examples are set forth in order to illustrate the invention. They are not meant to be construed as limiting.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<PARA ID="P-00260" LVL="7"><PTEXT><PDAT>Preparation of the Polymer Matrix A 1.0&times;1.0&times;1.0 cm matrix was prepared as follows. First, a Teflon&reg; mold having outer dimensions of about 1.60&times;1.60&times;1.85 cm and having inner dimensions of about 1.0&times;1.0&times;1.0 cm, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 1A-1E</PDAT></FGREF><PDAT>, was assembled. The mold had six sides, each side having holes with a diameter of 0.95 mm, placed 0.10 cm apart. One side of the mold was attached to the three connected sides by means of screws, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1C. A</PDAT></FGREF><PDAT> fifth side was attached by placing the holes in the piece over the guide-pins, as shown in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>D. Scotch&reg;-brand adhesive tape was placed over the holes on all five sides.</PDAT></PTEXT></PARA>
<PARA ID="P-00261" LVL="0"><PTEXT><PDAT>Poly(lactic acid-co-glycolic acid) (PLGA) was ground to a fine powder using a refrigerated grinder. Liquid nitrogen was added, as needed, during grinding to maintain the PLGA in a solid form.</PDAT></PTEXT></PARA>
<PARA ID="P-00262" LVL="0"><PTEXT><PDAT>Paraffin (Fisher Chemicals) was ground using the same procedure. The paraffin particles were then sieved through a series of meshes.</PDAT></PTEXT></PARA>
<PARA ID="P-00263" LVL="0"><PTEXT><PDAT>200 mg of the PLGA was placed on a watch glass. 1-2 mL methylene chloride was added, and the resulting mixture was stirred for about 1-2 minutes with a metal spatula to form a viscous paste. 400 mg of 500-425 &mgr;m paraffin particles and 400 mg 300-425 &mgr;m paraffin particles were added to the paste. Methylene chloride was added as needed, in aliquots of about 0.5 mL, to maintain the consistency of a thick paste. When a relatively homogenous mixture was obtained, the mixture was packed into the mold. In order to avoid the formation of air bubbles, one corner of the mold was packed with the mixture </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT> first, as shown in FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>. The rest of the mold was then filled with the mixture.</PDAT></PTEXT></PARA>
<PARA ID="P-00264" LVL="0"><PTEXT><PDAT>The sixth side of the mold was placed over the guide pins and pressed firmly against the frame of the mold. The mold was then placed in a 150 mL beaker containing 100 mL hexane. The porogen was extracted by leaving the mold in boiling hexane for 2 minutes. After this time, the mold was removed from the hexane, and the adhesive tape was removed. The mold was then placed in boiling hexane for an additional 13 minutes to extract more of the porogen.</PDAT></PTEXT></PARA>
<PARA ID="P-00265" LVL="0"><PTEXT><PDAT>The mold was then removed from the hexane. The top of the mold was removed, and the mold was placed in a 150 mL beaker containing 100 mL of fresh hexane. The mold was kept in boiling hexane for 15 minutes to extract more of the porogen.</PDAT></PTEXT></PARA>
<PARA ID="P-00266" LVL="0"><PTEXT><PDAT>The mold was then removed from the hexane, and the matrix was carefully removed from the mold. The porogen was then extracted in fresh hexane (boiling) for 15 minutes. After this time, the matrix was removed from the hexane; the remaining porogen was extracted in 100 mL fresh hexane (boiling) for an additional 15 minutes.</PDAT></PTEXT></PARA>
<PARA ID="P-00267" LVL="0"><PTEXT><PDAT>The matrix was air-dried (using house air), then lyophilized for 24 hours, to remove any remaining polymer solvent and porogen solvent. The density of the finished matrix was 120-150 mg/cc.</PDAT></PTEXT></PARA>
<PARA ID="P-00268" LVL="0"><PTEXT><PDAT>In separate experiments, 200 mg of PLA or PLGA or PMMA was dissolved in 2-3 ml methylene chloride or chloroform. After the polymer was completely dissolved (as determined by lack of any particulates) 800 mg of paraffin particles with a size ranging from 500-300 gm were mixed in with a spatula to yield a putty including the polymer, paraffin and solvent. This mixture was then compacted into a 1 cubic centimeter Teflon&reg; mold and placed in a beaker containing 60 ml of warm hexane for extraction of the paraffin. After 15 minutes, the mold was dismantled and the porous polymeric cube was released. The cube was then further subjected to two separate extractions of 15 minutes each in warm hexane to remove any residual traces of paraffin. The resulting porous polymeric cubes had a porosity greater than 85%.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<PARA ID="P-00269" LVL="7"><PTEXT><PDAT>Measurement of Residual Paraffin</PDAT></PTEXT></PARA>
<PARA ID="P-00270" LVL="0"><PTEXT><PDAT>The method for preparing the polymer matrix was repeated, using PLLA as the polymer. Electron spectroscopy for chemical analysis (ESCA) was used to analyze the top 20-25 &angst; of the exterior face of the matrix prepared. As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT>, the oxygen/carbon ratio is approximately 2:3. This value is close to the theoretical value for PLLA, which has a ratio of oxygen atoms to carbon atoms of 2:3. This result indicates that there is very little, if any, paraffin remaining on the exterior face of the matrix.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<PARA ID="P-00271" LVL="7"><PTEXT><PDAT>Growth of Bovine Bone Marrow Stromal Cells on Polymer Matrix</PDAT></PTEXT></PARA>
<PARA ID="P-00272" LVL="7"><PTEXT><PDAT>Phase I: Cell Isolation and Expansion</PDAT></PTEXT></PARA>
<PARA ID="P-00273" LVL="0"><PTEXT><PDAT>Bone marrow cultures were established from the tibia and femur of 2-3 week old bovine calves. The contents of the bone marrow cavity were aseptically harvested in Dulbecco&apos;s Modified Eagle Medium (DMEM). Single cell suspensions were made by repeatedly passing the marrow through needles of different gauges (16 to 20); the cells were then resuspended in DMEM supplemented with 10% fetal bovine serum (FBS), 0.1 mM nonessential amino acids (NEAA), 100 U/ml penicillin and 100 mg/L streptomycin (P/S). The white blood cells were counted using a hemocytometer, plated in 100 mm Petri dishes at 2&times;106 cells per dish (approximately 25&times;103 cells/cm</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>) in 10 ml of medium supplemented with 1 ng/ml fibroblast growth factor-2 (FGF-2, also called bFGF), and cultured in a humidified 37&deg; C./5% CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>incubator (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>, phase I).</PDAT></PTEXT></PARA>
<PARA ID="P-00274" LVL="0"><PTEXT><PDAT>Bone Marrow Stromal Cells (BMSC) were selected based on their ability to adhere to the Petri dish. Non-adherent hematopoietic cells were removed with the culture medium during refeeding. The medium was changed after 3 days, then twice per week thereafter. When the BMSC became near confluent (approximately 2-3 weeks after the primary culture was established), they were detached using 0.25% trypsin/1 mM ethylenediamine tetraacetic acid (EDTA), then replated in 100 mm dishes at 3&times;105 cells per dish. After 1 more week, when the dishes again became confluent, 1st passage (P1) cells were trypsinized and seeded onto polymer scaffolds.</PDAT></PTEXT></PARA>
<PARA ID="P-00275" LVL="7"><PTEXT><PDAT>Phase II: Cell Seeding onto Polymer Scaffolds</PDAT></PTEXT></PARA>
<PARA ID="P-00276" LVL="0"><PTEXT><PDAT>Prior to cell seeding, the polymer scaffolds were pre-wetted in culture medium, threaded onto needles (1-2 scaffolds per needle, 1-2 needles per flask), positioned using 3 mm segments of silicone tubing, and fixed to a stopper in the mouth of a 25 ml spinner flask. The flasks were filled with 30 ml of medium, placed in a humidified 37&deg; C./5% CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>incubator with the side arm caps loosened to permit gas exchange, and magnetically stirred at 75 rpm. After 2 hours, the flasks were inoculated with 3&times;10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>BMSC per scaffold (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>, phase II). FGF-2 (1 ng/ml) was added to the culture medium in this phase to increase the proliferation rate and to maintain the osteogenic potential of BMSC.</PDAT></PTEXT></PARA>
<PARA ID="P-00277" LVL="0"><PTEXT><PDAT>Constructs composed of scaffolds with various additives incorporated were prepared. The control construct was cultured on a scaffold composed of PGA mesh. A second construct (Sample A) was cultured on a matrix of PLA/PEG (80:20). A third construct (Sample B) was also cultured on a scaffold of PLA/PEG (80:20). A fourth construct (Sample C) was cultured on a scaffold composed of PLA/PEG (80:20), with calcium carbonate added.</PDAT></PTEXT></PARA>
<PARA ID="P-00278" LVL="7"><PTEXT><PDAT>Phase III: 3D Construct Cultivation</PDAT></PTEXT></PARA>
<PARA ID="P-00279" LVL="0"><PTEXT><PDAT>After 3 days, when cell attachment to the scaffolds was complete (as inferred from the absence of cells in the culture medium), the cell-polymer constructs were transferred to 35 mm diameter dishes coated with a thin layer of 1% agarose and placed on an orbital shaker (75 rpm) for further cultivation (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>, phase III). Each construct was cultured in 5 ml of DMEM containing 10% FBS, 0.1 mM NEAA, 50 mg/L ascorbic acid, 0.4 mM proline and P/S. In this phase, FGF-2 was not added to the culture medium. In some groups, the medium was further supplemented with 7 mM &bgr;-glycerophosphate (bGP) and 10</PDAT><HIL><SP><PDAT>&minus;8 </PDAT></SP></HIL><PDAT>M dexamethasone (dex) to induce mineralization and osteogenic differentiation. The medium was completely replaced twice per week. The compositions of the constructs are summarized in Table 2.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Composition of constructs</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="28pt" align="center"/>
<colspec colname="2" colwidth="56pt" align="left"/>
<colspec colname="3" colwidth="49pt" align="center"/>
<colspec colname="4" colwidth="84pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Sample</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Matrix polymer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Matrix additive</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Culture medium additive</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Control</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PGA mesh</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>FBS, NEAA, ascorbic acid,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>proline, P/S</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PLA/PEG (80:20)</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>FBS, NEAA, ascorbic acid,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>proline, P/S</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PLA/PEG (80:20)</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>FBS, NEAA, ascorbic acid,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>proline, P/S bGP, dex</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>C</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>PLA/PEG (80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>calcium</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>FBS, NEAA, ascorbic acid,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>carbonate</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>proline, P/S bGP, dex</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00280" LVL="7"><PTEXT><PDAT>Results</PDAT></PTEXT></PARA>
<PARA ID="P-00281" LVL="0"><PTEXT><PDAT>After 4 weeks in culture, the cell-polymer constructs of Samples A, B, and C maintained the initial size and shape of the scaffold, and were completely colonized by cells (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 10B</PDAT></FGREF><PDAT>, </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>D). The sample grown on the PGA control mesh contracted and collapsed into a small mass that consisted primarily of undegraded polymer (FIG. </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>A). The original size of the scaffold is shown by the dotted lines in these figures.</PDAT></PTEXT></PARA>
<PARA ID="P-00282" LVL="0"><PTEXT><PDAT>Cross-sections of the constructs were stained with alizarin red. The background intensity of the stain was negligible, as assessed using a section of a non-mineralized sample (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>A). Multicenter formation of mineralized foci was observed throughout the extracellular matrix (ECM) in the constructs that were cultured on PLA/PEG (80:20) matrices in the presence of bGP and dex (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>B). The construct that was cultured on a matrix composed of PLA/PEG(80:20) with calcium carbonate added, in the presence of &bgr;-glycerophosphate and dex, showed even more mineralization (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>C), while the control construct showed negligible mineralization (FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>A).</PDAT></PTEXT></PARA>
<PARA ID="P-00283" LVL="0"><PTEXT><PDAT>These observations exhibit the ability of the matrices of the invention to maintain their sizes and shapes in the presence of cells; they also highlight the effects of different additives that can be incorporated in the matrices.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<PARA ID="P-00284" LVL="7"><PTEXT><PDAT>Human Bone Marrow Stromal Cells</PDAT></PTEXT></PARA>
<PARA ID="P-00285" LVL="0"><PTEXT><PDAT>Human BMSC were isolated and expanded as described in I. Martin et al., </PDAT><HIL><ITALIC><PDAT>Endocrinology </PDAT></ITALIC></HIL><PDAT>138:4456-4462 (1997). They were then seeded onto polymer scaffolds as described in Example 3, and cultured during Phase III using a culture medium composition formulated to induce chondrogenic differentiation of BMSC (described in F. P. Barry et al., </PDAT><HIL><ITALIC><PDAT>Trans Orthop Res Soc </PDAT></ITALIC></HIL><PDAT>228:38, (1997)). Histological and immunohistochemical (collagen type II stain) results showed that after 3 weeks, the BMSC were able to differentiate into chondrocytes and to produce a cartilaginous ECM containing collagen type II (FIG. </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>). This result indicates that the three-dimensional architecture of the polymer scaffold provides a defined, temporary structure for cell attachment. At the same time, it allows for the establishment of cell-to-cell contacts, which are thought to initiate the differentiation into chondrocytes.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<PARA ID="P-00286" LVL="7"><PTEXT><PDAT>Bovine Chondrocytes</PDAT></PTEXT></PARA>
<PARA ID="P-00287" LVL="0"><PTEXT><PDAT>Articular cartilage was harvested aseptically from the femoropatellar grooves of knee joints from 2-3 week old bovine calves. The tissue was chopped into 2 mm cubes for cell isolation. Chondrocytes were isolated by digestion with type II collagenase as described in L. E. Freed et al., </PDAT><HIL><ITALIC><PDAT>J Biomed Mat Res </PDAT></ITALIC></HIL><PDAT>27:11-23 (1993). The cells were resuspended in DMEM containing 10% FBS, 0.1 mM NEAA, 0.4 mM proline, 50 mg/L ascorbic acid, and P/S.</PDAT></PTEXT></PARA>
<PARA ID="P-00288" LVL="0"><PTEXT><PDAT>Cell seeding was performed as described for the BMSC (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>, Phase II). Four constructs were prepared. The control sample was grown on a PGA mesh. Sample A was grown on a matrix composed of PLA; Sample B was grown on a matrix of PLA/PEG (80:20); and Sample C was grown on a matrix of PLA/PEG (60:40).</PDAT></PTEXT></PARA>
<PARA ID="P-00289" LVL="0"><PTEXT><PDAT>5&times;10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>cells per scaffold were seeded and cultured without the addition of FGF-2. After 3 days, the cell-polymer constructs were transferred to 35 mm diameter dishes coated with 1% agarose and placed on an orbital shaker (75 rpm) for further cultivation (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT>, Phase III).</PDAT></PTEXT></PARA>
<PARA ID="P-00290" LVL="7"><PTEXT><PDAT>Results</PDAT></PTEXT></PARA>
<PARA ID="P-00291" LVL="0"><PTEXT><PDAT>Chondrocytes seeded on the polymer scaffolds were able to colonize the entire scaffold and to produce cartilaginous extracellular matrix (ECM) rich in sulfated glycosaminoglycans (GAG) and in collagen type II, as assessed in tissue cross-sections stained with Safranin-O for GAG and by immunohistochemistry. The chondrocytes were also able to retain their differentiated phenotype in the inner tissue phase (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>A). The differentiated phenotypes were not observed in the samples grown on the control PGA mesh (FIG. </PDAT><HIL><BOLD><PDAT>13</PDAT></BOLD></HIL><PDAT>B).</PDAT></PTEXT></PARA>
<PARA ID="P-00292" LVL="0"><PTEXT><PDAT>The amount of residual matrix was also measured. After 4 weeks in culture, the amount of non-resorbed polymer was significantly lower in the samples containing higher percentages of PEG (Table 3). Thus, the matrices that showed faster degradation rates corresponded to the matrices that allowed for higher extracellular matrix homogeneity produced by the cells growing in the matrix (FIGS. </PDAT><HIL><BOLD><PDAT>14</PDAT></BOLD></HIL><PDAT>A-</PDAT><HIL><BOLD><PDAT>14</PDAT></BOLD></HIL><PDAT>C).</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 3</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Percentage of non-resorbed polymer</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="133pt" align="left"/>
<colspec colname="2" colwidth="84pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Material</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>% non-resorbed polymer</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="133pt" align="left"/>
<colspec colname="2" colwidth="84pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>PLA (Sample A, FIG. 14A)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22.7</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLA-PEG (80-20) (Sample B, FIG. 14B)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12.0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLA-PEG (60-40) (Sample C, FIG. 14C)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.7</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<PARA ID="P-00293" LVL="7"><PTEXT><PDAT>Artificial Nose</PDAT></PTEXT></PARA>
<PARA ID="P-00294" LVL="0"><PTEXT><PDAT>A PLA scaffold in the shape of a human nose was carved and seeded with bovine chondrocytes. After 2 weeks, the pores were completely filled with cartilaginous matrix; at the same time, the scaffold was able to retain its complex geometry (FIGS. </PDAT><HIL><BOLD><PDAT>15</PDAT></BOLD></HIL><PDAT>A and </PDAT><HIL><BOLD><PDAT>15</PDAT></BOLD></HIL><PDAT>B).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 7</PDAT></STEXT></H>
<PARA ID="P-00295" LVL="7"><PTEXT><PDAT>Variation of Mechanical Properties</PDAT></PTEXT></PARA>
<PARA ID="P-00296" LVL="0"><PTEXT><PDAT>Six different polymer matrices were prepared, using different polymer compositions: PLGA, PLLA, and PMMA, PLGA/PEG, PLA/PEG, and PLA/PEG/CaCO</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>. The mechanical properties were measured using a Dynamic Mechanical Analyzer, using disc-shaped samples having a diameter of 4-7 mm and a thickness of 2-4 mm. Stress is the amount of force applied to the sample; strain is the amount by which the sample compresses.</PDAT></PTEXT></PARA>
<PARA ID="P-00297" LVL="0"><PTEXT><PDAT>As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 16</PDAT></FGREF><PDAT>, samples containing PLGA, PLLA, and PMMA compressed by about 5% when subjected to a stress of 140,000 Pa. A sample containing PLA/PEG/CaCO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>compressed by about 9%. Samples that were made with blends of PLGA/PEG (80:20) and PLA/PEG (80:20) compressed by about 16% and 38%, respectively. The samples of both blends returned to within 5% of their original size within one minute. The sample of PLGA/PEG (80:20) returned to essentially 100% of its original size substantially instantaneously. These results demonstrate the effects that different polymer compositions have on the mechanical properties of the matrices.</PDAT></PTEXT></PARA>
<PARA ID="P-00298" LVL="0"><PTEXT><PDAT>Table 4 summarizes additional mechanical properties of the matrices.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00004">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 4</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Mechanical properties of polymer and polymer blend matrices</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="84pt" align="left"/>
<colspec colname="2" colwidth="49pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="49pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Modulus (Mpa)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Modulus (MPa)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Strain at</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>140 KPa</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Material</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>at 4% strain</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>140 KPa</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>stress</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="84pt" align="left"/>
<colspec colname="2" colwidth="49pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="char" char="."/>
<colspec colname="4" colwidth="49pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.356</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.036</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.136</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.28</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.115</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA-PEG (80-20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.499</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.333</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.048</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.58</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.57</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLA-PEG (80-20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.537</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>37.41</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.383</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLA-PEG (80-20)-CaCO</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>1.239</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9.01</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.968</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<H LVL="1"><STEXT><PDAT>EXAMPLE 8</PDAT></STEXT></H>
<PARA ID="P-00299" LVL="7"><PTEXT><PDAT>Controlled Release of Alkaline Phosphatase</PDAT></PTEXT></PARA>
<PARA ID="P-00300" LVL="0"><PTEXT><PDAT>In the control sample, PEG was dissolved in PBS buffer. Alkaline phosphatase (ALP) was added and the mixture was lyophilized to form a powder. After lyophilization, the ALP activity was below detection levels.</PDAT></PTEXT></PARA>
<PARA ID="P-00301" LVL="0"><PTEXT><PDAT>PEG (200 mg) and alkaline phosphatase (ALP) (1000 units) were dissolved in about 1 mL of PBS buffer containing 1.0% bovine serum albumin (BSA). The mixture was frozen and lyophilized to form a powder. The ALP activity of the powder was 0.557 units/mg, which represents a loss of about 9-fold with respect to the initial enzymatic activity.</PDAT></PTEXT></PARA>
<PARA ID="P-00302" LVL="0"><PTEXT><PDAT>The PLA/PEG (80:20) matrices were loaded with ALP using the PEG/ALP mixture described above and incubated at 4&deg; C. in PBS buffer containing 1.0% bovine serum albumin (BSA) for up to 7 weeks. Samples of the solution were taken at timed intervals and assayed for ALP activity (Sigma kit No. 245). ALP activity was expressed as active units per mg of initial construct weight. The results are shown in FIG. </PDAT><HIL><BOLD><PDAT>17</PDAT></BOLD></HIL><PDAT>. As shown there, ALP can be released from the matrix for extended periods of time; for example, ALP can be released for up to 1000 hours. The release time can be controlled by loading different amounts of ALP. The more ALP that is loaded on a matrix, the longer the release time.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 9</PDAT></STEXT></H>
<PARA ID="P-00303" LVL="7"><PTEXT><PDAT>Polymer Blends</PDAT></PTEXT></PARA>
<PARA ID="P-00304" LVL="0"><PTEXT><PDAT>Matrices made of polymer blends, with and without inorganic additives, were prepared using the general techniques described above. The following table summarizes the blends that were prepared, as well as their physical properties.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00005">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 5</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Polymer and polymer blend matrices</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="5">
<colspec colname="1" colwidth="49pt" align="left"/>
<colspec colname="2" colwidth="35pt" align="left"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="42pt" align="left"/>
<colspec colname="5" colwidth="63pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Polymer</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Additives</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>Composition</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Total</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>WT % of</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Bulk Properties</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(Ratios are</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Polymer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Polymer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Total</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Density (d),</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>wt %)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MW</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Weight</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Polymer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Resistivity (r)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;90,000-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 130-140 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA (85:15)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>128,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 130-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>300 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 220-260 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &ap; 160 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;10,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&emsp;6,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&tilde;5 mg, Rho-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>damine-B</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Alkaline</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Phosphatase</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(ALP)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>200 units</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>25% FITC-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 105-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;10,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Dextran</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(MW &equals;</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>71,200)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PBG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50% Cal-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 170-190 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>cium</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Carbonate</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(particle</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>size &lt;53 &mgr;m)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50% beta-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 170-200 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Glycero-</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>phosphate</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50% Unfired</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 200 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Hydroxy-</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>apatite</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(particle size</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>45-70 &mgr;m)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50% Hy-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 200 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>droxy</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Apatite</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(FinCera-</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>mica,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>particle size</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>212-500 &mgr;m)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLLA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100% Hy-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &ap; 300 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>droxy</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Apatite</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>(FinCera-</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>mica,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>particle size</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>212-500 &mgr;m)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>128,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 130-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>128,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>None</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 130-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>PLGA &plus; PEG</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>128,000 &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&tilde;5 mg, Rho-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 130-150 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(80:20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;20,000</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>damine-B</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>300 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30 mg, Col-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 250-300 mg/cc,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>loidal</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>No Conductivity</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Graphite</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>290 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100 mg, Col-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 274 mg/cc,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>loidal</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>r &equals; 4.96 K&OHgr;-cm</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Graphite</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>250 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg, Col-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &equals; 358 mg/cc,</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>loidal</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>r &equals; 0.840 K&OHgr;-cm</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Graphite</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>PMMA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>120,000</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>200 mg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100 mg,</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>d &ap; 300 mg/cc</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Micronized</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Polyethylene</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="5" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00305" LVL="0"><PTEXT><PDAT>All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Other Embodiments</PDAT></STEXT></H>
<PARA ID="P-00306" LVL="0"><PTEXT><PDAT>From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00307" LVL="0"><PTEXT><PDAT>1. A matrix comprising a macrostructure having a substantially continuous semi-solid network and voids, said matrix further comprising a microstructure having voids, wherein said microstructure is located within said semi-solid network.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00308" LVL="0"><PTEXT><PDAT>2. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said semi-solid network comprises a polymer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00309" LVL="0"><PTEXT><PDAT>3. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix comprises a copolymer having a carboxylic acid group or a copolymer having an amine group.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00310" LVL="0"><PTEXT><PDAT>4. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix comprises a conductive polymer selected from the group consisting of polypyrrole, polyaniline, polyacetylene, and polythiophene.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00311" LVL="0"><PTEXT><PDAT>5. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said semi-solid network consists essentially of a polymer or mixture of polymers.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00312" LVL="0"><PTEXT><PDAT>6. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the surface area of said matrix is at least 1 m</PDAT><HIL><SP><PDAT>2</PDAT></SP></HIL><PDAT>/g.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00313" LVL="0"><PTEXT><PDAT>7. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said voids of said macrostructure are substantially continuous.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00314" LVL="0"><PTEXT><PDAT>8. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein at least 10% of said voids of said macrostructure and said voids of said microstructure are connected.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00315" LVL="0"><PTEXT><PDAT>9. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said voids of said macrostructure and said voids of said microstructure are not connected.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00316" LVL="0"><PTEXT><PDAT>10. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, said voids of said macrostructure defining openings, wherein the average diameter of said openings and the average diameter of the cross-sections of said semi-solid network have a ratio of from 2:1 to 10:1.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00317" LVL="0"><PTEXT><PDAT>11. The matrix of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein said ratio is from 2:1 to 5:1.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00318" LVL="0"><PTEXT><PDAT>12. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the semi-solid network of a cubic portion of said matrix having dimensions of 0.5 cm on all sides and having voids defining openings having an average diameter of 50-500 &mgr;m has a connectivity number of at least 10.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00319" LVL="0"><PTEXT><PDAT>13. The matrix of </PDAT><CLREF ID="CLM-00012"><PDAT>claim 12</PDAT></CLREF><PDAT>, wherein said connectivity number is at least 20.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00320" LVL="0"><PTEXT><PDAT>14. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, a cross section of said semi-solid network having a maximum and a minimum diameter, wherein the ratio of said maximum diameter and said minimum diameter is from 1:1 to 10:1.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00321" LVL="0"><PTEXT><PDAT>15. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein at least 10% of the voids of said microstructure have a fractal dimension of at least 3.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00322" LVL="0"><PTEXT><PDAT>16. The matrix of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT>, wherein less than 10% of the voids of said macrostructure have a fractal dimension higher than 1.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00323" LVL="0"><PTEXT><PDAT>17. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is three dimensional.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00324" LVL="0"><PTEXT><PDAT>18. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the exterior face of said matrix is porous.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00325" LVL="0"><PTEXT><PDAT>19. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix has a porosity of at least about 20%.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00326" LVL="0"><PTEXT><PDAT>20. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is biodegradable.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00327" LVL="0"><PTEXT><PDAT>21. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is bioerodible.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00328" LVL="0"><PTEXT><PDAT>22. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is bioresorbable.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00023">
<PARA ID="P-00329" LVL="0"><PTEXT><PDAT>23. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is impermeable to cells.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00024">
<PARA ID="P-00330" LVL="0"><PTEXT><PDAT>24. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is permeable to bodily fluids.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00025">
<PARA ID="P-00331" LVL="0"><PTEXT><PDAT>25. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix is permeable to cells.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00026">
<PARA ID="P-00332" LVL="0"><PTEXT><PDAT>26. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix further comprises a living cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00027">
<PARA ID="P-00333" LVL="0"><PTEXT><PDAT>27. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix changes in size less than 50% when cells are added to said matrix.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00028">
<PARA ID="P-00334" LVL="0"><PTEXT><PDAT>28. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix has a compressive modulus of at least 0.4 MPa at 4% strain.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00029">
<PARA ID="P-00335" LVL="0"><PTEXT><PDAT>29. The matrix of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said matrix has a density of less than about 0.150 g/cc.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00000" ALT="embedded image" FILE="US06471993-20021029-D00000.TIF"/>
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06471993-20021029-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06471993-20021029-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06471993-20021029-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06471993-20021029-D00004.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06471993-20021029-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06471993-20021029-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06471993-20021029-D00007.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06471993-20021029-D00008.TIF"/>
<EMI ID="EMI-D00009" ALT="embedded image" FILE="US06471993-20021029-D00009.TIF"/>
<EMI ID="EMI-D00010" ALT="embedded image" FILE="US06471993-20021029-D00010.TIF"/>
<EMI ID="EMI-D00011" ALT="embedded image" FILE="US06471993-20021029-D00011.TIF"/>
<EMI ID="EMI-D00012" ALT="embedded image" FILE="US06471993-20021029-D00012.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00013" ALT="embedded image" FILE="US06471993-20021029-D00013.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00014" ALT="embedded image" FILE="US06471993-20021029-D00014.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00015" ALT="embedded image" FILE="US06471993-20021029-D00015.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00016" ALT="embedded image" FILE="US06471993-20021029-D00016.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00017" ALT="embedded image" FILE="US06471993-20021029-D00017.TIF" TYPE="HALFTONE"/>
<EMI ID="EMI-D00018" ALT="embedded image" FILE="US06471993-20021029-D00018.TIF"/>
<EMI ID="EMI-D00019" ALT="embedded image" FILE="US06471993-20021029-D00019.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06472157-20021029-D00001.TIF SYSTEM "US06472157-20021029-D00001.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06472157</PDAT></DNUM></B110>
<B130><PDAT>B2</PDAT></B130>
<B140><DATE><PDAT>20021029</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>10061693</PDAT></DNUM></B210>
<B211US><PDAT>10</PDAT></B211US>
<B220><DATE><PDAT>20020201</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12Q  168</PDAT></B511>
<B512><PDAT>C12P 1934</PDAT></B512>
<B512><PDAT>C07H 2104</PDAT></B512>
<B512><PDAT>C07H 2102</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435  6</PDAT></B521>
<B522><PDAT>435 911</PDAT></B522>
<B522><PDAT>435 912</PDAT></B522>
<B522><PDAT>536 221</PDAT></B522>
<B522><PDAT>536 243</PDAT></B522>
<B522><PDAT>536 2433</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Methods for detection of promoter polymorphism in a UGT gene promoter</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5786344</PDAT></DNUM>
<DATE><PDAT>19980700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Ratain et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>514100</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6066645</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Hausheer et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>514283</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 96/01127</PDAT></DNUM>
<DATE><PDAT>19960100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Araki et al., &ldquo;Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11,&rdquo; </PDAT><HIL><ITALIC><PDAT>Jpn J. Cancer Res.</PDAT></ITALIC></HIL><PDAT>, 84:697-702, 1993. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Beutler et al., &ldquo;Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS USA</PDAT></ITALIC></HIL><PDAT>, 95:8170-8174, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bosma et al., &ldquo;Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar Syndrome, Type I,&rdquo; </PDAT><HIL><ITALIC><PDAT>Hepatology</PDAT></ITALIC></HIL><PDAT>, 15:941-947, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bosman et al., &ldquo;The genetic basis of the reduced expression of bilirubin UDP-Glucuronosyltransferase 1 in Gilbert&apos;s Syndrome,&rdquo; </PDAT><HIL><ITALIC><PDAT>N. Eng. J. Med.</PDAT></ITALIC></HIL><PDAT>, 333:1171-1175, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Burchell et al., The UDP Glucuronosyltransferase gene suprefamily: suggested nomenclature based on evolutionary divergence, </PDAT><HIL><ITALIC><PDAT>DNA cell biol.</PDAT></ITALIC></HIL><PDAT>, 10:487-494, 1991. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Chen et al., &ldquo;Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA,&rdquo; </PDAT><HIL><ITALIC><PDAT>Biotechniques</PDAT></ITALIC></HIL><PDAT>, 6:632-638, 1988. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Clarke et al., &ldquo;The Uridine Diphosphate glucuronosyltransferase multigene family: function and regulation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Handbook of experimental pharmacology</PDAT></ITALIC></HIL><PDAT>, 112:3-43, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Coffman et al., &ldquo;Cloning and stable expression of a cDNA encoding a rate liver UDP-Glucuronosyltransferase (UDP_Glucuronosyltransferase 1.1) that catalyzes the glucuronidation of opiods and bilirubin,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Pharmacol.</PDAT></ITALIC></HIL><PDAT>, 47:1101-1105, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Coffman et al., &ldquo;Human UGT2B7 catalyzes morphine glucuronidation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Drug Metab Dispos.</PDAT></ITALIC></HIL><PDAT>, 25:1-4, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Di Rienzo et al., &ldquo;Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene&rdquo;, </PDAT><HIL><ITALIC><PDAT>American Society for Clinical Pharmacology and Therapeutics</PDAT></ITALIC></HIL><PDAT>, Ninety Ninth Annual Meeting, New Orleans, Abstract OII-B-3, p. 207, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Evans and Relling, &ldquo;Automated high-performance liquid chromatographic assay for the determinationof 7-ethoxycoumarin and umbelliferone,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Chromatogr.</PDAT></ITALIC></HIL><PDAT>, 578:141-145, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gram et al., &ldquo;Clinical relevance of gentic polymorphisms in drug oxidation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Clinical Relevance of Genetic Polymorphisms in Drug Oxidation</PDAT></ITALIC></HIL><PDAT>, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Green et al., &ldquo;Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides,&rdquo; </PDAT><HIL><ITALIC><PDAT>Drug Metab. Dispos.</PDAT></ITALIC></HIL><PDAT>, 23:299-302, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gunn,&ldquo;Hereditary Acholuric Jaundice,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Hered.</PDAT></ITALIC></HIL><PDAT>, 29:137-139, 1938. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gupta et al., &ldquo;Metabolic Fate of Irinotecan in humans: Correlation of Glucuronidation with Diarrhea,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cancer Res.</PDAT></ITALIC></HIL><PDAT>, 54:3723-3725, 1994. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gupta et al., &ldquo;Pharmacokinetic and pharmacodynamic evaluation of the topisomerase inhibitor Irinotecan in cancer patients,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Clin. Oncol.</PDAT></ITALIC></HIL><PDAT>, 15:1502-1510, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Harding et al., &ldquo;Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS, USA</PDAT></ITALIC></HIL><PDAT>, 85:8381-8385, 1988. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Iyer et al., &ldquo;Genetic basis for the glucuronidation of SN-38: Role of UGT*1 isoform,&rdquo; </PDAT><HIL><ITALIC><PDAT>Clinical Pharmacology and Therapeutics</PDAT></ITALIC></HIL><PDAT>, 61:Abstract, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Iyer et al., &ldquo;UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan,&rdquo; </PDAT><HIL><ITALIC><PDAT>Program Proceedings of the American Society of Clinical Oncology</PDAT></ITALIC></HIL><PDAT>, 16:Abstract, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kaneda et al., &ldquo;Metabolism and Pharmacokinetics of the campothecin analogue CPT-11 in the mouse,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cancer Res.</PDAT></ITALIC></HIL><PDAT>, 50:1715-1720, 1990. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>King et al., &ldquo;The Glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-Glucuronosyltransferase 1.1,&rdquo; </PDAT><HIL><ITALIC><PDAT>Arch. Biochem. Biophys.</PDAT></ITALIC></HIL><PDAT>, 332:92-100, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Monaghan et al., &ldquo;Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert&apos;s syndrome,&rdquo; </PDAT><HIL><ITALIC><PDAT>Lancet</PDAT></ITALIC></HIL><PDAT>, 347:578-581, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Owens and Ritter, &ldquo;Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity and regulation,&rdquo; </PDAT><HIL><ITALIC><PDAT>Progress in Nucleic Acid Research and Molecular Biology</PDAT></ITALIC></HIL><PDAT>, 51:305-338, 1995. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Purba et al., &ldquo;The metabolism of 17 &agr;-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites,&rdquo; </PDAT><HIL><ITALIC><PDAT>Br. J. Clin. Pharmacol.</PDAT></ITALIC></HIL><PDAT>, 23:447-453, 1987. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ritter et al., &ldquo;A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem.</PDAT></ITALIC></HIL><PDAT>, 267:3257-3261, 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ritter et al., &ldquo;Cloning of two humna liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem.</PDAT></ITALIC></HIL><PDAT>, 226:1043-1047, 1991. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Stocker, &ldquo;Bilirubin is an antioxidant of possible physiological importance,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 235:1043-1046, 1987. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tucker, &ldquo;Clinical implications of genetic polymorphism in drug metabolism,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Pharm. Pharmacology</PDAT></ITALIC></HIL><PDAT>, 46:417-424, 1994.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>26</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435  6</PDAT></B582>
<B582><PDAT>435 911</PDAT></B582>
<B582><PDAT>435 912</PDAT></B582>
<B582><PDAT>536 221</PDAT></B582>
<B582><PDAT>536 243</PDAT></B582>
<B582><PDAT>536 2433</PDAT></B582>
</B580>
<B590><B595><PDAT>1</PDAT></B595><B596><PDAT>2</PDAT></B596></B590>
</B500>
<B600>
<B630><B631><PARENT-US><CDOC><DOC><DNUM><PDAT>10/061693</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/251274</PDAT></DNUM><DATE><PDAT>19990216</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6395481</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B631></B630>
<B690US>
<DOC>
<DNUM><PDAT>20020115097</PDAT></DNUM>
<DATE><PDAT>20020822</PDAT></DATE>
<CTRY><PDAT>US</PDAT></CTRY>
<KIND><PDAT>A1</PDAT></KIND>
</DOC>
</B690US></B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Anna</PDAT></FNM><SNM><STEXT><PDAT>Di Rienzo</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Chicago</PDAT></CITY>
<STATE><PDAT>IL</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Lalitha</PDAT></FNM><SNM><STEXT><PDAT>Iyer</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Chicago</PDAT></CITY>
<STATE><PDAT>IL</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Mark J.</PDAT></FNM><SNM><STEXT><PDAT>Ratain</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Chicago</PDAT></CITY>
<STATE><PDAT>IL</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Arch Development Corporation</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Chicago</PDAT></CITY><STATE><PDAT>IL</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Fulbright &amp; Jaworski</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>W. Gary</PDAT></FNM><SNM><STEXT><PDAT>Jones</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Arun Kv.</PDAT></FNM><SNM><STEXT><PDAT>Chakrabarti</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1634</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon the presence of the polymorphisms. The invention further provides methods of predicting sensitivity to xenobiotics and diagnostic kits for detecting genetic polymorphisms.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This is a continuation of co-pending application Ser. No. 09/251,274, filed Feb. 16, 1999 now U.S. Pat. No. 6,395,481.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on a reasonable terms as provided for by the terms of Grant No. NSF-9317266 awarded by the National Science Foundation.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>Researchers have invested considerable effort attempting to identify the pharmacogenetic basis of idiosyncratic adverse drug reactions, particularly hypersensitivity reactions. There is clear evidence for pharmacogenetic influence on susceptibility to hypersensitivity reactions. One such pharmacogenetic influence is genetic polymorphism. Genetic polymorphism involve the regular and simultaneous existence in the same population of two or more discontinuous variants or genotypes in frequencies that cannot be due to recurrent mutations. Probably, the best known example of genetic polymorphism involves the different human blood groups. Genetic polymorphism at loci which encode enzymes involved in metabolism of toxic or carcinogenic compounds can have clinical implications in drug metabolism. The pharmacokintetic and pharmacodynamic consequences of the activity of a polymorphic enzyme depend upon whether it mediates metabolism of the parent drug, the metabolites or both, whether parent drug or metabolites or both are active, the overall contribution to clearance from the affected pathway, the potency of the active species, and the patency of competing pathways of elimination. Tucker, </PDAT><HIL><ITALIC><PDAT>Journal Pharmacology</PDAT></ITALIC></HIL><PDAT>, 46, 417-424 (1994). Examples of the various permutations have been illustrated by Gram, et al in Clinical Relevance of Genetic Polymorphisms in Drug Oxidation, (1992).</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>One group of polymorphic enzymes that has implications in drug metabolism is the glucuronosyltransferases. Glucuronosyltransferases (UGTs) are the enzymes responsible for converting endogenous, toxic or carcinogenic compounds into a more water soluble form so they may be excreted from the body. UGTs are members of the transferase class of enzymes and are characterized by their ability to catalyze reactions that transfer functional groups from one compound to another. During metabolism, UGTs render polarity to xenobiotics and other exogenous compounds by catalyzing the transfer of a glucuronate moiety from uridine diphosphate glucuronate to an acceptor &bgr;-D-glucuronoside to form a glucuronide conjugate which can then be secreted into the bile. In addition to catalyzing reactions to detoxify exogenous compounds, UGTs catalyze reactions that impart water solubility to endogenous compounds. For example, UGTs catalyze a reaction in the liver whereby bilirubin is rendered water soluble by conjugation to form bilirubin bisglucuronide, most of which is excreted in the bile.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Higher than normal levels of bilirubin in the blood can be caused by one such genetic polymorphism, Gilbert&apos;s Syndrome. Gilbert&apos;s Syndrome (GS) is a benign unconjugated hyperbilirubinemia characterized by the presence of higher than normal concentrations of bilirubin in the blood. The higher than normal levels of bilirubin in the blood often result in episodes of mild intermittent jaundice. Gilbert&apos;s syndrome hyperbilirubinemia occurs in the absence of structural liver disease and overt hemolysis. It is part of a spectrum of familial unconjugated hyperbilirubinemias including the more severe Crigler-Najjar (CN) Syndromes (types 1 and 2). GS is the most common inherited disorder of hepatic bilirubin metabolism occurring in 2-12% of the population and is often detected in adulthood through routine screening blood tests or the fasting associated with surgery or illness which unmasks the hyperbilirubinemia. The most consistent feature in GS is a deficiency in bilirubin glucuronidation but altered metabolism of drugs has also been reported. Altered rates of bilirubin production, hepatic heme production and altered hepatic uptake of bilirubin have been reported in some GS patients. Due to the benign nature of the syndrome and its prevalence in the population it may be more appropriate to consider GS as a normal genetic variant exhibiting reduced bilirubin glucuronidation capacity (which in certain situations such as fasting, illness or administration of drugs) could precipitate jaundice.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>In addition to bilirubin metabolism, the glucuronidation detoxification pathway is also responsible for detoxifying many other compounds. For example, two promising antitumor agents, Irinotecan (CPT-11) and TAS-103, are detoxified in the liver by the same pathway. While Irinotecan has been recently approved for repeats use in patients with metastatic colorectal cancer, TAS-103 is currently undergoing Phase I clinical trials in the United States. The active metabolite of Irinotecan, SN-38, and TAS-103 are both glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs) in vivo. The major dose-limiting toxicity of Irinotecan therapy is diarrhea, which is believed to be secondary to the biliary excretion of SN-38, the extent of which is determined by SN-38 glucuronidation. On the other hand, the major toxicity associated with TAS-103 therapy is leukopenia. In the case of both drugs, glucuronidation is the major detoxification pathway. In patients with GS or CN, where glucuronidation activity is low, increased susceptibility to drug toxicity is a major problem. There remains a need in the art for a method to detect genetic polymorphisms at loci which encode enzymes involved in metabolism of endogenous, toxic or carcinogenic compounds.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The present invention is directed to methods for detecting promoter polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for determining the presence of genetic polymorphisms within a uridine diphosphate glucuronosyltransferase and or its promoter, and preferably within the uridine diphosphate glucuronosyltransferase I (UGT1A1) promoter. The polymorphisms comprise a variation in the number of thymidine-adenine repeats, TA</PDAT><HIL><SB><PDAT>n</PDAT></SB></HIL><PDAT>, where n&equals;the number of TA repeats. Preferably the polymorphisms comprise the homozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, as well as the heterozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>The present invention also provides methods for screening individuals for variation in glucuronidation activity by detecting polymorphisms in a UGT promoter by determining the number of TA repeats in that UGT promoter. More specifically, the present invention provides methods for screening individuals for varying glucuronidation activity caused by the presence or absence of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>in the UGT1A1 promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The present invention provides methods for determining or optimizing drug dosages by detecting polymorphisms in a UGT promoter by determining the number of TA repeats in the UGT promoter. More specifically, the present invention provides methods of determining optimum dosages of drugs based upon the presence or absence of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>in the UGT1A1 promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>In another embodiment, the present invention provides methods for determining or optimizing drug dosages by screening individuals for variation in glucuronidation activity by detecting polymorphisms in a UGT promoter by determining the number of TA repeats in the UGT promoter. More specifically, the present invention provides methods for determining optimum dosages of drugs based upon varying glucuronidation activity caused by the presence or absence of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>in the UGT1A1 promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>The present invention also provides methods for predicting an individual&apos;s sensitivity to xenobiotics by detecting polymorphisms in a UGT promoter by determining the number of TA repeats in that UGT promoter. More specifically, the present invention provides methods for predicting an individual&apos;s sensitivity to xenobiotics caused by the presence or absence of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>in the UGT1A1 promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>In another embodiment, the present invention provides methods for predicting an individual&apos;s sensitivity to xenobiotics by screening individuals for variation in glucuronidation activity by detecting polymorphisms in a UGT promoter and determining the number of TA repeats in that UGT promoter. More specifically, the present invention provides methods for predicting an individual&apos;s sensitivity to xenobiotics based upon varying glucuronidation activity caused by the presence or absence of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>in the UGT1A1 promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the method comprises the steps of obtaining a DNA sample from an individual, amplifying the DNA comprising all or part of a UGT1 promoter which comprises the TATA box sequence upstream of the UGT1 exon 1, determining the number of TA repeats in the amplified DNA by gel electrophoresis or sequencing the amplified DNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>Preferably the DNA is amplified using the polymerase chain reaction (PCR) using a radioactively labeled pair of nucleotide primers that are designed to amplify the region of the promoter known to regulate expression of the UGT gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>Preferably, the DNA region correlating with expression levels of UGT is the promoter region comprising the TATA repeat sequence in which polymorphisms in the number of TA repeats has been shown to correlate with expression of the UGT gene. More preferably, the polymorphisms comprise &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>The invention further comprises a kit for screening individuals to detect polymorphisms in a UGT gene promoter, the kit comprising primers for amplifying DNA in a region comprising all or part of a UGT promoter which comprises the TATA box sequence upstream of the UGT exon 1. In a preferred embodiment, the kit also contains deoxynucleoside triphosphates, buffers, labels for detecting the polymorphisms and instructions. Most preferably, the polymorphisms comprise the homozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, as well as the heterozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>In another embodiment, the invention further comprises a kit for screening individuals for variation in glucuronidation activity by detecting polymorphisms in a UGT gene promoter, the kit comprising primers for amplifying DNA in a region comprising all or part of a UGT promoter which comprises the TATA box sequence upstream of the UGT exon 1. In a preferred embodiments, the kit also contains deoxynucleoside triphosphates, buffers, labels for detecting the polymorphisms and instructions. Most preferably, the polymorphisms comprise the homozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, as well as the heterozygous genotypes &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the invention which described presently preferred embodiments thereof and are not intended to limit the invention as described in the claims.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> displays correlation assay data demonstrating the correlation between in vitro SN-38 and bilirubin glucuronidation in human liver microsomes. Each data point represents the mean of three separate determinations.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> displays glucuronidation assay data demonstrating in vitro glucuronidation of SN-38 by cDNA-expressed UGT isoforms. Cell lysates from HK293 cells expressing UGT1A1 (&diams;), UGT1A4 (&square;) and UGT2B7 enzymes (&Dgr;), and membrane preparations of HK293 cells expressing UGT1A1 enzyme (&Circlesolid;), were screened for SN-38 glucuronidating activity. HK293 cells (&diam;) were used as a control. Each data point represents the mean of three separate determinations.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION</PDAT></STEXT></H>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>Hepatic glucuronidation results from the activities of a multigene family of UGT enzymes, the members of which exhibit specificity for a variety of endogenous substrates and xenobiotics. The UGT enzymes are broadly classified into two distinct gene families. The UGT1 locus codes for multiple isoforms of UGT, all of which share a C-terminus encoded by a unique set of exons 2-5, but which have a variable N-terminus encoded by different first exons, each with its own independent promoter. Bosma, et al., </PDAT><HIL><ITALIC><PDAT>Hepatology</PDAT></ITALIC></HIL><PDAT>., 15:941-947 (1992); Ritter, et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem</PDAT></ITALIC></HIL><PDAT>., 267:3257-3261 (1992). The variable first exons confer the substrate specificity on the enzyme. Isoforms of the UGT2 family are unique gene products of which at least eight isozymes have been identified. Clarke, et al. </PDAT><HIL><ITALIC><PDAT>Handbook of Experimental Pharmacology </PDAT></ITALIC></HIL><PDAT>112:3-43 (1994). The UGT1A1 isoform is the major bilirubin glucuronidation enzyme. Genetic defects in the UGT1A1 gene can result in decreased glucuronidation activity which leads to abnormally high levels of unconjugated serum bilirubin that may enter the brain and cause encephalopathy and kernicterus. Owens &amp; Ritter, </PDAT><HIL><ITALIC><PDAT>Progress in Nucleic Acid Research </PDAT></ITALIC></HIL><PDAT>&amp; </PDAT><HIL><ITALIC><PDAT>Molecular Biology</PDAT></ITALIC></HIL><PDAT>, 51:305-338 (1995). As described above, this condition is commonly known as Gilbert&apos;s syndrome. The molecular defect in Gilbert&apos;s Syndrome is a change in the TATA box within the UGT1A1 promoter. Bosma, et al., </PDAT><HIL><ITALIC><PDAT>N. Eng. J. Med</PDAT></ITALIC></HIL><PDAT>., 333:1171-1175 (1995); Monaghan, et al., </PDAT><HIL><ITALIC><PDAT>Lancet</PDAT></ITALIC></HIL><PDAT>, 347:578-581 (1996). This promoter usually contains a (TA)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>TAA element, but another allele, termed UGT1A1*28 or allele 7, is also present in human populations at high frequencies, and contains the sequence (TA)</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>TAA. This polymorphism in the promoter of the UGT1A1 gene results in reduced expression of the gene and accounts for most cases of Gilbert&apos;s Syndrome. Bosma, et al., </PDAT><HIL><ITALIC><PDAT>N. Eng. J. Med</PDAT></ITALIC></HIL><PDAT>., 333:1171-1175 (1995). As discussed below, overall, gene expression levels for the UGT1A1 promoter alleles are inversely related to the length of the TA repeat in the TATA box.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>The variation observed in this promoter may also account for the inter-individual and inter-ethnic variation in drug metabolism and response to xenobiotic exposure. UGTs have been shown to contribute to the detoxification and elimination of both exogenous and endogenous compounds. For example, the examples set out below demonstrate the role of the UGT1A1 isoform in the glucuronidation of SN-38 (7-ethyl-10-hydroxycamptothecin) to the corresponding glucuronide (10-O-glucuronyl-SN-38, SN-38G) as well as the glucuronidation of TAS-103 (6-&lsqb;&lsqb;2-(dimethylamino)ethy&rsqb;amino&rsqb;-3-hydroxy-7H-indeno&lsqb;2,1-c&rsqb;quinoline-7-one dihydrochloride) to its corresponding glucuronide (TAS-103G). SN-38 is the active form of Irinotecan (CPT-11,7-ethyl-10-&lsqb;4-(1-piperidino)-1-piperidino&rsqb;carbonyloxycamptothecin), which is a camptothecin derivative used in the treatment of metastatic colorectal cancer and other malignancies. The metabolism of SN-38 and TAS-103 are merely illustrative of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>Irinotecan is biotransformed by tissue and serum carboxylesterases to an active metabolite, SN-38, which has a 100-1,000-fold higher antitumor activity than Irinotecan. SN-38 is glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs) to form SN-38 glucuronide (10-O-glucuronyl-SN-38, SN-38G), which is inactive and excreted into the bile and urine although, SN-38G is sometimes deconjugated to form SN-38 by intestinal &bgr;-glucuronidase enzyme. Kaneda, et al., </PDAT><HIL><ITALIC><PDAT>Cancer Res</PDAT></ITALIC></HIL><PDAT>. 50:1715-1720 (1990).</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>The major dose-limiting toxicities of Irinotecan include diarrhea and, to a lesser extent, myelosuppression. Irinotecan-induced diarrhea can be serious and often does not respond adequately to conventional antidiarrheal agents. Takasuna, et al., </PDAT><HIL><ITALIC><PDAT>Folia Pharmacol. Jpn </PDAT></ITALIC></HIL><PDAT>105:447-460 (1995). This diarrhea may be due to direct enteric injury caused by the active metabolite, SN-38, which has been shown to accumulate in the intestine after intra peritoneal administration of Irinotecan in athymic mice. Araki, et al., </PDAT><HIL><ITALIC><PDAT>Jpn. J. Cancer Res</PDAT></ITALIC></HIL><PDAT>. 84:697-702 (1993). The results of a recently completed phase I clinical trial, demonstrated that there was an inverse relationship between SN-38 glucuronidation rates and severity of diarrheal incidences in patients treated with increasing doses of Irinotecan. Gupta, et al., </PDAT><HIL><ITALIC><PDAT>Cancer Res</PDAT></ITALIC></HIL><PDAT>. 54:3723-3725 (1994). These findings indicate that glucuronidation of SN-38 protects against Irinotecan-induced gastrointestinal toxicity. A complete discussion of the correlation between diarrhea and SN-38 glucuronidation, as well as a description of biochemical methods for determining glucuronidation levels can be found in U.S. Pat. No. 5,786,344 and WO96/01127 which are both incorporated herein by reference in their entirety. Likewise, the results of studies using TAS-103 demonstrate that glucuronidation of TAS-103 may protect against TAS-103 induced toxicity. Therefore, the conversion of these two toxic compounds by hepatic UGTs demonstrates the importance of monitoring glucuronidation activity as an indicator of susceptibility to toxicity caused by exposure to compounds that are metabolized by UGTs. Furthermore, differential rates of SN-38 glucuronidation among subjects may explain the considerable inter-individual variation in the pharmacokinetic parameter estimates and toxicities observed after treatment with anti-cancer drugs or exposure to xenobiotics. Gupta, et al., </PDAT><HIL><ITALIC><PDAT>Cancer Res</PDAT></ITALIC></HIL><PDAT>. 54:3723-3725 (1994); Gupta, et al., </PDAT><HIL><ITALIC><PDAT>J. Clin. Oncol</PDAT></ITALIC></HIL><PDAT>. 15:1502-1510 (1997).</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>When two species (Gunn rats (Gunn, C. H., </PDAT><HIL><ITALIC><PDAT>J. Hered</PDAT></ITALIC></HIL><PDAT>., 29:137-139 (1938)) and CN-1 patients) that are deficient in specific isoforms of UGT were screened for TAS-103 and SN-38 glucuronidation activity, there was approximately an 80% lower glucuronidation rate of TAS-103 in vitro and no in vitro glucuronidation of SN-38. These results demonstrate the role of the UGT1 family in catalyzing SN-38 and TAS-103 conjugation. Furthermore, these results demonstrate that the UGT isoform family does not play a role in the glucuronidation of SN-38. On the other hand, while the UGT1 family is the predominate isoform involved in TAS-103 glucuronidation, the UGT2 isoform family may also participate in TAS-103 glucuronidation. Failure to glucuronidate SN-38 and TAS-103 in these instances results specifically from the genetic defect in UGT1.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>Other experiments, explained below, confirm the association between the UGT1A1 isoform and SN-38 and TAS-103 glucuronidation. The results described herein show that substantial genetic variability exists in the UGT1A1 isoform family and particularly in the UGT1A1 promoter. This genetic variability has been shown to correlate with gene expression. For example, the presence of the 5 allele in the UGT1A1 promoter leads to increased gene expression while the presence of the 8 allele leads to reduced gene expression. Differences in gene expression levels may give rise to individuals with varying abilities to glucuronidate compounds metabolized by UGT. This prediction was confirmed through a correlation analysis of UGT1A1 promoter genotype and rate of in vitro SN-38 and TAS-103 glucuronidation.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>It follows therefore that individuals with the 8 allele may also have differing susceptibility to xenobiotics when compared to other genotypes when those compounds are metabolized by UGTs. On the other hand, the presence of the 5 allele that correlates with increased gene expression and higher glucuronidation activity may result in the administration of less than optimum drug dosages. For example, when a drug metabolized by UGTs is administered to an individual with this polymorphism, the increased glucuronidation activity may cause more of the drug to be converted into the inactive metabolite in a shorter period, thereby reducing the drug&apos;s effectiveness. Conversely, in the rare case of drugs and xenobiotics that require glucuronidation for activation, decreased glucuronidation activity may cause less of the activated form of the drug or xenobiotic to be available.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>The fact that repeated sequences are intrinsically unstable and tend to lengthen and shorten as a result of unequal crossing-over during meiosis may explain the presence of other alleles, in addition to &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, in the population. The examples below describe two additional alleles identified in human populations: allele 5, containing the sequence &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and allele 8, containing the sequence &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA. Interestingly, alleles 5 and 8 were found in population samples from Sub-Saharan Africa, where they occur at lower frequencies than the common alleles 6 and 7 although it is possible that these two alleles are present across a variety of ethnic groups. The frequency of allele 6 and 7 also appears to differ significantly across ethnic groups, with Asian and Amerindian populations showing the highest frequencies of allele 6. Conversely, alleles 6 and 7 occur at intermediate and similar frequencies among Caucasians and Sub-Saharan Africans.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>Several hypotheses may be proposed regarding the selective pressures that might be responsible for the observed pattern of inter-population variation at the UGT1A1 promoter. It was previously proposed that the maintenance of intermediate levels of bilirubin is adaptive, Beutler, et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 95:8170-8174 (1998), and that the alleles at this promoter would be maintained in the population by balancing selection. This hypothesis is based on the observation that bilirubin is a potent antioxidant likely to have physiological significance. Stocker, et al., </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 235:1043-1046 (1987). However, it is also known that glucuronidation is an important detoxification step for many endogenous as well as exogenous compounds. Clarke &amp; Burchell, </PDAT><HIL><ITALIC><PDAT>Handbook of Experimental Pharmacology</PDAT></ITALIC></HIL><PDAT>, FC Kaufman Ed., Berlin/Heidelberg:Springer-Verlag, p. 3-43 (1994). In addition to TAS-103 and SN-38, UGT1A1 is likely to act on other substrates present in the environment, e.g., dietary components, environmental pollutants and carcinogens, which require detoxification as well as playing a role in the metabolism of bilirubin and other endogenous compounds. Within this framework, maintaining high levels of UGT1A1 gene expression would ensure rapid elimination of toxic or endogenous compounds and be advantageous.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>As described herein, the correlation between in vitro glucuronidation rate and UGT1A1 promoter polymorphism found for alleles 6 and 7 has been shown to extend to alleles 5 and 8. Because these alleles appear to be present in subsets of human populations (for example, those of African origin), an even higher inter-individual variability in SN-38 and TAS-103 metabolism might be expected within these populations. Because the inverse relationship between TA repeat size and rate of SN-38 glucuronidation extends to alleles 5 and 8, a screening assay that identifies these alleles can facilitate individualization of drug therapy, identify individuals susceptible to xenobiotic exposure, and can be used to improve drug dosage calculations.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>The examples set forth below are intended to be illustrative of the present invention and are not intended to limit the scope of the invention as set out in the appended claims.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>Example 1 describes an SN-38 glucuronidation assay using liver microsomes from normal rats, normal humans, Gunn rats and CN-1 patients. Example 2 describes a 3&prime;-azido-3&prime;-deoxythymidine (AZT) glucuronidation assay used as a control. Example 3 describes correlation studies with in vitro SN-38 glucuronidation versus bilirubin and PNP glucuronidation in human liver microsomes. Example 4 describes an experiment designed to measure SN-38 glucuronidation by cDNA-expressed isoforms of UGT. Example 5 describes correlation studies with in vitro TAS-103 glucuronidation versus bilirubin and SN-38 glucuronidation. Example 6 describes the relationship between UGT1A1 promoter genotype and SN-38 glucuronidation. Example 7 describes non-limiting examples of diagnostic applications of the methods for screening for UGT1A1 genotype.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>SN-38 Glucuronidation Assay</PDAT></STEXT></H>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>To investigate which UGT enzymes are responsible for SN-38 glucuronidation, the in vitro metabolism of SN-38 was measured using normal human and rat liver microsomes, as well as microsomes from Gunn rats, Gunn, C. H., </PDAT><HIL><ITALIC><PDAT>J. Hered</PDAT></ITALIC></HIL><PDAT>., 29:137-139 (1938), and patients with Crigler-Najjar type I (CN-1) syndrome. Liver microsomes were prepared from normal humans, CN-1 patients, normal rats, and Gunn rats and assayed for SN-38 glucuronidation. Microsomes from human liver samples medically unsuitable for liver transplantation were acquired under the auspices of the Washington Regional Transplant Consortium. In addition, microsomes were prepared by differential centrifugation methods. Purba, H. S., et al., </PDAT><HIL><ITALIC><PDAT>Br. J. Clin. Pharmaocol</PDAT></ITALIC></HIL><PDAT>. 23:447-453, using human liver samples obtained with the approval of the Institutional Review Boards of institutions involved through the Liver Tissue Procurement and Distribution System. Investigations were performed with pooled microsomes from normal rats, normal humans and Gunn rats, while microsomes from CN-1 patients were used individually.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>Microsomes (1 mg/ml) were incubated with SN-38 (5 &mgr;M), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), and UDPGA (5 mM) in a 0.1 M Tris-HCl buffer medium (pH 7.4) for 30 minutes at 37&deg; C., in a final volume of 200 &mgr;l. After stopping the reaction with 400 &mgr;l methanol, the incubation mix was centrifuged at 2,500 rpm for 30 minutes at 4&deg; C. The supernatant was evaporated to dryness under nitrogen and in preparation of analysis by high pressure liquid chromatography (HPLC), the supernatant was reconstituted with 250 &mgr;l of a mobile phase consisting of 35% acetonitrile and 65% 0.1 M KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>containing 3 mM sodium heptane sulphonate (pH 4.0), used at a flow rate of 0.8 ml/min. A C</PDAT><HIL><SB><PDAT>18</PDAT></SB></HIL><PDAT>&mgr; Bondapak column (10 &mgr;m, 3.9&times;300 mm) was used with fluorescence detection at the following wavelengths: 355 nm and 515 nm. 100 &mgr;l aliquots of the reconstituted supernatant were injected into an HPLC assay system. CPT was used as the internal standard. The chromatographs obtained after in vitro glucuronidation of normal human and rat microsomes revealed three peaks corresponding to SN-38G, SN-38, and CPT. Retention times were approximately 3.5, 9, and 10 minutes, respectively. The peaks for each of these compounds were confirmed using standards of SN-38G, SN-38, and CPT.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>Inter-individual variations in rates of SN-38 glucuronidating activity were evaluated by screening 25 normal human liver microsomes for in vitro SN-38 glucuronidation activity. There was considerable variation in the rates of SN-38G formation among individuals, with a range of 0.5-26 pmol of SN-38G formed/min/mg microsomal protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>Chromatographs obtained after in vitro glucuronidation of CN-1 patients and Gunn rats revealed Only two peaks corresponding to SN-38 and CPT. Retention times for SN-38 and CPT were approximately 9 and 10 minutes, respectively. The absence of the peak at approximately 3.5 minutes indicates that microsomes from both CN-1 patients and Gunn rats lack SN-38 glucuronidating activity.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>AZT Glucuronidation Assay</PDAT></STEXT></H>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>To ensure the viability and functional enzymatic activity of the microsomal preparations, the UGT activity toward another substrate, AZT (3&prime;-azido-3&prime;-deoxythymidine) was investigated as a control. Liver microsomes from normal humans, CN-1 patients, normal rats, and Gunn rats were prepared as described above. Investigations were performed in pooled microsomes from normal rats, normal humans and Gunn rats, while microsomes from CN-1 patients were used individually.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>Microsomes were preincubated with oleolyl lysophosphatidylcholine (OLPC) (0.8% wt/wt. OLPC/microsomal protein) at 4&deg; C. for 20 minutes. The final reaction mixture contained 1 mg/ml preincubated microsomes, AZT (5 mM), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), 0.2 M Tris-HCl buffer (pH 7.3), and UDPGA (10 mM) in a final volume of 300 &mgr;l. After an incubation period of 1 hour at 37&deg; C., the reaction was stopped with the addition of 30 &mgr;l of HCl. Proteins were removed after centrifugation at 10,500 g for 5 minutes and 30 &mgr;l aliquots of the supernatant were subjected to HPLC analysis and the metabolites were detected in an ultraviolet detector at a wavelength of 265 nm. The mobile phase consisted of a 15:85 mixture of acetonitrile/ammonium phosphate buffer (0.1% vol/vol phosphoric acid, adjusted to pH 2.7 with ammonium hydroxide) used at a flow rate of 1 ml/min. Intact in vitro formation of G-AZT was observed in microsomes from all four sources.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>Using the HPLC conditions described above, UDPGA/UDP (coelution), G-AZT, and AZT eluted at approximately 2.6, 5.7 and 9.5 minutes, respectively. These peaks appeared consistently after incubation of AZT with microsomes from normal rats and humans as well as in Gunn rats and CN-1 patients. The retention times obtained were confirmed using standard solutions of the respective chemicals.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Glucuronidation Correlation Assay</PDAT></STEXT></H>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>To determine which UGT1 isoform is responsible for SN-38 glucuronidation, the correlation between the rates of formation of SN-38G and glucuronidation of bilirubin &amp; PNP was investigated. PNP was chosen because planar phenols such as PNP and acetaminophen are glucuronidated predominantly by UGT1A6, See Burchell, et al., </PDAT><HIL><ITALIC><PDAT>DNA cell biol</PDAT></ITALIC></HIL><PDAT>., 10:487-494 (1991); Harding, et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 85:8381-8385 (1988), although several other isoforms such as UGT1A1, UGT1A4, and UGT2B15 have been reported to play a role in PNP glucuronidation in humans. See King, et al., </PDAT><HIL><ITALIC><PDAT>Arch. Biochem. Biophys</PDAT></ITALIC></HIL><PDAT>., 332:92-100 (1996); Green, et al., </PDAT><HIL><ITALIC><PDAT>Drug Metab. Dispos</PDAT></ITALIC></HIL><PDAT>., 23:299-302 (1995). Bilirubin was chosen because bilirubin has been previously shown to be glucuronidated by two isozymes of UGT1: UGT1A1 and UGT1A4. Ritter, et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem</PDAT></ITALIC></HIL><PDAT>., 266:1043-1047 (1991).</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>The formation of bilirubin mono- and diglucuronides was quantified using </PDAT><HIL><SP><PDAT>14</PDAT></SP></HIL><PDAT>C-labeled UDPGA as follows. Human liver microsomes (0.5 mg/ml) were incubated with bilirubin (0.343 mM), L-&agr;-phosphatidylcholine (0.75 mg/ml), saccharolactone (8.5 mM), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), and &lsqb;</PDAT><HIL><SP><PDAT>14</PDAT></SP></HIL><PDAT>C&rsqb;UDPGA (5 mM) in a 0.5 M Tris-HCl medium (pH 7.4) for 60 minutes at 37&deg; C., in a final volume of 100 &mgr;l. The reaction was stopped with 100 &mgr;l of 0.7 M glycine-HCl buffer (pH 2.0). Radiolabeled bilirubin glucuronides were extracted into ethyl acetate (1 ml), and the radioactivity in 300 &mgr;l aliquots was measured using a liquid scintillation counter.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>The formation of glucuronidated PNP was quantified by the following method. A preincubated (4&deg; C. for 30 minutes) mixture of human liver microsomes (1 mg/ml) with Triton X-100 (0.025% vol/vol) was incubated (final volume 200 &mgr;l) with PNP (360 &mgr;M), EDTA (40 &mgr;M), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), UDPGA (2 mM) in a 0.1 M Tris-HCl buffer (pH 7.4) for 10 minutes at 37&deg; C. The reaction was stopped by the addition of 2.8 ml of 0.2 M glycine-NaOH buffer (pH 10.4). Samples were centrifuged at 2,500 rpm for 30 minutes, and UGT activity in the supernatant was analyzed colorimetrically in a spectrophotometer by measuring the disappearance of the substrate at a wavelength of 400 nm.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>There was a significant correlation between rates of formation of SN-38G and bilirubin mono- and diglucuronides as shown in FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. (Pearson correlation coefficient, r&equals;0.89, P&equals;0.0001). In contrast, there was a poor association between SN-38G formation and PNP glucuronidation (r)&equals;0.08, P&equals;0.703). The rates of PNP glucuronidation were distributed evenly among subjects (mean&plusmn;SEM 20.39&plusmn;2.4, range 16.48-23.82 nmol PNP glucuronidated/min/mg protein. The similarity between SN-38 and bilirubin glucuronidation suggests that bilirubin UGT may also be glucuronidating SN-38.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>SN-38 Glucuronidation by cDNA-expressed Isoforms of UGT</PDAT></STEXT></H>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>To determine which particular isozyme of UGT1 glucuronidates SN-38, HK293 cells transfected with and expressing cDNA encoding selected UGT1 isozymes and a member of the UGT2 family (UGT2B7) were screened for SN-38 glucuronidating activity. Culture media and conditions for stable expression of human UGT1A1, UGT1A4, and UGT2B7 have been described previously. Coffman, et al., </PDAT><HIL><ITALIC><PDAT>Mol. Pharmacol</PDAT></ITALIC></HIL><PDAT>., 47:1101-1105 (1995), Green, et al., </PDAT><HIL><ITALIC><PDAT>Drug Metab. Dispos</PDAT></ITALIC></HIL><PDAT>., 23:299-302 (1995); Coffman, et al., </PDAT><HIL><ITALIC><PDAT>Drug Metab. Dispos</PDAT></ITALIC></HIL><PDAT>., 25:1-4 (1997) all are incorporated herein by reference. Briefly, the XbaI/XhoI and BamHI-XhoI fragments of human UGT1A1, UGT1A4, and UGT2B7 were subcloned into the respective corresponding sites of the mammalian expression vectors pcDNA3, pREP9, and pcDNA3.1. HK293 cells were transfected with the vector-UGT isozyme using the calcium phosphate transfection method. Chen, et al., </PDAT><HIL><ITALIC><PDAT>Biotechniques</PDAT></ITALIC></HIL><PDAT>, 6:632-638 (1988). The cells were then assayed for glucuronidation activity as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>These experiments resulted in a clear demonstration of the role of UGT1A1 in glucuronidating SN-38 as shown in FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>. There was a lack of SN-38 glucuronidating activity in control HK293 cells and those expression UGT1A4 and UGT2B7, up to a protein concentration of 2 mg/ml. On the other hand, there was measurable SN-38G formation in cells expressing UGT1A1, which increased with increasing protein concentrations. The high correlation between SN-38 and bilirubin glucuronidation suggests that UGT1A1 is the isoform involved in SN-38 glucuronidation.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Correlation Between Rates of Formation of TAS-103G, SN-38G, and Glucuronidated Bilirubin</PDAT></STEXT></H>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>In an effort to demonstrate that UGT1A1 also plays a role in glucuronidation of other toxic compounds, the correlation between rates of formation of TAS-103G, SN-38G and glucuronidation of bilirubin was investigated. Microsomes (protein&equals;2 mg/ml) were obtained from liver samples from different species: human, rat, mice and ferrets. Microsomes were incubated with TAS-103 (80 &mgr;M), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), and UDPGA (2 mM) in 0.1 M Tris-HCl buffer (pH 7.4) for 20 minutes at 37&deg; C. Retention times of about 6, 9, and 15 minutes were obtained for TAS-103G, TAS-103, and TAS-1-018 (internal standard), respectively, after HPLC separation and UV (460 nm) detection.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>There were extensive inter-subject differences in the rates of TAS-103 glucuronidation &lsqb;mean area ratio of TAS-103G/TAS-1-018 peaks&equals;11.2&plusmn;5.9 (SD), range&equals;1.02 to 27.26&rsqb; in normal liver microsomes (n&equals;18). TAS-103 glucuronidation rates correlated significantly with the glucuronidation of SN-38 (the active metabolite of Irinotecan, (Pearson r&equals;0.94, P&lt;0.01) and bilirubin (r)&equals;0.82, P&lt;0.01), suggesting the involvement of UGT1A1 and/or UGT1A4 isoforms.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>The role of UGT1A1 was confirmed using microsomes from lymphoblast cells that were specifically transfected with cDNA expressing UGT1A1, UGT1A4, and UGT1A6 isoforms. TAS-103G formation was observed only in microsomes containing UGT1A1 enzymes (mean area ratio&equals;7.18). No TAS-103 glucuronidating activity was observed in microsomes containing UGT1A4, UGT1A6, or in control lymphoblasts. Microsomes from Gunn rats and CN-1 patients that lack bilirubin and SN-38 UGT activity exhibited intact, but low glucuronidating activity (Gunn rats: 3.32&plusmn;0.94; CN-1 patients: 2.75&plusmn;0.11), indicating that one or more of the UGT2 isoforms are also involved in TAS-103 glucuronidation. Even so, these findings indicate that TAS-103 is glucuronidated predominantly by UGT1. Therefore, individuals with decreased UGT1A1 activity, such as those with Gilbert&apos;s Syndrome, may be at an increased risk for toxicity induced by exposure to compounds metabolized by UGTs.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Relationship Between UGT1A1 Promoter Genotype and SN-38 Glucuronidation</PDAT></STEXT></H>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>The experiments described below demonstrate a significant correlation between UGT1A1 promoter genotype and rates of bilirubin and SN-38 glucuronidation in liver tissue samples, as well as the genetic role of UGT1A1 polymorphism in the metabolism of Irinotecan. SN-38 and bilirubin glucuronidation assays were performed in human liver microsomes. Four promoter alleles were found at the UGT1A1 locus: &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>TAA which have been well characterized and two new polymorphisms, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA. &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>TAA is the wild-type allele known to be associated with bilirubin levels within the normal range. &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>TAA is known to be associated with Gilbert&apos;s Syndrome phenotype which is characterized by reduced levels of gene expression and therefore reduced glucuronidation activity resulting in higher levels of bilirubin. As the following experiment illustrates, the presence of a longer TATA element, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, in the promoter region of the gene for bilirubin UDP-glucuronosyltransferase results in reduced expression of the gene and therefore, reduced glucuronidation activity resulting in higher SN-38 levels. Reduced glucuronidation activity is a signal that a genetic predisposition to toxicity may exist. In contrast, the presence of a shorter TATA element, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, in the promoter region of the gene for bilirubin UDP-glucuronosyltransferase results in increased expression of the gene and therefore, increased glucuronidation activity resulting in lower SN-38 levels.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>DNA isolated from caucasian livers was subjected to polymerase chain reaction and size differentiating gel electrophoresis. The variability in the number of TA repeats at the UGT1A1 promoter was genotyped as previously described by Monaghan, et al., </PDAT><HIL><ITALIC><PDAT>Lance</PDAT></ITALIC></HIL><PDAT>, 347:578-581 (1996) using polymerase chain reaction (PCR). Primer pairs A/B (SEQ ID NOs: 3 &amp; 4) or C/D (SEQ ID NOs: 1 &amp; 2) were used to amplify fragments of 253-255 base pairs and 98-100 base pairs, respectively. Amplifications were in 0.2 nmol/L of the four deoxynucleoside triphosphates (dATP, dCTP, dGTP, dTTP), 50 nmol/L of KCl, 10 nmol/L Tris-HCl (pH 9.0 at 25&deg; C.), 0.1% Triton X-100&reg;, 1.5 nmol/L MgCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, 0.25 &mgr;mol/L of each primer, 1 unit of Taq polymerase (Promega), and human genomic DNA (0.25-0.50 &mgr;g). The Perkin-Elmer Cetus DNA thermal cycler was used for the reactions and PCR conditions were: 95&deg; C. for 5 minutes followed by 30 cycles of 95&deg; C. for 30 seconds, 58&deg; C. for 40 seconds, and 72&deg; C. for 40 seconds.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>Amplification was confirmed before direct sequencing by agarose gel electrophoresis with &lsqb;&agr;</PDAT><HIL><SP><PDAT>-35</PDAT></SP></HIL><PDAT>S&rsqb;-dATP and the USB Sequenase PCR product sequencing kit. Sequenced products were resolved in 6% denaturing polyacrylamide gels. The dried gels were exposed overnight to autoradiographic film before being developed.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>Radioactive PCR was also used and in that case, amplification was done as described above using primer pair C/D (SEQ ID NOs: 1 &amp; 2) except that 2.5 pmol of primer C (SEQ ID NO: 1) was first radioactively 5&prime; end-labeled with 2.5 &mgr;Ci of &lsqb;&ggr;-</PDAT><HIL><SP><PDAT>32</PDAT></SP></HIL><PDAT>P&rsqb;-ATP. Products were resolved on 6% denaturing polyacrylamide gels and the wet gels were exposed to autoradiographic film (&minus;70&deg; C. for 15 minutes) before being developed.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>The three possible genotypes, determined by amplification/sequencing or radioactive PCR, were homozygosity for the common allele (6/6), heterozygosity (6/7) or homozygosity for the rarer allele (7/7).</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>In order to investigate the variability at the UGT1A1 promoter across ethnic groups, 11 samples drawn at random from aboriginal and admixed populations from different ethnic backgrounds were genotyped. The results, shown in Table 1 below, indicate that four alleles are present in human populations and their frequencies vary considerably across ethnic groups.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="280pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>GENOTYPE &amp; ALLELE FREQUENCIES AT THE UGT1A1 PROMOTER IN</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>UNSELECTED POPULATIONS</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="offset" colwidth="91pt" align="left"/>
<colspec colname="1" colwidth="98pt" align="center"/>
<colspec colname="2" colwidth="56pt" align="center"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>ALLELE</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>GENOTYPE</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>FREQUENCY</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>FREQUENCY (%)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(%)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="14">
<colspec colname="1" colwidth="91pt" align="left"/>
<colspec colname="2" colwidth="14pt" align="center"/>
<colspec colname="3" colwidth="14pt" align="center"/>
<colspec colname="4" colwidth="14pt" align="center"/>
<colspec colname="5" colwidth="14pt" align="center"/>
<colspec colname="6" colwidth="14pt" align="center"/>
<colspec colname="7" colwidth="14pt" align="center"/>
<colspec colname="8" colwidth="14pt" align="center"/>
<colspec colname="9" colwidth="14pt" align="center"/>
<colspec colname="10" colwidth="14pt" align="center"/>
<colspec colname="11" colwidth="14pt" align="center"/>
<colspec colname="12" colwidth="14pt" align="center"/>
<colspec colname="13" colwidth="14pt" align="center"/>
<colspec colname="14" colwidth="21pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>POPULATION</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5/6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5/7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7/7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7/8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>HWE</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="14" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Sub-Saharan Africans</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>Bamileke&apos; (Cameroon)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>38</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>42</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>42</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>24</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Pygmy Mbenzele (Cameroon)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>56</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>42</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Ewondo (Cameroon)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>60</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Asians</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Japanese</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>84</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>91</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>67</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Chinese</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>65</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>31</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>80</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Caucasians</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Bedouin (Saudi Arabia)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>56</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>69</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>31</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Sardinians</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>56</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>74</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>26</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>70</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Amerindians</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Kaingang (Brazil)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>80</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>89</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>50</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Guarani&apos; (Brazil)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>68</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>26</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>81</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>19</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>31</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Admixed</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Hispanics</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>41</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>41</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>61</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>38</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>44</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>ns</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="14" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>In addition to the common alleles 6 and 7, alleles that differ in fragment length from 6 and 7 by &minus;2 and &plus;2 base pairs, respectively were detected. These alleles were amplified and directly sequenced as described above and shown to contain &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA TA repeats, respectively. Alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA were found in population samples from Sub-Saharan Africa, were they occur at lower frequencies compared to the common alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>TAA. The finding of a Hispanic individual carrying allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA is likely due to genetic admixture with African Americans.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>To investigate whether alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA affected glucuronidation activity, 15 additional liver samples, collected from African Americans, were genotyped at the UGT1A1 promoter as described above. To determine the sequences of alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>TAA and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>TAA, primers A and B (SEQ ID NOs: 3 and 4, respectively) were used for both PCR and cycle sequencing. The amplification product was purified by using the QIAquick PCR purification kit and directly sequenced using the BigDye&trade; Terminator cycle Sequencing Ready Reaction kit and an ABI 377 automated sequencer.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>Microsomes (1 mg/ml) were obtained from human liver tissue samples and were incubated with SN-38 (5 &mgr;M), MgCl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mM), and UDPGA (5 mM) in a 0.1 M Tris-HCl buffer medium (pH 7.4) for 30 minutes at 37&deg; C., in a final volume of 200 &mgr;l. SN-38, SN-38G and the internal standard, CPT, were separated using high performance liquid chromatography (HPLC) coupled to fluorescence detection (</PDAT><HIL><SB><PDAT>ex</PDAT></SB></HIL><PDAT>&equals;355 nm and </PDAT><HIL><SB><PDAT>em</PDAT></SB></HIL><PDAT>&equals;515 nm). SN-38 reaction rates were linear for incubation times up to at least 1.5 hours and for final protein concentrations of up to 2 mg/ml. The results of this analysis, shown in Table 2 below, also include the liver samples of Caucasian origin from the first study. A significant trend toward a decrease in mean glucuronidation rate between genotype groups is observed (p&lt;0.01, nonparametric trend analysis), except for the 6/8 and 7/7 groups. Statistical analysis using the sum of alleles in a individual&apos;s genotype (instead of genotypes) indicated a significant difference between livers with allele sums 11 &amp; 12 (corresponding to genotypes 5/6, 5/7 and 6/6) and 13 &amp; 14 (corresponding to genotypes 6/7, 6/8, and 7/7) (p&lt;0.01).</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="offset" colwidth="63pt" align="left"/>
<colspec colname="1" colwidth="231pt" align="center"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry></entry>
<entry namest="OFFSET" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>UGT1A1 Promoter Genotype</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="91pt" align="left"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="21pt" align="center"/>
<colspec colname="4" colwidth="42pt" align="center"/>
<colspec colname="5" colwidth="42pt" align="center"/>
<colspec colname="6" colwidth="21pt" align="center"/>
<colspec colname="7" colwidth="42pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Sample</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5/6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5/7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6/8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7/7</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="63pt" align="left"/>
<colspec colname="2" colwidth="28pt" align="left"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="21pt" align="center"/>
<colspec colname="5" colwidth="42pt" align="center"/>
<colspec colname="6" colwidth="42pt" align="center"/>
<colspec colname="7" colwidth="21pt" align="center"/>
<colspec colname="8" colwidth="42pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Caucasians</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N (%)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0 (0)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0 (0)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15 (56)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9 (33)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0 (0)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3 (11)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>M &lcub;SE&rcub;</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>0.36 &lcub;0.03&rcub;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.25 &lcub;0.03&rcub;</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>0.09 &lcub;0.01&rcub;</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>African Americans</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N (%)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;3 (20)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1 (7)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;2 (13)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5 (33)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1 (7)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3 (20)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>M &lcub;SE&rcub;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.41 &lcub;0.1&rcub;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.39</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.32 &lcub;0.01&rcub;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.25 &lcub;0.03&rcub;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.12 &lcub;0.07&rcub;</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="8" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>M &equals; mean SN-38 glucuronidation rate (ratio measured as: peak area of SN-38 glucuronide &divide; peak area CPT, where CPT &equals; internal standard). </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><PDAT>SE &equals; standard error </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>To evaluate the functional viability of microsomal drug-metabolizing enzymes in the liver samples used in this study, the livers were screened for 7-ethoxycoumarin O-deethylation, as 7-ethoxycoumarin is oxidized to umbelliferone by multiple cytochrome P450 enzymes. The method used is described by Evans &amp; Relling, </PDAT><HIL><ITALIC><PDAT>J. Chromatogr</PDAT></ITALIC></HIL><PDAT>., 578:141-145 (1992). Rates of umbelliferone formation were within the expected range, indicating normal cytochrome P450 activity in these liver samples.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 7</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Diagnostic and Screening Applications</PDAT></STEXT></H>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>The findings described above which show the correlation between a polymorphism in the promoter of a UGT gene and levels of gene expression may be used in a number of different assays. For example, the methods described above can be used in diagnostic or screening assays wherein individuals are screened for the predisposition to drug and chemical sensitivity exhibited by individuals with varying levels of hepatic uridine diphosphate glucuronosyltransferases (UGTs).</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>In view of the fact that a significant number of cases of toxicity due to administration of drugs are caused by low levels of hepatic uridine diphosphate glucuronosyltransferases (UGTs) that can be traced to the presence of a longer TATA element, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, in the promoter region of the gene for bilirubin UDP-glucuronosyltransferase, a diagnostic application that identifies this genetic polymorphism is quite useful. Therefore, in one embodiment, the genotype of the UGT1A1 promoter is determined as described in Example 6. After screening for any of the polymorphism, the amount of drug administered should be adjusted to avoid drug induced toxicity or to optimize the therapeutic dose of the drug.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>Additionally, the methods described above are useful when an individual has a genotype that includes the presence of allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>. In a second embodiment, the genotype of the UGT1A1 promoter is determined as described in example 6. Specifically, the presence of allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>is confirmed. A certain percentage of potential chemotherapy patients (particularly those of Sub-Saharan African descent) may be expected to have this genotype as compared to normal subjects. The drug dose administered to these individuals may have to be increased to achieve maximum effectiveness. The presence of allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>is an indication that the individual has higher than normal glucuronidation activity which may lead to inactivation of the drug metabolites and excretion of a greater percentage of the drug administered. On the other hand, in a case where a drug requires glucuronidation for activation, dosages may require adjusting to compensate for the increased level of activation caused by the presence of allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>In addition to the previously described anti-cancer drugs, oral contraceptives provide another situation in which individuals with a UGT polymorphism may suffer clinical manifestations because of improper drug dosages. Women with genotypes that include alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>may be more susceptible to drug toxicity when taking acetaminophen and ethinyloestradiol concurrently. Since both drugs are primarily glucuronidated by the UGT1 isoform, combining them may lead to drug toxicity because of increased bioactivation of acetaminophen. In this method, the genotype is determined as described in Example 6. After determining the genotype of the individual&apos;s UGT1A1 promoter, proper drug dosages can be calculated and unnecessary cases of drug toxicity can be avoided.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>Not only are the methods described above useful in the context of screening for drug sensitivity, they are also useful in a screening assay to identify individuals who have a genetic polymorphism causing sensitivity to compounds found in the environment. A certain percentage of the population may be expected to have at least one copy of the &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>allele. These individuals will exhibit differential sensitivity to xenobiotics based upon their genotype. In a third embodiment, the genotype of the UGT1A1 promoter is again determined as described in Example 6. Individuals identified as having a genotype that includes allele &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>can be selected when a low sensitivity to xenobiotics is required. For example, individuals working in situations where they are exposed to chemicals could be screened as a rational basis for predicting the likelihood of developing clinical manifestations as a result of chemical exposure. Individuals with genotypes including alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>will exhibit increasing sensitivity when exposed to environmental xenobiotics because of reduced glucuronidation activity.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>In another diagnostic assay based upon the methods described above, it is possible to identify individuals who have a reduced ability to metabolize endogenous compounds because of reduced glucuronidation activity. The genotype of the UGT1A1 promoter is again determined as described in Example 6. Individuals with genotypes including alleles &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7 </PDAT></SB></HIL><PDAT>and/or &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8 </PDAT></SB></HIL><PDAT>may exhibit clinical manifestations of their inability to conjugate and excrete endogenous compounds.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>Also contemplated with the above embodiments of methods of screening for individuals predisposed to drug or chemical sensitivities are diagnostic kits for the determination of genotype of the UGT1A1 promoter. The diagnostic kits may comprise appropriate primers, deoxynucleoside triphosphates; buffers for amplification; labels for the detection of the alleles of interest; and instructions for use of said diagnostic kits.</PDAT></PTEXT></PARA>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>3</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>20</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence Synthetic
      Primer</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 1
gtcacgtgac acagtcaaac                                                 20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>19</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence Synthetic
      Primer</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 2
tttgctcctg ccagaggtt                                                  19
</PDAT>
</S400>
<S200>
<S210>
<PDAT>3</PDAT>
</S210>
<S211>
<PDAT>21</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence Synthetic
      Primer</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 3
aagtgaactc cctgctacct t                                               21
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>We claim: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>1. A method for detecting polymorphisms in a uridine diphosphate glucuronosyl transferase (UGT) gene promoter comprising determining the presence of eight (TA) repeats in said promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) obtaining DNA from an individual; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) amplifying all or part of said UGT1A1 gene promoter contained in said DNA; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) determining the number of TA repeats in said promoter. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> or </PDAT><CLREF ID="CLM-00002"><PDAT>2</PDAT></CLREF><PDAT> wherein said promoter is the UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT> wherein said DNA being amplified comprises all or part of a UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said DNA is amplified by the polymerase chain reaction (PCR) and said number of TA repeats is determined by gel electrophoresis.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said DNA is amplified by PCR and said number of TA repeats is determined by sequencing said amplified DNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said promoter has a genotype selected from the group consisting of &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>,/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>8. A method for detecting polymorphisms in a uridine diphosphate glucuronosyltransferase I (UGT1A1) gene promoter comprising determining the presence of eight (TA) repeats in said promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) obtaining DNA from an individual; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) amplifying all or part of said UGT gene promoter contained in said DNA; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) determining the number of TA repeats in said promoter. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>10. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> wherein said DNA being amplified comprises all or part of a UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> wherein said DNA is amplified by polymerase chain reaction (PCR) and said number of TA repeats is determined by gel electrophoresis.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> wherein said DNA is amplified by PCR and said number of TA repeats is determined by sequencing said amplified DNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>13. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> wherein said promoter has a genotype selected from the group consisting of &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>,/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>14. A method for screening individuals for variation in glucuronidation activity comprising detecting polymorphisms in a uridine diphosphate glucuronosyltransferase (UGT) gene promoter comprising determining the presence of eight (TA) repeats in said promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>15. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> comprising the steps of:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) obtaining DNA from an individual; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) amplifying all or part of said UGT gene promoter contained in said DNA; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) determining the number of TA repeats in said promoter. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>16. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> or </PDAT><CLREF ID="CLM-00015"><PDAT>15</PDAT></CLREF><PDAT> wherein said promoter is the UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>17. The method of </PDAT><CLREF ID="CLM-00016"><PDAT>claim 16</PDAT></CLREF><PDAT> wherein said DNA being amplified comprises all or part of a UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>18. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> wherein said DNA is amplified by the polymerase chain reaction (PCR) and said number of TA repeats is determined by gel electrophoresis.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>19. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> wherein said DNA is amplified by PCR and said number of TA repeats is determined by sequencing said amplified DNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>20. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> wherein said promoter has a genotype selected from the group consisting of &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>,/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>21. A method for screening individuals for variation in glucuronidation activity comprising detecting polymorphisms in a uridine diphosphate glucuronosyltransferase I (UGT1A1) gene promoter, the method comprising determining the presence of eight (TA) repeats in said promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>22. The method of </PDAT><CLREF ID="CLM-00021"><PDAT>claim 21</PDAT></CLREF><PDAT> comprising the steps of</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) obtaining DNA from an individual; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) amplifying all or part of said UGT gene promoter contained in said DNA; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) determining the number of TA repeats in said promoter. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00023">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>23. The method </PDAT><CLREF ID="CLM-00021"><PDAT>claim 21</PDAT></CLREF><PDAT> wherein said DNA being amplified comprises all or part of a UGT1A1 promoter.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00024">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>24. The method of </PDAT><CLREF ID="CLM-00021"><PDAT>claim 21</PDAT></CLREF><PDAT> wherein said DNA is amplified by polymerase chain reaction (PCR) and said number of TA repeats is determined by gel electrophoresis.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00025">
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>25. The method of </PDAT><CLREF ID="CLM-00021"><PDAT>claim 21</PDAT></CLREF><PDAT> wherein said DNA is amplified by PCR and said number of TA repeats is determined by sequencing said amplified DNA.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00026">
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>26. The method of </PDAT><CLREF ID="CLM-00021"><PDAT>claim 21</PDAT></CLREF><PDAT> wherein said promoter has a genotype selected from the group consisting of &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>5</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>, &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>, and &lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>,/&lsqb;TA&rsqb;</PDAT><HIL><SB><PDAT>8</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06472157-20021029-D00001.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06472169-20021029-D00001.TIF SYSTEM "US06472169-20021029-D00001.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00002.TIF SYSTEM "US06472169-20021029-D00002.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00003.TIF SYSTEM "US06472169-20021029-D00003.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00004.TIF SYSTEM "US06472169-20021029-D00004.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00005.TIF SYSTEM "US06472169-20021029-D00005.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00006.TIF SYSTEM "US06472169-20021029-D00006.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00007.TIF SYSTEM "US06472169-20021029-D00007.TIF" NDATA TIF>
<!ENTITY US06472169-20021029-D00008.TIF SYSTEM "US06472169-20021029-D00008.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06472169</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021029</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09676609</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000930</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12P  100</PDAT></B511>
<B512><PDAT>C12P 1500</PDAT></B512>
<B512><PDAT>C12P  722</PDAT></B512>
<B512><PDAT>C12N  120</PDAT></B512>
<B512><PDAT>C07H 2104</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435 41</PDAT></B521>
<B522><PDAT>435127</PDAT></B522>
<B522><PDAT>435156</PDAT></B522>
<B522><PDAT>435189</PDAT></B522>
<B522><PDAT>435193</PDAT></B522>
<B522><PDAT>435232</PDAT></B522>
<B522><PDAT>4352523</PDAT></B522>
<B522><PDAT>4353201</PDAT></B522>
<B522><PDAT>435822</PDAT></B522>
<B522><PDAT>435849</PDAT></B522>
<B522><PDAT>435911</PDAT></B522>
<B522><PDAT>435940</PDAT></B522>
<B522><PDAT>536 232</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Biocatalytic synthesis of shikimic acid</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 94/14955</PDAT></DNUM>
<DATE><PDAT>19940700</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>96 34961</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>EP 99 95 6926 Supplementary European Search Report.</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>21</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435 41</PDAT></B582>
<B582><PDAT>435127</PDAT></B582>
<B582><PDAT>435156</PDAT></B582>
<B582><PDAT>435189</PDAT></B582>
<B582><PDAT>435193</PDAT></B582>
<B582><PDAT>435232</PDAT></B582>
<B582><PDAT>4352523</PDAT></B582>
<B582><PDAT>4353201</PDAT></B582>
<B582><PDAT>435822</PDAT></B582>
<B582><PDAT>435849</PDAT></B582>
<B582><PDAT>435911</PDAT></B582>
<B582><PDAT>435940</PDAT></B582>
<B582><PDAT>536 232</PDAT></B582>
</B580>
<B590><B595><PDAT>8</PDAT></B595><B596><PDAT>13</PDAT></B596></B590>
</B500>
<B600>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>09/676609</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/240440</PDAT></DNUM><DATE><PDAT>19990129</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>00</PDAT></PSTA></PARENT-US></B632></B630>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>John W.</PDAT></FNM><SNM><STEXT><PDAT>Frost</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Okemos</PDAT></CITY>
<STATE><PDAT>MI</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Karen M.</PDAT></FNM><SNM><STEXT><PDAT>Frost</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Okemos</PDAT></CITY>
<STATE><PDAT>MI</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>David R.</PDAT></FNM><SNM><STEXT><PDAT>Knop</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Okemos</PDAT></CITY>
<STATE><PDAT>MI</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Board of Trustees operating Michigan State University</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>East Lansing</PDAT></CITY><STATE><PDAT>MI</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Harness, Dickey &amp; Pierce, P.L.L.C.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Tyakchand</PDAT></FNM><SNM><STEXT><PDAT>Saidha</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1652</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>A bioengineered synthesis scheme for the production of shikimic acid from a carbon source is provided. Methods of producing shikimic acid from a carbon source based on the synthesis scheme are also provided.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application is a continuation-in-part of Ser. No. 09/240,440 filed Jan. 29, 1999.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>SPONSORSHIP</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>Work on this invention was sponsored in part by the United States Department Of Agriculture, Grant No. 95-37500-1930, the National Science Foundation Grant No. CHE963368 amendment 002 and the National Institutes of Health, Grant No. GM58684. The Government may have certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The present invention is related to the production of shikimic acid and more specifically, to methods of producing shikimic acid from bioconversion of a carbon source.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>Shikimic acid is an attractive chiral synthon with its highly functionalized, six-membered carbocyclic ring and multiple asymmetric centers. A metabolic intermediate of aromatic amino acid biosynthesis, shikimic acid has emerged as an essential chiral starting material in the synthesis of neuraminidase inhibitors effective in the treatment of influenza. Kim. C.U. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 119:681 (1997); Rohloff, J.C. et al., </PDAT><HIL><ITALIC><PDAT>J. Org. Chem</PDAT></ITALIC></HIL><PDAT>. 63:4545 (1998). Chiral, as well as aromatic chemicals, can also be synthesized from shikimic acid. For example, acid catalyzed dehydration of shikimic acid affords p-hydroxybenzoic acid (Eykmann, J.F., </PDAT><HIL><ITALIC><PDAT>Ber. Dtch. Chem. Ges</PDAT></ITALIC></HIL><PDAT>. 24:1278 (1891)). p-Hydroxybenzoic acid, which has an annual production of 7&times;10</PDAT><HIL><SP><PDAT>6 </PDAT></SP></HIL><PDAT>kg, is the key precursor to parabens and a monomer used in the synthesis of liquid crystal polymers. Shikimic acid has also recently been used as the starting point for synthesis of a large combinatorial library of molecules. Tan, D.S. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 120:8565 (1998).</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Shikimic acid is obtained via tedious multi-step isolation procedures from plants. Unfortunately, current isolation of shikimic acid from the fruit of Illicium plants (Haslem, E., </PDAT><HIL><ITALIC><PDAT>Shikimic Acid: Metabolism and Metabolites</PDAT></ITALIC></HIL><PDAT>, Wiley &amp; Sons, New York, pp. 40-42 (1993)) precludes its use in kilogram-level synthesis.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Therefore, it would be desirable to provide a method to produce large quantities of shikimic acid. It would also be desirable if such a method were cost-efficient, using inexpensive starting materials. It would further be desirable if the method employed non-toxic compounds and was environmentally benign.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>A bioengineered synthesis scheme for production of shikimic acid from a carbon source is provided. In one embodiment, the bioconversion methods of the present invention comprise the microbe-catalyzed conversion of a carbon source to shikimic acid. The method comprises selecting a host cell, introducing into the host cell the ability to convert the carbon source to shikimic acid in the host cell, impeding in a pathway of the host cell the conversion of shikimic acid to shikimate-3-phosphate and culturing the host cell in the carbon source. The methods further comprise contolling the molar ratio of shikimic acid to quinic acid during culturing. As shown in the synthesis scheme of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, the microbe-catalyzed conversion step of the present invention requires four enzymes which may be provided by a recombinant microbe. In a preferred embodiment, the recombinant microbe is </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>designed to cause reduction of 3-dehydroshikimate to shikimic acid and to inhibit any further conversion of shikimic acid along the aromatic amino acid biosynthetic pathway.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>In another embodiment, methods are provided for increasing the production of shikimic acid with the recombinant microbes of the present invention. In a preferred embodiment, the methods comprise blocking the phosphoenolpyruvate carbohydrate phosphotransferase system of the host cell and introducing into the host cell the ability to transport glucose into the cell. In an alternate preferred embodiment, the methods comprise introducing into the host cell the ability to convert pyruvate to phosphoenolpyruvate. In a further preferred embodiment, the host cell is </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B. Production of shikimic acid in the methods of the present invention is increased when this strain of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is used as the host cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The biocatalytic synthesis method for shikimic acid provided herein, is believed to be environmentally benign, economically attractive, and utilizes abundant renewable sources as a starting material.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawing.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and subjoined claims and by referencing the following drawing in which:</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a schematic illustrating the bioengineered synthesis scheme of the present invention for producing shikimic acid;</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a graph showing the equilibrium of shikimic and quinic acids catalyzed by SP1.1/pKD12.112;</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a schematic illustrating the plasmid maps of the plasmids of the present invention;</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1/pKD12.112A;</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by EB1.1/pKD12.138A;</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1/pKD15.071B;</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1/pSC5.112B;</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1 ptsipSC6.090B;</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1/pSC6.090B;</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by SP1.1/pSC6.162A;</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by EB1.1/pKD12.112A;</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by EB1.1/pKD12.138A; and</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><PDAT> is a graph showing the production of shikimic acid over time from a carbon source catalyzed by EB1.1/pKD15.071B.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</PDAT></STEXT></H>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>A bioengineered synthesis scheme for the production of shikimic acid from a carbon source is provided herein. Methods of producing shikimic acid from a carbon source based on the synthesis scheme are also provided.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>In one embodiment, a method is provided wherein the carbon source is converted to shikimic acid by a recombinant microbe. Manipulation of the common aromatic amino acid biosynthetic pathway of the microbe results in a significant production of shikimic acid when the recombinant microbe is cultured in the presence of a carbon source. The carbon source is converted to 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) which is subsequently converted by 3-dehydroquinate synthase to 3-dehydroquinate (DHQ) which is then dehydrated to 3-dehydroshikimate (DHS) by 3-dehydroquinate dehydratase (c, FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). 3-dehydroshikimate is converted to shikimic acid by shikimate dehydrogenase (d, FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). Metabolism of shikimic acid may be prevented by blocking or impeding shikimate kinase activity (e,f, FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>), thus allowing for the accumulation of significant amounts of shikimic acid. In a preferred embodiment, the microbe will be unable to reabsorb shikimic acid from the medium due to a mutation in shikimate uptake (shiA). Thus, once formed, shikimic acid can not be converted into quinic acid or any other molecule in the pathway.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>In a further embodiment, methods are provided for increasing the production of shikimic acid from a carbon source in which the carbon source is converted to shikimic acid by a recombinant microbe. In a preferred embodiment, shikimic acid production is increased by recycling pyruvic acid back to phosphoenolpyruvate (PEP). In another preferred embodiment, the phosphoenolpyruvate carbohydrate phosphotransferase (PTS) system is inactivated and glucose transfer is controlled instead by the glf-encoded glucose facilitator and glk-encoded glucokinase.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>The bioconversion methods of the present invention are carried out under conditions of time, temperature, pH, nutrient type and concentration, aeration conditions, and controlled glucose concentrations, to provide maximal conversion of the carbon source to shikimic acid. As described in detail in the Specific Examples, in a preferred embodiment, a fed-batch fermentor is used to convert the carbon source to shikimic acid, followed by isolation of the shikimic acid from the fermentation broth by ion-exchange chromatography. The batch fermentor process and chromatography methods are known to those skilled in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>As used herein, the phrase &ldquo;carbon source&rdquo; is meant to include biomass derived carbon sources including, but not limited to, xylose, arabinose, glycerol, glucose and the intermediates in the Krebs cycle (e.g., dicarboxylic acids), either alone or in combination. In a preferred embodiment, the carbon source is glucose. The carbon source may be derived from renewable resources such as, without limitation, corn, sugar beets and sugar cane.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>In another embodiment, the recombinant microbe employed in the methods of the present invention is </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>. In a preferred embodiment, the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises an aroB cassette inserted into the serA locus and disruption of the aroL and aroK loci (e and f, FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). This recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>may further comprise a plasmid carrying aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, aroE and serA gene inserts. Shikimic acid accumulates due to the absence of the aroL- and arok-encoded isozymes of shikimate kinase which catalyze the conversion of shikimic acid to shikimate-3-phosphate. The second copy of aroB increases the catalytic activity of 3-dehydroquinate synthase, thereby introducing into the host cell the ability to increase the production of shikimic acid. Dell, K.A. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 115:11581 (1993). It will be appreciated, however, that the aroL and arok loci mutations are not essential and are employed to provide greater production of shikimic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSC5.112B carrying aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, SerA, aroE and glk gene inserts. The aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>gene insert encodes a mutant 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase isozyme (a, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) insensitive to feedback inhibition by aromatic amino acids or other aromatic molecules which increases carbon flow into the common aromatic amino acid biosynthetic pathway. Amplified shikimate dehydrogenase resulting from expression of aroE compensates for the enzyme&apos;s feedback inhibition by shikimic acid. Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol</PDAT></ITALIC></HIL><PDAT>. 92:1070 (1966); Brown, K.D. et al., </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta</PDAT></ITALIC></HIL><PDAT>. 428:550 (1976). Due to a mutation in the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>genomic serA locus required for </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized serA. The plasmid serA insert thus allows microbial growth in minimal salts medium, distinguishing the microbes.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pKD12.112 carrying aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, serA and aroE inserts. The aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>gene insert encodes a mutant 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase isozyme (a, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) insensitive to feedback inhibition by aromatic amino acids or other aromatic molecules which increases carbon flow into the common aromatic amino acid biosynthetic pathway. Amplified shikimate dehydrogenase resulting from expression of aroE compensates for the enzyme&apos;s feedback inhibition by shikimic acid. Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol</PDAT></ITALIC></HIL><PDAT>. 92:1070 (1966); Brown, K.D. et al., </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta</PDAT></ITALIC></HIL><PDAT>. 428:550 (1976). Due to a mutation in the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>genomic serA locus required for </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized serA. The plasmid serA insert thus allows microbial growth in minimal salts medium, distinguishing the microbes.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>In another embodiment, the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pKD12.138. This plasmid is derived from and carries the same gene inserts as pKD12.112 as well as a tktA gene insert encoding for transketolase. Transketolase catalyzes formation of </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-erythrose 4-phosphate, an unstable aldose phosphate typically maintained at vanishingly low concentrations in the cell. Elevated expression of transketolase provides additional </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-erythrose 4-phosphate for subsequent condensation with phosphoenolpyruvate to form 3-deoxy-D-arabino-heptulosonate-7-phosphate, the first committed intermediate of aromatic amino acid biosynthesis.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>In a further embodiment, the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pKD15.071B. This plasmid is derived from and carries the same gene inserts as pKD12.138 as well as a pps gene insert encoding for phosphoenolpyruvate (PEP) synthase. PEP synthase catalyzes the conversion of pyruvate back to PEP. Elevated expression of PEP synthase along with transketolase provides an increase in the amount of shikimic acid produced.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>In yet another embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSC5.112B. This plasmid is derived from and carries the same gene inserts as pkD12.138 as well as a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>glf gene insert encoding for glucose facilitator protein. Elevated expression of the glucose facilitator protein results in an increase in the yield of shikimic acid from the conversion of a carbon source.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In another embodiment, the recombinant microbe employed in the methods of the present invention is </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>. In a preferred embodiment, the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises an aroB cassette inserted into the serA locus and disruption of the aroL and aroK loci (e and f, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) and theptsH, ptsI, and crr genes involved in the PTS system of glucose transport. This recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>may further comprise an exogenous glucose transport system in place in place of the PTS system. In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>further comprises a plasmid carrying a glf gene insert. In a more preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>further comprises a plasmid carrying both glf and glk gene inserts. The glf gene encodes for a glucose facilitator protein and the glk gene encodes for glucokinase. The glucose facilitator protein provides the host cell with the ability to transport glucose into the cell. In a most preferred embodiment, the glf and glk genes are from </PDAT><HIL><ITALIC><PDAT>Zymononas mobilis</PDAT></ITALIC></HIL><PDAT>. This recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>may further comprise a plasmid carrying aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, aroE and serA gene inserts . Shikimic acid accumulates due to the absence of the aroL- and arok-encoded isozymes of shikimate kinase while the second copy of aroB increases the catalytic activity of 3-dehydroquinate synthase. Dell, K.A. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 115:11581 (1993). It w i b e appreciated, however, that the aroL and aroK loci mutations are not essential and are employed to provide greater production of shikimic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSC6.090B. This plasmid is derived from and carries the same gene inserts as pKD12.138 as well as a Ptacglfglk insert encoding for glucose facilitator protein and glucokinase. Elevated expression of the proteins increases the transport and utilization of glucose into the recombinant microbe, thereby increasing the production of shikimic acid. Furthermore, the rate of production of shikimic acid is increased with this construct.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>In an alternate preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSC6.162A. This plasmid is derived from and carries the same gene inserts as pKD12.138 as well as pps P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf gene insert encoding for glucose facilitator protein and PEP synthase.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In another embodiment, the aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, serA, aroE, tkt, pps, glf and/or glk genes are inserted directly into the genome of the host cell. Thus a plasmid would not be required for the production of shikimic acid from such a recombinant microbe.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Examples of the above-described preferred recombinant microbes of the present invention, </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112, SP2.1/pKD12.112, Sp1.1/pKD12.138, SP2.1/pKD12.138 and SP1.1 pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/pSC6.090B are described in Specific Example 1 and have been deposited with the American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, Va. 20108, under the terms of the Budapest TTeaty, and accorded the ATCC designation numbers 98905, 98903, 207055, 207054 and PTA-2578, respectively. The deposit will be maintained in the ATCC depository, which is a public depository for a period of 30 years, or 5 years after the most recent request, or for the effective life of a patent, which ever is longer, and will be replaced if the deposit becomes depleted or nonviable during that period. Samples of the deposit will become available to the public and all restrictions imposed on access to the deposit will be removed upon grant of a patent on this application.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>The following table sets forth the four enzymes required for the conversion of glucose to shikimic acid, the genes encoding same and the origin of the genes in the exemplary recombinant microbes of the present invention.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="112pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="left"/>
<thead>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>Enzyme&dagger;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Gene (origin)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="1" colwidth="14pt" align="right"/>
<colspec colname="2" colwidth="112pt" align="left"/>
<colspec colname="3" colwidth="91pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>a)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-deoxy-D-arabino-heptulosonic acid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>(plasmid)</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>7-phosphate synthase</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>b)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-dehydroquinate synthase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroB (additional copy inserted</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>into genome)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>c)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-dehydroquinate dehydratase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroD (genome)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>d)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3-dehydroshikimate dehydrogenase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroE (plasmid)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="3" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="3" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>&dagger;Enzymes a)-d) correspond to a-d of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1. </PDAT></FGREF></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>Although </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is specifically described herein as the microbe for carrying out the methods of the present invention, it will be appreciated that any microorganism such as the common types cited in the literature and known to those skilled in the art, may be employed, provided the microorganism can be altered to effect the desired conversion, e.g., carbon source to shikimic acid. Thus, it is envisaged that many types of fungi, bacteria and yeasts will work in the methods of the present invention. Such microorganisms may be developed, for example, through selection, mutation, and/or genetic transformation processes with the characteristic and necessary capability of converting one constituent of the synthesis scheme of the present invention to another. Methods for such development are well known to the skilled practitioner.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In order to carry out the bioconversion methods of the present invention, a solution containing a carbon source is contacted with the recombinant microbe to form a bioconversion mixture which is maintained under appropriate conditions to promote the conversion of the carbon source to the desired constituent, e.g., shikimic acid. In a preferred embodiment, the bioconversion mixture is maintained at a temperature of about 30&deg; C. to about 37&deg; C. and a pH of about 6.5 to about 7.5. It is preferred that the bioconversion mixture also contain other substances necessary to promote the viability of the recombinant microbes such as mineral salts, buffers, cofactors, nutrient substances and the like. The bioconversion mixture can be maintained under glucose limited conditions or glucose rich conditions. In a preferred embodiment, the rate of glucose addition is determined by the level of dissolved oxygen concentration. A preferred steady state over the course of fermentation is about 100 to about 200 &mgr;mol glucose or a dissolved oxygen concentration of about 5% to about 35% air saturation. In an alternate preferred embodiment, glucose rich fermentor conditions are maintained. The glucose concentration is preferably from about 5 g/L to about 50 g/L and more preferably from about 20 g/L to about 25 g/L.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>The more general requirements for the maintenance of viability of microorganisms are well known and specific requirements for maintaining the viability of specific microorganisms are also well known as documented in the literature, or are otherwise easily determined by those skilled in the art. The shikimic acid may then be recovered from the bioconversion mixture by methods known in the art (e.g., ion-exchange chromatography) and further purified by recrystallization.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Culturing of the recombinant microbes of the present invention produce not only shikimic acid, but can also produce quinic acid in the fermentation broth. If the quinic acid concentration is too high, it is difficult to purify the shikimic acid away from the quinic acid. In a preferred embodiment, the molar ratio of shikimic acid to quinic acid in the fermentor broth is such that shikimic acid can be purified away from quinic acid. Preferably, the molar ratio will be greater than about 9. More preferably, the molar ratio will be greater than about 20 and most preferably, it will be greater than about 40.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>In one embodiment, the molar ratios of shikimic acid to quinic acid in the fermentor broth are controlled by controlling the concentration of the carbon source during fermentation. While not wishing to be bound by theory, it is thought that at lower carbon source concentrations, shikimic acid in the fermentor broth is taken back up by the cells as an alternate carbon source and converted to quinic acid which is then secreted back into the fermentation broth. Increasing the concentration of the carbon source during fermentation inhibits this uptake of shikimic acid and lowers or eliminates the contaminating quinic acid. As a non-limiting example, increasing the glucose concentration by increasing the K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>from 0.1 to 0.8 and thus increasing the rate of addition of a 65% (w/v) glucose solution during fermentation of SP1.1/pKD12.112, resulted in an increase in the molar ratio of shikimic acid to quinic acid from 3.0 to 12.0.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>In an alternate embodiment, the molar ratios of shikimic acid to quinic acid in the fermentor broth are controlled by using glucose rich conditions. Glucose rich conditions comprise glucose concentrations preferably from about 5 g/L to about 50 g/L and more preferably, from about 20 g/L to about 25 g/L. As a non-limiting example, the glucose concentration is maintained at 25 g/L during fermentation of PSP1.1 pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/PSC6.090B, resulting in prefered molar ratios of shikimic acid to quinic acid (FIG. </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>In another embodiment, the molar ratio of shikimic acid to quinic acid is controlled by addition of non-metabolizable (non-hydrolyzable) glucose analogs to the fermentation medium. Preferably, the glucose analog is methyl glucopyranoside present at a concentration of between about 0.1 mM and about 10 mM. More preferably, it is present in a concentration of between about 0.5 and about 1.0 mM. The methyl glucopyranoside may be methyl-&agr;-glucopyranoside, methyl-&bgr;-glucopyranoside, or a mixture thereof. Because these analogs are non-hydrolyzable, they may be added only at the beginning of fermentation.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>In order to more fully demonstrate the advantages arising from the present invention, the following examples are set forth. It is to be understood that the following is by way of example only and is not intended as a limitation on the scope of the invention.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 1</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Creation Of Plasmids And Host Strains</PDAT></STEXT></H>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>Two host strains created for shikimic acid biosynthesis originated from two different </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>strains. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1 was created from RB791, a strain which differs from wild-type W3110 by only a single mutation. A second shikimate-producer, </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP2.1, was created from a strain possessing several characterized and an unknown number of uncharacterized mutations. SP2.1 was created from AB2848, an isolate of several rounds of chemical mutagenesis originally selected for a mutation in the dehydroquinate dehydratase-encoding aroD gene. Creation of two organisms for shikimic acid biosynthesis allowed evaluation of the effect of various culture parameters in different genomic backgrounds.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>Creation of SP1.1 began with insertion of aroB into the serA locus of RB791 via homologous recombination. This event led to an </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>with increased dehydroquinate synthase expression while inactivating expression of phosphoglycerate dehydrogenase, an enzyme necessary for de novo serine biosynthesis. Subsequent P1-mediated transduction of aroL478::Tn10 and aroK17::Cm</PDAT><HIL><SP><PDAT>R </PDAT></SP></HIL><PDAT>from </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>AL0807 afforded SP1.1 in which both isozymes of shikimate kinase are inactive. Creation of SP2.1 proceeded similarly but required the additional step of reintroduction of dehydroquinate dehydratase activity to the organism. After insertion of aroB into the serA locus of AB2848, P1-mediated transduction of a functional copy of aroD into the genome afforded an organism capable of aromatic amino acid biosynthesis but not serine biosynthesis. Subsequent P1-mediated transduction of aroL478::Tn10 and aroK17::Cm</PDAT><HIL><SP><PDAT>R </PDAT></SP></HIL><PDAT>from </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>AL0807 afforded SP2.1.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>Construction of EB1.1 followed exactly the same protocols as used for the generation of SP1.1 except that </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B (ATCC11303) was used as the starting host.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1 was subjected to P1 phage mediated transduction of (ptsH ptsl crr)::Kn</PDAT><HIL><SP><PDAT>R </PDAT></SP></HIL><PDAT>thereby knocking out the ptsH, ptsl and crr genes involved in the PTS system of glucose transport. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1 pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>was selected based on the following growth characteristics: growth on LB containing Tc. Cm and Km; growth on M9 containing aromatic amino acids, aromatic vitamins and serine only after transformation with plasmid pSC6.090B; no growth on M9 containing aromatic amino acids, aromatic vitamins and serine after transformation with plasmid pSC5.112A and formation of pinkish white colonies on MacConkey agar plates 15 supplemented with 1% glucose.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>Plasmid pKD12.112 is a pSU18-based vector (approximately 15 to 20 copies per cell) that contains genes encoding a feedback insensitive isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase (aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>), shikimate dehydrogenase (aroE), phosphoglycerate dehydrogenase (serA), and &bgr;-lactamase (Ap</PDAT><HIL><SP><PDAT>R</PDAT></SP></HIL><PDAT>). Expression of aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, serA, and &bgr;-lactamase proceed from their respective native promoters while aroE expression occurs from both its native promoter (designated P</PDAT><HIL><SB><PDAT>aroE</PDAT></SB></HIL><PDAT>) and from the strong hybrid promoter tac (P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>). Increased expression of a feedback insensitive isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase increases the percentage of metabolites directed into shikimate biosynthesis while increased shikimate dehydrogenase expression reduces the impact of this enzyme&apos;s inhibition by shikimic acid, thereby reducing byproduct dehydroshikimate formation. Inclusion of serA on pKD12.112 forces host strains SP1.1 and SP2.1 to maintain the plasmid in culture medium lacking serine supplementation. Finally, inclusion of the &bgr;-lactamase gene provides additional means of selective pressure for plasmid maintenance in SP1.1 and SP2.1. Resistance to ampicillin, however, was utilized only as a secondary selective pressure during preparation of fermentation inoculants. Ampicillin was never added to fermentation cultures.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>Plasmid pKD12.138 was prepared from pKD12.112 by insertion of transketolase-encoding tktA. This 9.9-kb plasmid was created by inserting the 2.2-kb tktA fragment from pMF51A into pKD12.112. Digestion of pMF51A with BamHI followed by treatment with Klenow fragment yielded the tktA gene with blunt ends. Plasmid pKD12.112 was linearized with HindIII and treated with Klenow fragment. Subsequent ligation of the tktA fragment to pKD12.112 resulted in pKD12.138A. The tktA gene is transcribed in the same orientation as the serA gene. Transketolase catalyzes formation of </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-erythrose 4-phosphate, an unstable aldose phosphate typically maintained at vanishingly low concentrations in the cell. Elevated expression of transketolase provides additional </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-erythrose 4-phosphate for subsequent condensation with phosphoenolpyruvate to form 3-deoxy-D-arabino-heptulosonate-7-phosphate, the first committed intermediate of aromatic amino acid biosynthesis. Increased transketolase expression improves both the rate of formation and the final titer of shikimic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>Plasmid pKD15.071B (11.9 kb) was constructed by replacing the 1.0-kb &bgr;-lac gene of pKD12.138A by the pps fragment from pKL1.87B. Plasmid pKL1.87B was digested with BamHI and HindIII and the resulting 3.0-kb pps fragment was treated with Klenow fragment. Following digestion of pKD12.138A with Ncol, the 8.9-kb fragment was modified to blunt ends using Klenow fragment. Ligation of these two purified fragments yielded pKD15.071A. The pps gene is transcribed in the opposite orientation relative to the tktA gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>Plasmid pSC5.112B (11.1 kb) was created by replacing the 1.0-kb -lac gene of pKD12.138A by the glf fragment from pTC325. The 1.9-kb glf gene was excised out of pTC325 along with the 0.3-kb P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>promoter by digestion with BamHI, HindIII and Xbal followed by treatment with Klenow fragment. Plasmid pKD12.138A was digested with Ncol and the 8.9-kb fragment was treated with Klenow fragment. The two purified fragments were ligated to generate pSC5.112B. The P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf gene is transcribed in the opposite orientation relative to tktA.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>Plasmid pSC6.090B (12.8 kb) was constructed by ligation of the P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glfglk cassette into pKD12.138. The P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glfglk cassette was excised out of pTC325 by digestion with BamHI and Xbal followed by treatment with Klenow fragment. Plasmid pKD12.138 was digested with Ncol and the 8.9-kb fragment was treated with Klenow fragment. The two purified fragments were ligated to generate pSC6.090B. The P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glfglk cassette is transcribed in the same orientation as the tktA gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>Plasmid pSC 6.142B (7.5 kb) was created by inserting the glf gene into pKL1.87A. Plasmid pTC325 was digested with BamHI, HindIII and Xbal and the resulting 2.2-kb P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf fragment was treated with Klenow fragment. Plasmid pKL1.87A was linearized by digestion with SalI followed by treatment with Klenow fragment. Ligation of the P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf fragment into pKL1.87A afforded pSC6.142B. The P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf gene is transcribed in the opposite orientation relative to the pps gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>Plasmid pSC6.162A (14.1 kb) was constructed by inserting the 5.2-kb PpsP</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf cassette from pSC6.142B into pKD12.138. Plasmid pSC6.142B was digested with BamHI and HindIII followed by treatment of the ppsP</PDAT><HIL><SB><PDAT>ta </PDAT></SB></HIL><PDAT>glf fragment with Klenow fragment. The 1.0-kb &bgr;-lac gene was excised from the 9.9-kb plasmid pKD12.138A and the remaining 8.9-kb fragment was treated with Klenow fragment. Ligation of the two purified DNA fragments afforded pSC6.162A. The P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>glf fragment was transcribed in the same orientation and the pps gene in the opposite orientation relative to the tktA gene.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 2</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Synthesis Of Shikimic Acid From Glucose</PDAT></STEXT></H>
<PARA ID="P-00062" LVL="7"><PTEXT><PDAT>I. Results</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>Culturing SP1.1/pKD12.112 for 42 h with K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>&equals;0.1 resulted in the synthesis of 27.2 g/L of shikimic acid, 12.6 g/L of quinic acid, and 4.4 g/L of 3-dehydroshikimic acid (DHS). DHS accumulation reflected the expected feedback inhibition of shikimate dehydrogenase by shikimic acid. Draths, K.M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 114:9725 (1992). By contrast, quinic acid biosynthesis was surprising given the absence in E. coli of quinic acid dehydrogenase which catalyzes 3-dehydroquinate and quinic acid interconversion. DHS was readily removed by heating the fermentor broth to convert DHS into protocatechuic acid which was absorbed by activated carbon during decolorization. Unfortunately, quinic acid contamination was in excess of what could be purified away from shikimic acid by crystallization.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>Minimizing the cytosolic concentration of 3-dehydroquinic acid appeared to be a reasonable strategy for reducing quinic acid contamination of the shikimic acid synthesized by </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112. The aroD gene encoding 3-dehydroquinate dehydratase was consequently localized on plasmid pKD12.152A along with aroE, aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>and serA. However, attendant amplified expression of 3-dehydroquinate dehydratase did not reduce the levels of quinic acid contamination in the shikimic acid synthesized by SP1.1/pKD12.152A under fed-batch fermentor conditions identical to those employed for SP1.1/pKD12.112. While not wishing to be bound by theory, these results suggest that quinic acid formation may not result from de novo biosynthesis but rather from equilibration of initially synthesized shikimic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>Equilibration of quinic and shikimic acids has previously been examined in cell-free extracts of Klebsiella pneumoniae. Mitsuhashi, S. et al., </PDAT><HIL><ITALIC><PDAT>Biochim. Biophy. Acta </PDAT></ITALIC></HIL><PDAT>15:268 (1954). To be relevant to quinic acid formation in </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112, the common pathway must be able to operate in vivo in the reverse of its normal biosynthetic direction. To test this possibility, SP1.1/pKD12.112 cells collected from the fermentor after 24 h were washed, resuspended in fresh minimal salts medium containing shikimic acid, and then shaken. Formation of quinic acid (solid bars, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) and 3-dehydroshikimic acid (hatched bars, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) along with a corresponding decrease in shikimic acid concentration (open bars, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) indicated that SP1.1/pKD12.112 can catalyze formation of quinic acid from initially synthesized shikimic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The possible role of shikimic acid transport from the culture medium into the microbial cytoplasm during observed equilibration pointed to a strategy for minimizing quinic acid contamination. Shikimic acid transport (Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol</PDAT></ITALIC></HIL><PDAT>. 92:1070 (1966); Brown, K. D. et al., </PDAT><HIL><ITALIC><PDAT>Biochim. Biophys. Acta </PDAT></ITALIC></HIL><PDAT>428:550 (1976)) in </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>may be an evolutionary vestige of a previous ability to catabolize shikimic and quinic acids as sole sources of carbon for growth and metabolism. Since utilization of non-glucose carbon sources is often subject to catabolite repression, increasing </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose availability might repress shikimic acid transport thereby minimizing formation of quinic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>The rate of </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose addition, and thus </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose availability, in all fermentation runs was controlled by the proportional-integral-derivative (PID) setting gain (K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>). For example, synthesis by </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112 of the mixture of shikimic and quinic acids (Table 2) employed a PID setting of K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>&equals;0.1. Increasing glucose availability by increasing the PID setting to K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>&equals;0.8 resulted (Table 2) in a drastic reduction in the formation of quinic acid throughout the entire fermentation. After 42 h of cultivation, </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112 synthesized 20.2 g/L of shikimic acid, 4.6 g/L of DHS, and only 1.9 g/L of quinic acid. Under identical conditions SP2.1/pKD12.112 synthesized 37 g/L of shikimic acid, 2.1 g/L of quinic acid and 4.2 g/L of DHS. The decrease in the synthesized titers of shikimic acid is consistent with the known impact of increased </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose availability on the concentration and yield of L-phenylalanine synthesized by </PDAT><HIL><ITALIC><PDAT>E coli</PDAT></ITALIC></HIL><PDAT>. Konstantinov, K.B. et al., </PDAT><HIL><ITALIC><PDAT>J. Ferment Bioeng</PDAT></ITALIC></HIL><PDAT>. 70:253 (1990); Konstantinov, K.B. et al., </PDAT><HIL><ITALIC><PDAT>J. Ferment Bioeng</PDAT></ITALIC></HIL><PDAT>. 71:350 (1991). More importantly, improvement of the shikimate:quinate molar ratio from 2.4:1 (K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>&equals;0.1) to 11.8:1 (K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>&equals;0.8) allowed quinic acid to be completely removed during crystallization of shikimic acid.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Products Synthesized By </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pKD12.112</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>As A Function Of Time And D-glucose Addition Parameters</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="42pt" align="left"/>
<colspec colname="1" colwidth="84pt" align="center"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>&equals; 0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>&equals; 0.8</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="offset" colwidth="42pt" align="left"/>
<colspec colname="1" colwidth="21pt" align="center"/>
<colspec colname="2" colwidth="42pt" align="center"/>
<colspec colname="3" colwidth="21pt" align="center"/>
<colspec colname="4" colwidth="35pt" align="center"/>
<colspec colname="5" colwidth="21pt" align="center"/>
<colspec colname="6" colwidth="35pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>SA</PDAT><HIL><SP><PDAT>a</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>QA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DHS</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>QA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DHS</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="offset" colwidth="14pt" align="left"/>
<colspec colname="1" colwidth="28pt" align="left"/>
<colspec colname="2" colwidth="21pt" align="char" char="."/>
<colspec colname="3" colwidth="42pt" align="char" char="."/>
<colspec colname="4" colwidth="21pt" align="center"/>
<colspec colname="5" colwidth="35pt" align="char" char="."/>
<colspec colname="6" colwidth="21pt" align="center"/>
<colspec colname="7" colwidth="35pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>12 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>18 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>24 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>30 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2.2</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>36 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3.5</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>42 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>27.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.6</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="7" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><HIL><SP><PDAT>a</PDAT></SP></HIL><PDAT>Concentrations in g/L of shikimic acid (SA), quinic acid (QA), and 3-dehydroshikimic acid (DHS) </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>Additional fermentation runs resulted in similar yields of shikimic acid and shikimic acid:quinic acid ratios. When the gain (K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL><PDAT>) for proportional-integral-derivative control for the glucose feed was set to 0.1, both SP1.1/pKD12.112 and SP2.1/pKD12.112 synthesized less than optimal mixtures of shikimic acid and quinic acid. SP1.1/pKD12.112 achieved a shikimic acid to quinic acid molar ratio of 3.0 while SP2.1/pKD12.112 achieved a molar ratio of 5.0 (Table 3). Attempts to obtain pure shikimic acid from culture broths with molar ratios in this range were unsuccessful. Although synthesis of byproduct DHS represents a loss in shikimic acid titers, DHS is easily separated from shikimic acid during purification. DHS formation was not an obstacle to obtaining pure shikimic acid.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="266pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 3</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Summary Of Fermentation Results</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<colspec colname="3" colwidth="14pt" align="center"/>
<colspec colname="4" colwidth="21pt" align="center"/>
<colspec colname="5" colwidth="21pt" align="center"/>
<colspec colname="6" colwidth="21pt" align="center"/>
<colspec colname="7" colwidth="42pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>SA</PDAT><HIL><SP><PDAT>a</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>QA</PDAT><HIL><SP><PDAT>a</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>DHS</PDAT><HIL><SP><PDAT>a</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>Molar Ratio</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Strain</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Modification</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>(g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SA:QA</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<colspec colname="3" colwidth="14pt" align="center"/>
<colspec colname="4" colwidth="21pt" align="char" char="."/>
<colspec colname="5" colwidth="21pt" align="char" char="."/>
<colspec colname="6" colwidth="21pt" align="center"/>
<colspec colname="7" colwidth="42pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>SP1.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>38.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3.0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP2.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&mdash;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>7.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP1.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>increase K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>0.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20.2</PDAT><HIL><SP><PDAT>b</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>1.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP2.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>increase K</PDAT><HIL><SB><PDAT>c</PDAT></SB></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>0.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36.6</PDAT><HIL><SP><PDAT>b</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>2.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP1.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>add M &agr;DG (1 mM)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>40.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&gt;40</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP2.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>add M &agr;DG (0.5 mM)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>39.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>SP1.1/pKD12.138</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>add M &agr;DG (1 mM); tktA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>51.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8.8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="4">
<colspec colname="1" colwidth="56pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="center"/>
<colspec colname="3" colwidth="14pt" align="center"/>
<colspec colname="4" colwidth="105pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>SP2.1/pKD12.138</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>add M &agr;DG (0.5 mM); tktA</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>did not change phase</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="4" align="left"><PTEXT><FOO ID="FOO-00003"><PTEXT><HIL><SP><PDAT>a</PDAT></SP></HIL><PDAT>after 48 h of culturing except as noted differently </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="4" align="left"><PTEXT><FOO ID="FOO-00004"><PTEXT><HIL><SP><PDAT>b</PDAT></SP></HIL><PDAT>after 42 h of culturing </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>When the gain controlling the glucose feed was increased from 0.1 to 0.8, significant improvement in the shikimic acid to quinic acid molar ratio was observed. Increasing K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>to 0.8 results in a stronger response by the glucose pump when the dissolved oxygen level deviates from its setpoint. Increased values of K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>therefore result in higher steady-state glucose concentrations in the culture medium. After 42 h of culturing with K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>set at 0.8, SP1.1/pKD12.112 synthesized 20.2 g/L of shikimic acid and only 1.9 g/L of quinic acid to achieve a molar ratio of 12 (Table 3). Comparable improvement was seen with SP2.1/pKD12.112 which achieved a molar ratio of 18 by synthesizing 36.6 g/L of shikimic acid and 2.2 g/L of quinic acid after 42 h (Table 3). Shikimic acid readily purified away from the quinic acid from culture broths in which the molar ratio exceeds approximately 9.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>Although increasing K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>effectively suppresses quinic acid formation, these runs are extremely difficult to control. Dissolved oxygens levels oscillate as a direct result of oscillations in glucose feeding rates. These runs must be closely monitored after approximately 36 h into the run in order to avoid large, unnecessary additions of glucose. Since the runs could routinely be nursed along through 42 h but rarely through 48 h without a loss of control, the runs were terminated after 42 h. Increasing the steady-state glucose concentration in the culture broth also had a significant impact on the rate of shikimic acid production for SP1.1/pKD12.112. At the higher gain, SP1.1/pKD12.112 synthesized 20.2 g/L of shikimic acid after 42 h, as compared to 33 g/L at this same time when the gain was set to the lower value. The effect on the rate of production, however, was not observed for SP2.1/pKD12.112.</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>An alternative to increasing K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>in order to suppress quinic acid formation was addition of a non-hydrolyzable glucose analog to the fermentation broth. Methyl </PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>-</PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucopyranoside (M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG) was added to the fermentation medium at the time of inoculation and the fermentation was then run without further adjustment. Addition of 1 mM M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG to the fermentation of SP1.1/pKD12.112 resulted in the synthesis of 40.3 g/L of shikimic acid (Table 3). Quinic acid was not detected. Although several concentrations were examined, 1 mM M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG was the minimum concentration that afforded complete suppression of quinic acid formation. Addition of M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG to SP2.1/pKD12.112 cultures also resulted in quinic acid suppression. After 48 h of culturing in the presence of 0.5 mM M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG, SP2.1/pKD12.112 (Table 3) synthesized 39.6 g/L of shikimic acid and 4.1 g/L of quinic acid, resulting in a molar ratio 11. Higher concentrations of M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG showed no further improvement in quinic acid suppression.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>With conditions established that adequately suppress quinic acid formation without significantly compromising control, attention was turned to increasing shikimic acid titers using transketolase overexpression. When cultured in the presence of 1 mM M</PDAT><HIL><SB><PDAT>&agr;</PDAT></SB></HIL><PDAT>DG, SP1.1/pKD12.138 synthesized 51.1 g/L of shikimic acid and 4.3 g/L of quinic acid, affording a molar ratio exceeding 13 (Table 3). Transketolase expression resulted in a 25% increase in shikimic acid titers while maintaining a molar ratio of shikimic acid to quinic acid that allows shikimic acid isolation. The concentration of DHS byproduct also increased to 8.8 g/L, providing added incentive to obtain a shikimate dehydrogenase insensitive to shikimic acid inhibition. When SP2.1/pKD12.138 was cultured under standard conditions, the fermentation never reached the point of phase change. At 33&deg; C. growth of SP2.1/pKD12.138 was slow and resulted in significant acetate production.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>Increases in shikimic acid production were obtained by manipulating the transport and utilization of glucose in the cell. One limiting step to shikimic acid production is the amounts PEP is available to the cell. Conversion of pyruvic acid into PEP is catalyzed by pps-encoded PEP synthetase, which expends two phosphodiester bonds of ATP to convert pyruvic acid into PEP. Although pps is a chromosomal locus in wild-type </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>, the regulation of this enzyme&apos;s transcription and in vivo catalytic activity has not been elaborated. Liao and coworkers were the first to report that overexpressed pps resulted in substantial increases in carbon flow directed into the common pathway of aromatic amino acid biosynthesis. U.S. Pat. No. 5,906,925; Patnaik, R. et al., </PDAT><HIL><ITALIC><PDAT>Appll. Environ. Microbiol</PDAT></ITALIC></HIL><PDAT>. 60, 3903 (1994).</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>PPS-overexpressing SP1.1/pKD15.071B synthesized (entry 3, Table 4; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT>) 66 g/L of shikimic acid in 23% yield from glucose under glucose rich fermentor conditions which compares with 52 g/l of shikimic acid synthesized in 18% yield by SP1.1/pKD12.138A (entry 2, Table 4; FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>). SP1.1/pKD12.138 is most appropriate for comparison with SP1.1/pKD15.071B since both constructs employ plasmid localized tktA. Overexpression of tktA-encoded transketolase is essential for increased carbon flow directed into aromatic amino acid biosynthesis to be realized upon overexpression of pps-encoded PEP synthetase.</PDAT><HIL><SP><PDAT>2a </PDAT></SP></HIL><PDAT>Patnaik, R. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Microbiol</PDAT></ITALIC></HIL><PDAT>. 60, 3903 (1994).</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00004">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="70pt" align="left"/>
<colspec colname="3" colwidth="35pt" align="center"/>
<colspec colname="4" colwidth="35pt" align="center"/>
<colspec colname="5" colwidth="42pt" align="center"/>
<colspec colname="6" colwidth="42pt" align="center"/>
<colspec colname="7" colwidth="35pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="7" rowsep="1"><PTEXT><PDAT>TABLE 4</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>SA yield</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Total yield</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Entry no.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Strain</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lsqb;SA&rsqb; (g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(mol/mol)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lsqb;DHS&rsqb; (g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lsqb;QA&rsqb; (g/L)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(mol/mol)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.112</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>38</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.138</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>52</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>24%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD15.071B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>66</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>29%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pSC5.112B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>70</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>24%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>19</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/pSC6.090B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>71</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>27%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>34%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pSC6.090B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>46</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>21%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>16</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pSC6.162A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>67</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>26%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>34%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.112A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>39</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>21%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.138A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>37</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>10&ensp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD15.071B</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>44</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22%</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>Equipping shikimate-synthesizing </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>with the glf-encoded glucose facilitator cloned out of </PDAT><HIL><ITALIC><PDAT>Zymononas mobilis </PDAT></ITALIC></HIL><PDAT>provides an opportunity to prevent loss of three carbon atoms for the transport of every six (glucose) carbon atoms by eliminating exclusive reliance on PTS-mediated glucose transport. The glf-encoded glucose facilitator does not require PEP expenditure, but typically requires a concentration gradient to drive transport into the microbial cytoplasm. This is not problematic since shikimic acid synthesis using </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 is best performed using an excess of glucose in the culture medium to prevent unwanted equilibration of shikimic acid with quinic acid. Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 121, 1603 (1999).</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Three permutations were explored for glf-mediated glucose transport. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>SP1.1/pSC5.112B retained the phosphoenolpyruvate carbohydrate phosphotransferase (PTS) system for glucose transport but was also equipped with the glf-encoded glucose facilitator. No glk-encoded glucose kinase was included in SP1.1/pSC5.112B since this construct was not completely dependent on the facilitator for glucose transport. It was thought that native glucokinase activity was sufficient for phosphorylation of the glucose transported by Glf. Other variations on this approach were SP1.1/pSC6.090B and SP1.1/pSC6.162A. SP1.1/pSC6.090B retained the PTS system but carried plasimid-localized glf and glk. SP1.1/pSC6.162 also retained the PTS system and carried plasmid localized glf but was additionally equipped with plasmid-localized pps for recycling of PTS-generated pyruvic acid back to PEP. Keeping the PTS system operational while equipping the construct with facilitated glucose transport was employed in SP1.1/pSC5.112B and SP1.1/pSC6.090B due to concerns of what impact inactivating the PTS system would have on the growth and metabolic vigor of E. col. This was a particular concern given the high density conditions employed in the microbial syntheses of shikimic acid under fed-batch fermentor conditions. Along these lines, the final variant is SP1.1pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>pSC6.090B, which had PTS-mediated glucose transport inactivated and is completely dependent on the glf-encoded facilitator and glk-encoded kinase for glucose transport and phosphorylation.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>The highest yield (27%) and the highest titer (71 g/L) of shikimic acid was synthesized (entry 5, Table 4; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT>) by SP1.1pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/pSC6.090B under glucose rich fermentation conditions. This construct synthesed shikimic acid at the fastest rates observed for any shikimate-producer. SP1.1pts-IpSC6.090B synthesized 54 g/L of shikimic acid within 30 h (FIG. </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>). From 24 h to 30 h, SP1.1pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/pSC6.090B synthesized shikimic acid at a productivity of 5 g/L/h. SP1.1/pSC5.112B, which was capable of glucose transport by both PTS and Glf but lacked Glk, was also a good shikimate-producing construct (entry 4, Table 4; FIG. </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT>) with 70 g/L of shikimic acid synthesized in 24% yield under the same conditions. However, SP1.1/pSC5.112B did not produce shikimic acid as rapidly as SP1.1pts</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>/pSC6.090B. The expression of both glf and glk along with retention of PTS-mediated glucose transport in SP1.1/pSC6.090B resulted in a significant reduction in the titers (46 g/L) of synthesized shikimic acid (entry 6, Table 4; FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>). The attempt with SP1.1/pSC6.162 to combine the glf and pps strategies in one construct did not result in an improvement in shikimic acid titers or yields (entry 7, Table 4, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT>) relative to what was observed for SP1.1/pSC5.112B (PTS with Glf) or SP1.1/pKD15.071B (PTS with Pps).</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>Another strategy to increase the synthesized titers and yields of shikimic acid is to explore use of a different microbe. Constructing a shikimate-synthesizing </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B construct allows the advantage that many of the cloning techniques used to construct the shikimate-synthesizing </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 constructs could be used. Geneticists have historically favored </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 while </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B was favored by physiologists due to its more rapid growth relative to </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 in minimal medium. Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 121, 1603 (1999). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B is also naturally deficient in a number of proteases that may be responsible for the decline in AroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>activity that is often observed during stationary phase. Ongoing commercialization of ethanologenic </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B constructs for production of ethanol from neutralized hydrosylate of sugar cane bagasse suggests that </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B may be quite resilient towards osmotic stress associated with synthesis of high concentrations of shikimic acid. Flores, N. et al., </PDAT><HIL><ITALIC><PDAT>Nature Biotechnology</PDAT></ITALIC></HIL><PDAT>, 620, 1996 (1996).</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B construct EB1.1/pKD12.112A had higher DAHP synthase specific activities (Table 5) relative to the parallel </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 construct SP1.1 pKD 2.112A under glucose rich fermentation conditions. Similarly, EB1.1/pKD12.138 had higher DAHP synthase specific activities (Table 5) relative to the parallel </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 construct SP1.1/pKD12.138. However, DAHP specific activities were not any more stable over time for the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B constructs (entry 1 and 2, Table 4) relative to the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 constructs (entry 3 and 4, Table 5). Transketolase specific activities were substantially higher for the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>B constructs relative to the corresponding parallel </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>K12 constructs (entry 5 vs. entry 7, entry 6 vs entry 8, Table 5).</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00005">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="70pt" align="left"/>
<colspec colname="3" colwidth="21pt" align="center"/>
<colspec colname="4" colwidth="35pt" align="center"/>
<colspec colname="5" colwidth="21pt" align="center"/>
<colspec colname="6" colwidth="28pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="6" rowsep="1"><PTEXT><PDAT>TABLE 5</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Entry no.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Strain</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>24 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>36 h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>48 h</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="offset" colwidth="112pt" align="left"/>
<colspec colname="1" colwidth="105pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>DAHP synthase specific activities</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="70pt" align="left"/>
<colspec colname="3" colwidth="21pt" align="char" char="."/>
<colspec colname="4" colwidth="35pt" align="char" char="."/>
<colspec colname="5" colwidth="21pt" align="char" char="."/>
<colspec colname="6" colwidth="28pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.112A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.51</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>1.13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.99</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.84</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.138A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.82</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.80</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.49</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.41</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.112A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.37</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.35</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.37</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.31</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.138A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.068</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.192</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.128</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.096</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="offset" colwidth="112pt" align="left"/>
<colspec colname="1" colwidth="105pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Transketolase specific activities</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="70pt" align="left"/>
<colspec colname="3" colwidth="21pt" align="char" char="."/>
<colspec colname="4" colwidth="35pt" align="char" char="."/>
<colspec colname="5" colwidth="21pt" align="char" char="."/>
<colspec colname="6" colwidth="28pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.112A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.073</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.34</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.39</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>EB1.1/pKD12.138A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.50</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.73</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.53</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.112A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.024</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.18</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>SP1.1/pKD12.138A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.11</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.17</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.21</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0.35</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="6" align="left"><PTEXT><FOO ID="FOO-00005"><PTEXT><PDAT>specific activities are in units/mg; 1 unit &equals; 1 &mgr;mol/min </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>Despite the higher specific activities of DAHP synthase and transketolase, EB 1.1/pKD2.112 (entry 8, Table 4) synthesized approximately the same titers (39 g/L) of shikimic acid albeit at a higher yield (17%) relative to SP1.1/pKD12.112 A (entry 1, Table 4). Neither plasmid localization of tktA in EB1.1/pKD12.138A (entry 9, Table 4) or plasmid localization of pps in EB1.1 /pKD15.071B (entry 10, Table 4) improved both the titer and yield of synthesized shikimic acid relative to EB 1.1/pKD12.112 (entry 8, Table 4).</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>Microbial synthesis of shikimic acid as described in the present invention can supplant isolation of this hydroaromatic from plant sources which has limited shikimic acid&apos;s synthetic utility. At the same time, increased availability of shikimic acid will portend wider utilization of this hydroaromatic. The theoretical maximum yield for microbial synthesis of shikimic acid is 43% from </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose. Draths, K.M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc</PDAT></ITALIC></HIL><PDAT>. 117:2395 (1995). Comparison with the yields achieved thus far for microbial synthesis of shikimic acid (14-22%) along with the apparent lack of toxicity of this hydroaromatic toward the microbial biocatalyst suggest that sizable increases in yields and titers are possible. Such improvements coupled with economies of scale associated with large scale fermentation can even extend utilization of shikimic acid from chiral synthon to disposable chirality employable in the manufacture of large-volume aromatic chemicals.</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="7"><PTEXT><PDAT>II. Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>General. For </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR quantitation of solute concentrations, solutions were concentrated to dryness under reduced pressure, concentrated to dryness one additional time from D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, and then redissolved in D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing a known concentration of the sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP) purchased from Lancaster Synthesis Inc. Concentrations were determined by comparison of integrals corresponding to each compound with the integral corresponding to TSP (&dgr;&equals;0.00 ppm) in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR Spectrometer (300 MHz).</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>Culture Medium. All medium was prepared in distilled, deionized water. M9 salts (1 L) contained Na</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6 g), KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(3 g), NaCl (0.5 g) and NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl (1 g). M9 minimal medium (1 L) consisted of 1 L of M9 salts containing </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose (10 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.12 g), thiamine hydrochloride (0.001 g), </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-phenylalanine (0.040 g), </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-tyrosine (0.040 g), </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-tryptophan (0.040 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), and 2,3-dihydroxybenzoic acid (0.010 g). Ampicillin was added (0.05 g/L) where indicated. Solutions of M9 salts, MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, and glucose were autoclaved individually and then mixed. Aromatic amino acids, aromatic vitamins, and ampicillin were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>Fermentation medium (1 L) contained K</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(7.5 g), ammonium iron (III) citrate (0.3 g), citric acid monohydrate (2.1 g), L-phenylalanine (0.7 g), </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-tyrosine (0.7 g), </PDAT><HIL><SMALLCAPS><PDAT>L</PDAT></SMALLCAPS></HIL><PDAT>-tryptophan (0.35 g), and concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(1.2 mL). Fermentation medium was adjusted to pH 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH before autoclaving. The following supplements were added immediately prior to initiation of the fermentation: </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-glucose (20 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.24 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), 2,3-dihydroxybenzoic acid (0.010 g), and trace minerals including (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>(Mo</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>24</PDAT></SB></HIL><PDAT>)5.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0037 g), ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.7H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0029 g), H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>BO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(0.0247 g), CuSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.5H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0025 g), and MnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0158 g). </PDAT><HIL><SMALLCAPS><PDAT>D</PDAT></SMALLCAPS></HIL><PDAT>-Glucose and MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>were autoclaved separately while aromatic vitamins and trace minerals were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>Fermentations Under Glucose Limited Conditions. Fermentations employed a 2.0 L working capacity B. Braun M2 culture vessel. Utilities were supplied by a B. Braun Biostat MD that was controlled by a DCU-1. Data acquisition utilized a Dell Optiplex Gs</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>5166M personal computer equipped with B. Braun MFCS/Win software. Temperature, pH, and glucose feeding were controlled with PID control loops. Temperature was maintained at 33&deg; C. pH was maintained at 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2 N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Dissolved oxygen (D.O.) was measured using a Mettler-Toledo 12 mm sterilizable O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>sensor filted with an Ingold A-type O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>permeable membrane. D.O. was maintained at 10% air saturation.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>Inoculants were started by introduction of a single colony into 5 mL of M9 medium containing ampicillin. The culture was grown at 37&deg; C. with agitation at 250 rpm for 24 h and subsequently transferred to 100 mL of M9 medium containing ampicillin. After growth at 37&deg; C., 250 rpm for an additional 12 h, the inoculant was ready for transfer into the fermentation vessel. The initial glucose concentration in the fermentation medium was 20 g/L. Three staged methods were used to maintain D.O. levels at 10% air saturation during the course of run. With the airflow at an initial setting of 0.06 L/L/min, D.O. concentration was maintained by increasing the impeller speed from its initial set point of 50 rpm to its preset maximum of 940 rpm. With the impeller constant at 940 rpm, the mass flow controller then maintained D.O. levels by increasing the airflow rate from 0.06 L/L/min to a preset maximum of 1.0 L/L/min. At constant impeller speed and constant airflow rate, D.O. levels were finally maintained at 10% air saturation for the remainder of the fermentation by oxygen sensor-controlled glucose feeding. At the beginning of this stage, D.O. levels fell below 10% air saturation due to residual initial glucose in the medium. This lasted for approximately 1 h before glucose (65% w/v) feeding started. The PID control parameters were set to 0.0 (off) for the derivative control (</PDAT><HIL><SB><PDAT>&tgr;D</PDAT></SB></HIL><PDAT>) and 999.9 s (minimum control action) for integral control (</PDAT><HIL><SB><PDAT>&tgr;l</PDAT></SB></HIL><PDAT>). X</PDAT><HIL><SB><PDAT>p </PDAT></SB></HIL><PDAT>was set to 950% to achieve a K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>of 0.1 and 125% to achieve a K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>of 0.8.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>Fed-Batch Fermentation Under Glucose Rich Conditions. Fed-batch cultures were performed in a 2.0 L capacity Biostat MD B-Braun fermentor connected to a DCU system and a Dell Optiplex Gs</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>5166M personal computer loaded with B-Braun MFCS/win software for data acquisition and automatic process monitoring. The temperature, pH and dissolved oxygen (D.O.) were controlled with PID control loops. The temperature was maintained at 33&deg; C., D.O. at 10% and the pH was kept steady at 7.0 by addition of either concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. D.O. levels were monitored using a Mettler-Toledo 12 mm sterilizable O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>sensor fitted with an Ingold A-type permeable membrane.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>A typical inoculant was started by introduction of a single colony of the strain under investigation into 5 mL of complete M9 medium. This starter culture was grown with agitation at 250 rpm for 24 h at 37&deg; C. The culture was then transferred to 100 mL of complete M9 medium and grown for an additional 10 h at 37&deg; C. and 250 rpm before being transferred to the fermentor containing 1.0 L of fermentation medium. The fermentation can be divided into three distinct stages based on the method used to maintain the D.O. at 10%. In the first stage, with the air flow set at 0.06 L/L/min, the impeller speed ramped up from 50 rpm to 750 rpm. Once the maximum impeller speed was attained, the mass flow controller maintained the D.O. level at 10% by increasing the airflow from 0.06 L/L/min to 1.0 L/L/min. Once the air flow rate levelled off at 1.0 L/L/min at a constant impeller speed of 750 rpm, glucose was manually pumped into the fermentor so as to maintain an average glucose concentration of 25 g/L throughout the run. At this stage, the D.O. level was maintained at 10% by allowing the impeller speed to vary from 750 rpm tp 1600 rpm. Fermentations were typically run for 60 h.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>Analysis of Fermentation broth. During the course of the fermentation, 5 mL aliquots were removed every 6 h starting at 12 h into the run. Cell densities were determined by measurement of absorbance at 600 nm (OD</PDAT><HIL><SB><PDAT>600</PDAT></SB></HIL><PDAT>) Dry cell weight (g/L) was calculated using a conversion factor of 0.43 g/L/OD</PDAT><HIL><SB><PDAT>600</PDAT></SB></HIL><PDAT>. The fermentation sample was centrifuged using a Beckman microfuge. A portion (0.5-1.0 mL) of the supernatant was concentrated to dryness under reduced pressure, treated with 1.0 mL of D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O and again concentrated to dryness. The residue obtained was dissolved in 1.0 mL D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing 10 mM of the internal standard, sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP, &equals;0.00 ppm), purchased from Lancaster Synthesis Inc. Concentrations of metabolites in the culture supernatant were determined by comparison of integral values corresponding to each metabolite in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra with the integral corresponding to TSP. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR spectrometer (300 MHz).</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>Purification of Shikimic Acid from Fermentation Broth. The fermentation broth (1100-1200 mL) was centrifuged at 14000g for 20 min and the cells were 5 discarded. The resulting supernatant was refluxed for 4 h, cooled to room temperature, and the pH adjusted to 2.5 by addition of concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. After centrifugation at 14000 g for 20 min, a clear yellow solution was poured away from the cellular debris and adjusted to pH 6.9 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH. The solution was combined with 5 g of Darco KB-B activated carbon, swirled at 50 rpm for 1-2 h, and then filtered through Whatman 5 filter paper. Filtered material was washed with an additional 250 mL of water. The combined filtrates were then treated in the same way with a second batch of activated carbon.</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>Following treatment of the solution with carbon, the dark color was less intense than prior to treatment, but the solution was not colorless. Addition of glacial acetic acid to a final concentration of 15% afforded a clear, yellow solution which was then eluted through a column of AG1-x8 (acetate form, 5 cm&times;20 cm) at 4&deg; C. Following elution of the column with an additional 400 mL of 15% aqueous acetic acid, the combined eluents were passed through a column of Dowex 50 (H</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>form, 5 cm&times;20 cm) at 4&deg; C. which was then washed with 400 mL of 15% aqueous acetic acid. The eluents off the cation exchange column were combined and concentrated to approximately 150 mL by boiling and then to dryness by rotary evaporation, leaving a hard white solid (83% recovery through this step). Recrystallization from a mixture of methanol and ethyl acetate afforded shikimic acid as a fine white powder (61% recovery based on shikimic acid quantified in crude fermentation broth).</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying drawing and claims, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>All references cited herein are incorporated by reference as if fully set forth. In addition, U.S. Ser. No. 09/240,441, entitled &ldquo;Biocatalytic Synthesis Of Quinic Acid,&rdquo; filed Jan. 29, 1999, is also expressly incorporated by reference.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>We claim: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>1. A method for the production of shikimic acid from a carbon source comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a) providing a microbe selected from the group consisting of bacteria and fungi including yeast, wherein the microbe comprises one or more enzyme-encoding recombinant DNA molecules, wherein the encoded enzyme is selected from the group consisting of 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase, 3-dehydroquinate synthase, 3-dehydroquinate dehydratase, and 3-dehydroshikimate dehydrogenase, and wherein the microbe further comprises an inactivating mutation of at least one DNA molecule which encodes a shikimate kinase isozyme, and wherein the microbe further comprises an inactivating mutation in at least one DNA sequence which encodes a gene involved in the phosphoenolpyruvate carbohydrate phosphotransferase system; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b) culturing the microbe in the presence of the carbon source; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>c) isolating the shikimic acid produced. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the microbe is an </PDAT><HIL><ITALIC><PDAT>E. coli. </PDAT></ITALIC></HIL></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding 3-dehydroshikimate dehydrogenase is a recombinant aroE.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding 3-dehydroquinate synthase is a recombinant aroB.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the inactivating mutation or deletion of at least one DNA sequence which encodes a shikimate kinase isozyme produces an elimination or reduction in shikimate kinase activity.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the inactivating mutation or deletion of at least one DNA sequence which encodes a shikimate kinase isozyme is a deletion mutation in either or both of an aroK and an aroL gene.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the microbe further comprises a recombinant DNA sequence encoding a glucose transport facilitator protein.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding a glucose transport facilitator protein comprises a glf sequence.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the glf sequence is from </PDAT><HIL><ITALIC><PDAT>Zymononas mobilis. </PDAT></ITALIC></HIL></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>10. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the microbe further comprises a recombinant DNA sequence encoding a glucose kinase.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding a glucose kinase comprises a glk sequence.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00011"><PDAT>claim 11</PDAT></CLREF><PDAT>, wherein the glk sequence is from </PDAT><HIL><ITALIC><PDAT>Zymononas mobilis. </PDAT></ITALIC></HIL></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>13. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase encodes a 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase insensitive to feedback inhibition, thereby increasing the flow of carbon from the carbon source into the common aromatic amino acid biosynthetic pathway of the microbe.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>14. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase insensitive to feedback inhibition is a recombinant aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>15. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the recombinant DNA sequence encoding 3-dehydroquinate dehydratase is a recombinant aroD.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>16. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein culturing the cell in the presence of the carbon source further comprises culturing the cell in the presence of an excess amount of the carbon source.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>17. The method of </PDAT><CLREF ID="CLM-00016"><PDAT>claim 16</PDAT></CLREF><PDAT>, wherein the excess amount of the carbon source produces a molar ratio of shikimic acid to quinic acid which is greater than about 9.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>18. The method of </PDAT><CLREF ID="CLM-00017"><PDAT>claim 17</PDAT></CLREF><PDAT>, wherein the carbon source is glucose.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>19. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein culturing the cell in the presence of the carbon source comprises culturing the cell in the presence of a carbon source and a non-hydrolyzable glucose analog.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>20. The method of </PDAT><CLREF ID="CLM-00018"><PDAT>claim 18</PDAT></CLREF><PDAT>, wherein the non-hydrolyzable glucose analog is methyl glucopyranoside.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>21. The method of </PDAT><CLREF ID="CLM-00020"><PDAT>claim 20</PDAT></CLREF><PDAT>, wherein the methyl glucopyranoside is present in an amount of from about 0.5 mM to about 1.0 mM.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06472169-20021029-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06472169-20021029-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06472169-20021029-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06472169-20021029-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06472169-20021029-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06472169-20021029-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06472169-20021029-D00007.TIF"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06472169-20021029-D00008.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06472190-20021029-C00001.CDX SYSTEM "US06472190-20021029-C00001.CDX" NDATA CDX>
<!ENTITY US06472190-20021029-C00001.MOL SYSTEM "US06472190-20021029-C00001.MOL" NDATA MOL>
<!ENTITY US06472190-20021029-C00001.TIF SYSTEM "US06472190-20021029-C00001.TIF" NDATA TIF>
<!ENTITY US06472190-20021029-D00001.TIF SYSTEM "US06472190-20021029-D00001.TIF" NDATA TIF>
<!ENTITY US06472190-20021029-D00002.TIF SYSTEM "US06472190-20021029-D00002.TIF" NDATA TIF>
<!ENTITY US06472190-20021029-D00003.TIF SYSTEM "US06472190-20021029-D00003.TIF" NDATA TIF>
<!ENTITY US06472190-20021029-D00004.TIF SYSTEM "US06472190-20021029-D00004.TIF" NDATA TIF>
<!ENTITY US06472190-20021029-D00005.TIF SYSTEM "US06472190-20021029-D00005.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06472190</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021029</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09527145</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000316</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12P  740</PDAT></B511>
<B512><PDAT>C12N  120</PDAT></B512>
<B512><PDAT>C12N 1500</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435156</PDAT></B521>
<B522><PDAT>43525233</PDAT></B522>
<B522><PDAT>4353201</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Biocatalytic synthesis of galloid organics</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4172960</PDAT></DNUM>
<DATE><PDAT>19791000</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Baldwin et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5168056</PDAT></DNUM>
<DATE><PDAT>19921200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frost</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4351723</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5272073</PDAT></DNUM>
<DATE><PDAT>19931200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frost et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435155</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5629181</PDAT></DNUM>
<DATE><PDAT>19970500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frost et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435156</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5776736</PDAT></DNUM>
<DATE><PDAT>19980700</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frost et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435108</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5798236</PDAT></DNUM>
<DATE><PDAT>19980800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Frost et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>435136</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>2653446</PDAT></DNUM>
<DATE><PDAT>19770600</PDAT></DATE>
<CTRY><PDAT>DE</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>75151832</PDAT></DNUM>
<DATE><PDAT>19750000</PDAT></DATE>
<CTRY><PDAT>JP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 95/07979</PDAT></DNUM>
<DATE><PDAT>19950300</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Deschamps A. M. et al, Production of gallic acid from tara tannin by bacterial strains, Biotechnology Letters, 1984, 6, 237-242.* </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nakajima H et al.: &ldquo;Decarboxylation of gallate by cell-free extracts of </PDAT><HIL><ITALIC><PDAT>Streptococcus faecalis </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Klebsiella pneumoniae </PDAT></ITALIC></HIL><PDAT>isolated from rat feces.&rdquo; Journal of the Food Hygienic Society of Japan, vol. 33, No. 4, 1992, pp. 371-377. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Frost J W et al.: &ldquo;Biocatalytic syntheses of aromatics from D-glucose: renewable microbial sources of aromatric compounds&rdquo; Annual Review of Microbiology, vol. 49, 1995, pp. 557-579. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Frost J W: &ldquo;Biocatalytic synthesis of galloid organics from glucose;&rdquo; Abstr. Pap. Am. Chem. Soc. 209</PDAT><HIL><SP><PDAT>th </PDAT></SP></HIL><PDAT>ACS National Meeting Anaheim, CA, vol. 209, No. 2, Apr. 2, 1995, p. 132-BTEC. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Osawa R et al.: &ldquo;Metabolism of tannin-protein complex by facultatively anaerobic bacteria isolated from koala feces.&rdquo; Biodegradation, vol. 4, No. 2, 1993, pp. 91-99. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Werner I et al.: &ldquo;Retrobiosynthetic NMR studies with 13C-labeled glucose. Formation of gallic acid in plants and fungi.&rdquo; Journal of Biological Chemistry, vol. 272, No. 41, 1997, pp. 25474-25482. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Richman J E et al.: &ldquo;Reaction of 3-dehydroshikimic acid with molecular oxygen and hydrogen perioxide: Products, mechanism, and associated antioxidant activity.&rdquo; Journal of the American Chemical Society, vol. 118, No. 46, 1996, pp. 11587-11591. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Frost J: &ldquo;Renewable feedstocks.&rdquo; Chem. Eng. (Rugby, Engl.); vol. 611, May 16, 1996, pp. 32-35. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kamborakis S et al.: &ldquo;Synthesis of Gallic Acid and Pyrogallol from Glucose: Replacing Natural Product Isolation with Microbial Catalysis,&rdquo; Journal of American Chemistry Society, vol. 122, 2000, pp. 9042-9043. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Draths, K.M. et al., Benign by Design; &ldquo;Microbial Biocatalysis,&rdquo; Anasta, P.T.; Farris C.S. Ed.; ACS Symposium Series 577; American Chemical Society: Washington, D.C., Chap. 3, p. 32 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Draths, K.M. et al., &ldquo;Environmentally Compatible Synthesis of Adipic Acid from D-Glucose,&rdquo; J. Am. Chem. Soc. 116:399 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Draths, K.M. et al., &ldquo;Environmentally Compatible Synthesis of Catechol from D-Glucose,&rdquo; J. Am. Chem. Soc. 117:2395 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Entsch, B. et al., &ldquo;Catalytic Function of Tyrosine Residues in para-Hydroxybenzoate Hydroxylase as Determined by the Study of Site-directed Mutants,&rdquo; J. Biol. Chem. 266:17341 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Eschrich, K. et al., &ldquo;Role of Tyr201 and Tyr 385 in substrate activation by p-hydroxybenzoate hydroxylase from </PDAT><HIL><ITALIC><PDAT>Pseudomonas fluorescens</PDAT></ITALIC></HIL><PDAT>,&rdquo; Eur. J. Biochem. 216:137 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Frost, J.W. et al., &ldquo;Dehydroquinate Synthase from </PDAT><HIL><ITALIC><PDAT>Escherichia coli</PDAT></ITALIC></HIL><PDAT>: Purification, Cloning, and Construction of Overproducers of the Enzyme,&rdquo; Biochemistry 23:4470 (1984). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Haslam, E. et al., &ldquo;The Biosynthesis of Gallic Acid,&rdquo; J. Chem. Soc. 1854 (1961). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kawakubo, J. et al., &ldquo;Isolation of a Gallic Acid-producing Microorganism with Sake Cake Mediuim and Production of Gallic Acid,&rdquo; Biosci. Biotech. Biochem. 57:1360 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Korth, H., &ldquo;Bildung von Galluss&auml;ure-haltigen N&auml;hrmedium durch </PDAT><HIL><ITALIC><PDAT>Enterobacter cloacae </PDAT></ITALIC></HIL><PDAT>und </PDAT><HIL><ITALIC><PDAT>Pseudomonas fluorescens</PDAT></ITALIC></HIL><PDAT>,&rdquo; Arch. Mikrobiol. 89:67 (1973). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Li, K. et al., &ldquo;Fed-Batch Fermentor Synthesis of 3-Dehydroshikimic Acid Using Rcombinant </PDAT><HIL><ITALIC><PDAT>Escherichia coli</PDAT></ITALIC></HIL><PDAT>,&rdquo; Biotechnol. Bioeng. 64:61 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Li, K. et al., &ldquo;Synthesis of Vanillin from Glucose,&rdquo; J. Am. Chem. Soc. 120:10545 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nichols, N.N. et al., &ldquo;Repression of 4-Hydroxybenzoate Transport and Degradation by Benzoate: a New Layer of Regulatory Control in the </PDAT><HIL><ITALIC><PDAT>Pseudomonas putida </PDAT></ITALIC></HIL><PDAT>&bgr;-Ketoadipate Pathway,&rdquo; J. Bacteriol. 177:7033 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nichols, N.N. et al., &ldquo;PcaK, a High-Affinity Permease for the Aromatic Compounds 4-Hydroxybenzoate and Protocatechuate from </PDAT><HIL><ITALIC><PDAT>Pseudomonas putida</PDAT></ITALIC></HIL><PDAT>,&rdquo; J. Bacteriol. 179:5056 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ogino, T. et al., &ldquo;Biosynthesis of aromatic compounds: 13C NMR spectroscopy of whole </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>cells,&rdquo; PNAS (USA) 79:5828 (1982). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rivero, F. et al., &ldquo;Spore germination in Phycomyces blakesleeanus,&rdquo; Mycologia 86:781 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Snell, K. et al., &ldquo;Synthetic Modification of the </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>Chromosome: Enhancing the Biocatalytic Conversion of Glucose into Aromatic Chemicals,&rdquo; J. Am. Chem. Soc. 118:5605 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Weaver, L.M. et al., &ldquo;Cloning of an aroF Allele Encoding a Tyrosine-Insensitive 3-Deoxy-D-arabino-Heptulosonate 7-Phosphate Synthase,&rdquo; J. Bacteriol. 172:6581 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Zeida, M. et al., &ldquo;Purification and Characterization of Gallic Acid Decarboxylase from </PDAT><HIL><ITALIC><PDAT>Pantoea agglomerans </PDAT></ITALIC></HIL><PDAT>T71,&rdquo; Appl. Environ. Micriobiol. 64:4743 (1998).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>22</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435136</PDAT></B582>
<B582><PDAT>435156</PDAT></B582>
<B582><PDAT>43525233</PDAT></B582>
<B582><PDAT>43532001</PDAT></B582>
</B580>
<B590><B595><PDAT>5</PDAT></B595><B596><PDAT>9</PDAT></B596></B590>
</B500>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>John W.</PDAT></FNM><SNM><STEXT><PDAT>Frost</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Okemos</PDAT></CITY>
<STATE><PDAT>MI</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Board of Trustees operating Michigan State Univerisity</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>East Lansing</PDAT></CITY><STATE><PDAT>MI</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Harness, Dickey &amp; Pierce, P.L.C.</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Ponnathapu</PDAT></FNM><SNM><STEXT><PDAT>Achutamurthy</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B747>
<PARTY-US>
<NAM><FNM><PDAT>Malgorzata A.</PDAT></FNM><SNM><STEXT><PDAT>Walicka</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B747>
<B748US><PDAT>1652</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>The present invention provides a bioengineered synthesis scheme for the production of gallic acid from a carbon source. Methods of producing gallic acid from a carbon source based on the synthesis scheme are also provided. The gallic acid produces from these methods can be further converted to pyrogallol. Methods for the biosynthesis of pyrogallol from gallic acid are also provided.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>SPONSORSHIP</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>Work on this invention was sponsored in part by the National Science Foundation Grant No. CHE9633368 and the Environmental Protection Agency Grant No. CR822940. The Government may have certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The present invention is related to the production of galloid organics and more specifically to methods of producing gallic acid and pyrogallol from bioconversion of a carbon source.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>Among a spectrum of uses, gallic acid and pyrogallol are often incorporated into chemical syntheses to provide the trihydroxylated aromatic ring of biologically-active molecules such as the antibiotic trimethoprim 1, the coronary vasodilator trimetazidine 2, the insecticide bendiocarb 3, and the muscle relaxant gallamine triethiodide 4. The current commercial sources </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00001">
<CHEMCDX ID="CHEMCDX-00001" ALT="chemistry chemdraw file" FILE="US06472190-20021029-C00001.CDX"/>
<CHEMMOL ID="CHEMMOL-00001" ALT="chemistry mol file" FILE="US06472190-20021029-C00001.MOL"/>
<EMI ID="EMI-C00001" ALT="embedded image" HE="364.83615" WI="177.61275" FILE="US06472190-20021029-C00001.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00005" LVL="7"><PTEXT><PDAT>of gallic acid include gall nuts, an insect carapace harvested in China, and tara powder, an isolate derived from the ground seed pod of a tree found in Peru (Leston, G. In </PDAT><HIL><ITALIC><PDAT>Kirk</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Othmer Encyclopedia of Chemical Technology; </PDAT></ITALIC></HIL><PDAT>Kroschwitz, J. I.; Howe-Grant, M., Ed.; Wiley: New York (1996), Vol. 19, p. 778). Pyrogallol is currently synthesized by thermal decarboxylation of gallic acid in copper autoclaves (Leston, G. In </PDAT><HIL><ITALIC><PDAT>Kirk</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Othmer Encyclopedia of Chemical Technology; </PDAT></ITALIC></HIL><PDAT>Kroschwitz, J. I.; Howe-Grant, M., Ed.; Wiley: New York (1996), Vol. 19, p. 778).</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Because of the continuing uncertainties of supplies of gall nuts and tara powder, which are used for gallic acid and pyrogallol manufacture, there is interest in the development of synthetic processes. Various approaches were investigated in the synthesis of pyrogallol from readily available petrochemicals. The first synthetic pyrogallol that was industrially manufactured used basic hydrolysis of 2,2,6,6-tetrachlorocyclohexanone (German Patent No. 2,653,446). The preparation of the starting material by chlorination of cyclohexanone in the presence of collidine as the catalyst has been patented (British Patent No. 1,258,700). Cyclohexanone&apos;s main commercial synthesis begins with benzene, a petroleum-derived chemical with known toxic and carcinogenic activity. Other synthetic approaches involve hydroxylation of resorcinol with 50% H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>in the presence of hexafluoroacetone at 60&deg; C. to give a mixture of pyrogallol and 1,2,4-trihydroxybenzene (Japan Patent No. 75151832), or hydrolysis of 2,6-dimethoxyphenol using 48% hydrobromic acid (U.S. Pat. No. 4,172,960). The 2,6-dimethoxyphenol is produced by reaction of 2,6-dibromophenol with sodium methoxide.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Therefore, it would be desirable to provide methods for obtaining large quantities of gallic acid and pyrogallol that did not require the isolation of natural products from non-row crops. It would also be desirable if the methods were cost-efficient using inexpensive starting materials. Furthermore, such methods should be simple and environmentally benign.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>A bioengineered synthesis scheme for production of gallic acid from a carbon source is provided. In one embodiment, the bioconversion methods of the present invention comprise the microbe-catalyzed conversion of a carbon source to gallic acid. As shown in the synthesis scheme of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, the microbe-catalyzed conversion of the present invention requires five enzymes which may be provided by a recombinant microbe. In a preferred embodiment, the recombinant microbe is </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>designed to cause the two-step conversion of 3-dehydroshikimic acid to gallic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>A bioengineered scheme for the production of pyrogallol from gallic acid is also provided. In one embodiment, the bioconversion methods of the present invention comprise the microbe-catalyzed conversion of gallic acid to pyrogallol. As shown in the synthesis scheme of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, the microbe-catalyzed conversion step requires one enzyme which may be provided by a recombinant microbe. In a preferred embodiment, the recombinant microbe is </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>designed to cause the decarboxylation of gallic acid to pyrogallol.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>The biocatalytic synthesis methods for gallic acid and pyrogallol provided herein are believed to be environmentally benign, economically attractive, and utilize abundant renewable sources as a starting materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and subjoined claims and by referencing the following drawings in which:</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a schematic illustrating the bioengineered synthesis scheme of the present invention for producing gallic acid and pyrogallol;</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a schematic illustrating the restriction enzyme maps of plasmids pSK6.161, pSK6.232 and pSK6.234;</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a graph showing the production of gallic acid by aerobic cultivation by </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.161;</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a graph showing the conversion of 3-dehydroshikmic acid to gallic acid by KL7/pSK6.76 when 3-dehydroshikimic acid was added to the cell culture in one portion;</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is a graph showing the conversion of 3-dehydroshikimic acid to gallic acid by KL7/pSK6.76 when 3-dehydroshikimic acid was added in the cell culture with the glucose feed;</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> is a graph showing the conversion of protocatechuic acid to gallic acid by KL7/pSK6.118 when protocatechuic acid was added to the cell culture in one portion;</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a graph showing the conversion of protocatechuic acid to gallic acid by KL7/pSK6.118 when protocatechuic acid was added to the cell culture with the glucose feed;</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is a graph showing the conversion of gallic acid to pyrogallol catalyzed by RB791 serA::aroB/pSK6.234; and</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> is a graph showing the conversion of gallic acid to pyrogallol catalyzed by </PDAT><HIL><ITALIC><PDAT>Klebsiella oxytoca. </PDAT></ITALIC></HIL></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</PDAT></STEXT></H>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>A bioengineered synthesis scheme for the production of gallic acid from a carbon source is provided herein. Methods of producing gallic acid from a carbon source based on the synthesis scheme are also provided. A bioengineered synthesis scheme for the production of pyrogallol from a carbon source is also provided herein. Methods of producing pyrogallol from a carbon source based on the synthesis scheme are provided. In one embodiment, a method is provided wherein the carbon source is converted to gallic acid by a first recombinant microbe and the gallic acid further converted to pyrogallol by a second microbe.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>Gallic acid has been detected in cultures of </PDAT><HIL><ITALIC><PDAT>Phycomyces blakesleeanus </PDAT></ITALIC></HIL><PDAT>(Haslam, E. et al., </PDAT><HIL><ITALIC><PDAT>J. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>1854 (1961); Rivero, F. et al., </PDAT><HIL><ITALIC><PDAT>Mycologia </PDAT></ITALIC></HIL><PDAT>86:781 (1994)), </PDAT><HIL><ITALIC><PDAT>Pseudomonas fluorescens </PDAT></ITALIC></HIL><PDAT>(Korth, H., Arch. Mikrobiol. 89:67 (1973), </PDAT><HIL><ITALIC><PDAT>Entorobacter cloacae </PDAT></ITALIC></HIL><PDAT>(Korth, H., </PDAT><HIL><ITALIC><PDAT>Arch. Mikrobiol. </PDAT></ITALIC></HIL><PDAT>89:67 (1973), </PDAT><HIL><ITALIC><PDAT>Aspergillus terreus </PDAT></ITALIC></HIL><PDAT>(Kawakubo, J. et al., </PDAT><HIL><ITALIC><PDAT>Biosci. Biotech. Biochem. </PDAT></ITALIC></HIL><PDAT>57:1360 (1993), and recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>(Li, K. et al., </PDAT><HIL><ITALIC><PDAT>Biotechnol. Bioeng. </PDAT></ITALIC></HIL><PDAT>64:61 (1999)). However, the pathway for forming gallic acid in these microbes have not been elucidated. The biosynthetic scheme of the present invention (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) is novel in that it utilizes enzymes that are not involved in gallic acid synthesis in nature. For example, neither 3-dehydroshikimate dehydrogenase or protocatechuic hydroxylase activities have been detected in the microbes which are thought to produce gallic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>In one embodiment, a method is provided wherein the carbon source is converted to gallic acid by a recombinant microbe. Manipulation of the common aromatic amino acid biosynthetic pathway of the microbe results in a significant production of gallic acid when the recombinant microbe is cultured in the presence of a carbon source. The carbon source is converted to 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) which is subsequently converted by 3-dehydroquinate synthase to 3-dehydroquinate (DHQ) which is then dehydrated to 3-dehydroshikimic acid (DHS) by 3-dehydroquinate dehydratase (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). 3-dehydroshikimic acid is dehydrated to protocatechuic acid (PCA) by 3-dehydroshikimate dehydratase which is then converted by a mutant p-hydroxybenzoate hydroxylase to gallic acid (GA) (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). The recombinant microbe comprises the genes encoding for the enzymes necessary to convert the carbon source to gallic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>In an alternative embodiment, a method is provided for the conversion of 3-dehydroshimic acid to gallic acid by a recombinant microbe. The 3-dehydroshikimic acid is converted to protocatechuic acid by 3-dehydroshikimate dehydratase which is then hydrodroxylated to gallic acid by a mutant p-hydroxybenzoate hydroxylase. In a further embodiment, a method is provided for the conversion of the protocatechuic acid to gallic acid by a different recombinant microbe. The protocatechuic acid is converted to gallic acid by a mutant p-hydroxybenzoate hydroxylase.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>In yet another embodiment, a method is provided wherein the gallic acid is converted to pyrogallol by a second microbe. In a preferred embodiment, pyrogallol is produced from gallic acid by a recombinant microbe. The gallic acid is converted to pyrogallol by protocatechuic acid decarboxylase (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>The bioconversion methods of the present invention are carried out under conditions of time, temperature, pH, nutrient type and concentration, aeration conditions and glucose concentrations to provide maximal conversion of the carbon source to gallic acid and pyrogallol. As described in detail in the Specific Examples, in a preferred embodiment, a fed-batch fermentor is used to convert the carbon source to gallic acid and then pyrogallol, followed by isolation of either the gallic acid or pyrogallol from the fermentation broth by extraction with an organic solvent. The batch fermentor process and extraction methods are known to those skilled in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>As used herein, the phrase &ldquo;carbon source&rdquo; is meant to include biomass derived carbon sources, including but not limited to, polymeric and/or monomeric xylose, arabinose, and glucose, as well as glycerol, and the intermediates of the Krebs cycle (e.g., dicarboxylic acids), either alone or in combination. In a preferred embodiment, the carbon source is glucose. The carbon source may be derived from renewable resources such as, without limitation, corn, sugar beets and sugar cane.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>Enhanced expression of genes coding for proteins able to perform or control the induction of this divergent pathway or common aromatic pathway enzymatic functions is mediated by genetic elements transferable into a host cell. Genetic elements as herein defined include nucleic acids (generally DNA or RNA) having expressible coding sequences for products such as proteins, apoproteins, or antisense RNA, which can perform or control pathway enzymatic functions. The expressed proteins can function as enzymes, repress or derepress enzyme activity, or control expression of enzymes. The nucleic acids coding these expressible sequences can be either chromosomal (e.g., integrated into a host cell chromosome by homologous recombination) or extrachromosomal (e.g., carried by plasmids, cosmids, etc.). In addition, genetic elements are defined to include optional expression control sequences including promoters, repressors, and enhancers that act to control expression or derepression of coding sequences for proteins, apoproteins, or antisense RNA. For example, such control sequences can be inserted into wild-type host cells to promote overexpression of selected enzymes already encoded in the host cell genome, or alternatively can be used to control synthesis of extrachromosomally encoded enzymes.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>The genetic elements of the present invention can be introduced into a host cell by plasmids, cosmids, phages, yeast artificial chromosomes or other vectors that mediate transfer of the genetic elements into a host cell. These vectors can include an origin of replication along with cis-acting control elements that control replication of the vector and the genetic elements carried by the vector. Selectable markers can be present on the vector to aid in the identification of host cells into which the genetic elements have been introduced. For example, selectable markers can be genes that confer resistance to particular antibiotics such as tetracycline, ampicillin, chloramphenicol, kanamycin, or neomycin.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>A preferred means for introducing genetic elements into a host cell utilizes an extrachromosomal multi-copy plasmid vector into which genetic elements, in accordance with the present invention, are inserted. Plasmid borne introduction of the genetic element into host cells involves an initial cleaving of a plasmid with a restriction enzyme, followed by ligation of the plasmid and genetic elements, in accordance with the invention. Upon recircularization of the ligated recombinant plasmid, transduction or other mechanism for plasmid transfer is utilized to transfer the plasmid into the host cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>Suitable host cells for use in the present invention are members of those genera capable of being utilized for industrial biosynthetic production of desired aromatic compounds. Accordingly, host cells can include microbes which are capable of converting a carbon source to 3-dehydroshikimic acid. Non-limiting examples are </PDAT><HIL><ITALIC><PDAT>Escherichia coli, </PDAT></ITALIC></HIL><PDAT>Klebsiella, Neurospora, Nocardia and Saccharomyces. In a preferred embodiment the host cell is </PDAT><HIL><ITALIC><PDAT>E. coli. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>In one embodiment, the recombinant microbe </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is employed in the methods of the present invention. In a preferred embodiment, the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises a mutated aroE locus and an aroB/aroZ cassette inserted into the serA locus. This recombinant </PDAT><HIL><ITALIC><PDAT>E. coli, </PDAT></ITALIC></HIL><PDAT>designated KL7, may further comprise a plasmid carrying an aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>insert, a serA insert, a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert. The lack of aroE-encoded shikimate dehydrogenase results in increased synthesis of 3-dehydroshikimic acid. It will be appreciated, however, that the aroE locus mutation is not essential and is employed to ensure sufficient 3-dehydroshikimic acid formation. The 3-dehydroshikimic acid is converted into protocatechuic acid by genome-localized, aroZ-encoded 3-dehydroshikimate dehydratase. Plasmid-localized Pt</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* encodes a mutant p-hydroxybenzoate hydroxylase for conversion of protocatechuic acid into gallic acid. In addition, the second copy of aroB inserted into the genome increases 3-dehydroquinate synthase activity to the point where the enzyme no longer impedes carbon flow. Snell, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>118:5605 (1996).</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSK6.161 carrying a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert, an aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>insert, a serA insert and a lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>insert (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>). The P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert encodes for a mutant isozyme of p-hydroxy-benzoate hydroxylase able to convert protocatechuic acid to gallic acid. In this isozyme phenylalanine is substituted for tyrosine at amino acid position 385, enabling the hydroxylase to use protocatechuic acid as a substrate (Entsch, B. et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>266:17341 (1991); Eschrich, K. et al., </PDAT><HIL><ITALIC><PDAT>Eur. J. Biochem. </PDAT></ITALIC></HIL><PDAT>216:137 (1993)). In a preferred embodiment, the pobA* gene is from </PDAT><HIL><ITALIC><PDAT>Pseudomonas aeruginosa. </PDAT></ITALIC></HIL><PDAT>It will be appreciated by those skilled in the art however, that a gene encoding a hydroxylase able to convert protocatechuic acid to gallic acid may be used. The aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>insert encodes a 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthase isozyme insensitive to feedback inhibition which increase carbon flow into the common pathway. Due to a mutation in the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>genomic sera locus required for L-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized serA. The plasmid-localized serA insert thus allows microbial growth in minimal salts medium, distinguishing the microbes containing the plasmid from non-plasmid containing microbes.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>In another embodiment, the recombinant microbe comprises regulatory elements that control the expression of the pobA*-encoded p-hydroxybenzoate hydroxylase (or any hydroxylase able to convert protocatechuic acid to gallic acid) and subsequently the conversion of protocatechuic acid to gallic acid. Gallic acid is known to be toxic to cells in high concentrations, particularly when the cells are rapidly dividing such as in early- and mid-log phases. Gallic is much less toxic to cells in late-log and stationary phase. Preferably, the expression of the pobA* gene will be repressed until late-log or stationary phase of the cells. In a preferred embodiment, the expression of the mutant p-hydroxybenzoate hydroxylase will be controlled by a combination of the lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>-encoded lac repressor and a P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>promoter. Expression of the mutant p-hydroxybenzoate hydroxylase can be controlled by the concentration of isopropyl-&bgr;-D-thiogalactopyranoside in the culture medium. The use of such regulatory elements is well known to those skilled in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>The following table sets forth the five enzymes required for the conversion of glucose to gallic acid, the genes encoding same, and the origin of the genes in the exemplary recombinant microbes of the present invention.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="126pt" align="left"/>
<colspec colname="2" colwidth="91pt" align="left"/>
<thead>
<row>
<entry namest="1" nameend="2" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Enzyme</PDAT><HIL><SP><PDAT>&dagger;</PDAT></SP></HIL></PTEXT></entry>
<entry><PTEXT><PDAT>Gene (origin)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>a) 3-deoxy-D-arabino-heptulosonic acid</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>(plasmid)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>&emsp;7-phosphate synthase</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>b) 3-dehydroquinate synthase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroB (additional copy inserted</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>into genome)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>c) 3-dehydroquinate dehydratase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroD (genomic)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>d) 3-dehydroshikimate dehydratase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>aroZ (inserted into genome)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>e) p-hydroxybenzoate hydroxylase</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>pobA* (plasmid)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="2" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="2" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><HIL><SP><PDAT>&dagger;</PDAT></SP></HIL><PDAT>Enzymes a)-e) correspond to a-e of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1. </PDAT></FGREF></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>In an alternative embodiment, 3-dehydroshikimic acid is converted to gallic acid by a recombinant microbe. The recombinant microbe comprises genes encoding for 3-dehydroshikimate dehydratase and the mutant isozyme of p-dehydroxybenzoate hydroxylase. The conversion of 3-dehydroshikmic acid to protocatechuic acid is catalyzed by 3-dehydroshikimate dehydratase and the subsequent conversion of protocatechuic acid to gallic acid is catalyzed by the p-hydroxybenzoate hydroxylase. In a preferred embodiment, the recombinant microbe is </PDAT><HIL><ITALIC><PDAT>E coli </PDAT></ITALIC></HIL><PDAT>comprising plasmid carrying a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert, and an aroZ insert. In a more preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is KL7 further comprising the plasmid pSK6.76 carrying an aroZ insert, a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert and a serA insert. The aroZ insert encodes for a 3-dehydroshikmate dehydratase. The P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert encodes for an isozyme of p-hydroxybenzoate hydroxylase able to hydroxylate protocatechuic acid to gallic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>In yet another embodiment, protocatechuic acid is converted to gallic acid by a recombinant microbe. The recombinant microbe comprises a gene encoding for the mutant isozyme of p-hydroxybenzoate hydroxylase able to hydroxylate protocatechuic acid to gallic acid. In a preferred embodiment, the recombinant microbe is </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprising a plasmid carrying a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert. In a more preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is KL7 further comprising the plasmid pSK6.118 carrying a lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>insert, a P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert and a serA insert.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>The 3-dehydroshikimic acid and protocatechuic acid can be obtained from various sources. Preferably, 3-dehydroxshikimic acid is obtained by the conversion of glucose by a recombinant microbe. For example, culturing of recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL3/pKL4.79B converts glucose to 3-dehydroshikimic acid (Li, K. et al., </PDAT><HIL><ITALIC><PDAT>Biotechnol. Bioeng. </PDAT></ITALIC></HIL><PDAT>64:61 (1999)).</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In another embodiment, gallic acid is converted to pyrogallol by a recombinant microbe. In a preferred embodiment, a recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>microbe is employed in the methods of the present invention. In a more preferred embodiment the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is RB791serA::aroB, which comprises an aroB cassette inserted into the serA locus and a plasmid carrying aroY and serA gene inserts. The gallic acid is converted to pyrogallol by plasmid-localized, aroy-encoded protocatechate decarboxylase. In a preferred embodiment, the aroY gene is from </PDAT><HIL><ITALIC><PDAT>Klebsiella pneumoniae. </PDAT></ITALIC></HIL><PDAT>The second copy of aroB increases 3-dehydroquinate synthase activity to the point where the enzyme no longer impedes carbon flow.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>In a preferred embodiment, the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises plasmid pSK6.234 carrying an aroY insert and a serA insert. As described above, the aroY gene insert encodes procatechuate decarboxylase. Although the normal substrate for protocatechuate decarboxylase is protocatechuic acid, it was discovered that it also catalyzes the decarboxylation of gallic acid to pyrogallol. Due to a mutation in the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>genomic serA locus required for L-serine biosynthesis, growth in minimal salts medium and plasmid maintenance follows from expression of plasmid-localized serA. The serA insert thus allows microbial growth in minimal salts medium, distinguishing the microbes containing the plasmid from non-plasmid containing microbes.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>In an alternate embodiment, gallic acid is converted to pyrogallol by Klebsiella bacteria. Both </PDAT><HIL><ITALIC><PDAT>K. pneumoniae </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>express protocatechuic decarboxylase and can catalyze the conversion. Addition of gallic acid to the fermentation broth of a </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>culture resulted in a 95% conversion to pyrogallol in 12 hours.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>In another embodiment, gallic acid is converted to pyrogallol by a microbe under fed-batch fermentation conditions in which the gallic acid is added to the fermentation broth when the microbe is in stationary phase. Protocatechuic decarboxylase is a cytosolic enzyme and it was not previously known if gallic acid in the fermentation medium could be taken up by the cells to produce pyrogallol. Cells cultured in shake flasks did not convert gallic acid to pyrogallol, suggesting that gallic acid is not taken up by the cells under those conditions. Addition of gallic acid to the culture medium after the cells were cultured to stationary phase in a fed-batch fermentor resulted in a 97% conversion to pyrogallol within 14 hrs. Therefore, the microbes of the present invention have the ability to convert gallic acid to pyrogallol. It is further known that gallic acid, pyrogallol and especially catechol (the product from decarboxylation or any protocatechuic acid contaminant) can be toxic to growing cells, but are less toxic when the cells are in late log or stationary phase. Therefore, addition of gallic acid to cells cultured to stationary phase will give the best yield of pyrogallol.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In a further embodiment, the conversion of gallic acid to pyrogallol is under anaerobic conditions. It was found that formation of pyrogallol was sensitive to air, decreasing the final yield of product obtained. In a preferred embodiment, the fermentation broth is sparged with a continuous flow of nitrogen upon addition of gallic acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>In yet another embodiment, the gallic acid is produced from a carbon source by a recombinant microbe and then to pyrogallol by a second microbe. The gallic acid can be in the fermentation broth of the first microbe or purified from the broth.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Examples of the above-described preferred recombinant microbes of the present invention, </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.161, RB791serA::aroB/pSK6.234, KL7/pSK6.76 and KL7/pSK6.118 are described in Specific Examples 1-4 and have been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209, under the terms of the Budapest Treaty, and accorded the ATCC designation numbers PTA-1514, PTA-1594, PTA-1513, and PTA-1512, respectively. The deposit will be maintained in the ATCC depository, which is a public depository, for a period of 30 years, or 5 years after the most recent request, or for the effective life of a patent, whichever is longer, and will be replaced if the deposit becomes depleted or nonviable during that period. Samples of the deposit will become available to the public and all restrictions imposed on access to the deposit will be removed upon grant of a patent on this application.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>It will be appreciated that the pobA* gene, aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>gene, aroY gene, serA gene and the genes encoding 3-dehydroshikimate dehydratase, protocatechuic decarboxylase and/or a hydrolase for converting protocatechuic acid to gallic, can be inserted directly into the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>genome. Such a recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>would not require a plasmid to produce significant amounts of gallic acid or pyrogallol.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>Although </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is specifically described herein as the microbe for carrying out the methods of the present invention, it will be appreciated that any microorganism such as the common types cited in the literature and known to those skilled in the art, may be employed, provided the microorganism can be altered to effect the desired conversion (e.g., carbon source to gallic acid, carbon source to 3-dehydroshikimate, carbon source to protocatechuic acid, 3-dehydroshikimate to gallic acid, protocatechuic acid to gallic acid, etc.) Thus, it is envisaged that many types of fungi, bacteria and yeasts will work in the methods of the present invention. Such microorganisms may be developed, for example, through selection, mutation, and/or genetic transformation processes with the characteristic and necessary capability of converting one constituent of the synthesis scheme of the present invention to another. Methods for such development are well known to the skilled practitioner.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>In order to carry out the bioconversion methods of the present invention, a solution containing a carbon source is contacted with the recombinant microbe to form a bioconversion mixture which is maintained under appropriate conditions to promote the conversion of the carbon source to the desired constituent, e.g., gallic acid. In a preferred embodiment, the bioconversion mixture is maintained at a temperature of about 30&deg; C. to about 37&deg; C. and a pH of about 6.5 to about 7.5. It is preferred that the bioconversion mixture also contain other substances necessary to promote the viability of the recombinant microbes such as mineral salts, buffers, cofactors, nutrient substances and the like. The more general requirements for the maintenance of viability of microorganisms are well known and specific requirements for maintaining the viability of specific microorganisms are also well known as documented in the literature, or are otherwise easily determined by those skilled in the art. The gallic acid or pyrogallol may then be recovered from the bioconversion mixture by methods known in the art (e.g., organic extraction).</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>The foregoing and other aspects of the invention may be better understood in connection with the following examples, which are presented for purposes of illustration and not by way of limitation.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 1</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Biocatalytic Synthesis Of Gallic Acid From Glucose</PDAT></STEXT></H>
<PARA ID="P-00051" LVL="7"><PTEXT><PDAT>I. Results</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>Biosynthesis of gallic acid has been narrowed to two possible routes (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). Leston, G., In </PDAT><HIL><ITALIC><PDAT>Kirk</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Othmer Encyclopedia of Chemical Technology; </PDAT></ITALIC></HIL><PDAT>Kroschwitz, J. I.; How-Grant, M., Ed; Wiley: New York, 1996, Vol. 19, p. 778. Oxidation of 3-dehydroshikimic acid (DHS) by a dehydrogenase followed by spontaneous tautomerization could directly yield gallic acid. Alternatively, dehydration of DHS followed by hydroxylation (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>) of the resulting protocatechuic acid (PCA) could lead to gallic acid. Gallic acid has been detected in cultures of </PDAT><HIL><ITALIC><PDAT>Phycomyces blakesleeanus </PDAT></ITALIC></HIL><PDAT>(Haslam, E. et al., </PDAT><HIL><ITALIC><PDAT>J. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>1854 (1961); Rivero, F. et al., </PDAT><HIL><ITALIC><PDAT>Mycologia </PDAT></ITALIC></HIL><PDAT>86:781 (1994)), </PDAT><HIL><ITALIC><PDAT>Pseudomonas fluorescens </PDAT></ITALIC></HIL><PDAT>(Korth, H., Arch. Mikrobiol. 89:67 (1973), </PDAT><HIL><ITALIC><PDAT>Entorobacter cloacae </PDAT></ITALIC></HIL><PDAT>(Korth, H., Arch. Mikrobiol. 89:67 (1973), </PDAT><HIL><ITALIC><PDAT>Aspergillus terreus </PDAT></ITALIC></HIL><PDAT>(Kawakubo, J. et al., </PDAT><HIL><ITALIC><PDAT>Biosci. Biotech. Biochem. </PDAT></ITALIC></HIL><PDAT>57:1360 (1993), and recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>(Li, K. et al., </PDAT><HIL><ITALIC><PDAT>Biotechnol. Bioeng. </PDAT></ITALIC></HIL><PDAT>64:61 (1999)). However, neither DHS dehydrogenase or PCA hydroxylase activities have been detected in these microbes. DHS dehydratase activity unrelated to gallic acid biosynthesis can be detected in </PDAT><HIL><ITALIC><PDAT>Klebsiella pneumoniae </PDAT></ITALIC></HIL><PDAT>and the encoding aroZ locus has been cloned. Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>116:399 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>In Benign by Design; </PDAT></ITALIC></HIL><PDAT>Anasta, P. T.; Farris C. S. Ed.; ACS Symposium Series 577; American Chemical Society: Washington, D.C., Chap. 3, p. 32 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>117:2395 (1995). Although native PCA hydroxylase activity has not been reported, mutagenesis of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas aeruginosa </PDAT></ITALIC></HIL><PDAT>pobA locus encoding p-hydroxybenzoate hydroxylase produces a mutant isozyme that hydroxylates PCA to form gallic acid. Entsch, B. et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>266:17341 (1991); Eschrich, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Biochem. </PDAT></ITALIC></HIL><PDAT>216:137 (1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>The genome of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 contained a mutation in the aroE locus and an aroBaroZ cassette site-specifically inserted to disrupt the serA locus. Plasmid pSK6.161 carried serA, P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA*, lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>, and aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>inserts. DHS accumulated in KL7/pSK6.161 due to the absence of aroE-encoded shikimate dehydrogenase activity. The genome-localized cassette provided the aroZ-encoded dehydratase activity for conversion of DHS into PCA. DHS synthesis, in turn, was determined by the catalytic activity of 3-deoxy-D-arabino-heptulosonic acid-7-phsophate (DHAP) synthase. Since feedback inhibition is the most important determinant of this enzyme&apos;s catalytic activity (Ogino, T. et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>USA</PDAT></ITALIC></HIL><PDAT>) 79:5828 (1982)), a feedback-insensitive isozyme encoded by aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>under the control of its native promoter was utilized (Weaver, L. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>172:6581 (1990)). The combination of lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>-encoded lac repressor andpobA* expressed from a P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>promoter enabled p-hydroxybenzoate hydroxylase activity and the conversion of PCA into gallic acid to be controlled by the concentration of isopropyl-&bgr;-D-thiogalactopyranoside (IPTG) added to the culture medium (Li, K., et al., </PDAT><HIL><ITALIC><PDAT>Biotechnol. Bioeng. </PDAT></ITALIC></HIL><PDAT>64:61 (1999)). The serA insert ensured plasmid maintenance when KL7/pSK6.161 was cultured in medium lacking L-serine supplementation.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>Cultivation of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.161 for 48 h in a fermentor under glucose-rich, nitrogen-rich culture conditions led to the formation of gallic acid (20 g/L), 3-deoxy-D-arabino-heptulosonic acid (DAH) (8.9 g/L), DHS (11 g/L), PCA (0.90 g/L), and glutamic acid (14 g/L) (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>). DAH accumulation was surprising given that this metabolite has not previously been observed when two genomic copies of aroB are expressed as in KL7 (Snell, K. D. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>118:5605 (1996)). It was subsequently discovered that PCA competitively inhibits aroB-encoded 3-dehydroquinate synthase. The initial increase and subsequent decrease in PCA concentrations (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>) may indicate that KL7/pSK6.161 can recapture PCA initially exported into the culture medium. Glutamic acid accumulation can be traced to &agr;-ketoglutarate and ultimately to pyruvate formed from phosphoenolpyruvate during the transport and phosphorylation of glucose. While not wishing to be bound by theory, it is believed that KL7/pSK6.161 is apparently converting this pyruvate via pyruvate dehydrogenase and Krebs cycle enzymes into CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and &agr;-ketoglutarate, which is transaminated and exported into the culture medium as glutamic acid. Gallic acid and PCA were extracted from cell-free culture supernatants using ethyl acetate (EtOAc). After concentration of the charcoal-decolorized organic layer, addition of petroleum ether led to precipitation of gallic acid as a white powder free of PCA contamination.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="7"><PTEXT><PDAT>II. Materials and Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>General. For </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR quantitation of solute concentrations, solutions were concentrated to dryness under reduced pressure, concentrated to dryness one additional time from D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, and then redissolved in D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing a known concentration of the sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP) purchased from Lancaster Synthesis Inc. Concentrations were determined by comparison of integrals corresponding to each compound with the integral corresponding to TSP (&dgr;&equals;0.00 ppm) in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR Spectrometer (300 MHz). Glucose concentrations in fermentation broths were measured using the Glucose Diagnostic Kit purchased from Sigma.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>Culture Medium. All solutions were prepared in distilled, deionized water. LB medium contained (per L) Bacto tryptone (10 g), Bacto yeast extract (5 g), and NaCl (10 g). M9 salts contained (per L) Na</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6 g), KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(3 g), NaCl (0.5 g) and NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl (1 g). M9 minimal medium (per L) consisted of 1 L of M9 salts containing D-glucose (10 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.12 g), and thiamine hydrochloride (0.001 g). Aromatic amino acid supplementation consisted of L-phenylalanine (40 mg/L), L-tyrosine (40 mg/L), L-tryptophan (40 mg/L), potassium p-aminobenzoate (10 mg/L), p-hydroxybenzoic acid (10 mg/L), and 2,3-dihydroxybenzoic acid (10 mg/L). Serine (40 mg/L) and shikimic acid (40 mg/L) supplementation were added where necessary. Ampicillin (50 mg/L) and chloramphenicol (20 mg/L) were added where appropriate. Solutions of inorganic salts, D-glucose, and MgSO4 were autoclaved separately. Thiamine, antibiotics, and growth supplements including amino acids and vitamins were sterilized through 0.22-&mgr;m membranes prior to addition to the medium. Solid medium was prepared by addition of 1.5% (w/v) Difco agar to the medium solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>Fermentation medium (1 L) contained K</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(7.5 g), ammonium iron (III) citrate (0.3 g), citric acid monohydrate (2.1 g), L-phenylalanine (0.7 g), L-tyrosine (0.7 g), L-tryptophan (0.35 g), and concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(1.2 mL). Fermentation medium was adjusted to pH 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4O</PDAT></SB></HIL><PDAT>H before autoclaving. The following supplements were added immediately prior to initiation of the fermentation: D-glucose (23 g or 30 g, as specified), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.24 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), 2,3-dihydroxybenzoic acid (0.010 g), and trace minerals including (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>(Mo</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>24</PDAT></SB></HIL><PDAT>).4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0037 g), ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.7H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0029 g), H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>BO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(0.0247 g), CuSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.5H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0025 g), and MnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0158 g). Inorganic salts containing the aromatic amino acid supplements were autoclaved separately from solutions of D-glucose and MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Aromatic vitamins and trace minerals were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>Genetic Manipulations. Standard procedures were used for construction, purification, and analysis of plasmid DNA. Sambrook, J., et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning. A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>DH5&agr; served as the host strain for all plasmid constructions. PCR amplifications were carried out as described by Sambrook (Sambrook, J. et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). Each reaction (0.1 mL) contained 10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 2 mM MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 0.1% Triton X-100, dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), dTTP (0.2 mM), template DNA, 0.5 &mgr;M of each primer, and 2 units of Vent polymerase (New England Biolabs). Initial template concentrations varied from 0.02 to 1 &mgr;g.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>Strain Construction. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 (Li, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>120:10545 (1998)) was prepared by homologous recombination of an aroBaroZ cassette into the serA locus of AB2834 (Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>91:1494 (1966)). Localization of the serA gene in pMAK705 (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989)) followed by insertion of the aroBaroZ cassette into a restriction site internal to serA was used to direct recombination of the cassette into the serA locus of the genome. Plasmid pMAK705 contains a temperature-sensitive pSC101 replicon. Since derivatives of pMAK705 replicate at 30&deg; C. but are unstable at 44&deg; C., isolation of all pMAK705 derivatives required culturing at 30&deg; C.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>Digestion of pD2625 (GCI) with EcoR V and Dra I liberated a 1.9-kb serA fragment. Plasmid pMAK705 was digested with BamH I and modified to blunt ends by treatment with the Klenow fragment of DNA polymerase. Subsequent ligation of the serA fragment to pMAK705 afforded pLZ1.68A. The aroBaroZ cassette was created as follows. Plasmid pSK4.99A contains a 2.1 kb aroZ fragment inserted into the BamH I site of pSU18. The aroB gene was obtained as a 1.7 kb fragment following digestion of pJB14 (Frost, J. W. et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>23:4470 (1984)) with EcoR I. After treatment with the Klenow fragment, the aroB-encoding fragment was cloned into the Sma I site of pSK4.99A to afford pKL4.237A. The resulting 3.9 kb aroBaroZ cassette of pKL4.237A was amplified by PCR such that BamH I recognition sequences were included at the 5&prime;- and 3&prime;-ends. Insertion of the cassette into the BamH I site of serA in pLZ1.68A yielded pKL4.276B. Both aroB and aroZ are transcribed in the opposite orientation relative to the lac promoter of pKL4.276B.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>Conditions for homologous recombination were based on those previously described (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989); Ohta, K. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Microbiol. </PDAT></ITALIC></HIL><PDAT>57:893 (1991)). Competent AB2834 cells were transformed with pKL4.276B. Following heat-shock treatment, cells were incubated in LB at 44&deg; C. for 1 h and subsequently plated onto LB plates containing chloramphenicol. Plates were incubated at 44&deg; C. for approximately 20 h before colonies appeared. The resulting colonies were inoculated into 5 mL of LB containing no antibiotics, and the cells were grown at 30&deg; C. for 12 h to allow excision of the plasmid from the genome. Cultures were diluted (1:20000) in LB (5 mL) without antibiotics, and two more cycles of growth at 30&deg; C. for 12 h were carried out to enrich cultures for more rapidly growing cells that had lost the temperature-sensitive replicon. Cultures were then diluted (1:20000) into LB and grown at 44&deg; C. for 12 h to promote plasmid loss from the cells. Serial dilutions of each culture were spread onto LB plates and incubated at 30&deg; C. overnight. The resulting colonies were screened on plates to select for recombined colonies. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 was isolated based on the following growth characteristics: growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid and serine; no growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid; growth on LB; and no growth on LB containing chloramphenicol.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>pSK6.161. Plasmid pSK6.161 (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) is an 8.8 kb pSU18-based plasmid that contains a 1.1 kb aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>-encoding insert, a 2.0 kb lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>-encoding insert, a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA*-encoding insert, and a 1.9 kb serA-encoding insert. Strains containing pSK6.161 are resistant to chloramphenicol. The 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment originated from pSK4.176, a vector created by cloning a 1.2 kb PCR product encoding the pobA* ORF amplified from pIE130 (Entsch, B. et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>266:17341 (1991)) into the EcoR I site of pKK223-3 (Brosius, J. et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>USA</PDAT></ITALIC></HIL><PDAT>) 81:6929 (1984)). Subsequent digestion of pSK4.176 with BamH I liberated a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>Fed-batch Fermentation. Cultures were grown in a 2.0 L capacity Biostat MD B-Braun fermentor connected to a DCU system and a Dell Optiplex Gs&plus;5166M personal computer equipped with B-Braun MFCS/win software. The temperature and pH were controlled with a PID controller. Substrate feeding was controlled either manually or via PID controller. The temperature was maintained at 36&deg; C. pH was maintained at 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2 N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Dissolved oxygen (D.O.) was measured using a Braun polarographic probe and was set at either 10% or 20% air saturation, as indicated. Antifoam (Sigma 204) was pumped in manually as needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>KL7/SK6.161 Fermentation. A single colony of KL7/pSK6.161 was inoculated into 5 mL of LB containing chloramphenicol and supplemented with glucose (4 g/L). Cells were grown overnight at 37&deg; C. with agitation. Cells from 3 mL of the culture were harvested by centrifugation, washed in M9 salts, and used to inoculate 100 mL of M9 minimal medium (500 mL Erlenmeyer flask) containing D-glucose (8 g/L), aromatic amino acids and aromatic vitamin supplementation, and chloramphenicol. After growth at 37&deg; C., 250 rpm for 12 h, the inoculant was ready for transfer into the fermentator vessel.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>A set of stainless steel baffles was set inside the fermentation vessel to facilitate oxygen transfer. The initial glucose concentration in the fermentation medium was 30 g/L, and the fermentation was run at 36&deg; C. After inoculation of the vessel, the fermentation process was divided into three stages according to three different methods used to maintain (D.O.) at the desired 10% air saturation during the course of the fermentation. With the airflow at an initial setting of 0.06 L/L/min, D.O. concentration was maintained by increasing the impeller speed from a preset minimum of 50 rpm to a preset maximum of 750 rpm. This first stage lasted approximately 10 h. With the impeller then held constant at 750 rpm, the mass flow controller maintained D.O. levels by increasing the airflow rate from 0.06 L/L/min to a preset maximum of 1.0 L/L/min. This second stage lasted approximately 2 h. In the final stage of control, which was utilized for the remainder of the fermentation, airflow was manually set at a point in the range of 1.0-1.65 L/L/min and the impeller speed was again allowed to vary to maintain the D.O. set point of 10% air saturation. Increasing the airflow above 1.0 L/L/min was necessary to maintain D.O. set point while keeping the impeller below a maximum desired value of 1500 rpm. During the third stage of the fermentation, addition of glucose (60% w/v) was controlled manually such that the glucose concentration was maintained in the range of 15-25 g/L. IPTG (30 mg) was added to the fermentation every 6 h starting 12 h after inoculation and continuing until the fermentation was complete.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>Fermentation broth was harvested by centrifugation at 13000 g for 10 min, and the cells were discarded. Fermentation broth (450 ml) containing gallic acid (105 mM, 17.8 g/L), protocatechuic acid (5 mM, 0.78 g/L), 3-dehydroshikimic acid (15 mM, 2.5 g/L), 3-deoxy-D-arabino-heptulosonic acid (24 mM, 4.9 g/l), and glutamic acid (95 mM, 14 g/L) was adjusted to pH 2.3 by addition of concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. After centrifugation at 13000 g for 10 min to remove precipitated protein, the aqueous solution was extracted three times with ethyl acetate (350 mL portions). The organic layers were combined and filtered under reduced pressure through a thin layer of Darco G-60 (100 mesh) activated charcoal in a buchner funnel. The filtrate was concentrated to 80 mL, mixed with 100 mL of petroleum ether, and chilled in an ice bath. Gallic acid (5.8 g, 72% isolated yield) was isolated as a white powder. NMR analysis of the powder confirmed it to comprise gallic acid (</PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR (D20) &dgr;7.1 (s, 2H)).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 2</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Biocatalytic Synthesis Of Gallic Acid From 3-Dehydroshikimic Acid</PDAT></STEXT></H>
<PARA ID="P-00068" LVL="7"><PTEXT><PDAT>I. Results</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>Purified 3-dehydroshikimic acid was oxidized utilizing </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.76. Two different methods of 3-dehydroshikimic acid supplementation were used. In the first method, cells were grown until the maximum airflow was reached at 11 h, before a sterile-filtered solution (50 mL) of 3-dehydroshikimic acid (10.3 g,) was added in the culture supernatant (60 mM final concentration). Although the Lac repressor protein was not present in this plasmid, IPTG (15 mg) was added every 6 h starting at 12 h. Accumulation of protocatechuic acid was observed during the first 12 h following the 3-dehydroshikimic acid addition (24 h, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>) reaching a maximum value of 4.6 g/L and then slowly decreasing through the next 12 h (36 h, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>) reaching 3.5 g/L by the end of the fermentation run. At the same time 4/6 g/L of gallic acid were accumulated after 42 h of reaction time resulting in a 48% mol/mol yield based on added 3-dehydroshikimic acid (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>Alternatively, the 3-dehydroshikimic acid was added slowly with the glucose feed. The glucose feed solution was prepared by mixing 100 mL of a solution containing 18 g of 3-dehydroshikimic acid, with a 200 mL solution containing 120 g of glucose. An oxygen sensor controlled dissolved oxygen levels via addition of the solution containing glucose (0.4 g/mL) and 3-dehydroshikimic acid (0.06 g/mL, 0.35 mmol/mL). The rate of addition of the previous feed solution was about 8 mL/h and as a result approximately 0.5 g of 3-dehydroshikimic acid was added to the culture medium every hour. By the end of the fermentation run, the total amount of 3-dehydroshikimic acid added to the growing cells was 18 g, producing 6.3 g/L of gallic acid at 48 h in a 45% (mol/mol) yield based on added 3-dehydroshikimic acid. Significant amounts of protocatechuic acid (1.8 g/L) as well as unreacted 3-dehydroshikimic acid (4.2 g/L) were present at the end of the run (FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>). A 20 mL aliquot of fermentation broth was taken at 24 h, 36 h, and 48 h for determination of PHB hydroxylase activity. Although pobA* activities were stable throughout the fermentation, the majority of gallic acid was produced in stationary phase (after 24 h). Interestingly, the concentration of protocatechuic acid showed an initial increase reaching a maximum value of 3.4 g/L at 36 h, after which the concentration of protocatechuic acid steadily decreased to 1.8 g/L at 48 h (FIG. </PDAT><HIL><BOLD><PDAT>5</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="7"><PTEXT><PDAT>II. Materials and Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>General. For </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR quantitation of solute concentrations, solutions were concentrated to dryness under reduced pressure, concentrated to dryness one additional time from D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, and then redissolved in D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing a known concentration of the sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP) purchased from Lancaster Synthesis Inc. Concentrations were determined by comparison of integrals corresponding to each compound with the integral corresponding to TSP (&dgr;&equals;0.00 ppm) in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR Spectrometer (300 MHz). Glucose concentrations in fermentation broths were measured using the Glucose Diagnostic Kit purchased from Sigma.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>Culture Medium. All solutions were prepared in distilled, deionized water. LB medium contained (per L) Bacto tryptone (10 g), Bacto yeast extract (5 g), and NaCl (10 g). M9 salts contained (per L) Na</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6 g), KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(3 g), NaCl (0.5 g) and NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl (1 g). M9 minimal medium (per L) consisted of 1 L of M9 salts containing D-glucose (10 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.12 g), and thiamine hydrochloride (0.001 g). Aromatic amino acid supplementation consisted of L-phenylalanine (40 mg/L), L-tyrosine (40 mg/L), L-tryptophan (40 mg/L), potassium p-aminobenzoate (10 mg/L), p-hydroxybenzoic acid (10 mg/L), and 2,3-dihydroxybenzoic acid (10 mg/L). Serine (40 mg/L) and shikimic acid (40 mg/L) supplementation were added where necessary. Ampicillin (50 mg/L) and chloramphenicol (20 mg/L) were added where appropriate. Solutions of inorganic salts, D-glucose, and MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>were autoclaved separately. Thiamine, antibiotics, and growth supplements including amino acids and vitamins were sterilized through 0.22-&mgr;m membranes prior to addition to the medium. Solid medium was prepared by addition of 1.5% (w/v) Difco agar to the medium solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>Fermentation medium (1 L) contained K</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(7.5 g), ammonium iron (III) citrate (0.3 g), citric acid monohydrate (2.1 g), L-phenylalanine (0.7 g), L-tyrosine (0.7 g), L-tryptophan (0.35 g), and concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(1.2 mL). Fermentation medium was adjusted to pH 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH before autoclaving. The following supplements were added immediately prior to initiation of the fermentation: D-glucose (23 g or 30 g, as specified), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.24 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), 2,3-dihydroxybenzoic acid (0.010 g), and trace minerals including (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>(Mo</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>24</PDAT></SB></HIL><PDAT>).4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0037 g), ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.7H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0029 g), H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>BO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(0.0247 g), CuSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.5H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0025 g), and MnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0158 g). Inorganic salts containing the aromatic amino acid supplements were autoclaved separately from solutions of D-glucose and MgSO4 Aromatic vitamins and trace minerals were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>Genetic Manipulations. Standard procedures were used for construction, purification, and analysis of plasmid DNA (Sambrook, J., et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>DH5&agr; served as the host strain for all plasmid constructions. PCR amplifications were carried out as described by Sambrook (Sambrook, J. et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). Each reaction (0.1 mL) contained 10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)2SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 2 mM MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 0.1% Triton X-100, dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), dTTP (0.2 mM), template DNA, 0.5 &mgr;M of each primer, and 2 units of Vent polymerase (New England Biolabs). Initial template concentrations varied from 0.02 to 1 &mgr;g.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Strain Construction. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 (Li, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>120:10545 (1998)) was prepared by homologous recombination of an aroBaroZ cassette into the sera locus of AB2834 (Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>91:1494 (1966)). Localization of the serA gene in pMAK705 (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989)) followed by insertion of the aroBaroZ cassette into a restriction site internal to serA was used to direct recombination of the cassette into the serA locus of the genome. Plasmid pMAK705 contains a temperature-sensitive pSC101 replicon. Since derivatives of pMAK705 replicate at 30&deg; C. but are unstable at 44&deg; C., isolation of all pMAK705 derivatives required culturing at 30&deg; C.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>Digestion of pD2625 (GCI) with EcoR V and Dra I liberated a 1.9-kb serA fragment. Plasmid pMAK705 was digested with BamH I and modified to blunt ends by treatment with the Klenow fragment of DNA polymerase. Subsequent ligation of the serA fragment to pMAK705 afforded pLZ1.68A. The aroBaroZ cassette was created as follows. Plasmid pSK4.99A contains a 2.1 kb aroZ fragment inserted into the BamH I site of pSU18. The aroB gene was obtained as a 1.7 kb fragment following digestion of pJB14 (Frost, J. W. et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>23:4470 (1984)) with EcoR I. After treatment with the Klenow fragment, the aroB-encoding fragment was cloned into the Sma I site of pSK4.99A to afford pKL4.237A. The resulting 3.9 kb aroBaroZ cassette of pKL4.237A was amplified by PCR such that BamH I recognition sequences were included at the 5&prime;- and 3&prime;-ends. Insertion of the cassette into the BamH I site of serA in pLZ1.68A yielded pKL4.276B. Both aroB and aroZ are transcribed in the opposite orientation relative to the lac promoter of pKL4.276B.</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>Conditions for homologous recombination were based on those previously described (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989); Ohta, K. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Microbiol. </PDAT></ITALIC></HIL><PDAT>57:893 (1991)). Competent AB2834 cells were transformed with pKL4.276B. Following heat-shock treatment, cells were incubated in LB at 44&deg; C. for 1 h and subsequently plated onto LB plates containing chloramphenicol. Plates were incubated at 44&deg; C. for approximately 20 h before colonies appeared. The resulting colonies were inoculated into 5 mL of LB containing no antibiotics, and the cells were grown at 30&deg; C. for 12 h to allow excision of the plasmid from the genome. Cultures were diluted (1:20000) in LB (5 mL) without antibiotics, and two more cycles of growth at 30&deg; C. for 12 h were carried out to enrich cultures for more rapidly growing cells that had lost the temperature-sensitive replicon. Cultures were then diluted (1:20000) into LB and grown at 44&deg; C. for 12 h to promote plasmid loss from the cells. Serial dilutions of each culture were spread onto LB plates and incubated at 30&deg; C. overnight. The resulting colonies were screened on plates to select for recombined colonies. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 was isolated based on the following growth characteristics: growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid and serine; no growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid; growth on LB; and no growth on LB containing chloramphenicol.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>pSK6.76. Plasmid pSK6.76 is a 7.8 kb pSU18-based plasmid that contains a 1.1 kb aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>-encoding insert, a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA*-encoding insert, and a 1.9 kb serA-encoding insert. Strains containing pSK6.76 are resistant to chloramphenicol. The 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment originated from pSK4.176, a vector created by cloning a 1.2 kb PCR product encoding the pobA* ORF amplified from pE130 (Entsch, B. et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>266:17341 (1991)) into the EcoR I site of pKK223-3 (Brosius, J. et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>USA</PDAT></ITALIC></HIL><PDAT>) 81:6929 (1984)). Subsequent digestion of pSK4.176 with BamH I liberated a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>Fed-batch Fermentation. Cultures were grown in a 2.0 L capacity Biostat MD B-Braun fermentor connected to a DCU system and a Dell Optiplex Gs&plus;5166M personal computer equipped with B-Braun MFCS/win software. The temperature and pH were controlled with a PID controller. Substrate feeding was controlled either manually or via PID controller. The temperature was maintained at 36&deg; C. pH was maintained at 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2 N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Dissolved oxygen (D.O.) was measured using a Braun polarographic probe and was set at either 10% or 20% air saturation, as indicated. Antifoam (Sigma 204) was pumped in manually as needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>KL7/SK6.76 Fermentation. A single colony of KL7/pSK6.76 was inoculated into 5 mL of LB containing chloramphenicol and supplemented with glucose (4 g/L). Cells were grown overnight at 37 &deg; C. with agitation. Cells from 3 mL of the culture were harvested by centrifugation, washed in M9 salts, and used to inoculate 100 mL of M9 minimal medium (500 mL Erlenmeyer flask) containing D-glucose (8 g/L), aromatic amino acids and aromatic vitamin supplementation, and chloramphenicol. After growth at 37&deg; C. , 250 rpm for 12 h, the inoculant was ready for transfer into the fermentator vessel.</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>A set of stainless steel baffles was set inside the fermentation vessel to facilitate oxygen transfer. The initial glucose concentration in the fermentation medium was 23 g/L, and the fermentation was run at 360&deg; C. After inoculation of the vessel, the fermentation process was divided into three stages according to three different methods used to maintain (D.O.) at the desired 10% air saturation during the course of the fermentation. With the airflow at an initial setting of 0.06 L/L/min, D.O. concentration was maintained by increasing the impeller speed from a preset minimum of 50 rpm to a preset maximum of 750 rpm. This first stage lasted approximately 10 h. A sterile filtered aqueous solution of DHS (10.3 g, 6 mmol in 50 ml H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, pH 6.9) was then added as a single addition. With the impeller then held constant at 750 rpm, the mass flow controller maintained D.O. levels by increasing the airflow rate from 0.06 L/L/min to a preset maximum of 1.0 L/L/min. This second stage lasted approximately 2 h. In the final stage of control, which was utilized for the remainder of the fermentation, airflow was manually set at a point in the range of 1.0-1.65 L/L/min and the impeller speed was again allowed to vary to maintain the D.O. set point of 10% air saturation. Increasing the airflow above 1.0 L/L/min was necessary to maintain D.O. set point while keeping the impeller below a maximum desired value of 1500 rpm. During the third stage of the fermentation, addition of glucose (60% w/v) was controlled manually such that the glucose concentration was maintained in the range of 15-25 g/L. For addition of DHS with the glucose feed, a filter-sterilized solution of DHS (18 g in 100 ml H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, pH 6.8) was added to the glucose solution. IPTG (30 mg) was added to the fermentation every 6 h starting 12 h after inoculation and continuing until the fermentation was complete.</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>Samples (5 mL) of fermentation broth were taken at timed intervals. A portion (1 mL) was used to determine the cell density by measuring the absorption at 600 nm (OD</PDAT><HIL><SB><PDAT>600</PDAT></SB></HIL><PDAT>). The remaining 4 mL of each fermentation broth sample was centrifuged using a Beckman microfuge. A portion (0.5-2 mL) of the culture supernatant was used for </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR analysis. The OD</PDAT><HIL><SB><PDAT>600 </PDAT></SB></HIL><PDAT>was converted to the cell dry weight by using a conversion coefficient determined as follows: Fermentation broth with a known OD</PDAT><HIL><SB><PDAT>600 </PDAT></SB></HIL><PDAT>was centrifuged, and all the cells were collected. After washing three times with fresh M9 salts (400 mL), the cells were transferred to a container and dried in a 100&deg; C. oven until the weight was constant. The dry cell weight was determined and a conversion coefficient (dry cell weight/OD</PDAT><HIL><SB><PDAT>600</PDAT></SB></HIL><PDAT>) of 0.43 was obtained using an average value of three experiments.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 3</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Biocatalytic Synthesis of Gallic Acid from Protocatechuic Acid</PDAT></STEXT></H>
<PARA ID="P-00084" LVL="7"><PTEXT><PDAT>I. Results</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>The conversion of 3-dehydroshikimic acid into gallic acid using intact </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>cells demonstrated the ability of this microbe to transport 3-dehydroshikimic acid. More importantly, the intracellular formation of H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and gallic acid, both resulting from pobA* expression, were not sufficient to preclude microbe viability and gallic acid synthesis. Furthermore, the decline in the concentration of protocatechuic acid in the culture supernatant of KL7/pSK6.76 during the final 12 h of continuous 3-dehydroshikimate addition suggested that protocatechuic acid transport into the cytoplasm was occurring. Previous literature precedent indicated that </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>was incapable of transporting protocatechuic acid into its cytoplasm form the culture supernatants. Nichols, N. N. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>177:7033 (1995); Nichols, N. N. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>179:5056 (1997). In agreement with the literature, cultivation of KL7/pSK6.118 under shaken flask conditions in the presence of protocatechuic acid showed essentially no gallic acid formation, with the concentration of protocatechuic acid remaining unchanged after 24 h of cultivation.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>However, when KL7/pSK6.118 was cultured under fed-batch fermentor conditions, 7.7 g/L of gallic acid was synthesized (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT>) after addition of protocatechuic acid (9 g) in one portion when the maximum airflow rate of 10 h was reached. The yield (mol/mol) of the gallic acid formation based on the 3-dehydroshikmic acid added in the fermentation broth was 80%. The decrease in protocatechuic concentration corresponded to an approximately equimolar increase in gallic acid concentration. Apparently, recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>cultured under fed-batch fermentor conditions is capable of protocatechuate transport into its cytoplasm.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>The same gallic acid titer (7.3 g/L) was produced if instead of one portion, protocatechuic acid was added slowly with the glucose feed (FIG. </PDAT><HIL><BOLD><PDAT>7</PDAT></BOLD></HIL><PDAT>). An oxygen sensor was used to control dissolved oxygen levels in the culture medium via glucose addition. The feeding solution contained glucose (0.4 g/mL) and 0.053 g/mL (0.34 mol/mL) of protocatechuic acid, and as a result, the addition of this metabolite was controlled from the rate of glucose consumption by the biocatalyst. The feeding rate was about 7.5 mL/h resulting in addition of around 0.4 g of protocatechuic acid per hour. The yield (mol/mol) of gallic acid synthesized based on protocatechuic acid addition to the fermentation broth was 54%. Addition of IPTG (15 mg) every 6 h starting from the time of maximum airflow was necessary to induce the mutant p-hydroxybenzoate hydroxylase expression (0.038 U/mg). In contrast to pSK6.76 plasmid, plasmid pSK6.118 carries the repressor Lac protein and IPTG addition was necessary for adequate expression of the hydroxylase. Comparable activities of the hydroxylase were obtained during synthesis of gallic acid from 3-dehydroshikimic acid and during synthesis of gallic acid from protocatechuic acid. However, addition of protocatechuic acid resulted in an increase of 1 g/L of gallic acid compared to 3-dehydroshikimic acid supplementation.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="7"><PTEXT><PDAT>II. Materials and Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>General. For </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR quantitation of solute concentrations, solutions were concentrated to dryness under reduced pressure, concentrated to dryness one additional time from D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, and then redissolved in D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing a known concentration of the sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP) purchased from Lancaster Synthesis Inc. Concentrations were determined by comparison of integrals corresponding to each compound with the integral corresponding to TSP (&dgr;&equals;0.00 ppm) in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR Spectrometer (300 MHz). Glucose concentrations in fermentation broths were measured using the Glucose Diagnostic Kit purchased from Sigma.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>Culture Medium. All solutions were prepared in distilled, deionized water. LB medium contained (per L) Bacto tryptone (10 g), Bacto yeast extract (5 g), and NaCl (10 g). M9 salts contained (per L) Na</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6 g), KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(3 g), NaCl (0.5 g) and NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl (1 g). M9 minimal medium (per L) consisted of 1 L of M9 salts containing D-glucose (10 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.12 g), and thiamine hydrochloride (0.001 g). Aromatic amino acid supplementation consisted of L-phenylalanine (40 mg/L), L-tyrosine (40 mg/L), L-tryptophan (40 mg/L), potassium p-aminobenzoate (10 mg/L), p-hydroxybenzoic acid (10 mg/L), and 2,3-dihydroxybenzoic acid (10 mg/L). Serine (40 mg/L) and shikimic acid (40 mg/L) supplementation were added where necessary. Ampicillin (50 mg/L) and chloramphenicol (20 mg/L) were added where appropriate. Solutions of inorganic salts, D-glucose, and MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>were autoclaved separately. Thiamine, antibiotics, and growth supplements including amino acids and vitamins were sterilized through 0.22-&mgr;m membranes prior to addition to the medium. Solid medium was prepared by addition of 1.5% (w/v) Difco agar to the medium solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>Fermentation medium (1 L) contained K</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(7.5 g), ammonium iron (III) citrate (0.3 g), citric acid monohydrate (2.1 g), L-phenylalanine (0.7 g), L-tyrosine (0.7 g), L-tryptophan (0.35 g), and concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(1.2 mL). Fermentation medium was adjusted to pH 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH before autoclaving. The following supplements were added immediately prior to initiation of the fermentation: D-glucose (23 g or 30 g, as specified), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.24 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), 2,3-dihydroxybenzoic acid (0.010 g), and trace minerals including (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>(Mo</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>24</PDAT></SB></HIL><PDAT>).4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0037 g), ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.7H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0029 g), H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>BO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(0.0247 g), CuSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.5H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0025 g), and MnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0158 g). Inorganic salts containing the aromatic amino acid supplements were autoclaved separately from solutions of D-glucose and MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Aromatic vitamins and trace minerals were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>Genetic Manipulations. Standard procedures were used for construction, purification, and analysis of plasmid DNA (Sambrook, J., et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>DH5&agr; served as the host strain for all plasmid constructions. PCR amplifications were carried out as described by Sambrook (Sambrook, J. et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). Each reaction (0.1 mL) contained 10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 2 mM MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 0.1% Triton X-100, dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), dTTP (0.2 mM), template DNA, 0.5 &mgr;M of each primer, and 2 units of Vent polymerase (New England Biolabs). Initial template concentrations varied from 0.02 to 1 &mgr;g.</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>Strain Construction. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 (Li, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>120:10545 (1998)) was prepared by homologous recombination of an aroBaroZ cassette into the serA locus of AB2834 (Pittard, J. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>91:1494 (1966)). Localization of the serA gene in pMAK705 (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989)) followed by insertion of the aroBaroZ cassette into a restriction site internal to serA was used to direct recombination of the cassette into the serA locus of the genome. Plasmid pMAK705 contains a temperature-sensitive pSC101 replicon. Since derivatives of pMAK705 replicate at 30&deg; C. but are unstable at 44&deg; C., isolation of all pMAK705 derivatives required culturing at 30&deg; C.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>Digestion of pD2625 (GCI) with EcoR V and Dra I liberated a 1.9-kb serA fragment. Plasmid pMAK705 was digested with BamH I and modified to blunt ends by treatment with the Klenow fragment of DNA polymerase. Subsequent ligation of the serA fragment to pMAK705 afforded pLZ1.68A. The aroBaroZ cassette was created as follows. Plasmid pSK4.99A contains a 2.1 kb aroZ fragment inserted into the BamH I site of pSU18. The aroB gene was obtained as a 1.7 kb fragment following digestion of pJB14 (Frost, J. W. et al., </PDAT><HIL><ITALIC><PDAT>Biochemistry </PDAT></ITALIC></HIL><PDAT>23:4470 (1984)) with EcoR I. After treatment with the Klenow fragment, the aroB-encoding fragment was cloned into the Sma I site of pSK4.99A to afford pKL4.237A. The resulting 3.9 kb aroBaroZ cassette of pKL4.237A was amplified by PCR such that BamH I recognition sequences were included at the 5&prime;- and 3&prime;-ends. Insertion of the cassette into the BamH I site of serA in pLZ1.68A yielded pKL4.276B. Both aroB and aroZ are transcribed in the opposite orientation relative to the lac promoter of pKL4.276B.</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>Conditions for homologous recombination were based on those previously described (Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989); Ohta, K. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Microbiol </PDAT></ITALIC></HIL><PDAT>57:893 (1991)). Competent AB2834 cells were transformed with pKL4.276B. Following heat-shock treatment, cells were incubated in LB at 44&deg; C. for 1 h and subsequently plated onto LB plates containing chloramphenicol. Plates were incubated at 44&deg; C. for approximately 20 h before colonies appeared. The resulting colonies were inoculated into 5 mL of LB containing no antibiotics, and the cells were grown at 30&deg; C. for 12 h to allow excision of the plasmid from the genome. Cultures were diluted (1:20000) in LB (5 mL) without antibiotics, and two more cycles of growth at 30&deg; C. for 12 h were carried out to enrich cultures for more rapidly growing cells that had lost the temperature-sensitive replicon. Cultures were then diluted (1:20000) into LB and grown at 44&deg; C. for 12 h to promote plasmid loss from the cells. Serial dilutions of each culture were spread onto LB plates and incubated at 30&deg; C. overnight. The resulting colonies were screened on plates to select for recombined colonies. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7 was isolated based on the following growth characteristics: growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid and serine; no growth on M9 containing L-tyrosine, L-phenylalanine, shikimic acid; growth on LB; and no growth on LB containing chloramphenicol.</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>pSK6.118. Plasmid pSK6.118 is a 7.6 kb pSU18-based plasmid that contains a 2.0 kb lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>-encoding insert, a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA*-encoding insert, and a 1.9 kb serA-encoding insert. Strains containing pSK6.118 are resistant to chloramphenicol. The 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment originated from pSK4.176, a vector created by cloning a 1.2 kb PCR product encoding the pobA* ORF amplified from pIE130 (Entsch, B. et al., </PDAT><HIL><ITALIC><PDAT>J. Biol. Chem. </PDAT></ITALIC></HIL><PDAT>266:17341 (1991)) into the EcoR I site of pKK</PDAT><HIL><BOLD><PDAT>223-3 </PDAT></BOLD></HIL><PDAT>(Brosius, J. et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>USA</PDAT></ITALIC></HIL><PDAT>) 81:6929 (1984)). Subsequent digestion of pSK4.176 with BamH I liberated a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* fragment.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>Fed-batch Fermentation. Cultures were grown in a 2.0 L capacity Biostat MD B-Braun fermentor connected to a DCU system and a Dell Optiplex Gs&plus; 5166M personal computer equipped with B-Braun MFCS/win software. The temperature and pH were controlled with a PID controller. Substrate feeding was controlled either manually or via PID controller. The temperature was maintained at 36&deg; C. pH was maintained at 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2 N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Dissolved oxygen (D.O.) was measured using a Braun polarographic probe and was set at either 10% or 20% air saturation, as indicated. Antifoam (Sigma 204) was pumped in manually as needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>KL7/SK6.118 Fermentation. A single colony of KL7/pSK6.118 was inoculated into 5 mL of LB containing chloramphenicol and supplemented with glucose (4 g/L). Cells were grown overnight at 37&deg; C. with agitation. Cells from 3 mL of the culture were harvested by centrifugation, washed in M9 salts, and used to inoculate 100 mL of M9 minimal medium (500 mL Erlenmeyer flask) containing D-glucose (8 g/L), aromatic amino acids and aromatic vitamin supplementation, and chloramphenicol. After growth at 37&deg; C., 250 rpm for 12 h, the inoculant was ready for transfer into the fermentator vessel.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>A set of stainless steel baffles was set inside the fermentation vessel to facilitate oxygen transfer. The initial glucose concentration in the fermentation medium was 23 g/L, and the fermentation was run at 36&deg; C. After inoculation of the vessel, the fermentation process was divided into three stages according to three different methods used to maintain (D.O.) at the desired 10% air saturation during the course of the fermentation. With the airflow at an initial setting of 0.06 L/L/min, D.O. concentration was maintained by increasing the impeller speed from a preset minimum of 50 rpm to a preset maximum of 750 rpm. This first stage lasted approximately 10 h. For a one time addition, a sterile solution of PCA was added (9 g in 50 ml H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, pH 6.8). With the impeller then held constant at 750 rpm, the mass flow controller maintained D.O. levels by increasing the airflow rate from 0.06 L/L/min to a preset maximum of 1.0 L/L/min. This second stage lasted approximately 2 h. In the final stage of control, which was utilized for the remainder of the fermentation, airflow was manually set at a point in the range of 1.0-1.65 L/L/min and the impeller speed was again allowed to vary to maintain the D.O. set point of 10% air saturation. Increasing the airflow above 1.0 L/L/min was necessary to maintain D.O. Let point while keeping the impeller below a maximum desired value of 1500 rpm. During the third stage of the fermentation, addition of glucose (60% w/v) was controlled manually such that the glucose concentration was maintained in the range of 15-25 g/L. For addition with the glucose feed, a sterile solution of PCA (16 g in 100 ml H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, pH 6.8) was added to the glucose. IPTG (30 mg) was added to the fermentation every 6 h starting 12 h after inoculation and continuing until the fermentation was complete.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>Samples (5 mL) of fermentation broth were taken at timed intervals. A portion (1 mL) was used to determine the cell density by measuring the absorption at 600 nm (OD</PDAT><HIL><SB><PDAT>600</PDAT></SB></HIL><PDAT>). The remaining 4 mL of each fermentation broth sample was centrifuged using a Beckman microfuge. A portion (0.5-2 mL) of the culture supernatant was used for </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR analysis. The OD</PDAT><HIL><SB><PDAT>600 </PDAT></SB></HIL><PDAT>was converted to the cell dry weight by using a conversion coefficient determined as follows: Fermentation broth with a known OD</PDAT><HIL><SB><PDAT>600 </PDAT></SB></HIL><PDAT>was centrifuged, and all the cells were collected. After washing three times with fresh M9 salts (400 mL), the cells were transferred to a container and dried in a 100&deg; C. oven until the weight was constant. The dry cell weight was determined and a conversion coefficient (dry cell weight/OD600) of 0.43 was obtained using an average value of three experiments.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 4</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Biocatalytic Synthesis Of Pyrogallol From Gallic Acid</PDAT></STEXT></H>
<PARA ID="P-00101" LVL="7"><PTEXT><PDAT>I. Results</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>Pyrogallol is typically generated as a catabolic intermediate by microbes using either gallic acid or tannic acid as a sole source of carbon during growth (Armstrong, S. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Basic Microbiol. </PDAT></ITALIC></HIL><PDAT>34:123 (1994)). The most extensively characterized nonoxidative decarboxylase capable of converting gallic acid into pyrogallol has been isolated from </PDAT><HIL><ITALIC><PDAT>Pantoea agglomerans </PDAT></ITALIC></HIL><PDAT>T71 (Zeida, M. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Micriobiol. </PDAT></ITALIC></HIL><PDAT>64:4743 (1998)). In the present invention, the conversion of gallic acid into pyrogallol was based on the fortuitous discovery that aroY-encoded PTA decarboxylase (Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>116:399 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>In Benign by Design; </PDAT></ITALIC></HIL><PDAT>Anasta, P. T.; Farris C. S. Ed.; ACS Symposium Series 577; American Chemical Society: Wash., D.C., Chap. 3, p. 32 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>117:2395 (1995)) isolated from </PDAT><HIL><ITALIC><PDAT>K. pneumoniae </PDAT></ITALIC></HIL><PDAT>also catalyzes the decarboxylation of gallic acid to pyrogallol. PCA decarboxylase has previously been used in microbial syntheses of catechol and adipic acid from glucose (Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>116:399 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>In Benign by Design; </PDAT></ITALIC></HIL><PDAT>Anasta, P. T.; Farris C. S. Ed.; ACS Symposium Series 577; American Chemical Society: Wash., D.C., Chap. 3, p. 32 (1994); Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>117:2395 (1995)).</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>Synthesis of pyrogallol from glucose was attempted using </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.232. Plasmid pSK6.232 carried an aroY insert in addition to serA, P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>pobA*, lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>, and P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>. KL7/pSK6.232 cultured under fermentor conditions failed to grow beyond 18 h of cultivation and dissolved O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>levels could not be controlled after 24 h. Neither gallic acid or pyrogallol formation could be detected. Only formation of catechol was observed suggesting that the rate of in vivo decarboxylation of PCA was significantly more rapid than mutant p-hydroxybenzoate hydroxylase-catalyzed hydroxylation of PCA. Catechol formation and its associated toxicity (Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>117:2395 (1995)) towards microbes may explain the early cessation of growth and loss of dissolved O</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>control.</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>Synthesis of pyrogallol subsequently switched to a strategy where gallic acid solutions containing PCA contamination were added to the culture medium of RB791serA::aroB/pSK6.234, which carried plasmid-localized aroY and utilized the same system for plasmid maintenance as KL7/pSK6.161. It was unlear whether protocatechuate decarboxylase expressed in RB791serA::aroB/pSK6.234 would have access to the gallic acid added to the culture medium although this strategy, from the outset, benefited from the knowledge that stationary phase </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>are more tolerant of catechol&apos;s toxicity (Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>117:2395 (1995)). Accordingly, RB791serA::aroB/pSK6.234 was cultured under fermentor conditions to stationary phase. Gallic acid and PCA were added to the culture medium to give conentrations of 115 mM and 4.5 mM, respectively, followed by termination of glucose addition. Airflow was also terminated and the fermentor was sparged with a continuous flow of N</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. Within 14 h (FIG. </PDAT><HIL><BOLD><PDAT>8</PDAT></BOLD></HIL><PDAT>), gallic acid and PCA were converted into a solution containing 112 mM pyrogallol (97%) and 4 mM catechol. Repetition of the decarboxylation with culture supernatant produced by KL7/pSK6.161 resulted in a 93% yield of pyrogallol. The concentrations of DHS, DAH, and glutamic acid remained unchanged. Pyrogallol was isolated from cell-free culture supernatants by extraction with EtOAc. Removal of solvent from the charcoal-decolorized organic layer followed by heating under vacuum to remove catechol contamination afforded pyrogallol as a white solid.</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="7"><PTEXT><PDAT>II. Materials and Methods</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>General. For </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR quantitation of solute concentrations, solutions were concentrated to dryness under reduced pressure, concentrated to dryness one additional time from D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O, and then redissolved in D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O containing a known concentration of the sodium salt of 3-(trimethylsilyl)propionic-2,2,3,3-d</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>acid (TSP) purchased from Lancaster Synthesis Inc. Concentrations were determined by comparison of integrals corresponding to each compound with the integral corresponding to TSP (&dgr;&equals;0.00 ppm) in the </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR. All </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectra were recorded on a Varian VXR-300 FT-NMR Spectrometer (300 MHz). Glucose concentrations in fermentation broths were measured using the Glucose Diagnostic Kit purchased from Sigma.</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>Culture Medium. All solutions were prepared in distilled, deionized water. LB medium contained (per L) Bacto tryptone (10 g), Bacto yeast extract (5 g), and NaCl (10 g). M9 salts contained (per L) Na</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6 g), KH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(3 g), NaCl (0.5 g) and NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>Cl (1 g). M9 minimal medium (per L) consisted of 1 L of M9 salts containing D-glucose (10 g), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.12 g), and thiamine hydrochloride (0.001 g). Aromatic amino acid supplementation consisted of L-phenylalanine (40 mg/L), L-tyrosine (40 mg/L), L-tryptophan (40 mg/L), potassium p-aminobenzoate (10 mg/L), p-hydroxybenzoic acid (10 mg/L), and 2,3-dihydroxybenzoic acid (10 mg/L). Serine (40 mg/L) and shikimic acid (40 mg/L) supplementation were added where necessary. Ampicillin (50 mg/L) and chloramphenicol (20 mg/L) were added where appropriate. Solutions of inorganic salts, D-glucose, and MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>were autoclaved separately. Thiamine, antibiotics, and growth supplements including amino acids and vitamins were sterilized through 0.22-&mgr;m membranes prior to addition to the medium. Solid medium was prepared by addition of 1.5% (w/v) Difco agar to the medium solution.</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>Fermentation medium (1 L) contained K</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>HPO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(7.5 g), ammonium iron (III) citrate (0.3 g), citric acid monohydrate (2.1 g), L-phenylalanine (0.7 g), L-tyrosine (0.7 g), L-tryptophan (0.35 g), and concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(1.2 mL). Fermentation medium was adjusted to pH 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH before autoclaving. The following supplements were added immediately prior to initiation of the fermentation: D-glucose (23 g or 30 g, as specified), MgSO</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(0.24 g), p-hydroxybenzoic acid (0.010 g), potassium p-aminobenzoate (0.010 g), 2,3-dihydroxybenzoic acid (0.010 g), and trace minerals including (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>(Mo</PDAT><HIL><SB><PDAT>7</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SB><PDAT>24</PDAT></SB></HIL><PDAT>).4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0037 g), ZnSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.7H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0029 g), H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>BO</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(0.0247 g), CuSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>.5H2O (0.0025 g), and MnCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.4H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (0.0158 g). Inorganic salts containing the aromatic amino acid supplements were autoclaved separately from solutions of D-glucose and MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Aromatic vitamins and trace minerals were sterilized through 0.22-&mgr;m membranes.</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>Genetic Manipulations. Standard procedures were used for construction, purification, and analysis of plasmid DNA (Sambrook, J. et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>DH5&agr; served as the host strain for all plasmid constructions. PCR amplifications were carried out as described by Sambrook (Sambrook, J. et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual; </PDAT></ITALIC></HIL><PDAT>Cold Spring Harbor Laboratory: Plainview, N.Y. (1990)). Each reaction (0.1 mL) contained 10 mM KCl, 20 mM Tris-HCl (pH 8.8), 10 mM (NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 2 mM MgSO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, 0.1% Triton X-100, dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), dTTP (0.2 mM), template DNA, 0.5 &mgr;M of each primer, and 2 units of Vent polymerase (New England Biolabs). Initial template concentrations varied from 0.02 to 1 &mgr;g.</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>Strain Construction. </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>RB791serA::aroB was prepared from RB791 by homologous recombination of the aroB gene into the serA locus. Localization of the serA gene in pMAK705 followed by insertion of aroB into a restriction site internal to serA directed recombination of aroB into the serA locus of the RB791 genome. Digestion of pKAD63 (Snell, K. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>118:5605 (1996)) with Sph I liberated a 1.9 kb serA fragment, which was subsequently inserted into the Sph I site of pMAK705 to afford pKAD76A (Snell, K. D. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>118:5605 (1996)). The aroB gene was obtained as a 1.7 kb fragment following digestion of pJB14 with EcoR I. Insertion of the aroB fragment into the EcoR I site of serA was complicated by two additional EcoR I sites in pKAD76A. Following partial EcoR I digestion of pKAD76A the resulting DNA fragments were resolved on an agarose gel, and the 7.4 kb fragment corresponding to linearized plasmid was isolated. Ligation of the linearized pKAD76A to the 1.7 kb EcoR I fragment of aroB afforded candidates which were screened for inability to complement the serine auxotrophy of </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>JC158 (Clark, A. J., </PDAT><HIL><ITALIC><PDAT>Genetics </PDAT></ITALIC></HIL><PDAT>48:105 (1963)). Plasmid pKL3.82A was isolated in which aroB was found to be localized in the EcoR I site internal to the serA sequence. Homologous recombination of the serA::aroB locus of pKL3.82A into RB791 followed the procedure described by Hamilton, C. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617 (1989) and Ohta, K. et al., </PDAT><HIL><ITALIC><PDAT>Appl. Environ. Microbiol. </PDAT></ITALIC></HIL><PDAT>57:893 (1991). </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>RB791 serA::aroB was isolated based on the following growth characteristics on agar plates: no growth on M9, growth on M9 containing serine, no growth on LB containing chloramphenicol, and growth on LB.</PDAT></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>pSK6.232. Plasmid pSK6.232 (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) is a 12.1 kb pJF118EH-based plasmid (Furste, J. P. et al., </PDAT><HIL><ITALIC><PDAT>Gene </PDAT></ITALIC></HIL><PDAT>48: 119 (1986)) that contains a 1.1 kb aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>ORF transcribed from the vector encoded P</PDAT><HIL><SB><PDAT>tac </PDAT></SB></HIL><PDAT>promoter, a 2.3 kb aroY-encoding insert, a 1.5 kb P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA* insert, and a 1.9 kb serA-encoding insert. Strains containing pSK6.232 are resistant to ampicillin. Expression of aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>and pobA* is regulated by IPTG addition, which is mediated by the pJF118EH-encoded lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>pSK6.234. Plasmid pSK6.234 (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT>) is a 6.5 kb pSU18-based vector which contains a 2.3 kb aroY-encoding insert and a 1.9 kb serA-encoding insert. Strains containing pSK6.234 are resistant to chloramphenicol.</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>Fed-batch Fermentation. Cultures were grown in a 2.0 L capacity Biostat MD B-Braun fermentor connected to a DCU system and a Dell Optiplex Gs&plus; 5166M personal computer equipped with B-Braun MFCS/win software. The temperature and pH were controlled with a PID controller. Substrate feeding was controlled either manually or via PID controller. The temperature was maintained at 36&deg; C. pH was maintained at 7.0 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH or 2 N H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. Dissolved oxygen (D.O.) was measured using a Braun polarographic probe and was set at either 10% or 20% air saturation, as indicated. Antifoam (Sigma 204) was pumped in manually as needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>RB791serA::aroB/pSK6.234 Fermentation. A single colony of RB791serA::aroB/pSK6.234 was inoculated into 5 mL of LB containing chloramphenicol and supplemented with glucose (4 g/L). Cells were grown overnight at 37&deg; C. with agitation. Cells from 3 mL of the culture were harvested, washed in M9 salts, and used to inoculate 100 mL of M9 minimal medium (500 mL Erlenmeyer flask) containing D-glucose (8 g/L) and chloramphenicol. After growth at 37&deg; C., 250 rpm for 10 h, the inoculant was ready for transfer into the fermentor vessel.</PDAT></PTEXT></PARA>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>The initial glucose concentration in the fermentation medium was 23 g/L, and the fermentation was run at 36&deg; C. Three staged methods were used to maintain D.O. at 20% of air saturation during the fermentation process. In the first stage, the airflow was set to 0.06 L/L/min and D.O. was maintained by increasing the impeller speed from a preset minimum value of 50 rpm to a preset maximum value of 940 rpm. This stage of the fermentation required approximately 5.5 h. The second stage began after the impeller speed reached its maximum value at which time the mass flow controller maintained D.O. levels at 20% air saturation by increasing the airflow. Approximately 1.5 h were needed for the airflow to increase from 0.06 L/L/min to its preset maximum rate of 1.0 L/L/min. In the third stage, at a constant impeller speed of 940 rpm and a constant airflow of 1.0 L/L/min, D.O. levels were maintained at 20% saturation by oxygen-sensor-controlled glucose (60% w/v) feeding. The PID control parameters were set to 0.0 (off) for the derivative control (&tgr;</PDAT><HIL><SB><PDAT>D</PDAT></SB></HIL><PDAT>) and 999.9 s (minimum action control) for integral control (&tgr;</PDAT><HIL><SB><PDAT>I</PDAT></SB></HIL><PDAT>). X</PDAT><HIL><SB><PDAT>p </PDAT></SB></HIL><PDAT>was set to 950% to achieve a K</PDAT><HIL><SB><PDAT>c </PDAT></SB></HIL><PDAT>of 0.1. The third stage of control was continued until a gallic acid-containing solution was added to the fermentor broth.</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>RB791serA::aroB/pSK6.234-catalyzed decarboxylations were performed on two different solutions. In one case, gallic acid monohydrate (149 mmol, 28 g) and protocatechuic acid (5.8 mmol, 0.9 g) were combined in 80 mL of water and the pH was adjusted to 6.5 by addition of concentrated NH</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>OH. After autoclaving for 7 minutes, the homogeneous solution was ready for addition into the fermentor. In a second case, cell-free fermentor broth (1 L) produced by KL7/pSK6.161 containing gallic acid (118 mM, 20 g/L), protocatechuic acid (4.5 mM, 0.7 g/L), 3-dehydroshikimic acid (23.8 mM, 4.1 g/L), 3-deoxy-D-arabino-heptulosonic acid (32.0 mM, 6.6 g/L), and glutamic acid (102 mM, 15 g/L) was utilized. In each case, gallic acid-containing solution was added in a single portion to a fermentation of RB791serA::aroB/pSK6.234 which had been growing for 24 h past inoculation. Airflow was exchanged for nitrogen flow of 0.5 L/L/min and glucose addition was discontinued. Decarboxylation was followed by </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR analysis of cell-free fermentor broth at two hour intervals. Complete decarboxylation of gallic acid was usually observed approximately 14 h after addition of gallic acid-containing solution to the fermentor.</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>Fermentation broth was harvested by centrifugation at 13000 g for 10 min, and the cells were discarded. Fermentor broth (1 L) containing pyrogallol (49 mM, 6.2 g/L), catechol (3 mM, 0.33 g/L), 3-dehydroshikimic acid (12 mM, 2.0 g/L), 3-deoxy-D-arabino-heptulosonic acid (16 mM, 3.3 g/l), and glutamic acid (51 mM, 7.5 g/L) ) was adjusted to pH 2.3 by addition of concentrated H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>. After centrifugation at 13000 g for 10 min to remove precipitated protein, the solution was adjusted to pH 7 by addition of NaOH and then extracted three times with ethyl acetate (600 mL portions). The combined organic fractions were back extracted with one portion of brine (150 mL). The organic layer was stirred with Darco G-60 activated charcoal (4 g) for 5 min and then filtered through celite. Concentration of the filtrate to dryness yielded an off-white powder (5.9 g, 95% isolated yield) consisting of a 33:1 molar ratio of pyrogallol to catechol. High vacuum sublimation of the material in a Kugelrohr apparatus at 61&deg; C. for 1 h resulted in selective sublimation of the contaminating catechol, yielding pure pyrogallol (5.4 g, 87% isolated yield). </PDAT><HIL><SP><PDAT>1 </PDAT></SP></HIL><PDAT>H NMR (D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O) &dgr;6.75 (dd, J&equals;9 Hz, 1H), 6.55 (d, J&equals;9 Hz, 2H).</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SPECIFIC EXAMPLE 5</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Biocatalytic Synthesis Of Pyrogallol from Gallic Acid by </PDAT><HIL><ITALIC><PDAT>Klebsiella oxytoca </PDAT></ITALIC></HIL></STEXT></H>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>In the gallic acid decarboxylation reactions, cleaner pyrogallol (PGL) product may be expected if the contaminating protocatechuic acid (PCA) was metabolized by </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1 as a result of this organism&apos;s ability to use protocatechuic acid as a sole source of carbon for growth. Protocatechuic acid was always present in the gallic acid (GA) fermentation solutions and resulted in catechol contamination of product pyrogallol.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>Initial protocatechuic acid decarboxylations using </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1 utilized the standard conditions that were previously employed for the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>biocatalyst (see, Specific Example 4). </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1 was grown to stationary phase in a fermentor, before addition of a mixture (150 mL) of GA.H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O (28 g) and PCA (1.5 g). No pyrogallol or catechol was observed after 6 h of reaction and the concentration of gallic acid and protocatechuic acid remained unchanged. Interestingly, protocatechuic acid was not metabolized, even though the glucose feed was terminated prior to addition of the GA/PCA mixture. The fermentation conditions employed for </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>-catalyzed decarboxylations were therefore not appropriate for </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1.</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1 cells cultured under fermentor conditions until maximum airflow was reached at 6 h, and then grown for 2 more hours to mid-log phase. The GA/PCA mixture was then added. Glucose addition was continued after GA/PCA addition to maintain an excess of glucose and the airflow was decreased to 0.5 L/L/min. Approximately 2-4 h later, D.O. levels begun to increase and could not be controlled by glucose addition. At this point, airflow was terminated and N</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>sparging initiated and maintained at 0.25 L/L/min until the end of the run. In a typical experiment gallic acid (114 mM, 19.4 g/L) and protocatechuic acid (12 mM, 1.8 g/L), were decarboxylated in 12 h to pyrogallol (105 mM, 13.2 g/L) and catechol (10 mM, 1.5 g/L) in 95% (mol/mol) yield (FIG. </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT>). Purification or pyrogallol from the </PDAT><HIL><ITALIC><PDAT>K. oxytoca </PDAT></ITALIC></HIL><PDAT>M5a1 solutions was identical to that as previously described for </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>(see, Specific Example 4).</PDAT></PTEXT></PARA>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>Under the fermentation conditions employed for gallic acid decarboxylation, an excess of glucose was always present. However, its rate of utilization by the microbe declined as the pyrogallol concentration increased. Growth inhibition was usually observed after 3-4 after addition of the GA/PCA mixture. In experiments where the glucose feed was terminated before decarboxylation was finished (80 mM PGL, 25 mM GA, 160 mM glucose) at 7 h, complete decarboxylation by 14 h was observed without any further glucose consumption. In similar experiments where glucose was consumed by 3 h (50 mM PGL, 62 mM GA) as a result of one time addition, incomplete reaction was observed even after 19 h or reaction time (78 mM PGL, 34 mM GA) when no additional glucose was added. Protocatechuic acid (12 mM) was not metabolized even under these glucose-limited conditions. It appears, that although glucose is not necessarily consumed in large amounts during decarboxylation, its presence is important for completing the reaction. In a typical run, around 70 g of glucose were consumed, a number almost identical to the 72 g that were consumed by </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>for the same reaction.</PDAT></PTEXT></PARA>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>The decarboxylation reaction was due to an aroY-encoded PCA decarboxylase gene that is native to Klebsiella. The aroY gene, which encodes PCA decarboxylase, was originally isolated from a genomic library of </PDAT><HIL><ITALIC><PDAT>K. pneumoniae </PDAT></ITALIC></HIL><PDAT>(Draths, K. M. et al., </PDAT><HIL><ITALIC><PDAT>J. Am. Chem. Soc. </PDAT></ITALIC></HIL><PDAT>119:2395 (1995)). Although this enzyme&apos;s primary substrate was protocatechuic acid, complete decarboxylation of gallic acid by recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>expressing an aroY from a plasmid was achieved. Using partially purified enzyme, the activity of AroY towards the decarboxylation of both gallic acid and protocatechuic acid has been previously established.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><PDAT>The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying drawings and claims, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the invention as defined in the following claims.</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>All references cited herein are incorporated by reference as if fully set forth.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>I claim: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>1. A method for the production of gallic acid from a carbon source, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a) providing a host cell which is capable of converting the carbon source to 3-dehydroshikimic acid and comprising a recombinant DNA encoding an enzyme which converts 3-dehydroshikimic acid to protocatechuic acid and a recombinant DNA encoding an enzyme which converts protocatechuic acid to gallic acid; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b) culturing the host cell in the presence of the carbon source. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the host cell is selected from the species </PDAT><HIL><ITALIC><PDAT>E. coli. </PDAT></ITALIC></HIL></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the recombinant DNA encoding an enzyme which converts protocatechuic acid to gallic acid is a recombinant DNA encoding a p-hydroxybenzoate hydroxylase.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00128" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT> wherein the recombinant DNA encoding a p-hydroxybenzoate hydroxylase is a </PDAT><HIL><ITALIC><PDAT>Pseudomonas aeruginosa </PDAT></ITALIC></HIL><PDAT>pobA*.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00004"><PDAT>claim 4</PDAT></CLREF><PDAT> wherein the pobA* is in a plasmid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00005"><PDAT>claim 5</PDAT></CLREF><PDAT> wherein the plasmid is pSK6.161.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the enzyme which converts the 3-dehydroshikimic acid to protocatechuic acid is 3-dehydroshikimate dehydratase.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00132" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT> wherein the recombinant DNA encoding the 3-dehydroshikimate dehydratase is aroZ.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00133" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT>, wherein the aroZ is in a serA locus of the host cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00134" LVL="0"><PTEXT><PDAT>10. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the host cell further comprises a recombinant DNA molecule encoding an isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase insensitive to feedback inhibition by aromatic amino acids or other aromatic molecules.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT> wherein the recombinant DNA molecule encoding an isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase is aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00011"><PDAT>claim 11</PDAT></CLREF><PDAT> wherein the aroF</PDAT><HIL><SP><PDAT>FBR </PDAT></SP></HIL><PDAT>is in a plasmid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>13. The method of </PDAT><CLREF ID="CLM-00012"><PDAT>claim 12</PDAT></CLREF><PDAT> wherein the plasmid is pSK6.161.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>14. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT> wherein the host cell further comprises a lacl</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>gene encoding a lac repressor.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>15. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> wherein the lac1</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>is in a plasmid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>16. The method of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT> wherein the plasmid is pSK6.161.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00141" LVL="0"><PTEXT><PDAT>17. The method of </PDAT><CLREF ID="CLM-00014"><PDAT>claim 14</PDAT></CLREF><PDAT> wherein the expression of p-hydroxybenzoate hydroxylase is repressed when culturing the host cell until late-log phase or stationary phase.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>18. A method for producing gallic acid from a carbon source comprising culturing, in the presence of the carbon source, a cell which has been transformed by introducing into the cell (a) a recombinant DNA encoding an enzyme which converts 3-dehydroshikimic acid to protocatechuic acid and (b) a recombinant DNA encoding an enzyme which converts protocatechuic acid to gallic acid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>19. A method for the production of gallic acid from a carbon source comprising converting the carbon source to gallic acid with a recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprising the genes encoding an isozyme of 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase insensitive to feedback inhibition by aromatic amino acids or other aromatic molecules, a 3-dehydroquinate synthase, a 3-dehydroshikimate dehydratase, and a mutant p-hydroxybenzoate hydroxylase capable of catalyzing the hydroxylation of protocatechuic acid to gallic acid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00144" LVL="0"><PTEXT><PDAT>20. The method of </PDAT><CLREF ID="CLM-00019"><PDAT>claim 19</PDAT></CLREF><PDAT> wherein the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a) an aroZ cassette inserted into a serA locus; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>b) a plasmid comprising P</PDAT><HIL><SB><PDAT>tac</PDAT></SB></HIL><PDAT>pobA*, lacl</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>, aroF</PDAT><HIL><SP><PDAT>FBR</PDAT></SP></HIL><PDAT>, and serA inserts. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00145" LVL="0"><PTEXT><PDAT>21. The method of </PDAT><CLREF ID="CLM-00020"><PDAT>claim 20</PDAT></CLREF><PDAT> wherein the plasmid is pSK6.161.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>22. The method of </PDAT><CLREF ID="CLM-00019"><PDAT>claim 19</PDAT></CLREF><PDAT> wherein the recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>is </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>KL7/pSK6.161.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06472190-20021029-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06472190-20021029-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06472190-20021029-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06472190-20021029-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06472190-20021029-D00005.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06473730-20021029-D00000.TIF SYSTEM "US06473730-20021029-D00000.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00001.TIF SYSTEM "US06473730-20021029-D00001.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00002.TIF SYSTEM "US06473730-20021029-D00002.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00003.TIF SYSTEM "US06473730-20021029-D00003.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00004.TIF SYSTEM "US06473730-20021029-D00004.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00005.TIF SYSTEM "US06473730-20021029-D00005.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00006.TIF SYSTEM "US06473730-20021029-D00006.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00007.TIF SYSTEM "US06473730-20021029-D00007.TIF" NDATA TIF>
<!ENTITY US06473730-20021029-D00008.TIF SYSTEM "US06473730-20021029-D00008.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06473730</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021029</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09290643</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>19990412</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>G06F 1727</PDAT></B511>
<B512><PDAT>G06F 1721</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>704  9</PDAT></B521>
<B522><PDAT>707531</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Method and system for topical segmentation, segment significance and segment function</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5642520</PDAT></DNUM>
<DATE><PDAT>19970600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Takeshita et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  3</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5748805</PDAT></DNUM>
<DATE><PDAT>19980500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Withgott et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>382306</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5799268</PDAT></DNUM>
<DATE><PDAT>19980800</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Boguraev</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  9</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5913185</PDAT></DNUM>
<DATE><PDAT>19990600</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Martino et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  8</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6038560</PDAT></DNUM>
<DATE><PDAT>20000300</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Wical</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>707  5</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6070133</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Brewster et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  9</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6199034</PDAT></DNUM>
<DATE><PDAT>20010300</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Wical</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  9</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6212494</PDAT></DNUM>
<DATE><PDAT>20010400</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Boguraev</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>704  9</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B562><NCIT><STEXT><PDAT>M. Hearst, &ldquo;Multi-Paragraph Segmentation of Expository Text,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proceedings of the 32</PDAT></ITALIC></HIL><HIL><SP><PDAT>nd </PDAT></SP></HIL><HIL><ITALIC><PDAT>Annual Meeting of the Association for Computational Linguistics </PDAT></ITALIC></HIL><PDAT>(1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>D. Marcu, &ldquo;The Rhetorical Parsing of Natural Language Texts,&rdquo; </PDAT><HIL><ITALIC><PDAT>The Proceedings of the 35</PDAT></ITALIC></HIL><HIL><SP><PDAT>th </PDAT></SP></HIL><HIL><ITALIC><PDAT>Annual Meeting of the Association for Computational Linguistics </PDAT></ITALIC></HIL><PDAT>at pp. 96-103 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Y. Yaari, &ldquo;Segmentation of Expository Text by Hierarchical Agglomerative Clustering,&rdquo; </PDAT><HIL><ITALIC><PDAT>Recent Advances in NLP 1997, Bulgaria </PDAT></ITALIC></HIL><PDAT>(1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>J. Justeson and S. Katz, &ldquo;Technical Terminology: Some Linguistic Properties and an Algorithm for Identification in Text,&rdquo; </PDAT><HIL><ITALIC><PDAT>Natural Language Engineering</PDAT></ITALIC></HIL><PDAT>, vol. 1(1) at pp. 9-29 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>C. G. Youmans, &ldquo;A New Tool for Discourse Analysis: The Vocabulary-Management Profile,&rdquo; </PDAT><HIL><ITALIC><PDAT>Language</PDAT></ITALIC></HIL><PDAT>, vol. 67 at pp. 763-789 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>R. J. Passonneau and D. J. Litman, &ldquo;Intention-Based Segmentation: Human Reliability and Correlation with Linguistic Cues,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proceeding of the 31</PDAT></ITALIC></HIL><HIL><SP><PDAT>st </PDAT></SP></HIL><HIL><ITALIC><PDAT>Annual Meeting of the Association of Computation Linguistics</PDAT></ITALIC></HIL><PDAT>, pp. 148-155 (1993).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>35</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>704  1</PDAT></B582>
<B582><PDAT>704  9</PDAT></B582>
<B582><PDAT>704 10</PDAT></B582>
<B582><PDAT>707  3</PDAT></B582>
<B582><PDAT>707  4</PDAT></B582>
<B582><PDAT>707  5</PDAT></B582>
<B582><PDAT>707  6</PDAT></B582>
<B582><PDAT>707102</PDAT></B582>
<B582><PDAT>707530</PDAT></B582>
<B582><PDAT>707531</PDAT></B582>
<B582><PDAT>707532</PDAT></B582>
</B580>
<B590><B595><PDAT>8</PDAT></B595><B596><PDAT>13</PDAT></B596><B597US/>
</B590>
</B500>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Kathleen R.</PDAT></FNM><SNM><STEXT><PDAT>McKeown</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Wayne</PDAT></CITY>
<STATE><PDAT>NJ</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Judith L.</PDAT></FNM><SNM><STEXT><PDAT>Klavans</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Hastings-on-Hudson</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Min-Yen</PDAT></FNM><SNM><STEXT><PDAT>Kan</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Bethesda</PDAT></CITY>
<STATE><PDAT>MD</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>The Trustees of Columbia University in the City of New York</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>New York</PDAT></CITY><STATE><PDAT>NY</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Baker Botts LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Patrick N.</PDAT></FNM><SNM><STEXT><PDAT>Edouard</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>2654</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>A &ldquo;domain-general&rdquo; method for topical segmentation of a document input includes the steps of: extracting one or more selected terms from a document; linking occurrences of the extracted terms based upon the proximity of similar terms; and assigning weighted scores to paragraphs of the document input corresponding to the linked occurrences. In accordance with the present invention, the values of the assigned scores depend upon the type of the selected terms, e.g., common noun, proper noun, pronominal, and the position of the linked occurrences with respect to the paragraphs, e.g., front, during, rear, etc. Upon zero-sum normalization, the assigned scores represent the boundaries of the topical segments of the document input.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>The invention described herein was funded in part by a grant from the National Science Foundation, namely, NSF grant &num;IRI-9618797. The United States Government may have certain rights under the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>SPECIFICATION</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of any portion of the patent document, as it appears in any patent granted from the present application or in the Patent and Trademark Office file or records available to the public, but otherwise reserves all copyright rights whatsoever.</PDAT></PTEXT></PARA>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>An appendix containing source code listing utilized in practicing an exemplary embodiment of the invention is included as part of the Specification and is hereinafter referred to as Appendix A. Appendix A is found on pages 30-59 of the Specification.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>The present invention relates in general to the field of natural language processing and automatic text analysis and summarization. More particularly, the present invention relates to a method and system for topical segmentation of a document and classification of segments according to segment function and importance.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Identification of a document&apos;s discourse structure can be extremely useful in natural language processing applications such as automatic text analysis and summarization and information retrieval. For example, simple segmentation of a document into blocks of topically similar text can be useful in assisting text search engines to determine whether or not to retrieve or highlight a particular segment in which a query term occurs. Similarly, topical segments can be useful in assisting summary agents to provide detailed summaries by topic in accordance with a segment function and/or importance. Topical segmentation is especially useful for accurately processing long texts having multiple topics for a wide range of natural language applications.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Conventional methods for topical segmentation, such as in Hearst&apos;s TextTiling program, identify zero or more segment boundaries at various paragraph separations, which in turn identify one or more topical text segments. See M. Hearst, &ldquo;Multi-Paragraph Segmentation of Expository Text,&rdquo; Proceedings of the 32nd Annual Meeting of the Association for Computational Linguistics (1994). Topical segmentation is thus linear, but based solely upon the equal consideration of selected terms. Terms are regarded as equally important in deciding how to segment the document input, and as such segmentation does not leverage the differences between term types. TextTiling, in addition, makes no effort to measure the significance and function of identified topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>Other conventional methods use hierarchical segmentation to create tree-like representations of a document&apos;s discourse structure. See U.S. Pat. No. 5,642,520; D. Marcu, &ldquo;The Rhetorical Parsing of Natural Language Texts,&rdquo; </PDAT><HIL><ITALIC><PDAT>The Proceedings of the </PDAT></ITALIC></HIL><PDAT>35</PDAT><HIL><ITALIC><PDAT>th Annual Meeting of the Association for Computational Linguistics </PDAT></ITALIC></HIL><PDAT>at pp. 96-103 (1997); Y. Yaari, &ldquo;Segmentation of Expository Text by Hierarchical Agglomerative Clustering,&rdquo; Recent Advances in NLP 1997. Bulgaria (1997). Hierarchical segmentation attempts to calculate not only topic boundaries, but also subtopic and sub-subtopic boundaries. This is inherently a more difficult task and can be prone to more sources of error. Researchers also define &ldquo;topic&rdquo; differently such that many times a topic boundary in one text can correspond to a subtopic or a supertopic in another segmentation program.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>Still other conventional hierarchical schemes, for example, use complex &ldquo;attentional&rdquo; models or rules that look at the topic of discussion for a particular sentence; that is, the focus of the sentence. Attentional models are commonly used to determine pronominal resolution, e.g., what person does &ldquo;he&rdquo; or &ldquo;she&rdquo; refer to in the text, and usually require contextual knowledge that is often difficult to glean from the language input using automated methods. See U.S. Pat. No. 5,642,520.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Again, as with conventional linear segmentation schemes, no effort is made with conventional hierarchical schemes to determine the contextual significance or function of the identified topical segments.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>The aforedescribed limitations and inadequacies of conventional topical segmentation methods are substantially overcome by the present invention, in which a primary object is to provide a method and system for segmenting text documents so as to efficiently and accurately identify topical segments of the documents.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>It is another object of the present invention to provide system and method that identifies the significance of identified topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>It is yet another object of the present invention to provide system and method that identifies the function of identified topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In accordance with a preferred method of the present invention, a method is provided that includes the steps of: extracting one or more selected terms from a document; linking occurrences of the extracted terms based upon the proximity of similar terms; and assigning weighted scores to paragraphs of the document input corresponding to the linked occurrences, wherein the scores depend upon the type of the selected terms and the position of the linked occurrences with respect to the paragraphs, and wherein the scores represent boundaries of the topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>In accordance with another preferred method of the present invention, a method is provided for automatically extracting significant topical information from a document, the method including the steps of: extracting topical information from a document in accordance with specified categories of information; linking occurrences of the extracted topical information based on the proximity of similar topical information; determining topical segments within the document corresponding to the linked occurrences of the topical information; and determining the significance of the topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>In another aspect of the present invention, a computer program is provided for topical segmentation of a document&apos;s input. The computer program includes executable commands for: extracting selected terms from a document; linking occurrences of the extracted terms based upon the proximity of similar terms; and assigning weighted scores to paragraphs of the document input corresponding to the linked occurrences, wherein the scores depend upon the type of the selected terms and the position of the linked occurrences with respect to the paragraphs, and wherein the scores represent boundaries for the topical segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>In yet another aspect of the present invention, a computer program is provided for automatically extracting significant topical information from a document. The computer program includes executable commands for: extracting topical information from a document in accordance with specified categories of information; linking occurrences of the extracted topical information based on the proximity of similar topical information; determining topical segments within the document corresponding to the linked occurrences of the topical information; and determining the significance of the topical segments.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>For a complete understanding of the present invention and the advantages thereof, reference is now made to the following description taken in conjunction with the accompanying drawings in which like reference numbers indicate like features and wherein:</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a flow diagram of a preferred method for automatically extracting significant topical information from a document;</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a flow diagram representing a preferred embodiment of a computer program for implementing the method of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>;</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a flow diagram representing another preferred embodiment of a computer program for implementing the method of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>;</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is an example of a summary report generated by the computer program represented by the flow diagram of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> indicating the occurrences and type of occurrences for the term &ldquo;wine&rdquo; present in a document input;</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> shows an example of term linking for a common noun having a link length of n&equals;4 sentences;</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> shows an example of term linking for a proper noun having a link length of n&equals;8 sentences;</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> shows an example of term linking for a pronominal having a link length of n&equals;1 sentence;</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is an example of a summary report generated by the computer program represented by the flow diagram of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> indicating the occurrences, type of occurrences, links and segment scores associated with the term &ldquo;wine&rdquo; present in a document input;</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> shows an example of term weighting for proper and common nouns;</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> shows an example of term weighting for pronominals;</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT> shows an example of segment coverage; and</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT> shows a pseudocode listing for an algorithm for computing segment importance in accordance with the preferred embodiments of FIGS. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00031" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> shows a flow diagram of a preferred method </PDAT><HIL><BOLD><PDAT>100</PDAT></BOLD></HIL><PDAT> for automatically extracting significant topical information from a document. The method includes the steps of: extracting topical information from a document in accordance with specified categories of information (Step </PDAT><HIL><BOLD><PDAT>110</PDAT></BOLD></HIL><PDAT>); linking occurrences of the identified topical information based on the proximity of similar topical information (Step </PDAT><HIL><BOLD><PDAT>120</PDAT></BOLD></HIL><PDAT>); determining topical segments within the document corresponding to the linked occurrences of the topical information; and determining the significance of the topical segments (Step </PDAT><HIL><BOLD><PDAT>130</PDAT></BOLD></HIL><PDAT>). Topical information are terms that reflect the topical content of the text, preferably noun phrases (NP&apos;s) such as proper noun phrases or common noun phrases, and personal and possessive pronouns (pronominals). As described in detail below, the extracted topical information is then processed using a novel linear segmentation technique, wherein the document input is divided into adjacent segments. We achieve a 10% increase in both precision and recall over conventional topical segmentation techniques as discussed below with respect to a selected corpus of domain-independent news articles.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> shows a flow diagram of preferred embodiment of a computer program </PDAT><HIL><BOLD><PDAT>200</PDAT></BOLD></HIL><PDAT> that implements the method of FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. The program </PDAT><HIL><BOLD><PDAT>200</PDAT></BOLD></HIL><PDAT> includes a segmentation module </PDAT><HIL><BOLD><PDAT>210</PDAT></BOLD></HIL><PDAT>, a segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> and a segment function module </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT>. A flow diagram of a further preferred embodiment, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>, is provided as the Segmenter source code listing in Appendix A. The segmentation module </PDAT><HIL><BOLD><PDAT>210</PDAT></BOLD></HIL><PDAT> is embodied in the Termer source code listing and lines </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>-</PDAT><HIL><BOLD><PDAT>300</PDAT></BOLD></HIL><PDAT> of the Segmenter source code listing, and the significance and function modules </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT> in lines </PDAT><HIL><BOLD><PDAT>300</PDAT></BOLD></HIL><PDAT>-</PDAT><HIL><BOLD><PDAT>400</PDAT></BOLD></HIL><PDAT> of the Segmenter source code listing.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, the program </PDAT><HIL><BOLD><PDAT>200</PDAT></BOLD></HIL><PDAT> first includes a term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> for extracting selected terms from a document input, preferably to include at least three types of noun phrases, e.g., proper, common and pronominal noun phrases, that reflect the topical content of the document input. As further shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>, the document input in the form of raw text is pre-processed by module </PDAT><HIL><BOLD><PDAT>310</PDAT></BOLD></HIL><PDAT>, and then assigned a part of speech (POS) information by a term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT>. A source code listing of a term extraction module, Termer, is provided in Appendix A. However, the POS tagger or term extraction module can be any tagger or module known to those skilled in the art. A standard POS tagger or term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT>, for example, can combine a lexicon or table lookup with contextual probabilities, or just the lexicon. Preferably, in the interest of efficiency, a standard table lookup method favoring noun POS tags is used in the preferred methods and embodiments of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>In addition, the pre-processing module </PDAT><HIL><BOLD><PDAT>310</PDAT></BOLD></HIL><PDAT> of the flow diagram of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> further includes sentence and paragraph recognition modules </PDAT><HIL><BOLD><PDAT>312</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>314</PDAT></BOLD></HIL><PDAT>, which may be any suitable module or modules for providing sentence and paragraph delimitation information from a raw text document input. Source code listings of exemplary paragraph and sentence recognition modules LayoutRecognizer and SentenceRecognizer are also provided in Appendix A.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>Referring again to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, once POS tags have been assigned, occurrences of the above-identified noun phrases (terms) are retrieved by term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> by searching the document for nouns preceded by zero or more adjectives or nouns, i.e., the simple regular expression (Adj&verbar;Noun)*Noun. A &ldquo;term&rdquo; is thus defined as any word or words that satisfy this regular expression. This expression has been determined to be suitable for capturing simple noun phrases, and is not specially designed for identifying more complex noun phrases such as, for example, &ldquo;proprietor of Stag&apos;s Leap Wine Cellars in Napa Valley.&rdquo; See J. Justeson and S. Katz, &ldquo;Technical Terminology: Some Linguistic Properties and an Algorithm for Identification in Text,&rdquo;</PDAT><HIL><ITALIC><PDAT>Natural Language Engineering, </PDAT></ITALIC></HIL><PDAT>vol. 1(1) at pp. 9-29 (1995). Although not well-suited for complex noun phrases, the term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> functions to extract as many noun phrases as possible, since the emphasis is on high NP recalL Thus, noun phrases in the example &ldquo;proprietor of Stag&apos;s Leap Wine Cellars in Napa Valley&rdquo; would be extracted as three different phrases: &ldquo;proprietor,&rdquo; &ldquo;Stag&apos;s Leap Wine Cellars&rdquo; and &ldquo;Napa Valley.&rdquo;</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>After the selected terms are extracted, the term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> performs post-processing of the extracted terms to combine related term occurrences in accordance with any number of predefined language rules to form term links or units. For example, for possessive pronouns such as &ldquo;my&rdquo; or &ldquo;mine&rdquo; are merged with their appropriate personal pronoun, i.e., &ldquo;I&rdquo; Noun phrases are reduced or canonicalized according to their heads where possible. For example, if the noun phrases &ldquo;red wine&rdquo; and &ldquo;wine&rdquo; are found in the document input, occurrences of the terms &ldquo;red wine&rdquo; are subsumed into the occurrences of the term &ldquo;wine,&rdquo; under the strict condition that no other noun phrases, such as &ldquo;white wine,&rdquo; are identified having the head &ldquo;wine.&rdquo;</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>After post-processing, the term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> performs a final thresholding step in order to filter irrelevant words. See J. Justeson and S. Katz, &ldquo;Technical Terminology: Some Linguistic Properties and an Algorithm for Identification in Text,&rdquo; </PDAT><HIL><ITALIC><PDAT>Natural Language Engineering, </PDAT></ITALIC></HIL><PDAT>vol. 1(1) at pp. 9-29 (1995). By thresholding, the term extraction module </PDAT><HIL><BOLD><PDAT>212</PDAT></BOLD></HIL><PDAT> uses a predefined frequency threshold of a minimum of two occurrences to determine topicality. The frequency threshold however can be varied if desired. Any pronouns or noun phrases with fewer occurrences than the frequency threshold are discarded.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>Once extracted, the term linking module </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT> is implemented to evaluate the extracted terms so as to arrive at a topical segmentation of the document input. Given a single term and the distribution of its occurrences, related occurrences of the term are linked together using proximity as the metric for relatedness. If two occurrences of a term occur within a linking distance of n sentences, the two occurrences are linked together as a single unit. This process is repeated until no further larger units can be built.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>As indicated above, the link length or linking distance n refers to the number of sentences allowed to intervene between two occurrences of a single term. The linking distances n for the three categories of selected noun phrases, i.e., common noun phrases, proper noun phrases and pronominals, are selectable and have been found to depend upon the type of term in question, with proper nouns having the maximum allowable distance and the pronominal forms having the shortest linking distances. Proper nouns generally refer to the same entity, almost regardless of the number of intervening sentences. Common nouns often have a much shorter scope of reference, since a single token can be used to repeatedly refer to different instances of its class. Personal pronouns scope even more closely, since the referent to a personal pronoun could change over the course of a document. In addition, any unlinked terms are dropped from further consideration.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> illustrates the linking of term occurrences for the word &ldquo;wine&rdquo; having a linking distance n&equals;4. The figure is a partial output of the program of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> showing information related to a sample document input having a total of 8 paragraphs and 35 sentences. The first line labeled &ldquo;paras&rdquo; indicates the paragraph numbers of the document input, and the second line labeled &ldquo;sents&rdquo; indicates the sentence numbers numbered sequentially in a repeating sequence of 1 to 0(10). The third line labeled &ldquo;wine&rdquo; shows the frequency of occurrence for the word &ldquo;wine&rdquo; by paragraph and sentence, with &ldquo;x&rdquo; denoting a zero occurrence within a specified link. Therefore, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> shows that the word &ldquo;wine&rdquo; appears once in paragraph 2 (sentence 7), once in paragraph 3 (sentence </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>), once in paragraph 7 (sentence 2), and three times in paragraph 8 (twice in sentence 4, once in sentence 5). Accordingly, with a linking distance equal to four sentences, the term linking module </PDAT><HIL><BOLD><PDAT>214</PDAT></BOLD></HIL><PDAT> thus yields two links for the word &ldquo;wine&rdquo; in the sample document input.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 5-7</PDAT></FGREF><PDAT> show further examples of term linking in accordance with the present invention. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> shows a preferred linking distance n&equals;4 for common nouns, e.g., &ldquo;wine&rdquo;; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> shows a preferred linking distance n&equals;8 for proper nouns, e.g., &ldquo;John&rdquo;; and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> shows a preferred linking distance n&equals;1 for pronominals, e.g., &ldquo;they&rdquo; or &ldquo;them.&rdquo; In </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT>, for example, individual occurrences of the word &ldquo;wine&rdquo; in sentences 1 and 3 are linked together as a single unit because they are less than n&equals;4 sentences apart. Likewise, the occurrences at lines </PDAT><HIL><BOLD><PDAT>9</PDAT></BOLD></HIL><PDAT> and </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT> are linked together to form a second unit.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>Referring again to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, after the appropriate number of term links are established, the term weighting/segment boundaries module </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT> is implemented to assign a weight to each of the term links. Since paragraph level boundaries are not considered in the term linking step, each of the individual term links are first normalized to the paragraph level. Thus, each of the paragraphs is provided with a label indicating its positional relationship with respect to the individual term link(s) contained therein.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>In accordance with the present invention, four categories of paragraph labels are provided: front (f), rear (r), during (d) and no link (n). A &ldquo;front&rdquo; paragraph is defined as a paragraph in which a specified link begins, wherein a &ldquo;rear&rdquo; paragraph is defined as a paragraph in which a link just stopped occurring the paragraph before. &ldquo;During&rdquo; indicates a paragraph in which a link occurs, but one that is not a &ldquo;front&rdquo; paragraph. &ldquo;No link&rdquo; indicates any remaining unlabeled paragraphs.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>Referring again to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>, the common noun &ldquo;wine&rdquo; appears a total of six times as shown by the numbers in the third row of the figure. These occurrences have been grouped together to form two term links, as joined by the &ldquo;x&rdquo; marks between the occurrences. The bottom line labeled &ldquo;type&rdquo; shows the labeling of each paragraph shown in the first line according the above-described categories. As shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>, t is possible for a term (&ldquo;wine&rdquo;) to have multiple front and rear paragraphs, since a term may have more than a single link.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>Next, as described with reference to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, for each of the four categories of paragraph labeling, and for each of the three noun phrase types, the term weighting/segment boundaries module </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT> assigns a predefined segmentation weight to each of the paragraphs. Table 1 shows sample segmentation weights by term type and paragraph type.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Overview of Weighting and Linking scheme</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="3">
<colspec colname="offset" colwidth="49pt" align="left"/>
<colspec colname="1" colwidth="126pt" align="center"/>
<colspec colname="2" colwidth="42pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Paragraph Type with respect to Term</PDAT></PTEXT></entry>
<entry></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="1" colwidth="49pt" align="left"/>
<colspec colname="2" colwidth="28pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="35pt" align="center"/>
<colspec colname="5" colwidth="35pt" align="center"/>
<colspec colname="6" colwidth="42pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Term Type</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ldquo;front&rdquo;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ldquo;rear&rdquo;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ldquo;during&rdquo;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ldquo;no link&rdquo;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Link Length</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Proper NP</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&minus;3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>*</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Common NP</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&minus;3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>*</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Pronouns &amp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&ensp;1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13&ensp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&minus;1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>*</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Possessives</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="6" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00046" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> is similar tp </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>, but in addition shows on the fifth line labeled &ldquo;score&rdquo; the weighted score for each of the paragraphs of the previously discussed &ldquo;wine&rdquo; example. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 9 and 10</PDAT></FGREF><PDAT> show term weighting examples for proper and common nouns and pronominals.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>For noun phrases, it is assumed that the introduction of the term is a point at which a new topic may be opened (vocabulary introduction). See C. G. Youmans, &ldquo;A New Tool for Discourse Analysis: The Vocabulary-management Profile,&rdquo; </PDAT><HIL><ITALIC><PDAT>Language, </PDAT></ITALIC></HIL><PDAT>vol. 67 at pp. 763-789 (1991). Thus, a positive score is assigned to &ldquo;front&rdquo; paragraphs having proper and common noun phrases. Similarly, when a term is no longer being used, as in the &ldquo;rear&rdquo; paragraphs, the topic may be closed. However, since this observation may not be as direct as vocabulary introduction, and thus presumably not as strong a marker of topic change, a smaller positive score is assigned to &ldquo;rear&rdquo; paragraphs having proper and common noun phrases. Moreover, paragraphs in which the link persists throughout indicate that a topic continues; thus a negative score is assigned to &ldquo;during&rdquo; paragraphs.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>When scoring paragraphs having pronoun terms, the same rationale applies with some modifications. Since the majority of pronoun referents occur before the pronoun, i.e., anaphoric as opposed to cataphoric, the front boundary is not heavily weighted as for proper and common noun phrases, but instead emphasis is placed on the rear boundary.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>Thus, by assigning the appropriate weights to each of the paragraphs, a numerical score is provided that indicates which paragraphs are more likely to reflect topical boundary. The higher the numerical score, the higher the likelihood that the paragraph is a beginning of a new topical segment.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>Once the weighting process is completed, zero-sum normalization is performed by module </PDAT><HIL><BOLD><PDAT>216</PDAT></BOLD></HIL><PDAT> to determine exactly where the topical segments are located. First, as shown on the sixth line of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT>, a &ldquo;sum to balance in zero-sum weighting&rdquo; is computed for each of the extracted terms that equals the sum of all the individual paragraph scores corresponding to each term, e.g., the sum of all the &ldquo;front,&rdquo; &ldquo;rear&rdquo; and &ldquo;during&rdquo; paragraph scores. The negative of the sum to balance is then evenly distributed to the remaining &ldquo;no link&rdquo; paragraphs to ensure that the net sum of the weight assigned by the weighting of each term sums to zero, and thus that the weighting of the entire article also sums to zero.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>With respect to individual paragraphs, their summed score (sum of all terms) will result in a positive or negative total. A positive score indicates a boundary, a beginning of a new topical segment, whereas a negative score indicates a continuation of a segment. This use of zero-sum weighting solves the problem of finding a threshold, since the data is normalized around the value zero.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>Examination of Segmenter output indicates that zero-sum weighting for long or medium length documents yields good results. For the documents examined, namely documents of short length (800-1500 words), it has been observed that clusters of multiple consecutive paragraphs, all with a positive summed score, actually only have a single, true boundary. In these cases, local maxima, i.e., the maximally valued paragraph, for each of these clusters is considered the only true segment boundary. Thus, for documents of short length (800-1500 words), wherein the distribution of words tends to smear the segmentation values across paragraphs, the sole topical segment boundary is chosen to correspond to the local maxima of the individual paragraph scores.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>&ldquo;Training&rdquo; of the above-described segmentation algorithm was performed to derive the weights and link lengths n shown in Table 1. A total 225 settings were used to derive the optimal link lengths and weights for the three term types, i.e. common nouns, proper nouns and pronominal forms. Values for each of the types were optimized separately, meaning that optimal settings from the group of 225 settings were tried for each of the term types independently from the settings of the other term types; for each of the term types, 5 different settings were tried for the &ldquo;front&rdquo; weight, 5 different settings for the &ldquo;rear&rdquo; weight, 3 different settings for the &ldquo;during&rdquo; weight, and 3 different settings for the link length. By counting the number of correct segments, as judged by human subjects, the optimal values were determined for each weight and link length.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>Referring again to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, the topical segments generated by segmentation module </PDAT><HIL><BOLD><PDAT>210</PDAT></BOLD></HIL><PDAT> is then subject to additional processing by segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT>. The function of the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> is to measure the relevance of each segment as a function of a segment&apos;s importance and coverage as described below in detail. The segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> uses a two-stage, sequential approach for determining segment importance and coverage.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>First, the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> is used to compute the importance of one or more segments with respect to the content of the document input. &ldquo;Segment importance&rdquo; is defined as a measure of how related a given segment is to presenting key information about the article as a whole. The preferred metric, as included in the Segmenter code listing of Appendix A, is Term Frequency (TF)*Segment Frequency (SF). TF refers to the number of times the term appears in the document, whereas SF refers to the number of segments containing that term. As such, the present invention utilizes a variant of Salton&apos;s (1989) information retrieval metric, Term Frequency*Inverse Document Frequency (TF*IDF), to calculate the importance of a particular given segment. See G. Salton, </PDAT><HIL><ITALIC><PDAT>Automatic Text Processing: The Transformation, Analysis, and Retrieval of Information by Computer </PDAT></ITALIC></HIL><PDAT>(Addison-Wesley, Reading, Mass. 1989).</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>Intuitively, a segment containing noun phrases used in other segments of the document will be more central to the meaning of text than a segment that contains noun phrases used only within that one segment. Higher scores along the TF*SF metric indicate a more central segment, with which we equate with segment importance.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>Thus, the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> first calculates the TF*SF score for each term using the term occurrence information and segment boundaries provided by the segmentation module </PDAT><HIL><BOLD><PDAT>210</PDAT></BOLD></HIL><PDAT>. A raw segment importance score is then computed, which is the sum of the TF*SF scores of each of the terms in the segment. The raw segment importance score is then normalized by dividing the raw segment importance by the maximum of all raw segment importance scores for all segments. The normalized raw segment importance score is referred to as the &ldquo;segment importance score.&rdquo; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT> shows pseudocode for computing the segment importance score.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>However, in order to more accurately determine segment significance, the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> further computes a score that measures each segment&apos;s &ldquo;coverage&rdquo; within the document input. The notion of &ldquo;coverage&rdquo; is now illustrated with reference to the following example and FIG. </PDAT><HIL><BOLD><PDAT>11</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>With respect to hypothetical segments A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>, if the term units/links x and y contained therein are equivalent, it can be said that segment B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> has better &ldquo;coverage&rdquo; due to the fact that the noun phrases in B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> appear within all three segments, whereas the noun phrases in segment A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> appear only in two segments. Thus, to calculate segment coverage, the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> iterates over all the occurrences of all terms within a segment, and increments the coverage score by an appropriate amount. The amount depends on the number of terms previously seen that also fall in the same segment. Preferably, a harmonic series is used to determine the score: for the first occurrence of a term in some segment, the value &ldquo;1&rdquo; is added to the segment&apos;s coverage score; for a second occurrence of the same term in the same segment, the value &ldquo;&frac12;&rdquo; is added; for a third occurrence, the value &ldquo;&frac13;&rdquo;, and so forth.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>Therefore, in order to determine the segment coverage for a selected segment, segment coverage counters corresponding to each of the topical segments are initialized to zero. For each term occurring in the selected segment, the corresponding segment counter is incremented by an appropriate amount as determined by the number of linked occurrences (term units/links) within that selected segment. In addition, all of the other segment counters corresponding to the &ldquo;non-selected&rdquo; segments are incremented by an appropriate amount only if those &ldquo;non-selected&rdquo; segments contain the same term units/links found in selected segment. Reference is now made to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT> for an example showing the computation of segment coverage scores when using the above-mentioned harmonic series to increment the segment counters.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>In the case of document A in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 11</PDAT></FGREF><PDAT>, the x and y strings indicate linked occurrences or term units/links x andy. Each of the corresponding segment counters, i.e., segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and segment counter A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>, are initialized to zero prior to computation of the respective segment coverage scores. Thus, segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;0, segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>&equals;0, and segment counter A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>&equals;0.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>Next, consider the raw segment coverage score for A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> (RSC A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>). In order to compute RSC A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> is incremented by 1 to register a first occurrence of a term unit/link (term unit/link x) within the segment A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. Next, segment counters corresponding to all other &ldquo;non-selected&rdquo; segments containing occurrences of term unit/link x are also incremented in accordance with the harmonic series. Thus, segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> is incremented by 1. The value of the A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> segment counter, however, remains unchanged due to the absence of term unit/link x from segment A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>. Thus, after considering term unit/link x, segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;1, segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>&equals;1, and segment counter A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>&equals;0.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>Next, the segment significance module </PDAT><HIL><BOLD><PDAT>222</PDAT></BOLD></HIL><PDAT> considers the occurrences of the term unit/link y since term unit/link y is also found in segment A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. Since a term unit/link has already been detected in segments A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>, both the A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> segment counters are incremented by a lesser amount, 0.5, to register a second occurrence of a term unit/link (term unit/link y) within the segments A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>. Segment A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>, which has no occurrences of either term units/links x or y, remains unchanged at zero. Thus, after considering term unit/link y, segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;1.5(1&plus;0.5), segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>&equals;1 (1&plus;1.5), and segment counter A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>&equals;0 (0&plus;0). The raw segment coverage score for segment A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> is then given by the sum of the segment counters for segments A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>, i.e., RSC A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;1.5(A-1)&plus;1.5(A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&plus;0(A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;3.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>All the segment counter values are then re-initialized to zero in order to determine the raw segment coverage scores for the next selected segment. Thus, is accordance with this method, the raw segment coverage (RSC) scores for segment A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> is as follows: RSC (A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&equals;1.5 (A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>)&plus;1.5 (A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&plus;0&equals;3. Since no term unit/links were identified in segment A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>, RSC (A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;0.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>In the case of document B, segment counter B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, segment counter B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> and segment counter B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> are all initialized to zero: segment counter A-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;0, segment counter A-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>&equals;0, and segment counter A-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>&equals;0. For computing RSC B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, segment counter B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> and segment counter B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT> are incremented by 1 to register the occurrences of term unit/link x within the corresponding segments. Segment counter B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT> however remains at zero since there are no occurrences of term unit/link x. After considering term unit/link y, segment counter B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>&equals;1(1&plus;0), segment counter B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>&equals;1.5(1&plus;0.5) and segment counter B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>&equals;1(&plus;1). Thus, the RSC score for segment B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> is as follows: 1(B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>)&plus;1 (B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&plus;0(B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;2. Similarly, RSC (B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&equals;1(B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>)&plus;1.5(B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&plus;1 (B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;3.5; and RSC (B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;0(B-</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>)&plus;1(B-</PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>)&plus;1(B-</PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>)&equals;2.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>The raw segment coverage scores, as shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT>, are then normalized according to the following formula to yield the segment coverage score: segment coverage score&equals;raw segment coverage/maximum of all raw segment coverage scores for all segments.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>As further shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 12</PDAT></FGREF><PDAT>, the segment significance scores for each of the topical segments are computed by adding the corresponding segment importance and segment coverage scores. Nominally, segment significance scores range from 0.0 (not important) to 2.0 (maximally important).</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>In contrast to segment importance, which examines the prominence of a segment versus every other segment, the segment function module </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT> of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> considers the role of each segment in the discourse structure of the document input. The segment function module </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT> thus is aimed at measuring or characterizing the particular purpose or function of each segment with respect to the article as a whole. Each segment is thus classified into one of three different types of segments: a summary segment, an anecdotal segment, or a support segment.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>&ldquo;Summary&rdquo; segments are those segments of a document input that summarize the content of the document input. Such a segment is assumed to function as an overview, the summary occurring towards the beginning of the document input, or as a conclusion, i.e., near the end of the document input. Therefore, the position of the segment within the document is a critical factor. It has been found that summary segments are usually those segments having the highest segment importance from those segments that occur within the first and last 20% of a document input. In addition, the corresponding segment importance rating is usually within the top 10% of all segment importance ratings. Accordingly, a summary segment for a given document input is defined as that segment having the highest segment importance out of all segments occurring within the first and last 20% of the document input, wherein the segment importance rating of that segment is within the top 10% of all segment importance ratings. Preferably, the segment function module </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT> of the present invention is designed to recognize only one summary segment per document.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>&ldquo;Anecdotal&rdquo; segments or &ldquo;leads&rdquo; are opening remarks that catch the reader&apos;s attention and thus draw the reader into the main body of the article itself. Similarly, closing remarks are often clever comments for effect, but do not convey as much content as opening remarks. Ancedotal segments are thus limited to the first and last segments of the document input of an input document.</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>Empirical evidence suggests that in the domain of journalistic text, for example, at least a single person is introduced during an anecdotal segment to relate the interesting fact or narrative. This person is often not mentioned outside the segment; since the purpose of relating anecdotal information is limited in scope to the anecdotal segment itself. Accordingly, the segment function module </PDAT><HIL><BOLD><PDAT>224</PDAT></BOLD></HIL><PDAT> of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> looks for a proper noun phrase that occurs only within the candidate segment, and not in other segments. This first or last segment is then labeled as anecdotal, if it has not been already selected as the summary segment.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>&ldquo;Support&rdquo; segments are the default segment type. If a segment is not categorized as a summary or anecdotal segment, then it is categorized as a support segment.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>Thus, in addition to topical segmentation, the method and system of the present invention also prioritizes the identified discourse segments as to their relevance towards the whole document input: topical segments are identified that contribute some detail towards the main topic of the document input and that summarize the key points. As discussed below in detail, the method for determining segment significance of the present invention has been evaluated as part of the Segmenter program that utilizes highly pertinent segments to extract key sentences.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>The applicability of the Segmenter program was tested using general domain news articles. Generally, it was found that longer articles, usually those more than three pages in length, tended to have their own headers or bullets, and were excluded because of these prior segmentation markings. Thus, tests using Segmenter primarily focused on segmenting shorter articles, each roughly 800-1500 words in length: 15 from the Wall Street Journal in the Linguistic Data Consortium&apos;s 1988 collection, and 5 from the on-line The Economist from 1997.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>For the segmentation algorithm of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT>, a segmentation evaluation facility developed was used to gather segmentation judgments. Each of the 20 articles in the corpus was segmented by at least four human judges, and the majority opinion of segment boundaries was computed as the evaluation standard.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Table 2 below shows precision and recall results for the Segmenter computer program of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> as compared to conventional topical segmentation techniques. &ldquo;Precision&rdquo; is defined as the ratio of the number of correct segmentations made over the total number of segmentations made, and &ldquo;recall&rdquo; is defined as the ratio of the number of correct segmentations made over the total number of correct segmentations possible. As shown in Table 2 below, human judges achieved on average only 62.4% agreement with the majority opinion, i.e., the &ldquo;correct&rdquo; segmentation. Passonneau and Litman (1993) show that this surprisingly low agreement is often the result of evaluators being divided between those who regard segments as more localized and those who prefer to split only on large boundaries. See R. J. Passonneau and D. J. Litman, &ldquo;Intention-based Segmentation: Human Reliability and Correlation with Linguistic Cues,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proceeding of the </PDAT></ITALIC></HIL><PDAT>31 </PDAT><HIL><ITALIC><PDAT>st Annual Meeting of the Association of Computation Linguistics, </PDAT></ITALIC></HIL><PDAT>pp. 148-155 (1993).</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>Next, we verified that the task was well defined by testing for a strong correlation between the markings of the human judges. We tested for inter-judge reliability using Cochran&apos;s (1950) Q-test, also discussed in Passonneau and Litman (1993). A very high correlation was found between judges that showed that the task was indeed feasible to model; the results showed that there was less than a 0.15% chance on the average that the judges&apos; segment marks agreed by chance.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="385pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
<row>
<entry><PTEXT><PDAT>Evaluation Results on Precision and Recall Scales</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="6">
<colspec colname="offset" colwidth="49pt" align="left"/>
<colspec colname="1" colwidth="105pt" align="center"/>
<colspec colname="2" colwidth="7pt" align="center"/>
<colspec colname="3" colwidth="112pt" align="center"/>
<colspec colname="4" colwidth="7pt" align="center"/>
<colspec colname="5" colwidth="105pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>WSJ</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Econ.</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Total</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="12">
<colspec colname="offset" colwidth="49pt" align="left"/>
<colspec colname="1" colwidth="49pt" align="center"/>
<colspec colname="2" colwidth="7pt" align="center"/>
<colspec colname="3" colwidth="49pt" align="center"/>
<colspec colname="4" colwidth="7pt" align="center"/>
<colspec colname="5" colwidth="49pt" align="center"/>
<colspec colname="6" colwidth="7pt" align="center"/>
<colspec colname="7" colwidth="56pt" align="center"/>
<colspec colname="8" colwidth="7pt" align="center"/>
<colspec colname="9" colwidth="49pt" align="center"/>
<colspec colname="10" colwidth="7pt" align="center"/>
<colspec colname="11" colwidth="49pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Precision</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Recall</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Precision</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Recall</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Precision</PDAT></PTEXT></entry>
<entry></entry>
<entry><PTEXT><PDAT>Recall</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="13">
<colspec colname="offset" colwidth="49pt" align="left"/>
<colspec colname="1" colwidth="28pt" align="center"/>
<colspec colname="2" colwidth="28pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="28pt" align="center"/>
<colspec colname="7" colwidth="35pt" align="center"/>
<colspec colname="8" colwidth="28pt" align="center"/>
<colspec colname="9" colwidth="28pt" align="center"/>
<colspec colname="10" colwidth="28pt" align="center"/>
<colspec colname="11" colwidth="28pt" align="center"/>
<colspec colname="12" colwidth="21pt" align="center"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>Avg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Avg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Avg</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Avg.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Avg.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Avg.</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>S.D.</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry namest="OFFSET" nameend="12" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="13">
<colspec colname="1" colwidth="49pt" align="left"/>
<colspec colname="2" colwidth="28pt" align="char" char="."/>
<colspec colname="3" colwidth="28pt" align="char" char="."/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="char" char="."/>
<colspec colname="6" colwidth="28pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="center"/>
<colspec colname="8" colwidth="35pt" align="center"/>
<colspec colname="9" colwidth="28pt" align="char" char="."/>
<colspec colname="10" colwidth="28pt" align="center"/>
<colspec colname="11" colwidth="28pt" align="char" char="."/>
<colspec colname="12" colwidth="28pt" align="center"/>
<colspec colname="13" colwidth="21pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>Monte Carlo</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>29.0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33.3%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>.02</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.8%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33.3%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>.02</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>29.8%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>9.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33.3%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>.02</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>33%</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Hypergeo-</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30.6%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30.6%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.9%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.9%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>30.0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>32.0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>N/A</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>metric</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>TextTiling</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28.2%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.1</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>33.4%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>25.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.3%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>20.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.7%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>25.8%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>18.7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>29.8%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>27.8</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Segmenter</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>47.0</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>21.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45.1%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>24.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>28.6%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>26.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>22.67%&ensp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>25.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>42.6%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>23.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>39.6%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>25.9</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Human Judges</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>67.0%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>11.4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>80.4%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>8.9</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>55.8%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>17.2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>71.9%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>4.6</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>62.4%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13.5</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>78.2%</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>87.6</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="13" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>As shown by Table 2, segmentation results attained with Segmenter show a significant improvement over the TextTiling of Hearst, both in precision and recall. As a basis for these results, Table 2 shows two different baselines from which the Segmenter results are compared: the first being a Monte Carlo simulation that segments at paragraph breaks with a 33% probability. We executed this baseline 10,000 times on each article and averaged the scores. A second baseline was produced by applying a hypergeometric distribution, which calculates the probability of some number of successes by sampling without replacement. The hypergeometric distribution models the selection of N &ldquo;segment breaks&rdquo; randomly in a document with R possible segment breaks (for us, paragraphs breaks). Therefore, it is equivalent to a technique of randomly choosing places to segment if you knew ahead of time how many segments there were. However, as suggested by the results in Table 2, it can be shown that the correct number of segments, R, is difficult to determine. TextTiling&apos;s performance meanwhile falls below the hypergeomtric baseline; but on the average Segmenter outperforms it.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>In summary, we have presented a novel new method for representing the discourse structure of a document input while categorizing segment function is heretofore described. The foregoing demonstrate how retrieval of noun phrases and pronominal forms, along with a zero-sum weighting scheme, can be used for determining topical segments that accurately represent the content of the document input. Furthermore, term distribution is used to aid in identifying the role that the segment performs in the document. Evaluation results in terms of precision and recall indicate that the performance of the linear topical segmentation method of the present invention surpasses that of conventional segmentation schemes known in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>Although the present invention has been described in connection with particular embodiments thereof, it is to be understood that various modifications, alterations and adaptions may be made by those skilled in the art without departing from the spirit and scope of the invention. It is intended that the invention be limited only by the appended claims.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>1. A computer-based method for identifying topical segments of a document input, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>extracting one or more selected terms from a document; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>linking occurrences of said extracted terms based upon the proximity of similar terms; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>assigning weighted scores to paragraphs of said document input corresponding to said linked occurrences, wherein said scores depend upon the type of said selected terms and the position of said linked occurrences with respect to said paragraphs, and wherein said scores define boundaries of said topical segments; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>zero-sum normalizing said assigned weighted scores to determine said topical boundaries. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>2. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said selected terms are noun phrases.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>3. The method according to </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT>, wherein said noun phrases are proper, common and pronominal noun phrases.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>4. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said extracting step comprises identifying one or more noun phrases each having a noun preceded by an adjective or noun, if any.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>5. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said extracting step comprises the step of post-processing said extracted terms to merge occurrences of related terms in accordance with one or more language rules.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>6. The method according to </PDAT><CLREF ID="CLM-00005"><PDAT>claim 5</PDAT></CLREF><PDAT>, wherein said post-processing step comprises merging occurrences of possessive pronouns with a corresponding personal pronoun.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>7. The method according to </PDAT><CLREF ID="CLM-00005"><PDAT>claim 5</PDAT></CLREF><PDAT>, wherein said post-processing step comprises reducing a noun phrase in accordance with a corresponding head.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>8. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said extracting step comprises thresholding said extracted terms to filter out irrelevant terms.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>9. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said linking step comprises linking occurrences of said extracted terms in accordance with one or more predefined linking distances.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>10. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, further comprising the step of determining a segment significance for each of said topical segments to indicate the relevance of said topical segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>11. The method according to </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein determining said segment significance comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining a segment importance; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining a segment coverage. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>12. The method according to </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein determining said segment significance comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing a segment importance score; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing a segment coverage score; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing said segment importance score and segment coverage score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>13. The method according to </PDAT><CLREF ID="CLM-00012"><PDAT>claim 12</PDAT></CLREF><PDAT>, wherein said step of computing said segment importance score for a selected one of said topical segments comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing TF*SF values corresponding to each of said terms within said selected topical segment, wherein TF is defined as a term frequency and SF is defined as a segment frequency; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing said TF*SF values to obtain a TF*SF sum, wherein said sum represents said segment importance score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>14. The method according to </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein said segment coverage is defined at least in part on the number of said linked occurrences within the same topical segment.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>15. The method according to </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT>, wherein said step of computing said segment coverage score for a selected one of said topical segments comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>initializing segment counters to zero for each of the topical segments; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>incrementing, for linked occurrences contained within said selected segment, a corresponding one of said segment counters by a predetermined amount; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>incrementing one or more segment counters corresponding to non-selected segments by a predetermined amount only if said non-selected segments contain one or more of said linked occurrences contained within said selected segment; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing all of said segment counters to obtain a segment counter sum, wherein said sum represents said segment coverage score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>16. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, further comprising the step of determining a segment function to measure the relevance of said topical segments with respect said document input as a whole.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>17. The method according to </PDAT><CLREF ID="CLM-00016"><PDAT>claim 16</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more summary segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>18. The method according to </PDAT><CLREF ID="CLM-00016"><PDAT>claim 16</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more anecdotal segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>19. The method according to </PDAT><CLREF ID="CLM-00016"><PDAT>claim 16</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more support segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>20. The method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the linking step includes using at least a first linking distance for a first term type and a second linking distance for a second term type.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>21. The method according to </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>, wherein the linking step includes using a first linking distance for said proper noun phrases, a second linking distance for common noun phrases and a third linking distance for pronominal noun phrases.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>22. A computer based method for automatically extracting significant topical information from a document, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>extracting topical information from a document in accordance with specified categories of information; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>linking occurrences of said extracted topical information based on the proximity of similar topical information; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>assigning weighted scores to paragraphs of said document input corresponding to said linked occurrences, wherein said scores depend upon the type of said selected terms and the position of said linked occurrences with respect to said paragraphs, and wherein said scores represent boundaries of said topical segments; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>zero-sum normalizing said assigned weighted scores to determine said topical boundaries; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining topical segments within said document corresponding to said linked occurrences of said topical information; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining the significance of said topical segments. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00023">
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>23. The method according to </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT>, wherein said extracting step comprises extracting selected types of noun phrases from said document.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00024">
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>24. The method according to </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT>, wherein said step of determining topical segments comprises linking occurrences of said extracted noun phrases based upon the proximity of similar noun phrases.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00025">
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>25. The method according to </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT>, wherein said step of determining the significance of said topical segments comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining a segment importance; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>determining a segment coverage. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00026">
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>26. The method according to </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT>, wherein said step of determining said segment significance comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing a segment importance score; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing a segment coverage score; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing said segment importance score and segment coverage score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00027">
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>27. The method according to </PDAT><CLREF ID="CLM-00026"><PDAT>claim 26</PDAT></CLREF><PDAT>, wherein said step of computing said segment importance score for a selected one of said topical segments comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>computing TF*SF values corresponding for each of said terms within said selected topical segment, wherein TF is defined as a term frequency and SF is defined as a segment frequency; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing said TF*SF values to obtain a TF*SF sum, wherein said sum represents said segment importance score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00028">
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>28. The method according to </PDAT><CLREF ID="CLM-00026"><PDAT>claim 26</PDAT></CLREF><PDAT>, wherein said segment coverage is defined at least in part on the number of said linked occurrences within the same topical segment.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00029">
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>29. The method according to </PDAT><CLREF ID="CLM-00026"><PDAT>claim 26</PDAT></CLREF><PDAT>, wherein said step of computing said segment coverage score for a selected one of said topical segments comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>initializing segment counters to zero for each of the topical segments; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>incrementing, for linked occurrences within said selected segment, a corresponding one of said segment counters by a predetermined amount; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>incrementing one or more segment counters corresponding to non-selected segments by a predetermined amount only if said non-selected segments contain one or more of said linked occurrences contained within said selected segment; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>summing all of said segment counters to obtain a segment counter sum, wherein said sum represents said segment coverage score. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00030">
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>30. The method according to </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT>, further comprising the step of determining a segment function to measure the relevance of said topical segments with respect said document input as a whole.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00031">
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>31. The method according to </PDAT><CLREF ID="CLM-00030"><PDAT>claim 30</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more summary segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00032">
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>32. The method according to </PDAT><CLREF ID="CLM-00030"><PDAT>claim 30</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more anecdotal segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00033">
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>33. The method according to </PDAT><CLREF ID="CLM-00030"><PDAT>claim 30</PDAT></CLREF><PDAT>, wherein said step of determining a segment function comprises identifying one or more support segments.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00034">
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>34. A computer program for identifying topical segments of a document input, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for extracting selected terms from a document; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for linking occurrences of said extracted terms based upon the proximity of similar terms; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for assigning weighted scores to paragraphs of said document input corresponding to said linked occurrences, wherein said scores depend upon the type of said selected terms and the position of said linked occurrences with respect to said paragraphs, and wherein said scores represent boundaries for said topical segments; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for zero sum normalizing said assigned weighted scores to determine said topical boundaries. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00035">
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>35. A computer program for automatically extracting significant topical information from a document, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for extracting topical information from a document in accordance with specified categories of information; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for linking occurrences of said extracted topical information based on the proximity of similar topical information; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for assigning weighted scores to paragraphs of said document input corresponding to said linked occurrences, wherein said scores depend upon the type of said selected terms and the position of said linked occurrences with respect to said paragraphs, and wherein said scores represent boundaries of said topical segments; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for determining topical segments within said document corresponding to said linked occurrences of said topical information; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>means for determining the significance of said topical segments including determining a segment importance and determining a segment coverage.</PDAT></PTEXT></CLMSTEP>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00000" ALT="embedded image" FILE="US06473730-20021029-D00000.TIF"/>
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06473730-20021029-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06473730-20021029-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06473730-20021029-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06473730-20021029-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06473730-20021029-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06473730-20021029-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06473730-20021029-D00007.TIF"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06473730-20021029-D00008.TIF"/>
</SDODR>
</PATDOC>

